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1                                                                              INTRODUCTION 
    3 
1.1 CONCEPT OF CELL DEATH. 
In an organism cell death occurs in essentially two different ways: accidental cell death 
(ACD) or regulated cell death (RCD). ACD is consequence of severe damages and caused 
by mechanical damages, hypoxia, complement-mediated cell lysis or highly toxic agents. 
Uncontrolled cell swelling is showed at the end of this process. In RCD, cells die in 
response to a specific stimulus and genetically encoded machinery initiates cell death. The 
course of some ‘regulated cell death’ (RCD) variants can be influenced, at least to some 
extent, by specific pharmacologic or genetic interventions. The term ‘programmed cell 
death’ (PCD) is used to indicate RCD instances that occur as part of a developmental 
program or to preserve physiologic adult tissue homeostasis. In 1842, Carl Vogt was the 
first investigator who reported the appearance of physiological cell death during 
development of the midwife toad. Then, histologists started to recognize cell death as a 
natural process and different morphologies of cell death were described. Much of the 
work in the 19th century relied on the histological characterization of dying cells with 
limited recognition of its importance and regulation (1). 
In 1965, Lockshin and Williams used for the first time the concept of programmed cell 
death (PCD) to define the loss of cells observed in insect metamorphosis following a 
sequence of controlled steps towards their own destruction (2). 
Apoptosis was first decribed by Kerr and collaborators in 1972 (3), who established 
the morphological differences with necrotic cell death. Since 1970, several types of cell 
death have been characterized such as autophagy, necroptosis or pyroptosis, each one 
characterized by their own morphological and biochemical features (4).  The increasing 
number of cell death types has led to the creation of the Nomenclature Committee on cell 
death (NCCD) to normalize the classification of different cell death processes. The actual 
classification of cell death is not based on morphological features but on quantifiable 
biochemical parameters (5).  In the following sections the differential characteristics of 
the main cell death forms will be described. 
1.1.1 Apoptosis. 
Once the apoptotic process was characterized by Kerr et al. in 1972, research focused to 
determine the proteins involved in this process. However, our understanding of 
mechanisms involved in apoptosis of mammalian cells experienced the biggest progress 
in the 1990s when the genome of the nematode Caenorhabditis elegans (C. elegans) was 
sequenced. On one hand, some results demonstrated that a fixed number of cells were 
committed to die during development, and that this process was both, positively and 
negatively, regulated by specific genes (6). On the other hand, the discovery of the 
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linkage between the Bcl-2 gene (B-cell lymphoma 2) and some leukemia processes 
demonstrated that Bcl-2 protein was able to produce tumoral processes by suppressing 
cell death instead of promoting cell proliferation as usually happens with traditional 
oncogenes. The studies on C. elegans programmed cell death led to the identification of 
most of the intracellular proteins that mediate and regulate apoptosis (7). Subsequent 
studies demonstrated that related proteins operate in similar ways in many other 
metazoans, including humans (8). 
A large set of proteins and cellular components are used as biochemical markers of 
apoptosis.  There is a family of cysteine proteases (named caspases) that execute cell 
death by the cleavage of several intracellular substrates. Apoptosis is also regulated by a 
group of proteins known as BCL-2 family proteins, which activate or inhibit the cell death 
program. There are other relevant partners in the mammalian apoptotic process such as 
IAPs (Inhibitors of Apoptosis Proteins), APAF-1 (Apoptosis Protease Activating Factor-
1), mitochondrial apoptogenic factors such as cytochrome-c (Cyt-c), members of the TNF 
(Tumor Necrosis Factor) family and TNF receptors. 
The apoptotic program shows a well-characterized serie of morphological changes in 
cells that are committed to die.  In the early state of apoptosis cells round-up and undergo 
shrinkage and pyknosis, reducing their size (3). Pyknosis, the most characteristic feature 
of apoptosis, is generated by chromatin condensation. The process continues with the 
plasma membrane blebbing followed by nuclear fragmentation (karyorrhexis) and 
separation of cell fragments into apoptotic bodies. The organelle integrity is still 
maintained and plasma membrane remains intact. These bodies are phagocytosed by 
macrophages and finally removed within phagolysosomes. There is essentially no 
inflammatory reaction associated neither with apoptosis nor with the elimination of 
apoptotic cells due to these cells do not release their cellular content into the surrounding 
tissue; they are quickly phagocytosed by surrounding cells, avoiding secondary necrosis; 
and the inflammatory response of engulfing cells is not activated. Hence, the term 
apoptosis should be used exclusively in those cases of cell death wherein many of the 
above described biochemical and morphological features are observed!(9, 10). 
Importantly, apoptosis is a homeostatic mechanism to maintain cell populations in 
tissues and normally associated to development, aging (11) and defense mechanisms in 
immune reactions or following cell damaged by disease or toxic agents (12). Although 
there is a wide variety of stimuli and conditions, both physiological and pathological, that 
can trigger apoptosis, not all cells will necessarily die in response to the same stimulus.  
Alterations in the regulation mechanisms of cell death can generate a large variety of 
diseases such as cancer! (13), ischemia, neurodegenerative diseases (for example, 
Parkinson, Alzheimer, and Huntington’s disease), Amyotrophic Lateral Sclerosis, 
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autoimmune lymphoproliferative syndrome, and AIDS (14, 15). Some of them correlate 
with insufficient apoptosis whereas others are due to excessive apoptosis. For example, 
insufficient apoptosis correlates with the development of cancer and autoimmunity, while 
excessive apoptosis is linked to neurological diseases, heart failure and stroke (16, 17). 
For that reason, the study of the apoptotic mechanisms and the control of this cell death 
program has been intensively studied in the last decades with therapeutic purposes. 
1.1.2. Necrosis and necroptosis. 
Morphologically necrosis refers to a gain in cell volume (oncosis), swelling of organelles 
and plasma membrane permeabilization that produces cell rupture and subsequent loss of 
intracellular content. Unlike apoptotic cells, the nuclei of necrotic cells remain largely 
intact. Different organelles and cellular processes take part in necrotic cell death but the 
relationships among them are still unclear. The cellular changes include mitochondrial 
alterations (e.g., production of reactive oxygen species (ROS), and mitochondrial outer 
membrane permeabilization (MOMP)), lysosomal (lysosomal membrane 
permeabilization) and nuclear (hyperactivation of poly (ADP-ribose) polymerase-1) 
changes, lipid degradation in plasma membrane and an increase of cytosolic calcium 
(Ca2+) concentration that produce activation of non- caspase proteases like calpains and 
cathepsins (18, 19). The necrotic pathways can activate inflammatory response by the 
release of cytosolic molecules to the intercellular space through the damaged plasma 
membrane; in apoptosis these products are isolated inside macrophages. Alterations of the 
fine equilibrium between necrosis and apoptosis may be a key element in development of 
some diseases (20). 
Historically, necrosis has been considered an accidental or uncontrolled form of cell 
death, but recent studies have postulated that necrotic cell death is a regulated process, 
introducing terms ‘‘programmed necrosis’’ or ‘‘necroptosis’’ (18). Necroptosis is defined 
as a type of cell death that can be avoided by inhibiting RIP1 kinase. Several components 
have been implicated in necroptotic cell death, including death domain receptors (e.g., 
TNFR1, Fas/CD95 and TRAIL-R) and Toll-like receptors (e.g., TLR3 and TLR4). 
Interestingly, certain BCL-2 family members have been recently implicated in necroptosis 
regulation (21). 
1.1.3. Autophagic cell death. 
Autophagy is morphologically defined as a type of cell death that occurs in the absence of 
chromatin condensation but accompanied by massive autophagic vacuolization of the 
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cytoplasm. It is considered a highly conserved degradation pathway for bulk cellular 
components and is also generally agreed that autophagy is an important housekeeping 
process for degrading and recycling damaged organelles, long-lived proteins and cellular 
aggregates.. 
There are three different autophagy subclasses: macroautophagy, microautophagy and 
chaperone-mediated autophagy. The most studied is macroautophagy, morphologically 
known as the formation of double membrane autophagosomes, which take control of 
damaged organelles or unwanted cellular components and deliver them to lysosomes for 
degradation and recycling (22). The main difference with apoptotic cells is the absence of 
phagocytosis. 
Autophagy predominantly serves as a cell survival mechanism, via its suppressive role 
in necrotic cell death, such as necroptosis and poly ADP-ribose polymerase-1 (PARP-1)-
mediated cell death. More importantly, the anti-necrosis function of autophagy has 
relevant biological functions in various pathological processes and diseases, including 
cancer and neurodegenerative diseases and metabolic disorders (23). Nonetheless, there is 
a intense discussion around the dual role of autophagy in cell death and cell survival (24). 
When analyzing relationships between autophagy and cancer, a common challenge is to 
determine whether autophagy protects cell survival or contributes to cell death. 
Autophagy is well known to be crucial for cell survival under extreme conditions, and 
degradation of intracellular macromolecules provides energy required for minimal cell 
functioning when nutrients are scarce (25). Consequently, autophagic activation can play 
a protective role in early stages of cancer progression (26). On the other hand, autophagy 
behaves as a tumour suppressor by activating pro-autophagic genes and blocking anti-
autophagic genes in oncogenesis. However, autophagy can also play the reverse part (a 
pro-tumour role in carcinogenesis, named ‘Janus-faced’ effect) by regulating a number of 
pathways involving Beclin-1, Class III and I PI3K, mTORC1/C2 and p53 (26). 
Recent studies have also related some BCL-2 proteins with autophagic cell death 
regulation (27). The most studied example is the autophagy-related Beclin-1 protein, 
which contains a BH3-like region and has been found to interact with the anti-apoptotic 
Bcl-2, Bcl-xL and Mcl-1 proteins. Several BH3-only proteins or BH3 mimetics can elicit 
autophagy by displacing Beclin-1 from Bcl-2/Bcl-xL/Mcl-1 proteins at the level of the 
endoplasmic reticulum (ER) (28). 
1.1.4. Other types of programmed cell death. 
In addition to the pathways previously described, other programmed cell death 
mechanisms have been uncovered (Table 1.I), including cornification (produced by the 
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death and transformation of keratinocytes into corneocytes, providing structural stability, 
mechanic resistance, elasticity to the skin); anoikis (caused by cellular detachment of cells 
from the extracellular matrix or from other cells of surrounding tissue); pyroptosis (that 
generates caspase-1 activation when macrophages are infected by specific pathogens ); 
paraptosis (characterized by increased mitochondrial size and the presence of vacuoles in 
cytoplasm. This pathway is triggered by expression of the insulin-like growth factor 
receptor 1); and mitotic catastrophe (characterized by micronucleation and 
multinucleation and consequence of unproductive mitosis). The majority of these novel 
cell death pathways are cell-type specific and still remain poorly characterized (4) (Table 
1.I). 
1.1.5. Interrelationships between different Programmed cell death pathways. 
Apoptosis, autophagy and necrosis are different physiological processes with distinct 
morphological characteristics. However, there still exist intricate interrelationships 
between them. Under some circumstances, apoptosis and autophagy can exert synergistic 
effects, whereas in other situations autophagy can be triggered only when apoptosis is 
suppressed (29). Programmed necrosis is always triggered as a backup mechanism for 
apoptosis when caspases are inactivated (for example, by a pharmacological treatment 
with (zVAD-fmk) (30). However, shikonin-induced necroptosis can revert to apoptosis in 
the presence of necrostatin-1 (Nec-1), a specific necroptosis inhibitor. This death mode 
switch is partially due to conversion from mitochondrial inner membrane permeability to 
mitochondrial outer membrane permeability (MOMP) (31). Under certain conditions, 
apoptosis and programmed necrosis are induced simultaneously and deficiency of both 
apoptosis and necrosis can be found in some cancer cells (32). Moreover, programmed 
necrosis is accompanied by autophagy, but the specific relationship between them 
remains an enigma (19).  
The mode of cell death is influenced by many factors. One of them is the intensity of 
death stimulus. For example, low doses of cisplatin (CDDP) induce apoptosis, but higher 
doses trigger necrosis in mouse renal epithelial cells (33). In a similar way, a continued 
and weak signal of p53 usually promotes senescence; however, an intense p53 activation 
promotes apoptosis (34). Another factor is the energy requirement of the cell. When a cell 
is dying, bioenergetics consumption promotes necroptosis, since the apoptotic pathway 
requires a high energy consume (ATP) for the apoptosome formation  and caspase 
cascade activation (35). 
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Table 1.I. Functional classification of regulated cell death modes.!Adapted from!(4). 
 
Abbreviations; BCN1, beclin 1; Dcm, mitochondrial transmembrane potential; CrmA, cytokine response 
modifier A; DAPK1, death-associated protein kinase 1; EGFR, epidermal growth factor receptor; ERK1, 
extracellular-regulated kinase 1; IL, interleukin; MAP1LC3, microtubule-associated protein 1 light chain 3; 
MOMP, mitochondrial outer membrane permeabilization; NET, neutrophil extracellular trap; PAD4, 
peptidylarginine deiminase 4; PAR, poly(ADP-ribose); PARP1, poly(ADP-ribose) polymerase 1; PP2A, protein 
phosphatase 2A; ROCK1, RHO-associated, coiled-coil containing protein kinase 1; SQSTM1, sequestosome 1; 
TG, transglutaminase; Z-VAD-fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone; Z-YVAD-fmk, N-
benzyloxycarbonyl-Tyr-Val-Ala-DL- Asp-fluoromethylketone. A.  
 
!
Type of cell death Biochemical features Caspase 
dependence 
Inhibitory Mechanism 
Anoikis Downregulation of EGFR 
Inhibition of ERK1 signaling  
Lack of b1-integrin engagement  
Overexpression of Bim  
Caspase-3 (-6,-7) activation 
YES Bcl-2 overexpression 
Z-VAD-fmk administration 
Autophagic cell death MAP1LC3 lipidation 
SQSTM1 degradation 
NO VPS34 inhibitors 
AMBRA1, ATG5, ATG7, ATG12 
or BCN1 genetic inhibition 
 
Caspase-dependent intrinsic 
apoptosis 
MOMP 
Irreversible Dcm dissipation 
YES Bcl-2 overexpression  
Z-VAD-fmk administration 
Caspase-independent 
intrinsic apoptosis 
Release of IMS proteins 
Respiratory chain inhibition 
NO Bcl-2 overexpression 
Cornification Entosis Activation of transglutaminases 
Caspase-14 activation 
YES Genetic inhibition of TG1, TG3 or 
TG5  
Genetic inhibition of caspase-14 
Entosis RHO activation 
ROCK1 activation 
NO Genetic inhibition of 
metallothionein 2A 
Lysosomal inhibitors 
Extrinsic apoptosis by death 
receptors 
Death receptor signaling 
Caspase-8 (-10) activation  
BID cleavage and MOMP (in type II 
cells) 
Caspase-3 (-6,-7) activation 
YES CrmA expression 
Genetic inhibition of caspases (8 
and 3) 
Z-VAD-fmk administration 
 
Extrinsic apoptosis by 
dependence receptors 
Dependence receptor signaling 
PP2A activation 
DAPK1 activation 
Caspase-9 activation 
Caspase-3 (-6,-7) activation 
YES Genetic inhibition of caspases (9 
and 3) 
Genetic inhibition of PP2A 
Z-VAD-fmk administration 
 
Mitotic catastrophe Caspase-2 activation (in some instances) 
TP53 or TP73 activation (in some 
instances) 
Mitotic arrest 
NO Genetic inhibition of TP53 (in some 
instances) Pharmacological or 
genetic inhibition of caspase-2 (in 
some instances) 
Necroptosis Death receptor signaling 
Caspase inhibition  
RIP1 and/or RIP3 activation 
NO Administration of necrostatin(s)  
Genetic inhibition of RIP1/RIP3 
Netosis Caspase inhibition 
NADPH oxidase activation  
NET release (in some instances) 
NO Autophagy inhibition NADPH 
oxidase inhibition 
Genetic inhibition of PAD4 
Parthanatos PARP1-mediated PAR accumulation 
Irreversible Δψm dissipation  
ATP and NADH depletion  
PAR binding to AIF and AIF nuclear 
translocation 
NO Genetic inhibition of AIF 
Pharmacological or genetic 
inhibition of PARP1 
Pyroptosis Caspase-1 activation 
Caspase-7 activation 
Secretion of IL-1b and IL-18 
YES Administration of Z-YVAD-fmk 
Genetic inhibition of caspase-1 
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1.2. MAIN APOPTOTIC PATHWAYS. 
The mechanisms of apoptosis are highly complex and sophisticated, involving an energy-
dependent cascade of molecular events (Figure 1.1). There are two main apoptotic 
pathways: the extrinsic or death receptor pathway and the intrinsic or mitochondrial 
pathway. However, although the initial death signals are heterogeneous there is now 
evidence that both pathways are linked and that molecules from one pathway can 
influence the other! (36). There is an additional pathway called perforin/granzyme that 
induces apoptosis via granzyme A or B and involves T-cell mediated cytotoxicity. All 
These pathways converge with the cleavage and activation of the executioner caspases-
3/7 that results in DNA fragmentation, degradation of cytoskeletal and nuclear proteins, 
formation of apoptotic bodies and finally elimination by phagocytic cells (14, 37). 
1.2.1. Extrinsic apoptotic pathway. 
This pathway is initiated by the interaction of specific ligands (FasL, TNF-α or 
TRAILR) to the cysteine-rich extracellular domains of specific death receptors (FasR, 
TNFR1 or TRAIL). Following this binding, the cytoplasmic domain of death receptors 
(called the “death domain”) (38, 39) transmit the death signal from the surface to the inner 
of the cell  and then the cytoplasmic adapter proteins are recruited. FasL/FasR interaction 
recruits the adapter protein FADD and TNF-/TNFR1 recruits TRADD, FADD and RIP 
(40). Finally, “death-inducing signaling complex” (DISC) is formed by the interaction 
between FADD and procaspase-8 when death effector domains dimerize. Caspase-8 
and/or -10 are then activated generating the activation of executioner caspases-3/7 (41, 
42). 
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Figure 1.1. Extrinsic and intrinsic apoptotic pathways. In the extrinsic pathway, binding of the ligands to the 
corresponding death receptor triggers the recruitment of death domain (DD)-containing adaptor proteins (repr-
esented by FADD), procaspase-8 and -10 forming the supracomplex named DISC. Then caspase-8 (or-10) 
activates and promotes subsequent activation of executioner caspases-3 and -7, inducing apoptosis. The cleavage 
of the BH3-only protein Bid to generate tBid can also activate caspase-8, which is related to the intrinsic 
signaling pathway. In the mitochondrial pathway, mitochondrial outer membrane permeabilization (MOMP) 
produces the release of cytochrome c and other apoptogenic factors from mitochondria. In the cytosol the 
apoptosome is formed, triggering a caspase cascade by caspase-9 activation. The balance between anti-apoptotic 
BCL-2 proteins (represented by Bcl-2 and Bcl-xL) and pro-apoptotic BH3-only proteins (represented by tBid, 
Noxa, Puma, Bim and Bad) regulate the Bax/Bak activation and then the MOMP process. Inspired by (43)  
1.2.2. Intrinsic apoptotic pathway. 
The large variety of stimuli that initiate the signaling pathways of intrinsic apoptosis can 
behave in either a positive or negative manner. Negative signals correlate with the 
absence of hormones, cytokines and some growth factors that produce a failure of death 
programs suppression, thereby triggering apoptosis. Other stimuli generate apoptotic 
activation such as radiation (UV and gamma), DNA-damage, toxins, hypoxia, 
hyperthermia, viral infections, and free radicals (oxidative stress) (44). 
All of these stimuli act directly on targets within the cell that promote changes in the 
inner mitochondrial membrane, the loss of the mitochondrial transmembrane potential 
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(∆ψm) (45), alterations in mitochondrial structure and function (46) and the opening of 
the mitochondrial permeability transition (MPT) pore, finally triggering mitochondrial 
outer membrane (MOM) permeabilization (MOMP). In vertebrates, this is usually 
considered “the point of no return” of the apoptotic cascade (44). MOMP produces the 
release of two pro-apoptotic groups of proteins (normally located in the intermembrane 
space (IMS)) to the cytosol (47). The first group consists of cytochrome-c (Cyt-c, 12 kDa), 
Smac/DIABLO (25kDa), and the serine protease HtrA2/Omi (37kDa) (48). These 
proteins activate the caspase-dependent mitochondrial pathway. Cyt-c is loosely 
associated to the mitochondrial lipid cardiolipin (CL) in the mitochondrial inner 
membrane (MIM). When CL is oxidated upon MOMP, Cyt-c can diffuse to the cytosol, 
wherein it promotes the assembly of the apoptosome platform that includes Cyt-c, 
apoptosis protease activating factor (APAF-1), pro-caspase- 9 and ATP/dATP. This 
multiprotein complex activates caspase-9 producing caspase cascade activation (48-50). 
Smac/DIABLO and HtrA2/Omi are reported to promote apoptosis by inhibiting IAP 
(inhibitors of apoptosis proteins) activity (51, 52), thus favoring caspase activation.  
The second group of pro-apoptotic proteins, AIF (62 kDa) and endonuclease G (23 
kDa) are released from the mitochondria during apoptosis, but this is a late event that 
occurs after the cell has committed to die. Once released to the cytosol, both proteins 
translocate to the nucleus and mediate chromatin condensation and DNA fragmentation 
(53, 54). AIF and endonuclease G both function in a caspase-independent manner. 
The control and regulation of the apoptotic mitochondrial events, especially MOMP, 
is accomplished by the members of the Bcl-2 family of proteins (55). They govern 
mitochondrial membrane permeability and can be either pro-apoptotic or anti-apoptotic, 
establishing a complex interaction network within themselves and with other cellular 
factors to determinate whether cells dye by apoptosis or abort the process (56, 57). The 
main mechanism of action of the Bcl-2 family of proteins is regulation of Cyt-c release 
from the mitochondria via alteration of mitochondrial membrane permeability. 
1.3. THE BCL-2 PROTEIN FAMILY. 
 1.3.1. General classification. 
There are approximately 20 proteins in the BCL-2 family, defined by their α-helical 
composition of up to 4 BCL-2 homology domains (BH). Based on the cellular function 
this protein family is divided into 3 different groups: the anti-apoptotic BCL-2 proteins 
Bcl-2, Bcl-xL, Bcl-w, Mcl-1 A1 and Bcl-b (Diva), the pro-apoptotic BCL-2 effectors Bax, 
Bak and Bok and the pro-apoptotic BH3-only proteins Bid, Bik, Bim, Bmf, Noxa, Puma, 
1                                                                              INTRODUCTION 
    12 
Rambo, Bad and Hrk (56, 57)(Figure 1.2A). The presence of a BH3 motif defines all Bcl-
2 proteins (58). The BH3 domain is defined as a sequence that could form a four-turn 
amphipathic alpha helix containing the sequence motif A-X-X-X-A-X-X-A-B-C-X-A, 
wherein A represents a hydrophobic residue (one of these residues is an almost invariant 
leucine), B represents a small residual, typically glycine, and C is Asp or Glu (59). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
of BCL-2 domain’’ peptide) was used, in which the BH3 a helix is
fixed by a chemical staple. The BAX$BIM SAHB complex was
nevertheless unstable, precluding structural determination by
conventional NMR. Instead, paramagnetic relaxation enhance-
ment NMR oriented the BIM SAHB on the back face opposite
the BC groove of BAX. A shallow hydrophobic groove in BAX
devoid of pronounced ridges was defined by a1 and a6. This
occurred by displacing the a1-a2 loop and rearranging the
peripheral side chains (e.g., BAX Lys21 next to BIM Glu158) to
accommodate the BIM SAHB; the newly identified groove
appears similar to antiapoptotic BC grooves. Binding of the
BIM SAHB also induced subtle conformational changes to the
BAX BC groove, where a9 became loosely attached compared
to the free BAX structure. In addition, the BID and PUMA BH3
can promote remodeling of the BAX structure (Kim et al., 2009).
Whether a similar direct activator-binding strategy mediates
BAK activation is unknown. Modeling of the BIM SAHB on the
back face identified fewer clashes in BAK compared to BAX
(Figure 4I). However, NMR revealed a low-affinity complex
between the BID BH3 peptide and BAK-DTM (which mimics
the globular domain of membrane-targeted BAK) (Figure 4G).
The BID BH3 binding site overlapped with the partially occluded
Figure 4. Structural Highlights for theBCL-2
Family
(A) The ‘‘front’’ view of BCL-xL identifies the BCL-2
core and the respective locations of the four BH
regions. The PDB identifier is in parentheses.
(B) Surface representation of free BCL-xL, empha-
sizing amino acids participating in BH3 peptide
binding at the ‘‘front’’ face, identifies the BC
groove. Representations are partially transparent,
permitting identification, beneath the surface, of
contact side chains positioned 4 A˚ from a peptide.
With the exception of free BCL-xL and MCL-1 (C),
both having surface coloring based on all atoms of
peptide amino acids, surface coloring highlights
strictly the atoms within 4 A˚ from a peptide. PDB
residue numbering has been maintained. Labels
of acidic and basic amino acids are colored red
and blue, respectively.
(C) Free MCL-1.
(D) A1 bound to BIM BH3. The four conserved
hydrophobic residues/sites and the conserved
charged interactions are marked. Peptide amino
acid labels are bold.
(E) BCL-xL bound to BIM BH3.
(F) MCL-1 bound to BIM BH3.
(G) A model between BID BH3 (from the A1$BID
BH3 complex) and BAK-DTM, overlapping sites
of interaction (colored) identified by NMR spec-
troscopy.
(H) BIM SAHB modeling to the ‘‘back’’ face of free
BAX.
(I) BIM SAHB binding site on BAX.
BC groove of BAK, and major conforma-
tional changes were not detected. The
BAK BC groove is also implicated in ho-
modimerization, as illustrated by cross-
linking studies at cysteine residues engi-
neered within the BH3 and the BC
groove (Dewson et al., 2008). These
studies indicated that the formation of
BAK dimers involves reciprocal BH3$BC groove interactions;
and most recent studies revealed that high-order BAK oligomer
formation requires a6$a6 interactions to promote MOMP (Dew-
son et al., 2009).
Structures of Antiapoptotic and BH3-Only Protein
Complexes
The antiapoptotic BCL-2 family members have been extensively
studied at the molecular level by both NMR spectroscopy and
X-ray crystallography. A comprehensive review of antiapoptotic
BCL-2 family structures described free BCL-2, BCL-xL, BCL-w,
and the complexes between BCL-xL and the BAK and BAD BH3
peptides (Petros et al., 2004). The current portrait of antiapop-
totic proteins now includes A1 and MCL-1 structures in complex
with an extensive panel of BH3 peptides (Figures 4C–4F and 5A).
These recent structural insights are significant to cancer drug
discovery because MCL-1 and A1 are not targeted by the most
promising BH3 mimetics (e.g., ABT-737 and its analogs), which
only inhibit BCL-2, BCL-w, and BCL-xL (Oltersdorf et al., 2005).
There are structural similarities and differences between the
BCL-2 cores of A1, BCL-xL, and MCL-1 in the free and BH3
peptide-bound states (Figures 4B–4F). Analyses of their BC
grooves revealed a deep hydrophobic groove of variable width,
Molecular Cell 37, February 12, 2010 ª2010 Elsevier Inc. 303
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Figure 1.2. BCL-2 structural and functional organization. (A) Three subfamilies of BCL-2 proteins. BCL-2 
homology domains 1 to 3 constitute the BCL-2 structural core that forms the BCL-2 hydrophobic groove (the 
binding site of the BH3 domains of BCL-2 pro-apoptotic proteins). The family is divided into anti- and pro-
apoptotic members. The anti-apoptotic members share homology in all 4 BCL-2 homology (BH) domains (BH1-
4) and include A1, Bcl- 2, Bcl-xL, Bcl-w, Mcl-1 and Diva. The pro-apoptotic members are subdivided into 
“multidomain” proteins and “BH3-only” proteins. The multidomain proteins share homology domains 1 to 4, 
whereas the BH3-only proteins contain only one BH domain, the BH3, which binds the anti-apoptotic proteins. 
Many BCL-2 proteins also contain a hydrophobic transmembrane domain (TMD). In the BH3-only group, the 
TMD is confirmed for Bid, Bik, Rambo and Hrk (marked as red). (B) The Bcl-2 core of Bcl-xL (PDB:1MAZ)  
and the respective locations of the four BH regions. 
1.3.2. Structure of BCL-2 proteins. 
The X-ray and NMR structures of BCL-2 members revealed that the multidomain anti-
apoptotic and effector BCL-2 proteins are globular proteins that share a conserved ‘‘BCL-
2 core’’ (Figure 1.2B). This core is also preserved in BH3-only proteins Bid and Bik, 
even though they have the least structural homology to the folded members (60). The 
BCL-2 core is structured by eight amphipathic alpha (α) helices that hide and bury a 
central hydrophobic helix α5 (Figure 1.2B). In this structure, the hydrophobic groove (BC 
groove) is the result of BH1 (α4– α5), BH2 (α7– α8), BH3 (α2) and α3 coalescence, 
showing BC groove at the ‘‘front’’ of the BCL-2 core.  
Most of the structural studies used truncated forms that do not include the C-terminal 
hydrophobic domain of the Bcl-2 proteins (61, 62). The elimination of the hydrophobic C-
terminal domain improves the solubility of these proteins, so they can be easily produced 
in the high quantities required for structural studies, whereas full-length proteins are 
difficult to produce. Only in the case of Bax and Bcl-w the structure of the full-lengh 
protein has been determined by NMR (63, 64). In both cases the C-terminal domain 
occupies the hydrophobic pocket responsible of the interactions with other BCL-2 
proteins. 
The three dimensional structure of Bcl-xL lacking the C-terminal segment (∆C) (65), 
showed that BH domains 1 to 3 are close in order to form the hydrophobic groove 
wherein the BH3 domains of pro-apoptotic effectors (Bax, Bak and Bok) and BH3-only 
family members are able to bind  (65). Unusual features of Bcl-xL are the splicing forms 
Bcl-xS and Bcl-xAK (66, 67) with pro-apoptotic functions when the BH3 domain is 
absent. Moreover, the unstructured loop between 1 and 2 helices of Bcl-xL can be 
cleaved by caspases triggering its conversion again into a Bax-like pro-apoptotic protein 
(68). Bcl-2, Bcl-xL, A1, and Mcl-1 show structural differences and similarities in the 
BCL-2 cores structures, depending on the free and BH3 peptide-bound states. The BH3-
binding groove of Mcl-1 is flanked by regions of high positive electrostatic potential and 
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helix 3 and 4 are not as closely packed as seen in Bcl-xL (69). Moreover, the N-terminal 
PEST region of Mcl-1 negatively modulates BH3 peptide access to the groove (70). In the 
case of A1, the BH3 domain-binding groove has an acidic patch (71). For Bcl-2, the 
exposed BH3-binding groove presents topological and electrostatic potential differences 
respect to Bcl-xL hydrophobic groove (72).  
All together, the BC groove and α1/α6 structural components compose the BCL-2 
core and, in Bcl-w, Bcl-xL and Bax, the C-terminal helix binds and block this BC groove. 
Such an arrangement of alpha helices is similar to that of the membrane translocation 
domain of bacterial toxins, in particular diphtheria toxin and the colicins, and suggests 
that the Bcl-2 family proteins may be capable of forming pores. Indeed, Bcl-xL, Bcl-2, 
Bax, and Bid have been shown to possess ion channel activities in vitro in lipid bilayers or 
liposomes. This activity should be related with the mitochondrial permeability regulating 
function of these molecules (65) (73). The major differences between anti-apoptotic and 
effector proteins are structural features of the individual BCL-2 cores, wherein the C-
terminal TM tail modulate interactions with the BH3-only proteins. In addition, many 
BCL-2 family members use the C-terminal hydrophobic regions to target and/or anchor 
them to intracellular membranes. 
From an evolutionary point of view, differences in the structure as well as sequence of 
the various BH3-only proteins suggest a diverse origin and evolution of these molecules. 
This indicates that the BCL-2 family may be further divided into the core group  (Bcl-2, 
Bcl-xL, Bcl-w, Mcl-1, A1, Bax, Bak, Bok, Bik and Bid) that shares both the sequence and 
structure homology (common and ancient origin) and the group that differs in structure 
and sequence, including Bim, Puma, Rambo, Diva, Bad, Bmf Hrk and Noxa. This may 
further imply that non-conserved functions may be expected among these molecules (56, 
74). 
1.3.3. Anti-apoptotic BCL-2 proteins.  
The main function of anti-apoptotic BCL-2 proteins is the blockade of pro-apoptotic 
BCL-2 effectors (Bax and Bak) and BH3-only proteins to ensure MOM integrity. For that 
reason, they are mainly located in MOM, but can also be found in endoplasmic reticulum 
(ER) membrane and cytosol (75). All the members of this subfamily share the BH 
domains 1 to 4 and the  “BCL-2 core”. This subfamily include A1 (Bcl-2-related gene 
A1), Bcl-2, Bcl-xL (Bcl-2-related gene, long isoform), Bcl-w, and Mcl-1 (myeloid cell 
leukemia 1). 
Although these proteins are classified into one category the differences observed in the 
solution structures of the anti-apoptotic proteins generate differences in the patterns of 
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binding to BH3-only or BAX-like proteins in solution. For that reason, it is possible to 
separate the anti-apoptotic members in two subgroups: one includes Bcl-xL, Bcl-2 and 
Bcl-w and the other is formed by Mcl-1 and A1 (59, 69).  
Several studies, based on the genetic knockouts have revealed specific physiologic 
roles for the different anti-apoptotic proteins. The Bcl-2 KO mouse shows a normal 
development, but the adult mouse displays several dysfunctions in thymus, spleen and 
kidney due to increased apoptosis! (76). Bcl-xL KO mouse dies during embryonic 
development due to massive apoptosis of hematopoietic and neuronal cells (77), while the 
Bcl-w KO mouse has demonstrated its relevance in spermatogenesis!(78). Loss of Mcl-1 
blocked embryo implantation and is lethal in early embryonic stages!(79). Moreover, Mcl-
1 deletion in the adult mouse revealed the requirement of this protein for hematopoietic 
stem cell survival (80).  
1.3.4. Pro-apoptotic BCL-2 effectors. 
The pro-apoptotic BCL-2 effector subfamily includes: BCL2-related ovarian killer (Bok, 
Matador) BCL-2 antagonist killer 1 (Bak) and BCL-2-associated X protein (Bax). They 
are the responsible to permeabilize the MOM following apoptotic stimuli, therefore are 
found in MOM, although Bax is also located in cytosol in absence of apoptotic signalling 
(in normal healthy cells) and Bok and a fraction of Bak can be found in ER (81). BCL-2 
effectors are composed by BH3 domains 1 to 3 (82) and contain “BCL-2 core” structure, 
sharing sequence, domain, and structural homology (64, 65, 83) with anti-apoptotic 
members. Bak (in MOM) and Bax (in cytosol) are monomeric in absence of apoptotic 
stimuli. During apoptosis, both proteins undergo conformational changes at the MOM to 
activate and promote homo- and hetero-oligomerizations between them to triger MOMP. 
This fact has been largely corroborated in several studies using Bax/Bak KO mice, 
wherein the experimental data showed the absence of MOMP upon apoptotic activation 
(84). The majority of Bak /Bax DKO mice are embryonic lethal and the few mice that 
survive to birth (<10%) display a variety of apoptosis-related phenotypes, including 
interdigital webbing, splenomegaly, and lymphadenopathy. However, Bak KO and Bax 
KO mice display less aggressive phenotypes compared to the combined DKO mice. While 
the Bak KO (85) mice do not present any homeostatic or developmental defects, the Bax 
KO (86) mice show reproductive abnormalities and T and B cell hyperplasia. 
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1.3.5. Pro-apoptotic BH3-only proteins. 
The BH3-only proteins promote MOMP (triggered by appropriate stimuli) when they bind 
to and sequester anti-apoptotic BCL-2 family members, avoiding their association with 
the multi-domain effectors (Bax and Bak) or when they bind directly to these apoptotic 
effectors, activating them. They include Bid (BH3 interacting domain death agonist, Bim 
(BCL-2-interacting mediator of cell death), Puma (p53 up-regulated modulator of 
apoptosis), Bad (BCL-2 antagonist of cell death), Bik (BCL-2-interacting killer), Bmf 
(BCL.2-modifying factor), PMAIP1 (Phorbol-12-myristate-13-acetate-induced protein) 
commonly known as Noxa, Hrk (Activator of apoptosis harakiri), Rambo (BCL2-like 13) 
and Diva (Bcl-b, BCL2-like 10). All members of this this subclass share the BH3 domain. 
BH3-only proteins have been mainly classified as intrinsically unstructured proteins 
due to their structures have been solved (e.g. Bim, Bmf, Puma and Bad) without their C-
terminal regions, and only after interation to multidomain BCL-2 member, BH3-only 
proteins acquire a structured conformation. This correlates with the fact that synthetic 
peptides representing BH3 domains of almost all BH3-only proteins have been 
crystallized bound to anti-apoptotic members (60, 87). However, Bid protein is a globular 
protein that contains the BCL-2 core structural motif with one central hydrophobic helix 
(6) surrounded by the remaining seven amphiphathic helices (88).  Bid also contains a 
consensus sequence for caspase-8 cleavage localized between helices 2 and 3 that 
results crucial for Bid localization and interaction with Bax/Bak to promote MOMP (89). 
The different BH3-only KO mice showed tissue- and/or stimulus-specific effects in 
development and tissue homeostasis. Bid KO mice are developmentally normal and only 
show resistance to induced liver injury (90). Bim KO mice have lymphoid and myeloid 
cell hyperplasia (91). Hrk KO mice have defects in nerve growth factor withdrawal, 
generating apoptosis in sensory neurons (92). However, Puma KO mice display a broader 
role in ER stress, ischemia/reperfusion, bacterial/viral/ fungal infections, MOMP and 
apoptosis (93), showing resistance against several stimuli like irradiation, cytokine 
withdrawal and glucocorticoids.  
Bad KO generates diffuse lymphomas in large B cell (94). The lymphocytes of Bmf 
KO animals are resistent to apoptosis induced by glucocorticoids or histone deacetylase 
inhibitors (95). Bik KO does not show any significant effect and only in combination with 
Bim KO generate male infertility (96). Noxa KO shows mild resistance to etoposide in 
MEFs and thymocytes (97). All these studies highlight the existence of different models 
regarding the regulatory function of the BH3-only proteins.  
BH3-only proteins can interact to anti-apoptotic proteins to block their pro-survival 
function and/or can bind and activate Bax/Bak effectors directly. For that reason they are 
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divided in two groups: sensitizers/de-repressors and direct activators. Direct activators  
includes Bid, Bim, and Puma which are responsible (by direct interaction) for promoting 
the active form of Bax and Bak by conformational changes to induce MOMP (98, 99). 
This group of BH3-only proteins can also bind and inhibit the anti-apoptotic proteins. 
Furthermore, triple-knockout mice for Bid, Bim, and Puma (100) showed a similar 
phenotype compared to Bax/Bak KO mice, indicating their crucial role in BCL-2 effectors 
activity and MOMP. Of note, the role of Puma as activator is controversial (100), and 
Bid/Bim double-knockout generates a minor apoptotic phenotype,. 
The sensitizers/de-repressors subclass of BH3-only proteins is composed by Bad, Bmf, 
Hrk, and Noxa and their functions are associated to the blockade of anti-apoptotic BCL-2 
members (by binding hydrophobic groove of these) to induce MOMP (101-105). 
However, the precise mechanism(s) of interaction between BH3-only proteins and the 
anti-apoptotic BCL-2 network to promote Bax/Bak activation and MOMP remains to be 
elucidated.  
Finally, some BH3-only proteins such as Bik, Rambo or Diva have different behavior 
in comparison to the rest of the proteins present in this subgroup. Bik shares the BH3 
domain and the C-terminal domain with other BCL-2 family proteins. It is predominantly 
localized in the ER, interacts with Bcl-2, Bcl-xL, Bcl-w, A1 and Diva, and induces 
apoptosis through the mitochondrial pathway by selective activation of Bax, mobilizing 
calcium from the ER to the mitochondria and remodeling the mitochondrial cristae. Bik 
also induces non-apoptotic cell death in certain cell types by an unknown mechanism and 
appears to be a critical effector in apoptosis induced by toxins, cytokines and virus 
infection (106). Rambo shows high structural homology with the anti-apoptotic BCL-2 
members containing the four conserved BH motifs and a c-terminal membrane anchor 
region. Rambo does not interact with either anti-apoptotic (Bcl-2, Bcl-xL, Bcl-w, A1, 
Mcl-1) or pro-apoptotic (Bax, Bak, Bik, Bid, Bim, and Bad) members of the Bcl-2 family. 
In mammalian cells, Rambo is localized in mitochondria, and its over-expression induces 
apoptosis that is specifically blocked by the caspase inhibitors, IAPs. Surprisingly, the cell 
death activity promoted by Rambo is induced by its membrane-anchored C-terminal 
domain and not by the BCL-2 homology region (107). Diva/Bcl-B is considered an anti-
apoptotic member of the BCL-2 family and interacts with Bim and Bik BH3-only proteins, 
blocking apoptosis induced by Bax. However, Diva also acts as pro-apoptotic inducing 
apoptosis independently of the BH3 region through direct binding to APAF-1, thus 
preventing Bcl-xL from binding to the caspase-9 regulator APAF-1. For that reason, Diva 
apparently can both promote and inhibit apoptosis depending on the cellular context. In 
conclusion, the Figure 1.3 shows the interactions/relationships established between the 
different members of the BCL-2 family. In this highly orchestrated context, the relevance 
1                                                                              INTRODUCTION 
    18 
of the cytosolic domain in the interaction network has been extensively studied. However, 
the contribution of the TMD to this interaction network has been poorly investigated. 
 
 
Figure 1.3. Schematic representation of BCL-2 family interactions. Black and dark grey squares represent 
pro-apoptotic effectors and BH3-only proteins, respectively. Light grey squares represent the anti-apoptotic 
proteins. The arrows indicate an inducing effect, whilst the bars indicate an inhibitor/repressor effect.  
1.4. BCL-2 FAMILY: MODELS OF MECHANISM OF ACTION. 
All the models proposed for the apoptotic regulation of the BCL-2 family share some well 
established points such as: 
- BCL-2 anti-apoptotic proteins block the activation of the effectors Bax and Bak. 
- Bax and Bak are inactive in healthy cells, and their activation triggers MOMP 
and the release of the apoptogenic factors. 
- BH3-only proteins activate Bax and Bak and avoid the action of the anti-
apoptotic members.  
However, the mechanism of action for the different partners and the interaction 
network among them is still controversial. During the last decades, several studies have 
been developed to study the interaction networks between the different pro- and anti-
apoptotic members of the BCL-2 family, concluding that different models of MOMP 
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regulation mediated by the BCL-2 proteins are possible. The different models propose 
different binding partners and functions for both the BH3 and the anti-apoptotic family 
members. All these models accumulate positive evidence from a variety of assays to 
indicate that specific aspects of each model are correct, including co-immunoprecipitation 
assays in transfected cells, binding of peptides to truncated proteins in vitro, and gene 
knockout experiments in mice. In addition, the MOM itself also plays an important role in 
BCL-2 family member interactions and functions. Thus, four non-mutually exclusive 
models coexist to explain how interactions among the BCL-2 family proteins regulate 
MOMP and apoptosis (Figure 1.4). 
1.4.1. Initial models: rheostat, direct activation and de-repression.  
The first model of Bcl-2 regulation called “Rheostat” was hypothesized when Bax protein 
was discovered in 1993. This model is based on the ratio between anti-apoptotic members 
and pro-apoptotic proteins like Bcl-2 and Bax, respectively (105, 108). When an excess of 
Bax is generated compared to Bcl-2, apoptosis is triggered. Some years latter, when other 
BCL-2 proteins were identified, two classical models were elicited:  the “direct activation” 
and “de-repression” models. 
1.4.1.1. De-repression model. 
This model (also called indirect activation model) postulates that Bax and Bak are 
constitutively and structurally active in non-apoptotic conditions. Therefore, they need 
continuous binding to anti-apoptotic proteins to repress their activity. In this situation, the 
BH3-only proteins displace the anti-apoptotic proteins from Bax and Bak interaction to let 
MOMP (Figure 1.4). Specific combinations of different BH3-only proteins, activated by 
specific apoptotic signals, interact with different anti-apoptotic proteins and allow 
Bax/Bak activation by highly regulated mechanisms (59). For example, Bid, Bim and 
Puma show more pro-apoptotic effect than the rest of BH3 only proteins due to their 
direct interaction with the anti-apoptotic members; Furthermore, Noxa interacts with Mcl-
1 and A1 specifically while Bad only binds to Bcl-2, Bcl-xL, and Bcl-w (Figure 1.3). 
Only when Noxa and Bad are combinated cell death is induced (59). Of note, Bak is 
inhibited not only by Mcl-1 and Bcl-xL but also by VDAC2 (109, 110). 
However, the de-repression model does not explain that only a small fraction of 
Bax/Bak can be co-immunoprecipitated with anti-apoptotic proteins in vivo, in contrast to 
experimental data that suggest that all Bax/Bak needs to be neutralized for survival (111). 
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Figure 1.4. Models of apoptotic regulation by the BCL-2 family. (Upper panel) In the “Rheostat” model, the 
equilibrium between pro- and anti- apoptotic BCL-2 proteins is crucial to cell fate. De-repression (left) and 
Direct Activation models (right) highlight the role of BH3-only proteins and anti-apoptotic proteins. (Bottom 
panel) The Embedded Together model (right) and the Unified model (left) propose that BH3 proteins have to 
activate Bax/Bak and the inhibition of MOMP by the BCL-2 anti-apoptotic proteins is produced by their 
interaction with BH3 only proteins and/or Bax/Bak efectors.. The Embedded Together highlights the active role 
of MOM  in the interactions between BCL-2 family proteins. Adapted from (112). 
1.4.1.2. Direct activation model. 
The direct activation model postulates that Bax/Bak need to be activated to oligomerize 
and promote MOMP. In this scenario, BH3 proteins behave as: activators, such as Bim, 
Puma and tBid,  binding of Bax/Bak directly (113); or sensitizers (Bad,Noxa, Bmf, Hrk), 
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whose function is to block the anti-apoptotic proteins, releasing the BH3 activators from 
the anti-apoptotic proteins to Bax and Bak to generate MOMP (99, 113). In this context, 
several groups showed that tBID (BH3 activator) promotes MOMP by Bax/Bak activation 
(98, 114). 
The problem of this model is consequence of BCL-2 anti-apoptotic ability to bind and 
inhibit directly the activation of Bax/Bak (115). In addition, another problem is the 
difficulty to detect interactions between the BH3-only proteins and Bax/Bak. Moreover, 
de-repression model and the direct activation model postulate that all these interactions 
are unidirectional. The solution for these limitations was to propose a “hit-and-run” 
mechanism for Bax/Bak activation by BH3-only proteins based on transient interaction 
between BH3-only “ligands” and Bax/Bak “receptors” (99, 116).  
1.4.2. The embedded together model: role of membranes in apoptotic 
regulation. 
In the models previously described, the active role of membranes in the functions of Bcl-2 
family members is not considered. However, the BCL-2 proteins are mainly membrane-
inserted proteins via their C-terminal domain and the interactions between different Bcl-2 
members take place generally in the MOM. Moreover, these BCL-2 proteins generally 
have a different conformation when inserted in the mitochondrial membrane.  
The membrane-Embedded Model highlights the role of the MOM in the BCL-2 family 
protein interactions during apoptosis, mediating in these interactions rather than being 
only the place where this interaction network occurs. The model suggests that the 
association/insertion of BCL-2 proteins to the MOM promotes conformational changes in 
these molecules that affect their binding interactions (117, 118). For example, Bax 
undergoes conformation changes during activation when it translocates from a 
cytoplasmic location to a protein with helices 5, 6 and 9 integrated in the membrane. This 
conformational change is necessary to oligomerize with other Bax monomers to form a 
pore in the MOM, and this event only take place when Bax is inserted in MOM (119). 
Other example is Bid: Following caspase-8 cleavage, tBid targets MOM, undergoing 
conformational changes that allows tBid to activate Bax and the recruitment of 
cytoplasmic Bcl-xL (120). These tBid membrane interactions can be modulated by 
membrane lipid composition and, interestingly, the membrane interaction between tBid 
and Bax can promote redistribution of membrane lipids (121). 
This model exposes that the activation of Bax/Bak at the membrane is the rate-limiting 
step in MOMP. The BH3-only activators such as Bim, tBid and Puma can bind to MOM 
spontaneously where they recruit Bax (and some antiapototic members as Bcl-xL), 
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generating several conformational changes in Bax to induce oligomerization. Bak is 
constitutively located to the membrane, so this first step is not necessary. Anti-apoptotic 
proteins located in MOM bind to activator BH3 proteins (Bid, Puma and Bim)  inhibiting 
their pro-apoptotic function. However, in this context the activator proteins behave as 
sensitizers because they also inhibit anti-apoptotic proteins. For that reason, this kind of 
inhibition was called mutual sequestration (122).  
Based on the idea of the mutual sequestration, the difference between activator and 
inhibitor is more quantitative than qualitative and then the amount of anti-apoptotic and 
BH3-only proteins in MOM determinates these equilibria. 
Finally, this model introduces the concept of dominant negative of Bax/Bak that refers 
to the inhibition of Bax/Bak activation and oligomerization induced by the binding of 
BCL-2 antiapoptotic in the MOM context. 
1.4.3. Unified model. 
This model also takes into account the different modes of apoptotic inhibition and the role 
of mitochondrial dynamics in apoptosis regulation (123). In MODE 1 the anti-apoptotic 
proteins inhibit BH3-only activators (similar to mutual sequestration). MODE 2 
represents the inhibition of Bax/Bak by anti-apoptotic proteins (equivalent to dominant 
negative function of the anti-apoptotic proteins). Both mechanisms could inhibit MOMP, 
but binding to Bax/Bak is considered more effective than binding BH3-only activators, 
(123), due to once activated by a BH3-only protein, Bax and Bak can activate other 
Bax/Bak molecules (124). 
Thus, unlike the Unified model, the Embedded Together model proposes that the 
dominance of MODE 1 vs MODE 2 depends on the membrane bound dynamics refers to 
the amount of protein and post-translational modifications of the BCL-2 proteins. . 
Finally, the lipid composition of the MOM determines the binding interactions and 
functions of BCL-2 family proteins so “Lipid-Centric Model” has been also proposed 
(125, 126), wherein apoptosis-related lipids modulate the activation and action of BCL-2 
family members at the MOM level, either through a direct and stereoselective interaction 
(125), or via a bilayer-mediated effect (126). 
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1.5 MITOCHONDRIAL PORES: RELEVANCE OF 
MITOCHONDRIAL OUTER MEMBRANE (MOM) 
COMPOSITION IN ITS PERMEABILIZATION. 
Upon apoptotic stimuli, the release of Cyt-c and other pro-apoptotic proteins from 
mitochondria to cytosol involves different mechanisms represented in different models. 
Some of them propose that the presence of Cyt-c and other mitochondrial proteins in 
cytosol is produced by the loss of MOM integrity, whereas other models suggest that the 
formation of different types of channels produces an increase in MOM permeability, 
generating the release of these mitochondrial proteins. However, none of the MOMP 
models is able to integrate all the experimental data. 
1.5.1. Bax/Bak activation and oligomerization to form mitochondrial pores. 
The activation of Bax and Bak is ultimately regulated through complex protein-protein 
interactions between the direct activator BH3-only proteins and Bax/Bak at the MOM. 
However, the understanding of mechanisms leading to Bax/Bak activation is still 
controversial. Bax and Bak could be activated by the exposure to MOM components, like 
certain lipids (125) and by various physical factors as changes in pH and heat. However, 
the most studied mode of Bax/Bak activation is through activator BH3-only proteins 
binding (98, 116, 127). This interaction between BH3-only proteins and Bax/Bak is a 
transient interaction (99) described as a “hit and run” mechanism. After binding to 
activator BH3-only proteins, Bax/Bak undergo major conformational changes generating 
several structural changes of the N-terminal region that contains the BH3 domain, and 
helices 5, 6 and 9 (helix 9 only change its conformation in  Bax) (Figure 1.5) (119, 127). 
As a result of these structural arrangements, the affinity between Bax/Bak and BH3-only 
proteins decreases,  confirming the hypothesis of a ‘hit-and-run’ mechanism. 
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Figure 1.5. Bax and Bak undergo a step-wise activation mechanism. (A) In healthy cells, Bax is mainly in 
cytoplasmic conformation when apoptotic stimuli is absent. After apoptotic activation, Bax undergoes 
conformational changes triggering the insertion of helices 5, 6 and 9 into the membrane. The activated form of 
Bax generates the recruitment of more cytoplasmic Bax that oligomerizes promoting the MOMP. (B) Bak helix 
9 is constitutively inserted in the MOM. Upon apoptotic signaling, BH3 activators bind to Bak to generate 
conformational changes that trigger the insertion of helices 5, 6 into the membrane. Inspired by (112). 
Bak is constitutively present in MOM through insertion of its helix 9 (TM). The high 
affinity of Bak for membrane insertion may be due to the increased hydrophobicity of the 
Bak TM region (ΔG= -0.735) compared to that of Bax (ΔG= 0.510), which facilitates its 
binding to membranes rather than to the hydrophobic groove (128). Following activation 
by BH3-only binding, conformational changes produced, the rearrangement of the N-
terminus, exposing Bak BH3 domain and  inserting helix 5 and 6 into the MOM (129) 
(Figure 1.5A). The exposure of the BH3 domain promotes the dimerization Bak, forming 
A 
B 
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a “groove-to-groove” dimer, that can multimerize with other Bak dimers through an 6-
6 interaction (130). 
In contrast, the inactive form of Bax monomer is in continuous movement between the 
cytoplasm and mitochondria in healthy cells (131). In this inactive conformation, the 
hydrophobic helix 9 (TMD) is buried in the hydrophobic groove (132) to increase the 
solubility of Bax in cytosol. Recent studies, have been demonstrated that Bcl-xL is the 
responsible of Bax retro-translocation back from the MOM to the cytoplasm to avoid 
apoptotic activation! (133). This mechanism maintains low Bax levels in MOM. When a 
BH3-only binds to Bax, the resulting arrangements produce the release of 9 from the 
hydrophobic groove (119), increasing Bax affinity to MOM and promoting its membrane 
insertion. This process triggers the permeabilization of the MOM. In addition It is thought 
that not only Bax 9 inserts into the MOM but also5, 6, and (Figure 1.5B) and that 
activation of a single molecule of Bax can propagate the activation of other Bax 
molecules via the exposed BH3 domain, which manages Bax oligomerization (Figure 1.6!
(124)). Moreover, crystal structure of Bax, binded to Bid BH3 peptide showed that this 
interaction mediated by the hydrophobic groove of Bax generates a relevant position 
change of Bax helix 2 (134). Interestingly, this displacement debilitate the contacts 
between Bid BH3 peptide and Bax and facilitate Bax/Bak oligomerization (134). Then, it 
is thought that can be a credible explanation of  “hit and run mechanism”. 
1.5.2. MOMP: Bax/Bak pore formation in the MOM. 
Although the fact that Bax and Bak are the executioners of MOMP is extensively 
accepted, the way in which these proteins generate the pore to produce the 
permeabilization process is still unclear. Several models have been proposed describing 
the composition of the Bax/Bak pore (Figure 1.6). These models can be divided in two 
groups: On the one hand, Indirect Activation Models postulate that the Bax and Bak 
function is to modify the existing mitochondrial proteinaceous channels (see below) 
permeabilizing MOM via a physical interaction with the components of the mPTP 
(mitochondrial Permeability Transition Pore) found at mitochondrial contact sites (CS) 
(135). For example, Bax may increase the permeability of the MOM by regulating 
VDAC1 channels (Figure 1.7) (136). 
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Figure 1.6. Mechanisms of Bax/Bak MOMP. (A) The protein–lipidic pore mechanism involves the 
interactions of some lipids with Bax/Bak, regulating the pore formation. (B) In the Proteinaceus barrel-stave 
channel, only the  Bax/Bak oligomers are considered as components of the pore. (B1)!In The symmetrical model 
Bax/Bak oligomers are formed by the interaction of the BH3 domains into the canonical groove and  α6 helix 
interactions are the responsible of higher order oligomers. (B2) The asymmetrical model is based on the 
interaction of Bax BH3 domain with another Bax molecule by the non canonical groove. Inspired by (112). 
On the other hand, the Direct Activation Models postulate that the only partners 
contributing to pore formation are Bax and Bak. The structure of these channels could be 
a proteolipidic pore (Figure 1.6A) or a proteinaceous barrel-stave channel (Figure 1.6B). 
These models are based on the structural similarities found between BCL-2 proteins and 
bacterial pore-forming toxins (73) as well as the capability of activated Bax and Bak to 
permeabilize lipid membranes in the absence of other mitochondrial components (137, 
138).  
1.5.3. MOMP: Other mitochondrial channels with capacity to release 
apoptogenic proteins. 
There are other mitochondrial channels different to Bax/Bak pore complex that promote 
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different mechanism of release for Cyt-c and other pro-apoptotic molecules (Figure 1.6;!
(139)).  Some models suggest that MOM permeability is caused by proteins large enough 
to form channels that cross the MOM to allow the permeabilization and the release of 
proteins. However, other models consider that the efflux of the apoptogenic proteins is 
due to disruption of MOM integrity. Some of the alternative channels proposed as 
responsible of MOMP are described in this section. 
 
Figure 1.7. Release Models for the apoptogenic proteins from MIM space during apoptosis. (A) 
Permeability transition pore (PTP) is formed by VDAC (MOM), ANT (MIM) and CypD (matrix). (B) Bax-
VDAC hetero-oligomers. (C) VDAC1 homo-oligomer (regulated by oxidative stress and Ca2+) can also produce 
the release of apoptogenic proteins. (D) MOM rupture produced by VDAC closure promotes a non-specific 
release of apoptogenic proteins. (E) The mitochondrial apoptosis-induced channel (MAC)  formation is 
controlled by the apoptotic maquinery (BCL-2 proteins). (F) A lipid channel formed by the lipid ceramide. 
(G)(H)  Upon apoptosis induction, Bax and/or Bak activation and oligomerization promotes MOMP. Adapted 
from (140). 
The permeability transition pore. . The mPTP (permeability transition pore. Model A, 
Figure 1.7) is a multi-protein complex present at mitochondrial contact sites (CS)(135) 
composed by the adenine-nucleotide translocator (ANT, located in the MIM), the voltage-
dependent anion channel (VDAC, located in the MOM) and the cyclophilin-D (CyP-D, 
located into the matrix surface of the MIM) (141-143). PTP opening produces an increase 
of (Ca2+) ions and water in the mitochondrial matrix, generating mitochondrial swelling, 
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loss of membrane potential, and finally the loss of MOM integrity. PTP-induced cell 
death is generally considered to be necrotic rather than apoptotic (144). CypD was found 
to be essential for MOMP mediated by Ca2+ overload and this CypD-dependent MOMP 
regulates some forms of necrotic cell death but not apoptotic death (145). 
Of note, the mechanisms responsible for PTP opening and its physiological function 
are still unclear. Mitochondria isolated from animals models with ANT or VDAC KO 
genes show PTP opening produced by oxidative stress (ROS) and an increase of Ca2+ in 
the mitochondrial matrix, suggesting that more components of the PTP complex have to 
be uncovered (144, 146).   
VDAC1-Bax Hetero-oligomeric channel. Hetero-oligomers of VDAC1 and Bax form a 
high conductance channel also proposed as a mechanism for Cyt-c release (Model B, 
Figure 1.7; (147, 148)). Studies in VDAC1-depleted cells, wherein cisplatin-induced 
activation of Bax was inhibited (149), demonstrate that VDAC1 is involved in Bax-
mediated apoptosis. Furthermore, some proteins of the BCL-2 family, such as Bid, Bim, 
Bcl-2, and specially Bcl-xL interact with VDAC1, modulating the efflux mechanism of 
apoptotic proteins through this channel (150). Bcl-2 and Bcl-xL interact with VDAC1 
reducing channel conductance and apoptosis. However, mutated forms of VDAC1 avoid 
these interactions (151). It has been proposed that the interaction of Bax-Bim complex 
with VDAC produces Cyt-c release, and Bcl-xL prevents this release (152).  
Finally, other studies propose that Bax is the regulatory protein of oligomeric VDAC 
channel, promoting Cyt-c release through this pore (153). 
VDAC1 oligomerization. The single molecule VDAC1 pore diameter (2.5–3.0 nm) avoids 
the efflux of folded proteins like Cyt-c. However, homo-oligomers of VDAC1 can form a 
large protein-conducting channel following apoptosis stimuli to promote the release of the 
apoptogenic proteins (Model C, Figure 1.7;! (155)). However, the molecular mechanism 
that trigger VDAC1 oligomerization upon apoptosis induction remains unknown.  
Osmotic matrix swelling and MOM rupture leading to non-specific release from inter-
membrane proteins to the cytosol !. The dysregulation of ATP/ADP exchange produced by 
VDAC1 closure (Model D, Figure 1.7; (157)) generates a sudden increase in MIM 
permeability, mitochondria swelling, rupture of the MOM and finally the release of IMS 
proteins, such as Cyt-c, to the cytosol (158). 
Mitochondrial apoptosis-induced channel. Mitochondrial apoptosis-induced channel 
(MAC), a supramolecular high-conductance channel in the MOM, can be assembled 
during early apoptosis and serve as the Cyt-c release channel regulated by BCL-2 family 
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members (160, 161) Model E, Figure 1.7)). The complete molecular identity of MAC is 
unknown but recently it has been proposed that Bax is an essential constituent of this 
channel since depletion of Bax significantly diminishes MAC activity (162). 
Ceramides and the release of cytochrome c. Ceramides, a family of waxy lipid molecules, 
were postulated to form a pore in the MOM with a diameter large enough to 
accommodate Cyt-c (163). For that reason, this model suggests that a self-assembled 
ceramide-based lipid channel is formed in the MOM to release Cyt-c (Model F, Figure 
1.7; (163)). Ceramides can also promote the release of Cyt-c c by altering MIM lipid 
microdomains (164). In addition, ceramides in combination with low cholesterol 
concentrations could generate mitochondrial membrane microenvironments to facilitate 
Bax activation (165, 166). Finally, Bak (but not Bax) could activate ceramide synthesis. 
The increase in ceramide levels would result in synergistic channel formation at the MOM 
by ceramide and Bax/Bak, showing a different function of Bax and Bak in apoptosis (167). 
Depending on the cell death stimulus and the cell type the mechanisms and models of 
Cyt-c release proposed could co-exist within a single model of cell death (168). 
1.5.4. Role of mitochondrial membrane lipids in MOMP regulation.  
The involvement of lipids in MOMP has been suggested recently (169) since the lipid 
composition of the MOM changes during apoptosis. Current theories support that 
mitochondrial lipids are not only structural elements of the MOM but also display a 
functional role. The function of these lipids would be either to produce changes in the 
physical properties of the MOM and/or to interact specifically with some mitochondrial 
proteins (170, 171).  
The mitochondrial lipid composition is conserved among different cell types. This 
underscores the potential role of lipid composition changes as an additional regulation 
mechanism to control general processes as apoptosis. The lipid composition of the 
mitochondrial membrane in healthy conditions is: 40% phosphatidylcholine (PC), 30% 
phosphatidylethanolamine (PE), 5-10% Cardiolipin (CL), 15% phosphatidylinositol (PI), 
whereas phosphatidic acid (PA) and phosphatydilserine (PS) comprise approximately 5% 
(172).  
The relevance of membrane composition in Bcl-2 family regulation started with the 
importance of CL in liposome permeabilization process mediated by  tBid-Bax interaction 
(173) and the blockage of pores formation in MOM-like liposomes when this lipid was 
absent (121). CL is a four-alkyl groups mitochondria-specific membrane lipid with 
potentially two negative charges, localized predominantly to the inner mitochondrial 
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membrane. Only a minor fraction of CL is located in the MOM (173). However, it was 
observed that local CL concentrations at specific MOM domains known as the 
mitochondrial membrane contact sites (CS) can be as high as ≈25% (174).! Different 
studies indicate that during apoptosis the total content of CL at the MOM increases. 
Several reports have related CL and CS with Bid, indicating that CL can recruit Bid to 
MOM and mitochondrial CS specifically (175). CL also promotes caspase-8 translocation 
to mitochondrial localization, promoting then the activation of Bid (176). Of note, it has 
also been described that other phospholipids such as PC, PG and PE (177) allow 
membrane translocation of tBid. CL can also interact through its negatively charges with 
the lipid-binding region of Bad BH3-only protein (178). However, the role of CL in the 
apoptotic pathways is still controversial. 
Despite of mitochondria contains only 5% of the total cellular cholesterol, this lipid 
can also be relevant in apoptosis due to it regulates the fluidity of membranes in 
mammalian cells (179). An increase of cholesterol concentration produces a decrease of 
membrane fluidity that correlates to inhibition Bax-mediated MOMP (180) and resistance 
to chemotherapy in cancer cells, whereas low levels of  cholesterol are related to Bax 
activation via p53 (181, 182). However, role of cholesterol in apoptotic control is not fully 
characterized yet . 
Inside the sphingolipid group, the ceramide has been largely analyzed by its relevance 
in the MOMP and apoptosis (183). Increased amounts of ceramide at the mitochondria in 
response to apoptotic stimuli (TNF-, FAS ligand or DNA damage) promote Bax 
translocation to the MOM, MOMP and apoptosis (183, 184). Nevertheless the molecular 
mechanism by which ceramide promotes apoptosis is still controversial. In addition, 
hexadecenal (a downstream metabolite of ceramide) induces Bax activation  and pore 
formation in liposomes where CL is not present (125).  
Future studies will be needed to shed light on the role of lipids in MOMP and in the 
mitochondrial membrane regulation during apoptosis. 
1.6. BCL-2 TRANSMEMBRANE DOMAINS (TMDs): 
SUBCELLULAR TARGETING AND ROLE IN THE APOPTOTIC 
PATHWAY. 
Most of Bcl-2 proteins are defined as tail-anchored proteins that have a single, highly 
hydrophobic and helical C-terminal segment (known as transmembrane domain, TMD). 
The TM segments of the tail-anchored proteins range from 15 to 22 amino acids in length 
and are typically flanked by one to three positively charged residues. Protein folding in 
1                                                                              INTRODUCTION 
    31 
the cytoplasm of eukaryotic cells tends to occur co-translationally (Figure 1.8) (186) and a 
number of ribosome-associated chaperones are available to mediate co-translational 
folding. Hence, the N-terminal domains of tail-anchored proteins can fold, sequentially, 
before the hydrophobic tail emerges from the ribosome to be inserted into the membrane. 
This would prevent any unfavourable folding reactions that might otherwise occur 
between the cytosolic domain and either the hydrophobic tail or the membrane surface. 
Not surprisingly, since the N-terminus of the protein folds before the emergence of the 
membrane anchor from the ribosome, the membrane-insertion of tail-anchored proteins 
should occur post-translational. The length and the hydrophobicity of the TMD are 
important for the post-insertional sorting to the correct membrane within the secretory 
pathway and some works have postulated a relevant role of the flanking regions in 
defining the membrane-specificity of the tail-anchored proteins (187). 
 
 
 
 
 
 
 
Figure 1.8. Stages of targeting tail-anchored proteins to mitochondria. Tail-anchored proteins can fold in the 
cytoplasm co-translationally. The hydrophobic tail-segments interact with some proteins such as chaperones like 
HSP70 (green) to keep the proteins soluble in the cytosol. (Left side) Tail-anchored proteins can also interact 
with some subunits of the TOM complex (grey) to target to mitochondria. (Right side) Some Bcl-2 proteins can 
fold themselves and target to mitochondria. Inspired by (188). 
The BCL-2 family proteins are usually found not only in the mitochondria but also in 
the cytosol, the endoplasmic reticulum (ER) and the nucleus (189) (Figure 1.9). Although 
some Bcl-2 family members are targeted directly to the membrane on which they execute 
their function via specific targeting sequences, others require a secondary level of 
regulation allowing them to translocate to MOM in response to an apoptotic stimulus. 
Moreover, BCL-2 members that are not targeted to MOM seem to regulate MOMP from 
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Both Bak and Bax have a hydrophobic surface groove, 
indicating it may also be an important interaction site for the 
proapoptotic members. Indeed, while the structures of activated 
Bak and Bax are not yet available, our recent biochemical 
studies show that a BH3:groove interface forms between two 
activated Bak or Bax molecules (GD and RK, unpublished 
data).60 That is, the Bak and Bax activation process involves 
exposure of their BH3 domain, with this domain then able to 
bind to the groove in another molecule to form homodimers. 
This BH3:groove interaction is required to kill the cell.60,61
There is now structural information rega ding binding 
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the ER (190). This secondary level of regulation may act as a ‘safety switch’ preventing 
premature activation or inactivation of these proteins. Several groups have studied the 
mechanism used by the BCl-2 proteins target to mitochondria (191, 192) and they 
propose: 1) Direct anchorage post-translation of the BCL-2 TMD into the MOM. 2) 
Targeting mediated by the interaction with other BCL-2 members. 3) Interaction with 
non-BCL-2 family proteins, such as TOM/TIM complexes (193). 4) Interacting with 
mitochondrial lipids.  
Among the BCL-2 family, some members have a well-defined TMD with all the 
properties observed in the canonical tail-anchor sequences. These are the cases of the pro-
apoptotic proteins Bax and Bak, and the anti-apoptotic Bcl-2, Bcl-xL, Bcl-w and Mcl-1. 
For other BCL-2 proteins, such as Bok, A1, and some of the BH3-only proteins 
hydrophobic sequences can be detected, but these regions do not accomplish all the 
criteria established for the canonical TMDs. Furthermore, the targeting signals and 
mechanisms by which BCL-2 proteins reach their final destination are still controversial. 
 
Figure 1.9. Localization of Bcl-2 family proteins. BCL-2 proteins are present in the cytoplasm, ER and on the 
MOM in healthy cells. Bak is constitutively found on the MOM. Bax inactive form is found in the cytoplasm 
and translocates to MOM after apoptotic activation. Bcl-2 and Bcl-xL are mainly inserted into the MOM 
interacting with Bax and Bak to inhibit apoptosis. Bcl-w and Mcl-1 can be present in cytosol or integrated into 
the membrane. BH3-only proteins Rambo, Hrk are always present in MOM. The expression of Bim, Puma and 
Noxa is up-regulated following apoptotic signals, whereas Bad, Bim and Bid BH3-only proteins target to MOM 
following post-translationally modifications. Inspired by (194). 
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1.6.1. Subcellular distribution and targeting of BCL-2 anti-apoptotic 
proteins.  
In healthy cells, the majority of endogenous Bcl-2 is located in the ER membrane and 
associated with the nuclear envelope, and the remaining fraction (30%) is located on the 
MOM (195, 196). Bcl-xL and Bcl-w are both found in cytosolic form as membrane 
inserted (63, 197, 198). During apoptosis, they translocate from the cytosol to 
mitochondria. In the case of Bcl-w, its anchoring to the MOM is only triggered when a 
BH3-only protein binds to its hydrophobic groove (199). When comparing the TMDs of 
Bcl-2 and Bcl-xL, no great differences in length or in mean hydrophobicity were detected. 
However, MOM-targeted proteins such as Bcl-xL show an increased hydrophobicity in 
the C-terminal half of their TMD. On the other hand, proteins that are also targeted to the 
ER/nuclear envelope, such as Bcl-2, are more hydrophobic in the N-terminal half of their 
TMDs. In addition, the number of positive flanking residues of the TMD seems to play an 
important role in the mitochondrial membrane specific targeting of Bcl-2 anti-apoptotic 
proteins. High basicity surrounding the TMD usually leads to a more MOM-specific 
targeting, whereas TMDs surrounded by fewer basic residues have a higher tendency to 
be targeted to the ER membrane. In this sense, Bcl-xL can be specifically targeted to the 
MOM by increasing the net positive charge at the very terminus of the protein. 
Furthermore, a decrease in the number of basic residues at this region in Bcl-2 protein 
causes a decrease in MOM-specificity, leading to an accumulation of this protein on the 
ER/nuclear outer membrane.  
It has also been proposed that cytosolic binding proteins or putative membrane 
receptors can target the anti-apoptotic BCL-2 family members. For instance, it has been 
shown that the mitochondrial FK506-binding protein 38 (FKBP38) interacts with both 
Bcl-2 and Bcl-xL, probably by associating with members of the TOM machinery (200). 
Finally, the subcellular localization of Mcl-1 depends on the physiological cellular 
status and cell-type, Mcl-1 has been localized to the mitochondria, ER, the cytoplasm and 
the nucleus (201). 
1.6.2. Subcellular distribution and targeting of BCL-2 pro-apoptotic proteins.  
Bax, Bak and Bok were initially described to be targeted to the MOM wherein they are 
thought to exert their function. Recently, ER localization and, in consequence, ER 
specific functions have been reported for these proteins (189) (202). In addition to its 
membrane attached form, Bax is found up to 60% as a soluble protein in the cytosol in 
healthy cells and it is proposed to translocate to and insert into the MOM during apoptosis 
(132) . In contrast to Bax, Bak is inserted constitutively into the MOM and to a lesser 
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extent into the ER membrane (203). Moreover, the higher hydrophobicity of the C-
terminal hydrophobic region of Bak in comparison with Bax may account for the stable 
anchorage of the former but not the latter protein to the MOM. 
Bok is described as either having a nuclear or mitochondrial distribution. The C-
terminus of Bok does not fit the consensus for a functional tail-anchored, as it contains 
lysine and arginine residues within what should be the hydrophobic TMD. Whether or not 
Bok has a functional TMD remains controversial!(204). 
1.6.3. Subcellular distribution and targeting of BH3-only proteins.  
BH3-only proteins are located in the cytoplasm of healthy cells, but during apoptosis they 
are targeted to the MOM, either alone or in association with the multidomain BCL-2 
family members.  
Following apoptotic stimuli, BH3-only proteins Noxa, Puma, Bim, and Hrk are 
transcriptionally induced. In the cases of Bim, Bik, Bmf and Bad, are posttranslationally 
modified and/or proteolytically processed in response to apoptotic stimuli (191, 205). 
These modifications increase the affinity of BH3-only proteins for multidomain Bcl-2 
family members, directing some BH3-only proteins to the MOM and ER membrane (206). 
Alternatively, other BH3-only proteins seem to contain their own C-terminal TMD 
regions, such as Bik (constitutively localized to the ER), Hrk, Rambo, (both in MOM) and 
Bid targeting to MOM or ER directly or by protein-lipid interactions (207). In the case of 
Bim, Puma, Noxa and Bmf the presence of a TMD region is still controversial. A recent 
study postulates that the C-ternimal region of Noxa could be responsible of its 
mitochondrial targeting! (207). Bim and Bmf seem to be bound to cytoskeletal structures 
under healthy conditions. During apoptosis, they are released from the cytoskeleton to 
allow their translocation to the MOM and modulation of MOM-localized multidomain 
BCL-2 proteins (104, 208, 209) Recent studies propose that Bim spontaneously inserts 
into the MOM via its putative tail-anchor, and that binding to the MOM is crucial for 
activating Bax. However, it is unlikely because the putative tail-anchor sequence of Bim 
contains charged residues, which are normally incompatible with tail-anchored mediated 
insertion into the membrane. Bid is located in the cytosol in an inactive form in healthy 
cells. In response to apoptotic stimuli, Bid is cleaved by caspase-8 to form truncated Bid 
(tBid), translocating from cytosol to MOM to interact with the BCL-2 family proteins 
located in mitochondria. This targeting could be mediated by the interaction with the CL-
binding domains as in the case of Bad (210). In absence of apoptotic stimuli, 
phosphorylated Bad is sequestered in the cytosol by its interaction with 14-3-3 scaffold 
proteins and only after dephosphorylation is targeted to MOM (208). 
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Table 1.II. The TMD of the BCL-2 family. 
 
 
 
 
 
 
 
 
 
Underlined residues represent the flanking regions of the transmembrane domain, which are important in the 
subcellular targeting. The predicted sequences have been calculated using ΔG. Not confirmed (N.C). 
1.7. ROLE OF BCL-2 TMDs IN THE CONTEXT OF FULL-
LENGTH PROTEINS AND RELEVANCE IN MOMP DURING 
APOPTOSIS. 
1.7.1. Anti-apoptotic BCL-2 proteins.  
Bcl-2 
The Bcl-2 C-terminal tail improves the anti-apoptotic effects of the protein, including cell 
survival after IL-3 deprivation (211) and suppression of apoptosis caused by E1B-
defective adenovirus (212). Some authors have postulated that helices 5 and 6 of Bcl-2 are 
able to form pores in lipid membranes! (213, 214). Bcl-2 protein exhibited pore-forming 
activity with properties similar to those of the bacterial toxins, diphtheria toxin, and 
colicins, showing a dependence on low pH and acidic lipid membranes. In planar lipid 
bilayers, Bcl-2 formed two types of channels: discrete ion-conducting, cation-selective 
channels, with a four-helix bundle structure arising from Bcl-2 dimers and a larger 
!
BCL-2 
protei
n 
TMD Predicted sequence Target Role  
Bcl-2 Yes 212FSWLSLKTLLSLALVGACITLGAYLGHK239 ER,MOM,Nucleus Not clear 
Bcl-xL Yes 203SRKGQERFNRWFLTGMTVAGVVLLGSLFSRK233 MOM Apoptotic isoform,  Form pores 
Bcl-w Yes 163REGNWASVRTVLTGAVAL GALVTVGAFFASK193 MOM Not clear 
Mcl1 Yes 328IRNVLLAFAGVAGVGAGLAYLIR350 MOM,ER Apoptotic isoform 
Bfl-1 Yes 151KSGWMTFLEV TGKICEMLSL LKQYC175 MOM Form pores 
Bcl-B Yes 168FWRKQLVQAFLSCLLTTAFIYLWTRLL194 MOM NM23-H2 interaction 
Bax Yes  169TWQTVTIFVAGVLTASLTIWKKMG192 MOM Form Pores 
Bak Yes 188ILNVLVVLGVVLLGQFVVRRFFKS211 MOM VDAC2 interaction 
Bok Yes 186RSHWLVAALCSFGRFLKAAFFVLLPER212 ER,Golgi,Nucleus Not clear 
Bid Yes 144KEKTMLVLALLLAKKVA160 MOM Destabilize MOM, Form pores 
Bim N.C 179PRMVILRLLRYIVRLVWRMH198 MOM?? Not clear 
Bmf N.C 157NRVWWQILLFLHNLALNGEENRNG180 MOM?? Not clear 
Puma N.C 162RHRPSPWRVLYNLIMGLLPLPRGHRAPEMEPN193 MOM?? Not clear 
Noxa N.C  35KLNFRQKLLNLISKLFCSGT54 MOM?? Not clear 
Bad Yes 137TATQMRQSSSWTRVFQSWWDRNLGRGSSAPSQ168 MOM?? Not clear 
Bik Yes 136VLLALLLLLALLLPLLSGGLHLLLK160 ER Not clear 
Hrk Yes 61APGALPTYWPWLCAAAQVAALAAWLLGRRNL91 MOM Form pores 
Rambo Yes 457GKSILLFGGAAAVAILAVAIGVALRKK485 MOM Not clear 
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channel detected with progressively lower occurrence, implying the step-wise formation 
of larger oligomers of Bcl-2 in membranes. The role of the Bcl-2 C-terminus TMD in 
these pores is still unclear!(213, 214).  
Bcl-w 
Bcl-w C-terminus-deleted mutants lose their anti-apoptotic function, although they are 
still able to bind BH3-only proteins, such as Bim and Bad, suggesting that C-terminal 
residues modulate pro-survival activity by regulating the ligand access to the hydrophobic 
groove by the BH3-only proteins (63). However, further studies have to be designed 
focusing in the TMD specifically to evaluate the relevance of this TMD in apoptotic 
regulation and interaction with other Bcl-2 proteins. 
Bcl-xL 
Bcl-xL undergoes a conformational change from a cytosolic to a membrane bound state 
promoted by its TMD (215). When the Bcl-xL TMD is removed, a decrease in membrane 
insertion is observed. It has been demonstrated that Bcl-xL interacts with a Bak BH3 
domain peptide in the presence of membranes. Under these conditions, the TMD of the 
protein unfolds from the hydrophobic groove and inserts into the membrane (216). 
Some localization studies for Bcl-xL TMD have fused the TMD of Bcl-xL or the 
complete Bcl-xL to the yellow fluorescent protein (YFP) in order to investigate the 
relevance of the TMD in the targeting of the protein. Both YFP-Bcl-xL and YFP-Bcl-xL-
TMD localized to the mitochondria. However, cells expressing YFP-Bcl-xL-TMD 
showed increased autophagy and moderate cell death resistance in response to 
staurosporine (a classical apoptotic inductor), suggesting the existence of a secondary 
function of Bcl-xL mediated by the TMD (217). In contrast, YFP-Bcl-xL was diffusely 
distributed in the cells, and its expression did not alter the mitochondrial morphology 
compared with control cells. Recent studies have postulated that some isoforms of Bcl-xL 
that contain the TMD are pro-apoptotic! (66, 67, 218). This is the case for Bcl-xS that 
contains BH4, BH3 and TMD domains!(218). In constrast, Bcl-AK is constituted by BH4, 
BH2 and the TMD domain and does not interact with other Bcl-2 antiapototic proteins!(66, 
219). However, both isoforms promote different ways of caspase-dependent and caspase-
independent apoptosis. Interestingly, Bcl-xS can also disrupt the interaction between 
VDAC2 and the TMD of Bak, producing the caspase-dependent apoptosis (67).  
Furthermore, it has been postulated that Bcl-xL homodimerizes by the TMD, which 
could be related to its role in mitochondrial morphology alteration and apoptosis 
inhibition (220). As described previosly, this Bcl-xL TMD is also important to mediate 
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retrotranslocation of Bax from the mitochondria to the cytosol (221). Unexpectedly, 
substitution of the Bcl-xL TMD by the corresponding Bax segment reverses the Bax 
retrotranslocation activity of Bcl-xL, while Bcl-xL shuttling is independent of interactions 
with Bax or Bcl-xL (221). Therefore, it is not clear how the retrotranslocation of Bcl-xL 
to the cytosol is induced. 
Bfl-1 
The C-terminal domain of Bfl-1 (A1) significantly differs from Bcl-2, Bcl-xL, and Bcl-w 
TM sequences (222), and targets Bfl-1 specifically to mitochondria (see Table 1.II). Bfl-1 
may co-exist in two distinct conformational states: one with its C-terminal helix inserted 
in the hydrophobic groove and another with its C terminus bound to the MOM (223). The 
helix 9 of Bfl-1, and therefore the binding of Bfl-1 to mitochondria, is not essential for the 
anti-apoptotic activity of Bfl-1.  
A synthetic peptide called ATAP (amphipathic tail-anchoring peptide) derived from 
the C-terminal domain of Bfl-1 produces the release of fluorescent molecules of the size 
of Cyt-c from liposomes (224). In addition, although the pro-apoptotic activities of BH3 
peptides are largely inhibited by over-expression of anti-apoptotic proteins (Bcl-2 or Bcl-
xL) or the depletion of pro-apoptotic Bax and Bak in cells, the pro-apoptotic function of 
ATAP is not affected by these cellular factors (223). 
Mcl-1 
It has been established that the C-terminal domain of Mcl-1 becomes pro-apoptotic as a 
result of caspase-3 cleavage, and its physical interaction and cooperation with tBid, Bak, 
and VDAC1 promoted mitochondrial apoptosis. However, in these studies, the C-terminal 
domain included not only the putative TM segment but also by domain BH2 (225). For 
that reason, the specific role played by the TM segment in these observations is not clear. 
Bcl-B 
Bcl-B is also known as Bcl-2L10 or Diva in the mouse. Bcl-B has anti-apoptotic function 
in MOM, but interestingly it does not have BH3 motif (226). The deletion of the TMD in 
Bcl-B decreases its anti-apoptotic function and its association with intracellular organelles 
(227). Interestingly, it has been postulated that Bcl-B interacts with NM23-H2, a regulator 
of the Bcl-B activity, via its TMD (228). 
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1.7.2. Pro-apoptotic BCL-2 members.  
Bax 
Bax lacking the C-terminal domain is not functional and the insertion in MOM is blocked 
(229)! (230). There are three critical residues in the Bax TMD and its flanking regions: 
G179, S184 and P168. G179E mutant abrogates the Bax activation mediated by ABT-199 
antitumoral drug due to this mutation avoid its anchoring to the MOM! (230). The 
mutation of S184K led to the diffuse cytoplasmic localization of Bax after the cells had 
received an apoptotic signal and the deletion of this residue produces a Bax mutant 
constitutively localized in the mitochondria and more active than wild type Bax. P168 
mutants lack pro-apoptotic activity.  
Interestingly, the substitution of the C-terminus of Bax by that of Bcl-xL does not 
affect its subcellular localization but abrogates its pro-apoptotic properties (231).  In 
addition, mutations in the C-terminal part of the Bax protein impaired the inhibitory effect 
that anti-apoptotic Bcl-xL has on Bax insertion, suggesting that the conformation of the 
TMD plays a significant role in the Bax/Bcl-xL interaction (232). 
As previously described, the pore complex proposed by helices 5 and 6 of Bax can be 
proteolipidic (134) but no conclusive evidences about the participation of the C-terminal 
domain in this type of pores have been observed. In presence of phosphatidylglycerol in 
model membranes, the C-terminal domain of Bax formed complexes with these lipids 
(233). Moreover, a recent work suggests that the TMD of Bax could contribute to 
oligomerization process in the MOM, by direct TMD interaction between different 
molecules of Bax! (234). In the same line, other studies have suggested that Bax TMD 
could contribute the pore complex constitution. It was observed that Bax channels 
reconstituted in vitro showed voltage gating. Then, two different Bax channels have been 
proposed: Type A, which is homogeneous, small and voltage-gated; and Type B, which is 
large and voltage-independent (235). It has been suggested that the TMD of Bax may be 
involved in the formation of both. During apoptosis, changes in the lipid composition of 
the MOM can influence orientation and exposition of the C-terminal of Bax within these 
channels, modifying their organization. 
Several studies using vesicles with encapsulated carboxyfluorescein have been 
developed to determinate the role of the BCL-2 C-terminal domains in permeabilization 
of membranes. Some synthetic peptides of anti-apoptotic (Bcl-2) and pro-apoptotic (Bax 
and Bak) TMDs were used (236). The results highlighted that addition of both peptides to 
large unilamellar vesicles destabilized the vesicles and released encapsulated 
carboxyfluorescein (CF) at different degrees.  Moreover, it was observed that fluidity and 
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the increase in negative curvature promoted this release. In general, Bcl-2 and Bax TMD 
peptides produced the highest content release, with Bak TMD peptide close to these levels 
of release. In comparison to pure phosphatidylcholine vesicles, the addition of 
diacylglycerol produced an increase in the percentage of CF released in the case of Bak 
TMD peptide. However, the addition of cholesterol reduced the membrane fluidity and 
the TMD insertion (237, 238), reducing the capacity of the peptides to induce CF release.  
Recent works have proposed a model for pores (radius of at least 13 Å) based on the 
Bax TMD peptide (173VTIFVAGVLTASLTIWKKMG192) wherein eight peptide 
molecules form an "/ -ring structure within the membrane. This peculiar pore 
allowed the suggestion of a new mechanism through which Bax C-terminus can 
efficiently perforate cell membranes, a mechanism that differs from that accepted until 
now for other domains of Bax (239, 240). When this peptide is expressed intracellularly, 
it is translocated to the mitochondria and kills cancer cells, so the Bax TMD peptide 
represent a firm candidate for acting as molecular drug (241).  
Bak 
The hydrophobic C-terminal domain of Bak acts as a membrane anchor (242), promoting 
the localization of Bak as an integral MOM protein (Figure 1.9). Several works when 
replaced the C-terminal domain of Bak with Bax TMD (Bak/BaxCS), the chimeric protein 
rescues the stability and the function of Bak, but resulted in a semicytosolic protein with 
its hydrophobic TMD blocking its hydrophobic surface groove. Upon apoptotic signaling, 
Bak/BaxCS translocated to the MOM where inserted its TMD (128). 
On the other hand, some studies have found that the C-terminal domain of Bak 
interacts with model phospholipid membranes, altering their physical properties and 
making them leaky to carboxyfluorescein! (243). The peptide is folded to adopt a 
secondary structure in which -helix is predominant. These results suggest that this 
domain may help to create a pore through the MOM. 
It has been postulated that Bak interacts by the TMD (helix 9) with VDAC2 protein in 
the MOM. This interaction between TMD of Bak and VDAC2 suppresses the activation 
of Bak in healthy cells. During apoptosis, the arrival of the BH3-only protein tBid to 
MOM results in the release of Bak from VDAC2 (110). 
Bok 
Bok can also be classified as a tail-anchored protein (244). In fact, its C-terminal domain 
has been described as a “tail anchor” specific for targeting the Golgi and the ER, wherein 
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it develops its major pro-apoptotic functions (204). Interestingly, a splicing variant of Bok 
called Bok-S, which contains only the BH1, BH2 and the TMD, does not dimerize with 
anti-apoptotic proteins and forms mitochondrial channels to regulate apoptosis! (245). 
Because Bok-S does not interact with anti-apoptotic proteins, apoptosis mediated through 
Bok-S may be important in situations when unwanted cells need to be eliminated quickly 
despite the presence of anti-apoptotic proteins in the same cell. In the ovary and uterus 
known to express high levels of Bok transcripts, Bok-S expression could provide a short 
circuit to promote cell demise in hormone-dependent cell populations that express 
abundant anti-apoptotic proteins (such as Mcl-1) but have to be removed swiftly because 
of cyclic cell turnover during reproductive cycles!(245). 
1.7.3. BH3-only proteins.  
Bid. In the case of Bid, it is postulated that helix 6 and helix 7 have the ability to insert 
into the mitochondrial membrane (246). However, the capability of these regions to 
destabilize the mitochondrial membrane and to form channels is still controversial. 
Schendel et al. (247) described the channel forming activity of caspase-8 cleaved Bid or 
Bid lacking 55 N-terminal residues in planar lipid bilayers at acidic and neutral pH. 
Moreover, Kudla et al (248) reported that p15 Bid (a truncated form of Bid from residue 
Gly60 to the end of the protein) permeabilizes liposomes at physiological pH. In addition, 
recent studies postulate that CS interact with these helices and this interaction promotes 
the remodeling of the inner membrane and the cristae structures of the mitochondria in a 
Bax/Bak-independent manner (246). However, topology studies indicate that helices 6 to 
8 do not span the lipid bilayer (249). Helices 3 to 5 are amphipathic, and none of them are 
long enough to span the bilayer. These findings point to the existence of a mediator that 
would relay the signal from the outer membrane where Bid is targeted to the inner 
membrane. Furthermore, Terrones et al. (121) reported that tBid alone does not form 
pores in the membrane, but it activates Bax to form large lipic pores permeable to dextran 
molecules of 10–70 kDa.  
All these contradictory data expose that it is uncertain how the helices 6 to 8 might be 
involved in channel formation or membrane destabilization, so further studies are 
necessary to understand these phenomena.  
Bad. Bad presents a C-terminal region with the capacity to bind to MOM, although this 
tail is not homologous to the rest of the BCL-2 TMDs. As previously mentioned, Bad is 
regulated by phosphorylation, association with 14-3-3 proteins, binding to membrane 
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lipids and pore formation (178) (see section 1.6.3). Polzien et al. (250) demonstrated that 
the C-terminal region of Bad presents a well-ordered structure and stable conformation in 
aqueous solution, although the helical conformation increases in a lipid context. The 
interaction of the C-terminal region of Bad with its isolated BH3 domain promotes the 
formation of permanently open pores, although it is necessary the phosphorylation of 
serine 118 within the BH3 domain for effective pore formation. In contrast, the 
phosphorylation of serine 99 in combination with 14-3-3 association suppresses channel 
formation (250).  
Hrk. Hrk is inserted to the MOM through its TMD (251). Interestingly, the C-terminal 
region of Hrk adopts a predominantly  -helical structure with a clear insertion 
perpendicular to the plane of the membrane. These properties give Hrk C-terminal domain 
the capability to form pores in the mitochondrial membrane. The percentage of helix and 
its potential to destabilize membranes are modulated by phospholipid composition (252).  
Rambo. The TMD of Rambo is responsible of the mitochondrial targeting of this protein. 
It has also been demonstrated that Rambo causes apoptotic cell death independent of the 
Bax-Bak pore complex and that the TMD of this protein is crucial for its pro-apoptotic 
activity (107, 253). As described in Figure 1.3 Rambo does not interact with other BCL-2 
members (107). A recent work proposed that Rambo interacts with ANT protein (253), 
which is one of the components of the PTP in the mitochondrial membrane to generate 
non-mediated Bax/Bak apoptosis. However, the role of the TMD in the apoptotic 
activation is still controversial. 
Bik. Bik presents a well-defined TMD that targets mainly to ER (106, 254), but more 
studies need to be done to determinate the role of its TM region in the context of the full 
lengh protein Bik. 
Other BH3-only proteins 
The presence of a TM region in the BH3-only proteins Puma, Noxa, Bim and Bmf is 
currently under study. Some authors have recently concluded that these BH3-only 
proteins present a TMD region to target mitochondria (207, 255, 256). However, the 
presence of several polar residues inside their C-terminal sequence and the low 
hydrophobicity of these regions generate controversy about this issue.  
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1.8. APOPTOSIS AND DISEASE. 
As well as a pivotal role during development, apoptosis and BCL-2 proteins regulation 
are essential for homeostasis in mature tissues. For this reason, defects or abnormalities in 
cell death regulation contribute to a range of pathologies: in some cases by insufficient 
apoptosis, such as cancer and autoimmune lymphoproliferative syndrome (ALPS), 
whereas in another situations by excessive apoptosis such as ischemia or 
neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, 
Huntington’s disease, and Amyotrophic Lateral Sclerosis.  
1.8.1. Importance of BCL-2 family proteins in cancer. 
The balance between cell survival and cell death is a fine tuned process wherein slight 
imbalances are responsible of several diseases.  In fact, defective cell death mechanisms 
are now recognized as one of the six hallmarks of cancer (257).  The BCL-2 proteins, as 
crucial modulators of the apoptotic process, have been implicated in the development of 
several types of tumors.!In general, dysregulation of the BCL-2 proteins could contribute 
to cancer development and progression at different levels (258). They could be directly 
implicated in the generation of the disease (drivers) but also could be involved in the 
acquired resistance to antitumoral treatments. For that reason, apoptosis, cancer 
development, and cancer therapy are closely associated. Impaired apoptosis is critical for 
tumor development. Specifically, BCL-2 proteins play a crucial role as regulators in the 
mitochondrial permeabilization process. Depending on Bcl-2 subfamily affected, cancer 
cells have can be classified in: Class A cell death blockade is associated to loss of BH3-
only activator function. Class B is related to inactivation of Bax and Bak effectors, and 
class C is the result of upregulation of Bcl-xL/Bcl-2/Mcl-1. 
It is important to note that although alterations in BH3-only and Bax/Bak proteins 
expression have been reported in several cancers, such as colon and lung cancer, this is 
not a common phenotype. In contrast, the regulation of anti-apoptotic members is more 
widely demonstrated in many cancer types. This may be a mechanism selected for tumor 
cells to block the activity of several BH3-only proteins and Bax/Bak, along with 
additional metabolic and survival advantages conferred by increased anti-apoptotic BCL-
2 protein expression. 
1.8.1.1. Dysregulation of anti-apoptotic proteins. 
Overexpression of the BCL-2 pro-survival proteins by itself has not demonstrated to be 
related to highly tumorigenic profiles; however, in combination with additional alterations 
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as mutations that enhance tumor growth generates a severe increase of malignancy (259).. 
Bcl-2. High levels of BCL2 gene expression correlate with malignancy of human tumors 
(260, 261). Bcl-2 upregulation correlates with poor prognosis and/or clinical response in 
several cancers (262-264), and resistance to chemotherapy and radiation (260, 261). 
Moreover, some tumor-associated viruses (for example, Epstein-Barr virus (EBV) and 
Kaposi’s sarcoma-associated herpes virus (90)) encode homologue proteins of Bcl-2, 
developing similar anti-apoptotic functions (265).  
Bcl-xL. Bcl-xL also produces resistance to several apoptosis pathways (266). An increase 
of Bcl-xL expression is associated to multiple myeloma (MM) (267), pancreatic cancers  
in combination with c-myc overexpression (267, 268), prostate cancers associated to Bcl-
2 upregulation (269) and apoptotic resistance produced by constitutive activation of 
epidermal growth factor receptor (EGFR)(270)..  
Mcl-1. Mcl-1 overexpression was observed in leukemia, ovarian cancer and human 
cervical neoplasms patients (271, 272). 
1.8.1.2. Inactivation of pro-apoptotic proteins.  
In addition to upregulation of pro-survival genes, tumors also develop apoptosis 
resistance by loss of function or downregulation of pro-apoptotic proteins Bax and Bak, 
which are common in hematologic malignancies (273). Knockout or interference studies 
of Bax and Bak proteins, in particular in human colorectal carcinoma cells (274), 
demonstrated the role of these proteins in the apoptosis blockade of tumor cells. Bak 
downregulation has been observed in skin and pancreatic cancer (275, 276) and it is 
required for the transformation of intestinal epithelial cells to malignant cells, promoted 
by the ras oncogene!(277)..  
In the case of Bax, it was observed during the tumor clonal evolution of gastric and 
colon cancer cells that the clones with Bax inactivated and/or mutated showed a clear 
advantage in comparison to the clones with normal expression of Bax (278). The work of 
Manoochehri et al. concluded that Bax down-regulation could contribute as an important 
factor during both colorectal carcinogenesis and cell resistance to antitumoral agent 5-
Flourouracil (279). Furthermore, the contribution of Bax downregulation to drug 
responsiveness in cancer cells was also demonstrated when the resistance of no tumoral 
cells, with normal expression levels of Bax and also Bid, was compared to cancer colon 
cells with low or no expression of Bax and Bid! (280).! Of note, it was observed that a 
single nucleotide polymorphisms (SNPs) of Bax, rs4645878, showed a significantly 
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increased recurrence risk in gastric cancer correlated with a decrease of Bax expression 
and functionality!(281). 
1.8.1.3. Mutations of BH3-only proteins.  
Noxa and Puma. Since BH3-only proteins Noxa and Puma are transcriptional targets of 
p53, loss of p53 by itself suppresses apoptosis induced by these proteins (102, 282). 
Frameshift mutations causing loss of expression and mutation of BH domains of pro-
apoptotic proteins that lead to loss of their function are also common in colon cancers and 
result in apoptosis resistance (273).  
Puma and Noxa can also be activated independently of p53 and thus play a role in 
p53-independent apoptosis. Puma can be transcriptionally upregulated by FoxO3a CHOP, 
and E2F1! (283) in response to ER stress. This protein can also be negatively regulated 
through phosphorylation; therefore several chemotherapeutic strategies are focused to 
promote its proteasomal degradation! (284). Interestingly, Puma KO mice and Noxa KO 
mice have a normal phenotype during development and adult mice (93)(285). 
Bim. Bim activity is transcriptionally (Foxo3a, CHOP transcription factors) and 
posttranscriptionally  (Phosphorylation via JNK and MAPK) regulated. Some of these 
regulatory mechanisms are used as targets of chemotherapeutic drugs. Low levels of Bim 
protein are associated with colon cancer and B cell lymphoma a! (286). Bim KO mice 
present a normal development with an excess of myeloid and lymphoid cells (287). 
Bid. Caspase-2 produces Bid cleavage in response to ER stress (288). Furthermore, Bid 
cleavage can be regulated posttranslationally by phosphorylation in response to apoptosis 
DNA damage-induced (289). Bid KO mice show myeloproliferative and leukemic 
disorders with age (291).
 
Bad. Some breast and prostate cancers can be iniciated by dysregulation of Bad 
phosphorylation in PI3K/AKT pathway (293). If PTEN (an inhibitor of the pathway) is 
blocked, S136 is constitutively phosphorylated and Bad remains inactive. Bad KO mice 
experiments!(94) demonstrated that this BH3-only protein acts as tumor suppressor in the 
lymphocyte lineage. 
Bmf. The role of Bmf in tumorigenesis still remains to be fully elucidated, but there have 
been several reports suggesting that this protein plays a role in suppressing tumor 
development. In Bmf KO mice, lymphocytes are protected against apoptosis induced by 
glucocorticoids or histone deacetylase inhibition (95). It is important to note that in 
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hematopoietic tumors the disruption of normal cell adhesion is due to the lack of Bmf 
binding to some cytoskeletal components. Bmf upregulation promotes apoptosis in 
mammary epithelial morphogenesis and anoikis (295).
 
Moreover, histone deacetylase 
inhibitors (HDAC), used as chemotherapeutic agents in tumoral cells, upregulates Bmf 
expression due to the presence of CpG islands at its promoter.  
1.8.2. Antitumoral treatments based on BCL-2 proteins.  
The complex network between pro-apoptotic and anti-apoptotic members of the BCL-2 
family plays a crucial role in cellular fate determination. From a therapeutical standpoint, 
the process of apoptosis is intricately balanced, and then the recovery of this equilibrium 
after the dysregulation promoted by a tumoral process should be the goal of cancer 
therapy. Bcl-2 interfering strategies have been accepted as a potential approach to induce 
apoptosis in cancer cells. There are three classical strategies to overcome the 
cytoprotective effects of Bcl-2, Bcl-xL and Mcl-1 in cancer: inhibiting gene transcription, 
promoting mRNA degradation with antisense oligonucleotides, and directly blocking the 
function of these proteins with small-molecule drugs or peptides (Table 1.III). 
Recently, several studies focus on a new concept, the mitochondrial priming of a cell 
that could be used in cancer therapeutics (see 1.8.2.2) 
1.8.2.1. Pharmacological inhibition of bcl-2 proteins. 
Antisense oligonucleotides (ASOs) and antibodies 
This methodology is based on the introduction of a mRNA strand complementary to the 
target sequence in Bcl-2, generating a DNA heteroduplex that can be degraded by RNAse 
H and then silencing the target mRNA (296). One of the first drugs developed for 
inhibiting the BCL-2 family was Oblimersen (G-3139), an antisense complementary to 
the BCL2 gene. The problem of Oblimersen correlates to its limited effect over BCL-2 
network, observed in several clinical studies (297), because is targeted only against Bcl-2. 
Downregulation of Bcl-2 gene may generate upregulation of other anti-apoptotic BCL-2 
proteins, reducing the effect of this antisense (298).  
A similar strategy was used for Bcl-xL ASOs (299). Bcl-xL ASOs alone also have 
similar problems as Oblimersen. However, combinated treatments of ASOs and 
Oblimersen increase each other their anti-tumoral effect (300). Finally, Mcl-1 antisense 
strategy showed interesting results in vitro in hepatocellular carcinomas (HCC) in 
combination with cisplatin treatment (301). 
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Other strategies based on the use of antibodies or ribozimes against Bcl-2 have been 
tested, showing a significant effect in cotreatments with other chemotherapeutic agents in 
breast and other cancers (302). The main problem of this methodology is the low stability 
of antisense mRNA, limiting their use as therapeutic agents. 
Peptide and peptidomimetics 
Due to limitations of strategies based on anti-apoptotic BCL-2 downregulation, a new 
methodogy was developed focusing on the control of anti-apoptotic BCL-2 function. For 
example, Bax-BH3 peptide was designed to inhibit Bcl-xL protein specifically (304), 
binding to its hydrophobic groove. The success of this study opened the field to the design 
of short peptides based on the BH3 domain of several BH3-only proteins against the 
hydrophobic groove of the different anti-apoptotic proteins. 
BCL-2 C-terminal domain-derived peptides have also been designed as therapeutic 
agents. One example is  CT20p peptide derived from the C-terminal, alpha-9 helix of Bax 
(241). CT20p contains hydrophobic and cationic residues (typically present in TM 
domains) to associate with lipid membranes. Mitochondrial localization as well as the 
capability to release calcein from mitochondrial-like lipid vesicles without disrupting 
vesicle integrity were demonstrated (241). Moreover, CT20p amphipathic nature has let to 
combine with nanoparticles (pharmaceutical vehicle). CT20p has been tested in colon and 
breast cancer cells in vitro and in vivo, demonstrating its efficiency as tumoral cells killer 
(241). 
The pro-apoptotic activity of Bfl-1 peptide, based on its C-terminal domain, showed a 
clear independency of BCL-2 proteins. For that reason, it has been used as an anti-cancer 
drug in apoptosis-resistant tumors (224). . 
Small molecule inhibitors (SMIs) targeting BCL-2 proteins  
BH3 mimetics are organic molecules of low molecular weigths whose function is based 
on the blockade of the hydrophobic groove of anti-apoptotic BCL-2 proteins, imitating the 
mechanism of action used by BH3-only proteins to promote apoptosis. Some of these 
SMIs are in clinical and preclinical phases (Table 1.III): 
One of the most succesfull BH3 mimetics is ABT-737, developed by Abbott 
Laboratories. ABT-737 binds selectively to Bcl-2 (higher affinity), Bcl-xL and Bcl-w and 
is based on the BH3 domain of Bad. However, this molecule was not effective promoting 
apoptosis in Bax/Bak KO cells (305). Experimental data demonstrates that ABT-737 
results effective against several types of lung cancer in vitro and in vivo (306), follicular 
lymphoma and leukemia. However, tumoral cells with Mcl-1 upregulated showed 
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resistance to ABT-737 treatment (308). ABT-263 is an oral derivative with longer half-
life than ABT-737 that  also inhibits Bcl-2, Bcl-xL and Bcl-w. This molecule has been 
tested in clinical trials for small cell lung carcinomas (SCLCs) and leukemia (309). 
Gossypol (BL-193) binds to the hydrophobic groove of Bcl-2 and Bcl-xL!(310) and is 
a polyphenol derived from cottonseeds (311). This SMI has been modified several times 
in different isoforms such as (−)-BL-193!(312), TW37 and Apogossypolone (ApoG2) to 
increase its effectiveness against tumoral cells. Its mechanism of action is related to 
induction of  DNA breaks in the presence of metal ions (copper) (311). It is currently in 
clinical trials as a single agent and in combinated therapies (Table 1.III). TW-37 has 
higher affinity to Bcl-2, Bcl-xL in comparison to other BH3 mimetics.. ApoG2 can also 
bind to Mcl-1, results less toxic and then more specific than others BH3 mimmetics and it 
has been tested in different types of lymphomas (315). (-)AT-101 is the negative 
enantiomer of gossypol and has also been used in lymphomas (316). This molecule 
interacts with Bcl-2, Bcl-xL and Mcl-1, with a low IC50 (1-10 !M). Finally, One of the 
last gossypol derivative is Sabutoclax that inhibits Bcl-xL (with low binding affinity) Bcl-
2, Mcl-1 and Bfl-1 (317). Interestingly, this molecule did not generate toxicity in KO 
Bax/Bak KO MEFs and it had shown promising results in some types of lymphoma 
resistant to ABT-737 (318).  
Obatoclax is a synthetic molecule developed by Gemin X (GX015-070) that can 
inhibit Bcl-2, Bcl-xL, Bcl-w and also Mcl-1 although  the affinity values to Bcl-2 family 
are lower than ABT-737 (319). However, some of the mechanisms involved in Obatoclax 
function to promote cell death are not directly related to Bax/Bak effector proteins (321). 
For example, low concentrations of Obatoclax are able to block cell-cycle in S/G2 phase 
and can also trigger autophagy by Beclin-1 release from Mcl-1, or Atg7 dependent (322). 
However, its high toxicity restrict the use of this BH3 mimetic in humans.  
 
 
 
 
 
 
1                                                                              INTRODUCTION 
    48 
Table 1.III. Bcl-2-family targeting drugs. Adapted from (323). 
 
 
 
Class Name Target CSA Combination Tumor type CSC 
ASO 
 
Oblimersen sodium Bcl-2 Phase III 
Dacarbazene 
Doxorubicin 
Docetaxel 
Melanoma 
Hepatocellular 
HR-Prostate cancer 
Phase III 
Phase I/II 
Phase II 
 Bcl-xL antisense Bcl-xL Preclinical    
 Mcl-1 antisense Mcl-1 Preclinical    
BH3    
peptides 
 
 
 
 
Bim BH3 
  
Puma BH3 
                                   
Noxa BH3 
Bad BH3 
 
Bcl-2, Bcl-xL, 
Bcl-w, Mcl-1 
                         
Bcl-2, Bcl-xL, 
Bcl-w, Mcl-1 
Mcl-1 
Bcl-2 
Preclinical 
Cisplatin, 
Staurosporin, 
Doxoribicin, 
Etoposide 
Several, depending 
on the BH3 profile  
 
TMD 
peptides 
CT20p MOM destabilization Preclinical  
murine breast 
cancer tumor 
model 
 
 Bfl-1 C-terminal MOM destabilization Preclinical    
 
BH3 
mimetics 
 
 
 
Gossypol (AT-101) Bcl-2, Bcl-xL Phase II 
Paclitaxel, 
Carboplatin 
Cisplatin, 
Etoposide 
Docetaxel, 
Prednisone 
Lymphoma                       
, 
SCLC                               
, 
HR-Prostate cáncer                 
Phase I              
, 
Phase I/II         
,            
Phase I
 TW-37 Bcl-2, Bcl-xL, Mcl-1, Bfl-1 Preclinical  Lymphoma  
 Apogossypol (ApoG2) 
Bcl-2, Bcl-xL, 
Mcl-1 
Preclinical  Lymphoma  
 (-) AT-101 Bcl-2, Bcl-xL, Mcl-1 Phase II  B-cell lymphomas  
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1.8.2.2. Mitochondrial priming.  
To determine the threshold of apoptosis, regulation of the balance between pro- and anti-
apoptotic proteins is critical and depends on many factors. Cells express sufficient anti-
apoptotic proteins to bind and inactivate pro-apoptotic members and other pro-death 
signals that are present under physiological conditions (324). However, the amount of 
prosurvival proteins that a cell may dispose varies depending on the type of cell. Some 
cells in the hematopoietic and immune systems maintain relatively small buffers of anti-
apoptotic proteins (324) to activate their elimination quickly when the situation is 
required (325). However, highly specialized and fully differentiated cells with a longer 
lifespan display high expression levels of anti-apoptotic proteins to survive against 
stochastic fluctuations in cellular stress (324). These differences in the levels of anti-
apoptotic proteins can affect the outcome of chemotherapy treatments. These cells that 
have a small reserve of unbound anti-apoptotic proteins are ‘primed’ for apoptosis 
whereas cells with large reserves are ‘unprimed’ (Figure 1.10). When these two types of 
cells are treated with equal doses of chemotherapy, the primed cell will be more sensitive 
to apoptosis than the unprimed cell. The priming state of the mitochondria is important 
because cells within tumors that have undergone treatment and then recurred are 
Clinical state combinated (CSC); Clinical state alone (CSA) 
 (-) AT-101 Bcl-2, Bcl-xL, Mcl-1 Phase II  B-cell lymphomas  
 Sabutoclax               (BI-97C1) 
Bcl-2, Bcl-xL, 
Mcl-1, Bfl-1 Preclinical  B-cell lymphomas  
 ABT-737 Bcl-2, Bcl-xL, Bc-w Phase II/III Platinum 
Ovarian cáncer and 
leukemia 
Phase 
II/III 
 ABT-263 Bcl-2, Bcl-xL, Bc-w  Phase II/III  
(SCLCs) and 
leukemia 
 
 
Obatoclax               
(GX-15-070) 
 
Bcl-2, Bcl-xL, 
Bc-w, Mcl-1 
 
Phase II 
 
Etoposide 
Bortezomib 
Docetaxel             
Rituximab  
Extensive stage-
SCLC MCL, 
Hodgkin’s or Non 
Hodgkins 
lymphoma, MM  
NSCLC   
Lymphoma 
Phase II  
Phase II  
Phase II                                         
Phase II 
 HA-14 Bcl-2, Bcl-xL Preclinical Cisplatin MDA-MB-231 
breast cancer cells 
 
 BI-97D6 Bcl-2, Bcl-xL, Mcl-1, Bfl-1 Preclinical  
Prostate, lung 
cancer and 
lymphoma cell 
lines 
 
 
 BH-3 M6 
Bcl-2, Bcl-xL, 
Mcl-1 Precliniclal  
Lung 
adenocarcinoma 
cell line A549 
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frequently less primed, making them less sensitive to subsequent rounds of chemotherapy 
(324, 326). The selective pressure of chemotherapy likely culls primed cancer cells, 
leaving only unprimed cells to repopulate the tumor (324, 326). These unprimed relapsed 
tumors are frequently intractable. 
To analyze the mitochondrial priming state of a cell line, a functional assay called 
“BH3 profiling” has been developed to measure the apoptotic threshold in cancerous and 
normal cells! (113). The idea is to expose mitochondria to peptides and/or SMI derived 
from the BH3 domains of pro-death BH3-only proteins and measure the concentration 
necessary to induce MOMP (327). As an example, sensitivity of mitochondria to Bad 
BH3 or Noxa BH3 peptides indicates a selective dependence on Bcl-2 or Mcl-1, 
respectively (328, 329). In the case of Bim BH3 or Puma BH3 peptides, more 
promiscuous to bind to anti-apoptotic proteins, sensitivity indicates a highly primed state, 
with a low reserve of unbound anti-apoptotic proteins (324, 326, 329). Detection of 
MOMP (Figure 1.9) is measured by mitochondrial potential, which occurs when the anti-
apoptotic reserve cannot avoid the Bax and/or Bak activation in response to a fixed 
titration of pro-death BH3 peptides: the faster a cell is depolarized, or the lower 
concentration of peptide required for MOMP, the more primed it is. As the activities of 
the BCL-2 family proteins are regulated by several posttranslational modifications and 
interactions with other proteins (330), the treatment with fixed doses of pro-apoptotic 
peptides let to measure the integrated functional output of the BCL-2 family efficiently 
(324). 
It has been shown that increasing mitochondrial priming by treating cells with a drug, 
which binds to anti-apoptotic factors, increases the response of a myeloid leukaemia cell 
line to various cytotoxic agents! (331). These studies raise the possibility that increasing 
mitochondrial priming may be a useful adjunctive treatment to increase response to 
cytotoxic therapies in human cancer treatments. Therefore, Bcl-2 inhibition strategies also 
represent a form of ‘synthetic lethality’ that selectively kills cancer cells addicted to Bcl-2 
expression for survival. 
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Figure 1.10. Model of mitochondrial priming. (upper image) Unprimed cells have their, pro-apoptotic BH3 
only proteins sequestered by anti-apoptotic proteins. In primed cells (down), the anti-apoptotic proteins are 
blocked by treatments against their BH3 domain, releasing the pro-apoptotic proteins to decrease the MOMP 
threshold when Chemotherapy is applied. For this reason, a cell primed for apoptosis is more likely to undergo 
cell death in response to chemotherapy than an unprimed cell. Inspired by (324). 
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Apoptosis is a common type of programmed cell death. This cellular process is centrally 
regulated by the BCL-2 family proteins. Members of this family are found in the 
cytoplasm, ER and MOM in healthy cells. However, during apoptotis most of the 
interactions between these proteins occur at the membranes of intracellular organelles. 
The general aim of this Thesis is to expand the knowledge of the mechanism of action of 
the BCL-2 family proteins in the presence and absence of membranes. This aim was 
approached with the following specific objectives: 
 
• Despite the fact most BCL-2 proteins exert their functions in the mitochondrial 
membrane, the role of the TMDs in protein-protein interactions and apoptotic 
modulation has been poorly understood. The first objective of this project has 
been to determine the involvement of the BCL-2 TMDs in the interaction network 
of the BCL-2 protein family. The importance of BCL-2 TMDs interactions in the 
context of Bcl-2 full length proteins has also been studied, along with the 
functional relevance of BCL-2 TMDs in the apoptotic pathways. 
               
• The capacity of BH3-only proteins to insert into the mitochondrial membrane is 
controversial. Then, the second objective has been to clarify the ability of 
predicted BH3-only TMDs to insert into different biological membranes. 
 
• The role of BCL-2 cytosolic domains such as MOMP sensitizers in 
chemotherapy has been extensively studied. However, little is known about the 
contribution of BCL-2 TMDs to this process. The third objective of this thesis 
has been to investigate the contribution of BCL-2 TMDs-derived peptides to 
mitochondrial outer membrane permeabilization (MOMP) process. 
 
• This project also addresses the study of the different cell death pathways 
activated in response to proapoptotic drugs, depending on the apoptotic 
machinery available in the cell.  
 
According to accomplish these objectives, the project has been divided in four chapters as 
follow: 
CHAPTER I. Interactions between BCL-2 family members via their transmembrane 
domain (TMD): Relevance in apoptotic control.  !
CHAPTER II.!Insertion of BH3-only C-terminal domains into biological membranes. 
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CHAPTER III.! Peptides derived from the transmembrane domain of BCL-2 proteins as 
potential mitochondrial priming tools. 
 
CHAPTER IV.!BH3-mimetics and cisplatin-induced cell death proceeds through different 
pathways depending on the availability of death-related cellular components. 
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3.1 CHAPTER I. 
3.1.1. Design and cloning of ToxRed BCL-2 TMD constructs.  
Maltose-complementation assay was performed as described (332, 333) in order to 
determine the correct orientation and insertion in the inner membrane of constructs 
containing TM domains and to study transmembrane helix-helix associations in a natural 
membrane environment. ToxR original plasmids were kindly provided from Prof. 
William De Grado (UCSF School of Pharmacy). In this system, a putative transmembrane 
(TM) sequence is cloned between a sequence encoding the transcription activator domain 
of Vibrio cholerae ToxR and a sequence encoding the periplasmic domain of the E. coli 
MBP (see Figure 4.1). To determine whether the putative transmembrane sequence 
mediates transmembrane oligomerization, the ToxR-TM-MBP fusion proteins are 
expressed in E. coli MM39. Membrane localization of the fusion protein is detected based 
on complementation of a non-polar malE mutant E. coli MM39 strain. Insertion of the 
ToxR-TM-MBP fusion protein into the inner membrane, such that the MBP domain 
localizes to the periplasmic space, is detected by determining whether the bacteria are 
able to transport maltose and thus grow on maltose-minimal medium. Dimerization of the 
fusion protein is determined based on expression of the RFP gene, which is under the 
control of the ctx promoter.! Recognition of the promoter sequence only occurs when 
ToxR dimerize, and this dimerization is only possible if BCL-2 TMDs interact and bring 
closer the ToxR monomers to dimerize. The inactivating ToxR mutation R96K (ToxR*) 
was chosen as a system control (334) by its capability to dimerize but not to recognize the 
promoter sequence. GpA TMD was used as positive control of interaction, and the point 
mutant GpA G83I was used as negative control. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. pGL3 plasmid adapted to ToxR system. 
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To generate ToxR quimeric constructs, DNA oligonucleotides from BCL-2 TMD 
were designed and cloned in pGL3 ToxR-HA-MBP plasmid. This plasmid contains a 
sequence for ampicillin resistance and a polilinker site (Figure 3.1). Reverse and forward 
BCL-2 TMDs primers (100 µM) were annealed with annealing buffer (20 mM Tris-HCl, 
20 mM MgCl2, 500 mM NaCl), using Eppendorf 5331 Gradiant Master Cycler with a 
multistep temperature protocol (95ºC 10 min, 90°C 10 min and over night at 60°C). 
HindIII/XhoI restriction sites were introduced in primers flanking the TMD sequence. 
Annealed primers were treated 4 h with polynucleotide kinase (PNK, Roche) and ligated 
overnight with T4 DNA ligase (Promega) at 16ºC, using HindIII/XhoI restriction 
enzymes (Roche) to digest the ToxR plasmids for 2 h. Alkaline Phosphatase (Roche) was 
used 2 h to remove the 5’ phosphate in the ToxR vector. 
All the constructs were transformed by heat shock (90 sec at 42ºC) in E.coli DH5α 
competent cells and incubated in Lysogeny Broth (LB) for 30 minutes at 37°C, pelleted at 
3000×g and plated directly onto LB agar petri dish containing ampicillin. After 24 h, 
positive colonies were isolated and cultured on LB medium with ampicillin for 24 h at 
37°C. Plasmid DNA was isolated with QIAprep Spin MiniPrep Kit (Qiagen) for 
sequencing analysis. 
Primers for mutagenesis were designed with GeneRuler software. All transmembrane 
sequences were codon-optimized for E. coli. TMD mutants were cloned using standard 
site directed mutagenesis with commercially available Stratagene Quikchange II kit 
(Agilent, CA, USA). All molecular biology techniques were performed according to 
standard procedures. 
3.1.2. Expression of ToxR chimera. 
ToxR-TMD-MBP constructs (200 ng) were transformed using of 200 µL MM39 
competent cells with heat shock at 42°C for 90 sec and incubation on ice for two minutes, 
followed by addition of 800 µL LB medium and incubation with shaking at 37°C for one 
hour. The transformation mixture was pellet and plated in minimal-agar media in the 
presence of ampicillin 100 µg/ml. After 48 h, MM39 cells containing ToxR-TM-MBP 
plasmids were grown into LB with ampicilin for 6 h in triplicate. Then, cultures were 
pelleted and incubated with shaking in 24-well plates (Thermo scientific) at 37°C for 36 h 
into minimal media to grow to OD
600
 0.8. RFP emission spectra were collected by Wallac 
1420 Workstation with an excitation wavelength of 570 nm and emission wavelengths of 
620 nm. All the results obtained for each ToxR-TMD-MBP were normalized according to 
ToxR*-TMD-MBP basal fluoresecence signal and cell growth. 
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3.1.3. Immunoblotting experiments of ToxR-TMD chimera. 
MM39 cells were pelleted by centrifugation for 5 min at 3000×g, the supernatant was 
removed and cell pellets were resuspended in 10× initial volume of FastBreak cell lysis 
reagent (Promega). Then the cells were transfered to 1.5-mL Eppendorf tubes and the 
mixture was incubated at room temperature with gentle agitation for 30 min. Samples 
were centrifuged for 10 min and the spheroplasmic and periplasmic fractions were 
separated and quantified by the BCA protein assay kit (Thermo Scientific). 50 µg of 
protein from spheroplasmic fraction was dissolved in protein loading buffer (Tris-HCl pH 
6.8, 10% w/v SDS, 250 mM DTT, 0.03% w/v bromophenol blue, and 50% v/v glycerol), 
boiled 5 min at 95ºC and resolved by SDS-PAGE (acrylamide 12%). Then samples were 
transferred to nitrocellulose membranes, blocked with 5% non fat milk, washed three 
times with TBS-Tween 20 0.1% and incubated overnight at 4ºC with a specific primary 
antibody (MBP from New England Biolabs (#E8038S); HA C29F4 (#3724S) and c-myc 
9B11 (#2276S, from Cell Signaling). Membranes were washed with TBS-Tween 20 0.1% 
and probed with the appropriate secondary antibody α-mouse (1:3000, A4937, Sigma) or 
α-rabbit (1:3000,A0545, Sigma) conjugated to horseradish peroxidase for enhanced 
chemiluminescence detection (Amersham Pharmacia Biotech). 
3.1.4. Cell culture, treatments, transfections and chemicals.  
ABT-263 and staurosporine (STS) were from Abbott Laboratories and Deltaclone, 
respectively. The human cervix adenocarcinoma HeLa cell line was purchased from 
ATCC and Human colorectal carcinoma HCT 116 Wt, KO Bax/Bak, KO Bax, and KO Bak 
were kindly provided by Prof. Richard Youle and by Prof Bert Vogelstein. HeLa cell line 
was grown in Dulbecco's Modified Eagle's Medium (DMEM) and HCT 116 cells were 
grown in McCoy’s 5A medium, both supplemented with 10% fetal bovine serum (FBS). 
Cultures were maintained at 37°C in a 5% CO2 atmosphere. Cell media and FBS were 
purchased from GIBCO BRL Life Technologies. When indicated, cells were treated with 
0.1-1 µM of staurosporine and 5-15 µM of ABT-263. When required, 5 µM zVAD was 
administered 30 min after treatment addition, and cells were maintained in culture for 24 
h. All cell lines were transfected using LipofectamineTM 2000 (Invitrogen) or Turbofect 
Transfection Reagent (Thermo scientific) following the manufacturer’s protocol.  
3.1.5. BiFC-TMDs assays.  
BiFC (bimolecular fluorescence complementation) analyses were performed as previously 
described (335-337). Venus protein (a green variant of the yellow fluorescent portein, 
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YFP) can be separated in two fragments: BiFC-VN (1-155, with the point mutation I152L 
that decreases the signal noise and reduces false positive results) and BiFC-VC (155-238, 
A206K). The BiFC system is based on the capability of these fragments to reconstitute 
Venus protein when they are closer to each other. The transmembrane region of the 
different BCL-2 proteins were fused to both VN/VC with a linker sequence between the 
BCL-2 TMDs and the Venus fragments (see Figure 4.5A). When BCL-2 TMDs interact, 
Venus protein will be restored and green fluorescence emission will be measured. The 
nuclear proteins b-Jun and b-fos were used as positive control of interaction, as well as 
the truncated form d-Δfos that not interacts with d-jun to establish a negative control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Plasmids encoding for N- and C- terminal Venus protein (https://www.addgene.com). 
 
BiFC plasmids were adquired in Addgene (Figure 3.2, 27097 and 22011) and were 
modified with a linker and restriction site sequences behind Venus fragments, in order to 
clone the BCL-2 TMDs in the adequate topology. BCL-2 TMDs primers were then 
designed flanked with NotI restriction site to insert the TMDs in the C-terminal of each 
fragment of Venus. Reverse and forward BCL-2 TMDs primers (100 µM) were annealed 
in the presence of annealing buffer (20 mM Tris-HCl, 20 mM MgCl2, 500 mM NaCl), 
using Eppendorf 5331 Gradiant Master Cycler with a multistep temperature protocol 
(95ºC 10 min, 90°C 10 min and over night at 60°C). Annealed primers were treated 4 h 
with polynucleotide kinase (PNK, Roche) and ligated overnight with T4 DNA ligase 
(Promega) at 16ºC, using NotI restriction enzymes (Roche) to digest the ToxR plasmids 
for 2 h. Alkaline Phosphatase (Roche) was used 2 h to remove the 5’ phosphate in the 
ToxR vector. 
All the constructs were transformed by heat shock (90 sec at 42ºC) in E.coli DH5α 
competent cells and incubated in Lysogeny Broth (LB) for 30 minutes at 37°C, pelleted at 
3000×g and plated directly onto LB agar petri dish containing ampicillin. After 24 h, 
positive colonies were isolated and cultured on LB medium with ampicillin for 24 h at 
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37°C. Plasmid DNA was isolated with QIAprep Spin MiniPrep Kit (Qiagen) for 
sequencing analysis. 
BiFC-TMD point mutant constructs were obtained using standard site directed 
mutagenesis with Stratagene Quikchange II kit (Agilent, CA, USA). Finally, constructs 
were verified by sequencing. 
HeLa and HCT 116 cells were maintained under conditions recommended by the 
American Type Culture Collection. Cells were grown in six-well plates to 60% 
confluence and transfected with 0.25 to 1 µg of the plasmids expressing the proteins 
indicated in each experiment. Transfected cells were incubated at 37°C for 24 h and then 
Venus fluorescence emission was measured in a Wallac 1420 Workstation at 535 nm 
(using 500 nm as excitation wavelength). 
3.1.6. Immunoblotting of BiFC-TMD chimera. 
All cell extracts were prepared from 2×105 cells seeded in 6-well plates. After 24 h, cells 
were treated and/or transfected as indicated. Cells were scraped, washed with PBS and 
collected by centrifugation at 500×g 24 h later. Whole cell extracts were obtained by 
lysing cells in a buffer containing 25 mM Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 
1% SDS, plus protease and phosphatase inhibitors. Protein concentration was determined 
by BCA protein assay kit (Thermo Scientific). Cell lysates were dissolved in protein 
loading buffer (Tris-HCl pH 6.8, 10% w/v SDS, 250 mM DTT, 0.03% w/v bromophenol 
blue, and 50% v/v glycerol), boiled 5 min at 95ºC and resolved by SDS-PAGE 
(acrylamide 12%). Then samples were transferred to nitrocellulose membranes, blocked 
with 5% non fat milk, washed three times with TBS-Tween 20 0.1% and incubated 
overnight at 4ºC with a specific primary antibody. Membranes were washed again with 
TBS-Tween 20 0.1% and probed with the appropriate secondary antibody conjugated to 
horseradish peroxidase for enhanced chemiluminescence detection (Amersham Pharmacia 
Biotech). Antibodies against HA C29F4 (1:1000, #3724S), c-myc 9B11 (1:1000, #2276S), 
Caspase-3 (1:1000, #9662S) and Bax (1:1000, #2772) came from Cell Signaling. α-
tubulin antibody (#T8203) was from Sigma-Aldrich. Secondary antibodies α-mouse 
(1:3000, A4937) and α-rabbit (1:3000, A0545) were provided by Sigma. 
3.1.7. Determination of caspase activity upon transfection with BiFC-BCL-2 
TMD construts in HCT 116 cells.  
The purpose of this assay was to determine the activity of the apoptotic executioner 
caspase-3 in cells treated with BCL-2 TMDs and/or pro-apoptotic treatments. All cell 
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extracts were prepared from 2×105 cells seeded in 6-well plates. After 24 h, cells were 
treated and/or transfected as indicated above. 24 h later, cells were then scraped, washed 
with PBS and collected by centrifugation at 500×g. Pellets were resuspended in caspase 
assay buffer (PBS 10% glycerol, 0.1 mM EDTA, 2 mM DTT) supplemented with 
protease inhibitor cocktail (Sigma) and kept on ice for 5 min. Once pellets were frozen 
and thawed three times in liquid nitrogen, cell lysates were centrifuged at 14000 rpm for 5 
min and supernatants were collected. Quantification of total protein concentration was 
performed using the BCA protein assay kit (Thermo Scientific). Total protein (50 µg) was 
mixed with 200 µL of caspase assay buffer (PBS, 10% glycerol, 0.1 mM EDTA, 2 mM 
DTT) containing 20 µM of the Ac-DEVD-afc (Figure 3.3) (Enzo Life Sciences) caspase-3 
specific substrate. Caspase activity was continuously monitored following the release of 
fluorescent afc at 37°C using a Wallac 1420 Workstation (λexc 400 nm; λem 508 nm). 
Caspase-3 activity was expressed as the increase of relative fluorescence units per min 
(A.U.). 
 
 
 
 
 
 
 
 
Figure 3.3.!AC-DEVD-AFC Structure. 
3.1.8. Flow cytometry of BCL-2 TMDs in HCT 116 Wt and Bax/Bak KO.  
After treatment and/or transfection, the cell culture medium was collected to retain 
floating cells and attached cells were dislodged using 0.5% Trypsin-EDTA (GIBCO). 
Floating and attached cells were combined and harvested by centrifugation at 400×g 10 
min. Cell pellets were suspended in 100 µl binding buffer (10 mM HEPES pH 7.4, 140 
mM NaCl, 2.5 mM CaCl2) and incubated with 10 µl FITC Annexin V (BD Biosciences) 
and 10 µl of Propidium Iodide (PI, 6 µM; BD Biosciences) for 10 min at 37°C. Staining 
for Annexin V and PI was assessed by flow cytometry on a FC500 cytometer (Beckman 
Coulter) followed by data analysis using FlowJo software (Tree Star Inc). 
3.1.9. Immunofluorescence of BCL-2 TMD BiFC constructs in mitochondria.  
For confocal microscopy, 2×105 cells were seeded on glass cover slips to reach 50% 
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confluence next day. Cells were transfected as indicated in 3.1. To analyze the 
mitochondrial localization of the BCL-2 TMDs, HCT 116 cells were incubated (37ºC) 
with Mitotracker dye 500 nM (Invitrogen) 30 min. Microscopic images of living cells 
were taken 24 hours after transfection and colocalization was defined as completely 
overlapping or partially overlapping signals.  
For cytochrome c release assay, after cell attachment, spreading, and transfection with 
the BiFC-TMD constructs, HeLa and HCT 116 cells were fixed with 4% 
paraformaldehyde 20 min, following the treatment indicated in the corresponding figure. 
After three washes with PBS, cells were permeabilized with 0.1% Triton X-100 10 min 
and blocked in 2% gelatin PBS 30 min. Cells were then labeled with antibodies against 
Cyt-c (1:200; SC13561; Santa Cruz) in 2% gelatin PBS followed by an anti-mouse IgG-
Alexa 555 (1:400) secondary antibody also in 2% gelatin PBS (Invitrogen). Cover slips 
were mounted on glass slides with 5 µL of Mowiol/Dapi (nuclear marker, 5 µg/ml) 
(Sigma).  Images were obtained using confocal microscopy (LSM 510) with a 63x 
objective.  Two hundred cells were counted and classified according to the localization of 
Cyt-c in mitochondria (tubular morphology) or cytosol (diffuse pattern). Fluorescence 
images were analyzed with ImageJ 1.46i “JACoP plugin” according to the provider’s 
instructions. All background fluorescence was eliminated to avoid false-positives. All 
experiments were repeated three times. At least 30 images of each sample were analysed.  
3.1.10. Subcellular fractionation in HCT 116 cells. 
To obtain mitochondrial and cytosolic fractions, cells were harvested and centrifuged at 
1200×g for 5 min at 4ºC. Cell pellet were re-suspended in SEM buffer (10 mM HEPES, 
250 mM sucrose, pH 7.2) supplemented with protease inhibitors and homogenized with 
30 strokes in tight douncer. Then, samples were centrifuged at 500×g for 3 min at 4ºC to 
remove nuclear fractions. The supernatant was transferred to a new tube and subsequently 
subjected to a centrifugation step at 13 000×g for 30 min at 4ºC. The supernatant of this 
step, the cytosolic fraction, was ultracentrifuged at 100 000×g for 1 h at 4ºC, followed by 
an ultrafiltration step. Finally, cellular fractions were dissolved in protein Loading Buffer 
(Tris-HCl pH 6.8, 10% w/v SDS, 250 mM DTT, 0.03% w/v bromophenol blue, and 50% 
v/v glycerol), boiled 5 min at 95ºC, separated by SDS-PAGE (12%) and subjected to 
western blot analysis (see 3.1.6). Sedimented mitochondria were washed two times and 
then analyzed by SDS- PAGE and subsequent western blotting. Tom 20 FL-145 (1:1000, 
sc-11415, Santa Cruz) and GAPDH FL-335 (1:1000, sc-25778, Santa Cruz) were used as 
mitochondrial and cytosolic markers, respectively. C-myc 9B11 (1:1000, #2276S), 
antibody came from Cell Signalling. Secondary antibodies α-mouse (1:3000, A4937) and 
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α-rabbit (1:3000, A0545) were provided by Sigma. 
3.1.11. Cell toxicity assays LDH activity in HCT 116 cells. 
Lactate dehydrogenase (LDH) release is commonly used as a marker for necrotic/oncotic 
cell death. In this assay, release of the cytosolic enzyme lactate dehydrogenase from cells 
with a damaged plasma membrane (indicating necrotic cell death) to the culture medium 
is evaluated. Cytotox-ONE Homogeneous Membrane Integrity Assay Kit (Promega) was 
used for evaluation of cellular integrity of the cell cultures, measuring the enzymatic 
conversion of resazurin compound to resorufin fluorescent compound. The amount of 
resorufin formed is directly proportional to the amount of LDH released into the medium 
(Figure 3.4).  
 
 
 
 
 
 
 
 
 
Figure 3.4.! Lactate dehydrogenase (LDH) release. The amount of fluorescent resorufin is directly 
proportional to the amount of LDH released from a leaky cell (https://www.lifetechnologies.com). 
 
Briefly, cell cultures were plated and treated as described in section 3.1.4. After 24 h 
of transfection and/or treatment, cultures were centrifuged at 1500 rpm for 5 min and 
supernatants were recovered. 50 µL of the supernatant were mixed with 50 µL of 
commercial substrate in black 96-well plates and incubated in darkness at room 
temperature for 30min. Fluorescence was measured at a λexc 560 nm and λem 590 nm on 
the Wallac Victor 1420 spectrofluorimeter. Each sample was analyzed in triplicate and 
results were expressed as the percent of lactate dehydrogenase release for each sample 
compared to the positive control (100% release) 0.1% Triton X-100 treatment. 
3.1.12. Bioinformatic analysis of the BCL-2 sequences hydrophobicity.  
Prediction of TMDs was done using three of the most common methods available online: 
Dense Alignment Surface method in DAS server (http://www.sbc.su.se/~miklos/DAS/); 
TransMembrane Hidden Markov Model at the TMHMM Server v. 2.0 
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(http://www.cbs.dtu.dk/services/TMHMM/); while prediction of Gibbs Free Energy (ΔG) 
was obtained with ΔG prediction server v1.0 (http://dgpred.cbr.su.se/) using standard 
parameters in all cases. The entire protein sequences were obtained from UniProt 
(http://www.uniprot.org). 
3.1.13. Statistical analysis. 
Bars represent the mean ± s.d. of at least three independent experiments. Statistical 
significance was determined by Dunnett's Multiple Comparison Test (95%CI) using the 
Graph Pad software. p<0.05 was designated as statistically significant. 
 
 
3.2 CHAPTER II 
3.2.1. Enzymes and chemicals. 
The plasmid pGEM1, the TnT coupled transcription/translation system, the RiboMAX 
SP6 RNA polymerase system and rabbit reticulocyte lysate were from Promega (Madison, 
WI). Dog pancreas microsomes were purchased from tRNA Probes (College Station, TX),. 
GFP Plasmid was provided by addgene (#17999). [35S] Met and 14C-labeled methylated 
markers were from Perkin-Elmer. All the restriction enzymes were from Roche Molecular 
Biochemicals. Proteinase K (PK) was from Sigma-Aldrich (St. Louis, MO). The DNA 
plasmid, RNA clean-up, and PCR purification kits were from Qiagen (Hilden, Germany). 
The oligonucleotides were from Thermo (Ulm, Germany).  
3.2.2. Computer-assisted analyses of the BH3-only TMD sequences. 
Prediction of TM helices was performed using some of the most common methods 
available online described in 3.1.12. 
3.2.3. DNA manipulations. 
The BH3-only putative TMDs were introduced into the modified Lep sequence (Lep’, see 
Figure 5.1A) from the pGEM1 plasmid! (338, 339) between the SpeI and KpnI sites by 
PCR amplification (Taq polymerase Pwo, dNTPs and PCR Buffer provided by Roche) of 
the different TMD sequences containing appropriate restriction sites. For GFP-TMDs 
cloning sites were BglII and EcoRI. After PCR amplification, PCR products were purified, 
digested, and ligated to the corresponding Lep or GFP vector digested with the 
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appropriate enzymes using standard molecular biology protocols. All new constructs were 
confirmed by DNA sequencing. The Lep’ construct carried one glycosylation acceptor 
site in positions 3–5 of an extended sequence of 24 residues previously described!(340).  
3.2.4. In vitro transcription and translation of BH3-only TMDs in Lep’ 
constructs. 
Full-length Lep constructs were transcribed and translated in the presence of reticulocyte 
lysate (TnT Quick system (Promega)). 1 µg DNA template, 1 µL 35S-Met/Cys (5 µCi) and 
1 µL dog pancreas microsomes (341) (tRNA Probes) were added at the start of the 
reaction, and samples were incubated for 90’ at 30°C.  
After translation, membranes were collected by ultra-centrifugation at 10,000×g 4°C 
for 10 min using a TLA-45 rotor. Samples (pellets and supernatants) were dissolved in 
protein loading buffer (Tris-HCl pH 6.8, 10% w/v SDS, 250 mM DTT, 0.03% w/v 
bromophenol blue, and 50% v/v glycerol), boiled 5 min at 95ºC and analyzed by sodium-
dodecylsulfate-polyacrylamide gel electrophoresis (SDS-PAGE, acrylamide 12%). Fuji 
FLA3000 phosphorimager and ImageGauge software was used to visualize BH3-only 
TMD insertion. For proteinase K protection assay, the translation mixture was 
supplemented with 1 µL of 50 mM CaCl2 and 1 µL of proteinase K (4 mg/mL) and then 
digested 40 min on ice. The reaction was stopped by adding 1 mM 
phenylmethanesulfonylfluoride before SDS-PAGE analysis. Negative control experiments 
were developed in absence of microsomes. Lep native TMD (fragment H2) was used as 
positive control of insertion. All the experiments were repated at least three times. 
3.2.5. Design and cloning of ToxRed BH3-only TMD constructs. 
Maltose-complementation assay was performed as described in 3.1.1. (332, 333) in order 
to determine the correct insertion/orientation of BH3-only TMD constructs in the E. coli 
MM39 strain inner membrane.  
3.2.6. Expression of ToxRed chimera.  
ToxR-TMD-MBP constructs (200 ng) were transformed into 200 µL MM39 competent 
cells with heat shock at 42 °C for 90 sec and incubation on ice for two minutes, followed 
by addition of 800 µL LB medium and incubation with shaking at 37 °C for one hour. The 
transformation mixture was pelleted and plated in minimal-agar media in the presence of 
ampicillin (100 µg/ml) for two days to analyze the efficiency of the BH3-only TMD 
insertion. 
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3.2.7. Cell Lines and Cultures. 
The human cervix adenocarcinoma HeLa cells were obtained from the ATCC. Cells were 
grown in Dulbecco’s modified Eagle’s medium plus 10% FBS. GFP protein was fused at 
the N-terminus of the putative TM regions of the different BH3-only proteins as described 
in 3.2.3. GFP-TMD constructs were transfected into mammalian cells with 
LipofectamineTM 2000 (Invitrogen) as indicated in 3.1.4. 
3.2.8. Immunofluorescence of GFP BH3-only TMD constructs in HeLa cells.  
Immunolocalization assays were performed following the protocol described in 3.1.9. 
HeLa cells were labeled in the different assays with antibodies against Cyt-c (1:200; 
SC13561; Santa Cruz) and Grp78 (1:400; ab21685; Abcam) followed by an anti-mouse 
IgG-Alexa 555 secondary antibody (1:400; Invitrogen). Cover slips were mounted on 
glass slides with Mowiol/Dapi (Sigma).  Images were obtained using confocal 
microscopy (LSM 510) with a 63x objective.  Colocalization assays of the GFP-TMD 
constructs and Mitotracker dye!(500 nM, 20 min, 37ºC, Invitrogen) was also developed ex 
vivo. Microscopic images of living cells were taken 24 hours after transfection (green 
channel, λexc 488 nm, λemi 488 nm; Red channel, λexc 561 nm, λemi 598 nm). The 
experiments were reproduced three times. At least 30 images of each sample were 
analyzed. 
3.2.9. Immunoblotting and determination of caspase activity for BH3-only 
TMD construts in HeLa cells.  
After 24 h of GFP-TMD transfections, cells were treated as indicated in sections 3.1.6. 
and 3.1.7., GFP (1:1000, ab13970, Abcam) and α-tubulin (1:1000, #T8203, Sigma-
Aldrich) antibodies were used for immunoblotting. Caspase-3 activity was expressed as 
the increase of relative fluorescence units per min (A.U.). All assays were repeated at 
least three times. 
3.2.10. Statistical analyses. 
Statistical analyses were performed as described above (3.1.13). 
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3.3 CHAPTER III 
3.3.1. Bioinformatic analyses of BCL-2 TMD-pepts.  
The prediction of BCL-2 TMDs was performed as described in section 3.1.12. 
3.3.2 BCL-2 TMD Peptides Synthesis.   
Peptides were prepared by Fmoc (N-(9-fluorenyl) methoxycarbonyl)-based solid phase 
synthesis in a 433A Applied Biosystems peptide synthesizer with a Rink Amide Resin as 
reported previously (342, 343). Fmoc is a base-label protecting group for amines: 
incoming amino acids require protection of their amino group in order to obtain coupling 
to free amino attached to the resin. Elimination of Fmoc group was performed via base-
induced β-elimination. Then, dibenzofulvene and carbon dioxide are split off. Secondary 
bases such as piperidine add to the former molecule whereas bases such as DBU do not 
react with the dibenzofulvene, which has to be removed rapidly from the peptide resin or 
scavenged by a secondary amine (piperidine) to avoid irreversible attachment to the 
liberated amino group.  
Peptides were synthesized with 2 or 3 lysines on both the N- and C-termini of the 
selected sequences in order to improve solubility (see Table 6.I). Peptides were cleaved 
from the resin by treatment with triﬂuoroacetic acid (TFA, 70%) and puriﬁed by 
preparative/analitical RP-HPLC (Lichrospher1 100 C18, 10 mm) system up to 95% of 
peptide purity using different acetonitrile gradients in aqueous 0.1 % TFA. Identity was 
confirmed by MALDI-TOF mass spectroscopy. Stock solutions of the peptides were 
prepared in Milli-Q water and the concentrations were determined by spectrophotometry 
in NanoDrop 1000 (Thermo Scientific). 
3.3.3. Circular Dichroism (CD) Measurements. 
CD is a powerful tool for the analysis of secondary structure in proteins and peptides. 
This methodology is based on light absorption spectroscopy that measures the difference 
in absorbance of right- and left-circularly polarized light by a substance (Figure 3.5A). In 
proteins, the chromophores of interest include the peptide bond (absorption below 240 
nm), aromatic amino acid side chains (absorption in the range 260 to 320 nm) and 
disulphide bonds (weak broad absorption bands centered around 260 nm). For all of that, 
CD studies give information about secondary structure configuration (alpha helix, parallel 
and antiparallel beta sheet and turn) of the peptide/protein analyzed (Figure 3.5B). 
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Figure 3.5. Circular dichroism. (A) Scheme of circularly polarized light. (B) CD spectra of secondary 
structures. (http://chemistry.rutgers.edu/grad/chem585/lecture1.html). 
 
CD spectra were recorded between 190 and 250 nm at 25°C on a Jasco J-810 
spectropolarimeter in quartz cells of 0.1-cm path length. Peptides were dissolved at 10 
µM in phosphate buffer (50 mM, pH 7.0), and their ability to adopt a secondary 
conformation was analyzed in pure 2,2,2-trifluoro-ethanol (TFE), 1% sodium dodecyl 
sulfate (SDS), and methanol (MeOH, 50 and 100%), respectively. Each CD spectrum was 
the average of 20 scans performed at 1 nm intervals. CD spectra were interpreted with the 
K2D software provided by Dichroweb (available on the World Wide Web). Results are 
expressed as mean molar residue ellipticities (degrees x cm2 x dmol-1). For measurements 
with liposomes, 1 mM of extruded liposome solution (POPC:PE:PS:PI or POPC only) 
prepared in 10 mM Sodium Phosphate 137 mM NaCl pH7.4 buffer was added to the 
cuvette where peptide stocks (10mM HEPES 150 mM NaCl pH 7.4) were titrated in to 
incrementally increase the peptide-liposome ratio. The ratios 1:201, 1:101, 1:51 and 1:31 
were analysed to determine the effect of peptide concentration on structure. Calculation of 
Molar Ellipticity (θ) of the peptides and spectra smoothing was achieved using Jasco 
instrument software. 
3.3.4. Dynamic Light Scattering.   
Malvern instruments Zetasizer Nano Z red (Malvern Laboratories Ltd. Malvern, UK) was 
utilized to determine the size of liposome particles in the presence of peptide via DLS. 
The relationship between particle size and Brownian motion (Stokes-Einstein 
relationship) is utilized by the Zetasizer to determine the average size of a population of 
A B 
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particles in solution. 0.1 mM POPC:PE:PS:PI (5:3:1:1) liposome was measured in a low 
volume disposable cell initially followed by incremental addition of peptide to achieve the 
same peptide-liposome ratios as in the CD measurements. Samples were incubated in the 
Zetasizer at 20°C for a total of 10 min prior to reading to give sufficient time for 
interaction between the peptide and the liposome and a consistent thermal gradient 
throughout the sample. Each reading consisted of 12 scans each of 10 sec duration with 
parameters set to measure size in a low volume disposable sizing cell. The equilibration 
time was set to 60 sec and was included in the incubation time.  
3.3.5 Dual Polarization Interferometry (DPI). 
Dual polarization interferometry is a relatively new technique, which explores the 
molecular layers adsorbed to the surface of a waveguide by means of an electromagnetic 
evanescent wave of a laser beam; it measures the refractive index and the thickness of 
very thin films, and is also used to study the protein adsorption at solid/water interface. 
Furthermore, if the refractive index of the studied film is fixed, the birefringence can be 
observed quantitatively so that the anisotropy of the film can be analyzed. DPI is a 
quantitative and real-time technique with the dimensional resolution of the order of 
angstroms. DPI then measures the increase of membrane mass due peptide 
association/integration (represented in X axis) and the decrease of membrane order when 
peptides are inserted into the membrane (Y axis) (Figure 3.6).! DPI applications involve 
membrane protein and lipid studies, analyzing the formation of lipid bilayer, the 
understanding of lipid structures, affinity and kinetics of lipid–lipid and protein–lipid 
interactions, structural changes taking place during interactions, and the structural nature 
of protein–lipid complexes. 
Liposome preparation for dual polarization interferometry.  Thin lipid films of POPC 
(PM-like) and two MITO-like mixtures, POPC:POPE:POPS:POPI (5:3:1:1) and 
POPC:POPE:POPS:POPI/CL (4.8:2.8:1:1:0.4) were hydrated to 1 mM lipid concentration, 
10 mM  HEPES 150 mM NaCl pH 7.4 and buffer solution at 37 °C for 1 h with constant 
vortexing. The hydrated lipid suspension was sonicated in a water bath for ~30 min at 
37 °C and extruded before use through 50 nm polycarbonate membranes (19 times) using 
an Avestin Lipofast extruder (Ottawa, Canada). 
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Figure 3.6. Dual Polarization Interferometry (DPI) methodology. Birefringence (Y axis) is a measure of 
membrane ordering. A decrease in birefringence indicates peptide insertion. Mass (X axis). Inpired by (344). 
 
Deposition of supported lipid bilayer on sensor chips.  Planar supported lipid bilayers 
(SLBs) were prepared via in situ adsorption of liposomes to a silicon oxynitride 
waveguide sensor chip (see Supporting information for detailed description). A fresh 
bilayer was used for each individual peptide measurement and 160 µL of each 
concentration was injected sequentially onto the SLB in increasing concentrations at a 
flow rate of 40 µL/min with a total of 30 min equilibration time between injections.  
Data acquisition was carried out using AnaLight200 version 2.1.0 software and 
analyzed using AnaLight Explorer proprietary software (345, 346).  
3.3.6. Small Unilamellar Liposomes (SUV) Preparation and Calcein Release 
Assay. 
Calcein release assay was performed to study the capability of the TMD-pepts to 
destabilize mitochondrial membranes. Small Unilamellar Liposomes (SUV) with plasma 
membrane and mitochondrial composition were designed. 
Small unilamellar liposomes were prepared as previously reported (347)(Figure3.6). 
Lipid samples were dissolved in a 2:1 (v/v) chloroform:methanol mixture and dried under 
N2 stream in order to remove residual organic solvents. The dried lipid was suspended by 
vortexing in 150 mM Hepes buffer (pH 7.0) containing 90 mM of calcein. Lipid mixtures 
were incubated for 20’ at a temperature above the phase transition of the major 
phospholipid component of the liposome. The final phospholipid concentration was about 
30 mM. Disruption of multilamellar vesicle (LMV) suspensions by sonication 5 min at 
4°C with a probe tip sonicator produced small unilamellar vesicles (SUV) with diameters 
in the range of 15-50 nm. SUV were composed of phosphatidylcholine (PC):CL (7:3, 
mol:mol) as MITO-like and PC:cholesterol (7:3, mol:mol) as PM-like.  The lipid 
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suspensions, SUV were then centrifuged at 10000 rpm for 10’. Free calcein was removed 
by passage of the dispersion through a column of Sephadex G-50 (Sigma-Aldrich).  For 
calcein release assays fluorescence measurements were made with a Jasco FP6600 
Spectrofluorometer using 495 nm and 520 nm, as excitation and emission wavelengths 
respectively.  
    
 
 
 
 
Figure 3.7. Calcein Release Assay scheme. Composition of a small unilamellar vescicle. 
3.3.7. Mitochondrial Isolation and cytochrome-c Release Assays in MEFs. 
Mitochondria were freshly isolated from MEFs (mouse embryonic fibroblast) cells by 
differential centrifugation steps as described previously (348). Cells were pelleted and 
suspended in ice-cold IBc buffer (125 mM KCl, 5 mM KH2PO4, 2 mM MgCl2, 25 µM 
EGTA, 5 mM succinate, 5 µM rotenone, and 10 mM HEPES-KOH (pH 7.2)). A Douncer 
Tissue Grinder Homogenizer (Wheaton) was used for cell homogenization (20 strokes). 
Consequently samples was centrifuged at 600×g for 10 min at 4°C; the supernatant was 
recollected and centrifuged at 7,000×g for 10 minutes at 4°C. The pellet was washed and 
resuspended with ice-cold IBc and centrifuged another time at 7,000×g for 10 minutes at 
4°C. Mitochondria concentration was quantified with BCA Protein Assay Kit (Thermo 
Scientific) and kept on ice. Isolated mitochondria  (0,5 mg protein/ml) were then 
incubated with the different TMD-pepts (50 µM) in IBc Buffer for 30 min at 30°C. 
Reaction mixtures were centrifuged at 7,000×g for 10 min. Supernatant and pellet 
fractions were solubilized in protein sample buffer, analyzed by SDS/PAGE (14% gel) 
and transferred to nitrocellulose (BioRad). Membranes were developed against 
cytochrome c antibody (#4272, Cell Signaling), α-tubulin antibody (#T8203, Sigma-
Aldrich) and VDAC1/2/3 antibody (sc-98708, Santa Cruz).  
Cholesterol 
Phospholipid 
Calcein 
TMD-pepts 30 min 
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3.3.8 Mitochondria Swelling measurements. 
Isolated mitochondria were suspended (final concentration 0,5 mg/ml) in 100 µl of 
swelling buffer (120 mM KCl, 10 mM Tris-HCl, 5 mM MOPS, 5 mM KH2PO4, pH 7,4) 
in a 96-well plate. A basal signal line was assessed for 5 min and then mitochondria were 
treated with 50 µM of each TMD peptide and 100 µM CaCl2, respectively. Changes in 
absorbance caused by swelling were monitored using a microplate reader at 540 nm every 
5 min for 1 hour. 
 
 
 
 
 
 
Figure 3.8. Mitochondria Swelling scheme!(349). 
3.3.9 Cell Lines and Cultures. 
Mouse embryonic fibroblast (MEFs) Bax/Bak KO cell line was kindly provided by Dr. 
Guido Kroemer (INSERM, University of Paris). The human cervix adenocarcinoma HeLa 
cells were obtained from the ATCC. Wild type and Bax/Bak KO HCT 116 cells were 
kindly provided by Professors Bert Vogelstein (Howard Hughes Medical Institute) and 
Richard Youle (NIH, Bethesda). MEFs and HeLa were grown in Dulbecco’s modified 
Eagle’s medium plus 10% FBS. HCT116 cells were grown in McCoy´s 5A Modified 
Medium plus 10% FBS. Cells were incubated at standard conditions. Peptides were 
transfected with LipofectamineTM 2000 (Invitrogen). Briefly, peptides were combined 
with 2,5 µl of Lipofectamine and Opti-MEM® Reduced Serum Media (Invitrogen) for 30 
min at room temperature. Then cells with confluency >70% were incubated 4 h at 37ºC 
with the transfection mixure. Finally, transfection mixture was discarded and CDDP 
treated and non-treated cells were incubated at 37ºC up to 24 hours. 
3.3.10 Cell-based Caspase 3/7 Activation assays for BCL-2 TMD-pepts in 
different cell lines. 
All cell extracts were prepared from 2 × 105 cells seeded in 6-well plates.  After 24 h, 
cells were treated with a Lipofectamine/ peptide (3 or 10 µM) mixture for 4 h followed by 
administration of 35 µM cis-diammineplatinum(II) dichloride (cisplatin, CDDP). After 24 
OD (540 nm) 
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hours, cells were manipulated as described in 3.1.7. Western blot assay of caspase-3 was 
developed as indicate in 3.1.6. 
3.3.11. Flow Cytometry assays of BCL-2 TMD-pepts in different cell lines. 
Cells were harvested by centrifugation, suspended in binding buffer (10 mM HEPES pH 
7.4, 140 mM NaCl, 2.5 mM CaCl2) and incubated with 1 µl of tetramethylrhodamine 
methyl ester perchlorate (TMRM; 1 µM). To measure apoptotic or necrotic cell death, the 
FITC-Annexin V/PI kit (BD Biosciences) was used following manufacturer instructions 
(see 3.1.8). To quantify the release of cytochrome c from mitochondria, HeLa cells were 
seeded at 1.5 105 cell/mL and after 24 h in presence of TMD-pepts, the InnocyteTM Flow 
Cytometric cytochrome c Release kit (Calbiochem) was used according to the 
manufacturer’s recommendations. Staining was assessed by flow cytometry on a FC500 
instrument (Beckman Coulter) followed by data analysis using FlowJo software (Tree 
Star Inc). 
3.3.12. Measurement of cellular ATP. 
Relative cellular ATP content was measured by the ATPlite Kit (PerkinElmer) according 
to manufacturer's protocol. Cells were plated in 96-well plates at 8,000 cells per well to 
allow for attachment overnight. Cellular ATP content was measured using a luminescent 
plate reader 4 h after peptide treatment.  
3.3.13. Mitochondrial dysfunction assays (MTT) upon TMD-pepts treatment 
in different cell lines. 
MTT colorimetric assay is based on enzymatic reduction of a yellow tetrazolium salt, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), generating a purple 
formazan crystal in metabolically active cells (Figure 3.9). Formazan is then solubilized 
producing a concentration related to colorimetric signal at 570 nm, proportional to the cell 
number and activity. Cells were cultured in sterile 96-well microtiter plates at a seeding 
density of 8000 cells/well for the HCT116 lines and 3000 cells/well for HeLa cells. After 
seeding, cells were left to adhere to the plate overnight, and then they were treated with 
the compounds and/or TMD-pepts of interest and incubated at 37°C for 24 h. MTT 
reagent (5 mg/ml in PBS) was added to each well and plates were further incubated for 4 
h at 37°C. Finally, the medium was removed and the precipitated formazan crystals were 
dissolved in optical grade DMSO (dimethyl sulfoxide). Plates were read at 570 nm on a 
Wallac 1420 workstation (Perkin Elmer).  
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Figure 3.9. Reduction of the yellow MTT to the purple formazan. 
3.3.14. Cell viability assays of TMD-pepts in different cell lines. 
Cells were seeded in 96-well plates at a cellular density of 8000 cells/well for the 
HCT116 lines and 3000 cells/well for HeLa cells. After 24 h, cells were treated as 
previously described. Cells were detached and 0.5% trypan dye blue was added in 
solution. Live cells possess intact cell membranes that exclude the dye, whereas dead cells 
do not. Unstained (viable) and stained (non-viable) cells were counted separately in a 
hemacytometer and the total number of viable cells in the population was calculated. 
3.3.15. Statistical analyses. 
Statistical analyses were performed as described above (3.1.13). 
 
 
3.4 CHAPTER IV 
3.4.1 Cell culture, treatments and chemicals.  
ABT-737 and GX15-070 drugs were purchased from Abbott Laboratories and from 
SelleckBio, respectively; cis-diammineplatinum(II) dichloride (cisplatin, CDDP), 
rapamycin and 3-methyladenine (3MA) were obtained from Sigma Aldrich. QM31 is a 
perhydro-1,4-diazepine-2,5-dione whose general synthetic method has been recently 
reported (350). The HeLa cell line was purchased from ATCC, and mouse embryonic 
fibroblasts MEFs wt and KO Bax/Bak (84, 351)) were kindly provided by Dr. Guido 
Kroemer (INSERM, University of Paris) and Dr. Francesco Cecconi (IRCCS Fondazione 
Santa Lucia in Rome) (MEFs wt and KO Apaf-1). All the cell lines were grown in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS). Cultures were maintained at 37ºC in a 5% CO2 atmosphere. Cell media and 
FBS were purchased from GIBCO BRL Life Technologies. When indicated, cells were 
!
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treated with 1 µM of GX50-070, 25 µM of ABT-737, 30 µM of rapamycin or 30 µM of 
CDDP. When required, 10 mM MA (Methyl-adenine), 10 µM QM31 or 5 µM zVAD 
were administered 30 min after treatment addition, and cells were maintained in culture 
for 24 h. Assays were carried out between passage 6 and 10, in all cases. 
3.4.2 Caspase activity expermiments for different pro-apoptotic treatments 
in different cell lines. 
The caspase 3/7 activity assay was developed as indicated in 3.1.7. 
3.4.3 Flow cytometry assays for different drugs and cell lines.  
After drug treatment, cells were collected and treated following the protocol described in 
3.1.8. Cells were incubated with 10 µL FITC Annexin V (BD Biosciences) and 10 µL of 
DRAQ7 (6 µM; Biostatus) for 10 min at 37ºC. 
3.4.4 (MTT) mitochondrial dysfunction assays in different cell types. 
Mitochondrial functionality was measured following the protocol described in 3.3.13. 
Cells were cultured in sterile 96-well microtiter plates at a seeding density of 1500 
cells/well for the MEFs lines and 2000 cells/well for HeLa cells. Plates were read at 570 
nm on a Wallac 1420 workstation. 
3.4.5 Trypan blue exclusion assays with diverse pro-apoptotic drugs in 
different cell lines. 
Cells were cultured in sterile 96-well microtiter plates at a seeding density of 5000 
cells/well for the MEFs lines and 3000 cells/well for HeLa cells.  Trypan blue was used 
(see 3.3.14) to determinate the percentage of viable cells. 
3.4.6 Nuclei staining. 
The cells cultured on coverslips were stained with 300 nM 4’-6-diamidino-2-phenylindole 
(DAPI) solution. Morphology of the cell nuclei was observed using a fluorescence 
microscope (Leica Vertical DM6000) at an excitation wavelength of 350 nm. Nuclei are 
considered to have the normal phenotype when they glow blue brightly and 
homogenously. Apoptotic nuclei can be identified by either the condensed chromatin 
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gathering at the periphery of the nuclear membrane or a total fragmented morphology of 
nuclear bodies. 
3.4.7 Immunoblotting for the different pro-apoptotic treatments in different 
cell lines. 
Whole cell extracts were obtained as indicated in 3.1.6. The antibody against LC3 
(#2775) came from Cell Signaling and α-tubulin antibody (#T8203) was from Sigma-
Aldrich. 
3.4.8 Statistical analyses. 
All the values represent the mean ± s.d. of at least three independent experiments. 
Statistical significance was determined by one-way ANOVA using the Graph Pad 
software, p<0.05 was designated as statistically significant. 
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4.1. Introduction 
Protein–protein interactions among pro-apoptotic and anti-apoptotic members of the 
BCL-2 family are crucial to determine the final fate of cells. However, the molecular 
insights of that equilibrium remain poorly understood. The role of cytosolic domains from 
BCL-2 proteins in the molecular network of interactions that controls MOMP have been 
extensively studied (121), whereas TMDs have been traditionally considered as mere 
membrane anchors (196, 352).! 
In recent years, it has been demonstrated that while some of the BCL-2 members 
conserve their apoptotic function in the absence of their C-terminal TMDs, others need 
them to modulate biological activity (63, 110, 221). Taking into account the existence of 
these hydrophobic regions in almost all members of the BCL-2 protein family and the fact 
that they exert their function within the membrane, it is reasonable to hypothesize an 
active role for TMDs in regulation of apoptosis. 
As a first step to understand TMD molecular function, our objective was to establish 
the oligomerization state of these protein domains within the membrane and the 
interaction network among TMDs from different members of the BCL-2 protein family.  
All strategies have been performed maintaining proteins in its natural environment, the 
membrane. This is of particular interest in membrane protein interaction studies due to the 
existence of several interaction artifacts when proteins are extracted from the lipid bilayer. 
4.2. Results and discussion 
4.2.1. The oligomerization state of BCL-2 TMDs in membranes. 
To test whether BCL-2 TMDs, together with soluble domains, participate in the equilibria 
that govern MOMP, we have first analyzed the oligomeric state of these TMDs in live 
cells.  To address this question we have employed the prokaryotic ToxRed system (332, 
353) to determine whether the TMDs of anti- (Bcl-xL, Bcl-2, Bcl-w, Mcl-1 and Diva) and 
pro-apoptotic (Bax, Bak, Bid, Bik, Rambo) BCL-2 proteins (Table 4.I) are sufficient to 
cause self-association. In this assay, the TMD tested is inserted as an in-frame fusion 
between the ToxR (an N-terminal transcriptional activation domain) and MBP (a C-
terminal maltose-binding protein that is targeted to the periplasm)!(353). ToxR is in active 
state when dimerizes thought BCL-2 TMD association, recognizing then the ctx promoter 
and activating the transcription of RFP gene (Figure 4.1). The level of fluorescence 
emission at 615 nm indicates the strength/intensity of TMD-mediated self-association. 
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Proper insertion into the membrane can be verified by the ability of periplasmic MBP to 
restore the capability of E. coli MM39 mutant to grow on maltose as a sole carbon source 
(332).  
 
Table 1. BCL-2 TMD sequences cloned. The aminoacids underlined are cloned only in the BiFC constructs for 
mitochondrial targeting. G based on the Kyle and Doolittle algorithm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In each case fluorescence ratio between the ToxRed wt construct containing the BCL-
2 TM fragment (ToxR) and a ToxRed mutant construct (containing the TM domain of 
interest but a non functional version of the transcription factor ToxR (ToxR*)) has been 
included to account for basal cell fluorescence (Figure 4.1). 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic view of transmembrane interaction monitoring system (ToxR). The P1 construct 
consists in the N-terminal DNA binding domain of ToxR (a dimerization-dependent transcriptional activator) 
fused to a BCL-2 transmembrane domain  and a monomeric periplasmic anchor (the maltose binding protein).  
Association of the TMDs results in the ToxR-mediated activation of a RFP reporter gene. The level of 
fluorescence indicates the strength of TMDs association. The fluorescent assay is standardized with a ToxR 
mutant P2 construct unable to activate the expression of RFP reporter gene. 
 
As a positive control of interaction we used the Glycophorin A TMD (GpA TMD: 
EITLIIFGVMAGVIGTILLISYGI) a well characterized homo-dimeric transmembrane 
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Mcl1 IRNVLLAFAGVAGVGAGLAYLIR 23 -0.275 
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protein (354, 355) and the point mutant G83I of GpA TMD as a negative control. All the 
BCL-2 TMDs showed the capability to form homo-oligomers within the bacterial 
membrane with the exception of Bid TMD. Interestingly, the TMD of apoptotic 
executioner protein Bax causes the highest fluorescence. Western blots of whole cell 
lysates detected with anti-MBP antibodies (Figure 4.2.B, bottom) demonstrate that the 
levels of ToxR-(Bcl-TMD)-MBP are comparable, so the different fluorescence emission 
levels can be interpreted to arise from differences in TMD self-association in the E. coli 
inner membrane. We conclude that the BCL-2 TMDs with the exception of Bid associate 
strongly in the E. coli inner membrane.  
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Figure 4.2.  The TMDs from BCL-2 family proteins are involved in protein homo-oligomerization. (A) 
The formation of BCL-2 oligomers followed by the increase in fluorescence due to RFP expression mediated by 
ToxR transcription factor. The results are represented by the normalized fluorescence signal (ToxR/ToxR*) 
obtained with the ToxR system for the TMDs of the different BCL-2 proteins. Red bars represent positive 
interactions and white bars represent negative interactions. GpA positive control and point mutant GpA G83I  as 
negative control of interaction are showed in the first and second column, respectively. All the results represent 
the mean of three independent experiments. Dunnett's Multiple Comparison Test (95%CI) was used to compare 
with a positive control Glycophorin A TMD. (B) Equivalent expression levels of all constructs were confirmed 
by Western blot developed against HA antibody. 
 
The ability of the isolated TMDs to self-associate suggests that this property may 
underlie the previously observed functional importance of BCL-2 TMDs (356). 
Inspection of their amino acid sequences and comparison with previously reported 
interacting TM segments (357, 358) reveal glycines located roughly in the middle of TM 
segments as potential sources for strong helix-helix interactions. We have tested the 
sequence specificity of self-association using site-directed mutagenesis to find residues 
that were relevant in the molecular interacting interface between these quaternary 
structures (Figure 4.3). Several single point mutants were identified that partially disrupt 
formation of BCL-2 TMD homo-oligomers without affecting expression or insertion of 
the protein within the membrane (Figure 4.4A and B), demostrating existence of specific 
molecular interfaces. 
 
 
 
 
 
 
 
 
Figure 4.3. Multiple Transmembrane domain alignment for BCL-2 protein family (Homo sapiens) using 
CLUSTALW algorithm in MEGA 5.0 (GpA TM like outgroup). The positions of the different point mutans are 
highligthed in brown. 
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Figure 4.4. TMD mutants from BCL-2 family proteins corroborate the specificity of the homo-
oligomerizations. (A) Decrease of fluorescence signal in the ToxR system induced by point mutations of BCL-
2 TMDs. The drop in the fluorescence signal denotes homo-oligomer disruption. Red bars represent positive 
interactions and white bars represent negative interactions. GpA positive control and point mutant GpA G83I  as 
negative control of interaction are showed in the first and second column, respectively. (B) The equal expression 
of all constructs was confirmed by Western blot developed against HA antibody. 
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Altogether these results indicate that the BCL-2 TMDs populate the membrane in a 
non isolated (non-monomeric) state, establishing specific interactions with other TMDs 
that could be relevant for the function of full length BCL-2 proteins in a physiological 
environment. 
4.2.2. The oligomerization state of BCL-2  TMDs in the mitochondria. 
Once it was demonstrated that BCL-2 TMDs have the ability to self-interact in bacterial 
membranes, bimolecular fluorescence complementation (BiFC) assays were used to 
analyze the intracellular distribution and self-association of fluorescent-protein-tagged 
BCL-2-TMDs. BiFC assays permit the direct visualization of protein-protein interactions 
(PPI) in living cells (336, 337). The principles of this methodology are illustrated in Fig 
4.5A. Briefly, the proximity between two interacting molecules (BCL-2 TMDs) tagged 
with two complementary halves of the Venus Fluorescent protein (VN and VC) facilitates 
their maturation to a functional fluorescent protein, indicating oligomer formation. An 
improved BiFC assay with a high signal-to-noise ratio was selected to avoid background 
interferences (337). The system was adapted to clone BCL-2 TMDs at the C-terminal end 
of Venus protein fragments, according to their natural topology in full length proteins.   
Both, VN- and VC- BCL-2 TMD constructs were co-transfected in the HCT 116 colon 
cancer cells and formation of oligomers was evidenced by reconstitution of Venus protein 
and appearance of green fluorescence (Fig 4.5B). Co-expression of the positive PPI pair, 
b-Fos and b-Jun proteins, used as a positive control of the system (359), rendered high 
fluorescence whereas the mutant b-ΔFos and b-Jun fusion proteins produced low 
fluorescence values (Fig 4.5B, + and - respectively)(337). BCL-2 TMDs were able to 
reconstitute Venus fluorescent protein indicating the existence of homo-oligomers in live 
eukaryotic cells (Figure 4.5B). Immunoblotting experiments against c-myc and HA tags 
confirmed equivalent expression of both VN- and VC- constructs (Figure 4.5C). Then, the 
different association levels, account for the different fluorescence values observed and 
agree with the results obtained in the ToxR system (Figure 4.2A) where self-association 
of pro-apoptotic protein Bax causes also the highest fluorescence. !
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Figure 4.5. BCL-2 TMD Homo-oligomerizations in mammalian cells using BiFC strategy. (A) The 
Bimolecular fluorescence complementation system (BiFC) is based on the reconstitution of fluorescence from 
separate N- and C- terminal Venus protein fragments. This reconstitution depends on the establishment of 
interaction between BCL-2 TMDs. (B) BCL-2 TMD homo-oligomerization assays measured by BiFC in the 
HCT 116 cell line. The VC- and VN-Bcl constructs were transfected in the HCT 116 cell line and fluorescence 
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was measured 24 hours later. Average fluorescence intensity of three independent experiments is represented.  
Dunnett's Multiple Comparison Test (95%CI) was compare with negative control Fos/Jun. 
 
BCL-2 family members are targeted to the appropriate membrane either immediately 
after their synthesis or in response to an apoptotic stimulus. Targeting to mitochondria has 
been demonstrated to be mainly directed by the C-terminal region of these proteins (194, 
197, 229). The role of TMDs in apoptosis modulation has been controversial. 
Involvement of BCL-2 interactions in apoptosis modulation clearly requires oligomer 
formation to occur in the mitochondrial membrane. In this context, to study the 
intracellular distribution of BCL-2 TMD oligomers, microscopy studies of HCT 116 cells 
overexpressing VC/VN TMD constructs were performed. Cells were incubated with 
mitotracker dye to label active mitochondria. Confocal microscopy images showed a 
reticular distribution of the green fluorescence for BCL-2 TMD homo-oligomers that 
extensive colocalized with mitochondria (Figure 4.6A). Subcellular distribution of TMDs 
was also corroborated by cellular fractionation studies (Figure 4.6B). In these experiments 
c-myc antibody was used to detect VN BCL-2 TMD fusion proteins while the Tom 20 
protein and the Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used as 
mitochondrial (M) and cytosolic (C) markers, respectively. All BCL-2 TMDs were 
mainly localized in the mitochondrial fraction (M), in accordance with results obtained 
from confocal studies.  
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Figure 4.6. BCL-2 TMD Homo-oligomerizations take place in the mitochondria. (A) Confocal images of 
HCT 116 cells transfected with VC- and VN-BCL-2 constructs. The formation of homo-oligomers was observed 
in the green channel. Cells were incubated with Mitotracker to stain mitochondria (red channel). Co-
localizations are shown in yellow. (B) Subcellular fractionation of HCT 116 cells transfected with VC- and VN-
BCL-2 constructs. C-Myc antibody was used to localize the BCL-2 TMD constructs. Mitochondrial fraction (M) 
is monitored by the presence of Tom 20 mitochondrial protein and cytosolic fraction (C) by GAPDH.  
 
Selected TM helix mutants, previously analyzed in the ToxR system, were also 
analyzed by BiFC (Fig 4.7). Those mutations which destabilize BCL-2 TM helix 
oligomerization faces in bacterial membranes rendered VC/VN BCL2 TMD constructs 
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with lower fluorescence levels, corroborating the reduced oligomer formation capacity 
and the relevance of these residues in the helix-helix packing interfaces. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. BCL-2 homo-oligomerizations also showed high specificity in eukaryotic cells. Decrease of 
fluorescence signal in the BiFC system induced by point mutations of BCL-2 TMDs. The drop in the 
fluorescence signal denotes homo-oligomer disruption. Green bars represent positive interactions and white bars 
represent negative interactions. Average fluorescence intensity of three independent experiments is represented.  
Dunnett's Multiple Comparison Test (95%CI) was used to compare with negative control Fos/Jun. 
 
Alltogether results demonstrate the capability of the BCL-2 TMDs to form homo-
oligomers in the mitochondrial membrane of eukaryotic cells. Due to the relevance of the 
BCL-2 family proteins for the MOMP, their structural organization within the 
mitochondrial membrane should be relevant for the regulation of the mitochondrial 
outcome. 
4.2.3. The network of BCL-2 TMDs interactions. 
Control of MOMP is accomplished by a complex network of interactions between 
members of the BCL-2 family. For this reason, once the capability of BCL-2 TMDs to 
homo-oligomerize was established our next question was whether hetero-
oligomerizations within the membrane were also possible between the different BCL-2 
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TMD members. 
The ToxRed system permits the study of hetero-oligomerization by setting a 
competion through co-transforming bacterial cells with constructs carrying one BCL-2 
TMD construct fused to the ToxR and a second TMD fused to the disabled ToxR* moiety, 
unable to reconstitute the ToxR transcription factor (332, 353). Then, BCL-2 TMD cloned 
in the wild type ToxR could exclusively homo-oligomerize itself, showing the maximum 
level of fluoresecence (100%), or could also hetero-oligomerize with the other BCL-2 
TMD fused to the disabled ToxR*, generating a fluorescence decrease  (Figure 4.8). 
Furthermore, the GpA-TMD, a non-BCL-2 related TMD, was used as a negative control 
of hetero-dimerization. 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Schematic view of TM interaction monitoring system (ToxRed) adapted to evaluate hetero-
oligomer formation. Co-transformation with ToxR fused to one BCL-2 TMD plasmid and a second plasmid 
containing disabled ToxR* fused to a different BCL-2 TMD, renders up to three different types of oligomers: 
fluorescent (ToxR/ToxR) combinations and non-fluorescent (ToxR/ToxR* and ToxR*/ToxR*) combinations. 
 
Making use of this experimental procedure we studied the formation of hetero-
oligomers among TMDs from the different members of the BCL-2 protein family (Figure 
4.9). The results of these studies reveal a complex network of interactions among them.  
The network of TMD interactions obtained for the BCL-2 anti-apoptotic members reveals 
for example that there are not TM interactions between Bcl-2 and Bcl-xL (Figure 4.9A 
and 9B). Bcl-w TMD interactions (Figure 4.9C) were consistently observed with Bcl-2 
TMD and Bcl-xL TMD but not with Mcl-1 TMD (Figure 4.9C). Further, Mcl-1 TMD has 
an interaction pattern completely different to these obtained for Bcl-2 TMD and Bcl-xL 
TMD, since these latter two members share a similar pattern of interactions (Figure 4.9A, 
B and D). 
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Figure 4.9.  Specific hetero-oligomerization network among TMDs from BCL-2 family proteins. 
Normalized fluorescence signal obtained with the ToxR system for the combination of ToxR construct of BCL-2 
TMD with ToxR* constructs from the indicated BCL-2 proteins.  Red bars represent positive hetero-
oligomerizations (the decrease in fluorescence indicates the formation of hetero-oligomers as described in 
Figure 8. ToxR*. White bars represent negative hetero-oligomerizations. The ToxR control of BCL-2 TMD 
(first column) represents the maximum of fluorescence (100% homo-oligomerization). GpA was used as an 
outgroup and represents a negative hetero-oligomerization. The same experiments are shown for the ToxR-TMD 
constructs of Bcl-2 (A), Bcl-xl (B), Bcl-w (C), Mcl-1(D) and Bax (E) cotransfected with ToxR* -TMD 
constructs from the different BCL-2 proteins. 
 
Regarding the pro-apoptotic members, it should be noticed the differences found for 
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xL, Bax TMD interacts with all TMDs from the anti-apoptotic members tested with the 
E 
Mcl-1 TMD ToxR
Mc
l-1
Bc
l-2
Bc
l-x
L
Bc
l-w Ba
x
Ba
k
Ra
mb
o
Di
va Bi
d
Bi
k
Gp
A
40
50
60
70
80
90
100
110
%
 F
lu
or
es
ce
nc
e
*** ***
Bcl-2 TMDs ToxR*
*
Bax TMD ToxR
Ba
x
Bc
l-2
Bc
l-x
L
Bc
l-w
Mc
l-1 Ba
k
Ra
mb
o
Di
va Bi
d
Bi
k
Gp
A
40
50
60
70
80
90
100
110
%
 F
lu
or
es
ce
nc
e
+   Hetero-oligomerization -  Hetero-oligomerization
***
***
***
***
******
Bcl-2 TMDs ToxR*
D 
4                                                                                     CHAPTER I 
Interactions between the BCL-2 family members via their transmembrane domain (TMD): Relevance in the 
apoptotic control. 
   96 
exception of Mcl-1 TMD (Figure 4.9E). 
Interestingly, we observed the formation of hetero-oligomers between the two pro-
apoptotic Bax- and Bak proteins (Figure 4.9E). These two proteins have been found to be 
the main players in the formation of the mitochondrial pore (84, 127, 138). The relevance 
of their cytosolic domains for membrane permeabilization has been extensively studied 
but the contribution of their TMDs remains poorly understood. Our current data 
demonstrating the existence of hetero-oligomers between these important components 
could shed light onto the process of pore formation and regulation.  The results obtained 
in the hetero-dimerization experiments with all the BCL-2 TMDs led us to define the first 
global network of TMD interactions among the members of the BCL-2 family (Figure 
4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. The interactome of  BCL-2 TMDs. Integration of all the experimental data of homo- and hetero-
oligomerization from the ToxRed system led to the classification of four levels of interaction based on the 
fluorescence signal, generating the interaction network map of the BCL-2 TMDs. 
4.2.4. BCL-2-TMDs interactions in full-length proteins context. 
Different protein domains jointly and collectively define the overall activity of a protein 
(360). In this sense, the studies performed with isolated TMDs from BCL-2 proteins 
during a stage in Dr. Frank Edlich lab in the Institute of Biochemistry and Molecular 
Biology of Freiburg (Germany) had permitted us to separate the putative role of their 
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membrane anchors from the contribution of cytosolic domains to their network of MOM 
interactions. Once we demonstrated the existence of heterotypic interactions between 
isolated anti- and pro-apoptotic TMDs from BCL-2 proteins, we went one step further to 
understand their contribution to global protein function and analyzed hetero-dimerization 
of TMDs with full-length proteins in mitochondria.  
To perform these experiments self-interaction of VN/VC-BCL-2 TMDs, that 
reconstitutes the Venus fluorescent protein, was challenged with anti- and pro-apoptotic 
full length proteins (see scheme in Figure 411A). In this system a decrease of 
fluorescence indicates formation of hetero-oligomers between the Venus fluorescent 
protein and the appropriate full length protein.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11.  Schematic view of the interaction between some BCL-2 Full length (FL) proteins with BiFC-
TMD constructs through the transmembrane region specifically. (A) Cells are co-transfected with VN/VC 
BiFC-TMD constructs and different BCL-2 FL proteins. Interaction between BCL-2 FL proteins and TMD 
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constructs produces a decrease of the fluorescence (Venus protein is not recovered). (B) In this case, the TMD 
of Bax FL protein was replaced to the TMD of Bcl-xL  to evaluate the role of the cytosolic region in the TMD 
interactions. 
 
Making use of this approach we observed that self-interaction of VN/VC-Bax TMD 
was competed with Bax, Bcl-2 and Bcl-xL full length proteins (Figure 4.12A). A full-
length Bax protein in which the hydrophobic tail was replaced by the one from Bcl-xL 
(Bax-Bcl-xL tail) and the complementary Bcl-xL-Bax tail mutant also competed with Bax 
TMD self-interaction (Figure 4.11B). In all these experiments mitochondrial localization 
of VN Bax TMD recombinant protein was corroborated by cellular fractionation (Figure 
4.12B, right panel). These results agree with the interaction pattern determined for 
isolated Bax TMD in the ToxR assay where Bax TMD interacted with TMDs from Bax, 
Bcl-2 and Bcl-xL (Figure 4.9E). 
Interestingly, self-interaction of VN/VC-Bcl-2 TMD was only competed by Bcl-2 and 
Bax full-length proteins, but no competition with Bcl-xL full-length protein was observed 
(Figure 4.12B). Moreover, the recombinant Bax-Bcl-xL tail protein showed decreased 
competence when compared with the full-length Bax, whereas Bcl-xL-Bax tail protein 
competed similarly with Bax with Bcl-2 TMD self-interaction.  These results also validate 
the TMD interaction pattern observed for isolated Bcl-2 TMDs (Figure 4.9A) in the 
context of full-length proteins.  
Altogether our results demonstrate that interaction patterns observed for isolated Bcl-2, 
Bax, and Bcl-xL membrane anchor domains are mimicked in the presence of full-length 
proteins, thereby underpinning the relevance of these membrane-spanning regions in the 
modulation of MOM interactions among BCL-2 proteins. 
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Figure 4.12. Specific interactions between BCL-2 Full-length (FL) proteins and BiFC-TMD constructs. A) 
HCT 116 wt cell line was co-transfected with VN/VC BiFC Bax TMD constructs and different BCL-2 FL 
proteins. Interaction between BCL-2 FL proteins and Bax TMD constructs produces a decrease of the 
fluorescence (Venus protein is not recovered). Bcl-xl FL with the TMD of Bax and Bax FL protein with the 
TMD of Bcl-xl were also assayed to demonstrate the specificity of the interactions. B) The same design was 
used for VN/VC BiFC Bcl-2 TMD assays. C) Subcellular fractionation of HCT 116 cells transfected with the 
BCL-2 TMD protein BiFC constructs. C-myc was used to detect BiFC constructs. GAPDH and Tom 20 was 
used as cytoplasmic and mitochondrial markers, respectively. 
4.2.5. Relevance of BCL-2 TMDs in apoptosis. 
According to the function of the BCL-2 proteins in the control of apoptosis, the role of 
BCL-2 TMDs in this pathway was analyzed. Previous studies have demonstrated that 
some BCL-2 TM regions are able to destabilize the outer mitochondrial membrane (217, 
231) and/or generate pores to produce the release of apoptogenic proteins that induce 
apoptosis (68, 240). For that reason, the capability of these TMD to induce apoptosis was 
analyzed in HCT 116 Wt and HCT 116 DKO Bax/Bax.!The results of caspase-3 activity 
assay and Western blot indicated that some of the TMDs, specially Bax, Bak and Mcl-1 
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were able to produce apoptosis (Figure 4.13A). To further explore the mechanism of 
BCL-2 TMDs cell death induction we analyzed different markers of apoptosis and 
necrosis. Increase on cytosolic lactate dehydrogenase (LDH) activity in the medium as a 
consequence of cell lysis is considered a marker of necrotic cell death. LDH assays 
showed a non-significant release of this enzyme to the extracellular media, confirming 
that cell death was not due to necrosis (Figure 4.13B). The capacity of some BCL-2 TMD 
to generate apoptosis was also evaluated by confocal microscopy, using the release of 
Cyt-c as apoptotic marker (Figure 4.13C). Bcl-2, Bcl-xL and Bcl-w did not produce 
apoptotic activation. On the contrary, cells transfected with Bax, Mcl-1 and Bak TMD 
showed the cytosolic accumulation of Cyt-c, indicating apoptosis. 
The exposure of phosphatidylserine (PS) molecules on the outer leaflet of the plasma 
membrane is usually considered a hallmark of apoptosis (361). Thus, cell staining with 
FITC-labeled AnnexinV, which binds to PS, is a marker of early apoptotic events 
(AnnV+). Propidium iodide (PI) is a DNA intercalating agent that can be incorporated 
into cells only after major cell membrane damages (PI+). Hence, the combination of 
AnnV and PI cell staining is commonly used to distinguish apoptotic and necrotic cell 
death. Flow cytometry analyses were performed to evaluate the apoptotic profile of these 
TMDs (Figure 4.13D). Our results showed the characteristic profile of cells undergoing 
apoptosis, as both AnnV+ PI- (early apoptotic) and AnnV+ PI+ (late apoptotic) profiles 
were observed.  
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HCT 116 Wt 
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 1.67 22.90 0.762
B3  9477 94.77 0.653 22.90 0.398
B4    349 3.49 12.7 0.17 0.396
B2    142 1.42 42.7 0.10 24.1
B1     32 0.32 1.35 0.13 9.12
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  11923 100.00 210 19.19 441
A  10000 83.87 222 19.18 495
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  11923 100.00 6.04 20.53 441
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  11923 100.00 2.79 15.87 441
Runtime Results
Protocol: AnnexinPI ainhoa ok.PRO
Listmode File: HCT_wtFE_2014 001 00039893 643.LMD
Sample ID: HCT_wtFE_2014
Run Date: 05-Feb-14, 13:48:02Institution: 
User ID: I-12
Instrument SN: AF12034 Software Version: CXP        2.0 (042111) Page 1
Settings File: AnnexinPI ainhoa ok.PRO, 05-Feb-2014, 13:48:20
Analysis Date: 05-Feb-2014, 13:48:46 Acquisition Time/Events: 39.6s / 11923 (PROTOCOL)
Tube ID: NoRead
Plot/Legend not found
N.T 
0.5 1.5 
95 3.5 
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 3.07 5.06 1.76
B3   6590 65.90 0.781 5.02 0.474
B4   1995 19.95 6.12 0.44 0.636
B2   1023 10.23 12.5 0.29 10.8
B1    392 3.92 1.59 0.23 5.37
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38295 100.00 76.2 71.33 168
A  10000 26.11 128 27.53 341
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38295 100.00 1.98 1.76 168
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38295 100.00 1.28 19.86 168
Runtime Results
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S ttings File: AnnexinPI ainhoa ok.PRO, 05-Feb-2014, 13:52:33
Analysis Date: 05-Feb-2014, 14:01:42 Acquisition Time/Events: 13.9s / 38295 (PROTOCOL)
Tube ID: NoRead
Plot/Legend not found
STS 
4 10 
66 20 
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 3.48 3.11 1.38
B3   7384 73.84 0.815 3.09 0.532
B4   1628 16.28 10.8 0.27 0.828
B2    586 5.86 18.4 0.09 11.1
B1    402 4.02 1.27 0.25 5.03
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14269 100.00 217 55.42 461
A  10000 70.08 208 23.95 483
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14269 100.00 3.4 11.89 461
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14269 100.00 1.58 24.35 461
Runtime Results
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Listmode File: HCT_wtFE_2014 011 00039903 653.LMD
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Bax 
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 4.72 6.30 2.7
B3   6842 68.42 0.696 6.27 0.538
B2   1484 14.84 20 0.11 13.1
B4   1154 11.54 10.4 0.26 0.834
B1    520 5.20 1.35 0.19 5.37
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  4241 100.00 195 59.97 406
A  10000 70.22 194 30.44 445
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14241 100.00 4.73 9.27 406
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14241 100.00 2.84 33.22 406
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(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 2.58 13.26 1.27
B3   9013 90.13 0.709 13.28 0.449
B4    463 4.63 12.4 0.26 0.75
B2    402 4.02 33.6 0.10 18.2
B1    122 1.22 1.41 0.24 7.88
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14080 100.00 282 0.00 537
A  10000 71.02 232 17.09 504
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14080 100.00 3.7 23.60 537
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  14080 100.00 2.07 20.53 537
Runtime Results
Protocol: AnnexinPI ainhoa ok.PRO
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Region Number %Gated X-Mean HP X-CV Y-Mean
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B4   1720 17.20 6.8 0.81 0.665
B2    683 6.83 16 0.16 9.71
B1    324 3.24 1.53 0.19 4.84
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38282 100.00 73.8 62.14 166
A  10000 26.12 135 30.74 349
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38282 100.00 1.68 2.27 166
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  38282 100.00 0.871 17.82 166
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Figure 4.13. Apoptotic effect of the BCL-2 TMD in HCT 116 Wt. (A) Caspase 3-like activity measured in the 
HCT 116 Wt cells. Bars represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001. STS 
0.5µM was used as apoptotic inductor. Western blot was developed against Caspase-3 antibody and α-tubulin 
was used as load control. (B) LDH assay measured in HCT 116 Wt. Negative control represents cells transfected 
with empty plasmid and Triton 9% was used as posivive control. (C) Confocal images of HCT 116 Wt cells 
transfected with the different BiFC BCL-2 TMD constructs. Green fluorescence indicates TMD homo-
oligomerization. Release of Cyt-c (red channel) from Mitochondria to cytosol was used as apoptotic marker. 
Mitochondrial co-localizations were shown in yellow. (D) Cell death profile was analyzed by flow cytometry 
with with FITC Annexin V and PI. Third quadrant represents the apoptotic population. 
 
Interestingly, the capability of these BCL-2 TMDs to induce apoptosis is independent 
of the presence of Bax and Bak in the cell (Figure 4.14A, B and C). 
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Figure 4.14. Apoptotic effect of the BCL-2 TMD in HCT 116 DKO Bax/Bak. (A) Caspase-3-like activity 
measured in the HCT 116 DKO cells. Bars represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; 
***p < 0.001. STS 0.5µM was used as apoptotic inductor. Western blot was developed against Caspase-3 
antibody and α-tubulin was used as load control. (B) LDH assay measured in HCT 116 Wt. Negative control 
represents cells transfected with empty plasmid and Triton 9% was used as positive control.  (C) Cell death 
profile was analyzed by flow cytometry with with FITC Annexin V and PI. Third quadrant represents the 
apoptotic population. 
 
In Bax/Bak KO HCT 116 the apoptotic profile was exactly the same as that observed 
for wild type cells. This result opens up two possible hypotheses: 
• BCL-2 TMDs promote destabilization of the outer mitochondrial membrane inducing 
pores similar to that formed by Bax/Bak, and overcoming the absence of these proteins. 
• Interactions established by BCL-2 TMDs within the mitochondrial membranes modify 
the balance between anti- and pro-apoptotic BCL-2 proteins, generating an alternative 
pore complex induced by other membrane complexes previously described as responsible 
of MOMP!(362, 363).  
In both cases if Bax TMD oligomerization is necessary for the formation of these 
mitochondrial pores, introduction of a destabilizing point mutation in the TMD sequence 
should therefore result in a decrease of apoptosis induction capability. 
To test this hypothesis some of the Bax TMD point mutations identified as oligomer 
disruptors were introduced in the full-length Bax protein and in the VN/Bax TMD 
construct. HCT 116 cell were transfected with these mutants and caspase-3 activity at 24 
C 
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 1.39 0.65 1.77
B3   7374 73.74 0.383 0.67 0.432
B4   1280 12.80 3.59 0.97 0.542
B2    800 8.00 7.72 0.16 14.5
B1    546 5.46 0.469 0.54 4.05
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13903 100.00 168 64.63 372
A  10000 71.93 158 23.53 383
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13903 100.00 1.75 2.06 372
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13903 100.00 2.62 13.12 372
Runtime Results
Protocol: AnnexinPI ainhoa ok.PRO
Listmode File: Hct DKO FE 007 00039999 661.LMD
Sample ID: Hct DKO FE
Run Date: 07-Feb-14, 12:32:50Institution: 
User ID: I-12
Instrument SN: AF12034 Software Version: CXP        2.0 (042111) Page 1
Settings File: AnnexinPI ainhoa ok.PRO, 07-Feb-2014, 12:29:50
Analysis Date: 07-Feb-2014, 12:33:06 Acquisition Time/Events: 11.5s / 13903 (PROTOCOL)
Tube ID: NoRead
Plot/Legend not found
(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  17401 100.00 0.784 1.73 1.25
B3  15379 88.38 0.315 1.73 0.363
B2   1210 6.95 6.1 0.25 12.4
B4    624 3.59 2.05 0.77 0.781
B1    188 1.08 0.707 0.38 4.1
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  49536 100.00 39 65.83 109
A  17401 35.13 82.6 7.60 212
[A] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  17401 100.00 0.784 1.73 212
[A] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  17401 100.00 1.25 30.02 212
Runtime Results
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Plot/Legend not found
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(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 1.74 2.23 2.46
B3   5875 58.75 0.407 2.26 0.468
B4   2343 23.43 3.33 0.21 0.538
B2   1296 12.96 5.38 0.39 14
B1    486 4.86 0.522 0.31 4.91
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15350 100.00 153 76.97 327
A  10000 65.15 160 14.65 372
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15350 100.00 1.79 2.17 327
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15350 100.00 2.92 18.32 327
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(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 1.85 0.68 1.95
B3   6833 68.33 0.415 0.65 0.453
B4   1535 15.35 4.97 0.21 0.584
B2    851 8.51 8.97 0.15 14.3
B1    781 7.81 0.485 0.49 4.32
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15077 100.00 191 80.22 401
A  10000 66.33 165 24.09 392
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15077 100.00 2.25 0.68 401
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  15077 100.00 2.84 14.34 401
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(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  10000 100.00 1.71 4.51 1.63
B3   7576 75.76 0.359 6.12 0.39
B1   1127 11.27 0.425 0.67 3.37
B4    770 7.70 4.85 0.26 0.509
B2    527 5.27 19.4 0.38 17.3
[Ungated] SS Lin/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13050 100.00 179 ### 399
A  10000 76.63 186 23.55 436
[Ungated] FL1 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13050 100.00 2.37 6.22 399
[Ungated] FL3 Log/FS Lin
Region Number %Gated X-Mean HP X-CV Y-Mean
ALL  13050 100.00 2.1 19.64 399
Runtime Results
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STS 
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(10000) [A] FL1 Log/FL3 Log
Region Number %Gated X-Mean HP X-CV Y-Mean
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hours after transfection was measured. A significant reduction of this enzymatic activity 
was observed for the different mutants (when compared with their wt versions Figure 
4.15 A-C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Selected point mutants of the BCL-2 TMD attenuate the apoptotic effect of the Bax FL and 
selected Wt TMD in HCT 116 Wt. The maximum percentage of apoptotic induction (100%) represents the 
caspase-3 activity referred to the wt Bax FL (A), VN/wt Bax TMD (B) and VN/wt Mcl-1. Bars represent the 
mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001). 
M
ock
Ba
x F
L
Ba
x  
FL
 G
17
9P
Ba
x F
L +
1A
17
8 
0
25
50
75
100
A
po
pt
ot
ic 
ac
tiv
ity
 (%
)
*** ***
***
Bax
Į-tubulin
21 kDa
50 kDa
A 
C 
Mc
l-1
 TM
D
Mc
l-1
 TM
D 
G3
40
P
Mc
l-1
 TM
D 
G3
44
I
0
25
50
75
100
125
150
A
po
pt
ot
ic 
ac
tiv
ity
 (%
)
***
Ba
x T
M
D 
Ba
x T
M
D 
G1
79
P
Ba
x T
M
D 
F A
0
25
50
75
100
A
po
pt
ot
ic 
ac
tiv
ity
 (%
)
***
B 
4                                                                                     CHAPTER I 
Interactions between the BCL-2 family members via their transmembrane domain (TMD): Relevance in the 
apoptotic control. 
   106 
 
Interestingly, when these TMD mutations where introduced in the Bax FL protein, the 
pro-apoptotic activity was attenuated. Thus, a 30% decrease relative to the wild type Bax 
FL pro-apoptotic activity was achieved. Reduction on the apoptosis induction capability 
of Bax TMD was indeed higher (75%, Figure 4.15B). Furthermore, mutantions at the 
Mcl-1 TMD also decreased the apoptotic induction promoted by wild type Mcl-1 TMD 
(Figure 4.15C).  These results demonstrate that BCL-2 TMDs, together with soluble 
domains, participate in the equilibria that govern MOMP. 
Despite the putative existence of alternative apoptosis pathways we were interested in 
determining the relevance of BCL-2 TMDs in classical pathways of apoptosis induction. 
To accomplish this objective two different assays were performed: On one hand, the 
effect of some anti-apoptotic proteins (Bcl-2 and Bcl-xL) overexpressed in combination 
with the TMD of Mcl-1, Bax and Bak was evaluated. On the other hand, the effect of 
blocking anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w (309, 364) with the BH3 
mimetic ABT-263, was also analyzed. Overexpression of anti-apoptotic Bcl-xL or Bcl-2 
full-length proteins reduced the apoptosis induction promoted by VN/Bax TMD (Figure 
4.16A). Likely, anti-apoptotic proteins impede the formation of Bax homo-oligomers by 
competing through TMD hetero-oligomeric complexes that could account for the 
observed reduction of Bax TMD induced pro-apoptotic activity. Conversely, VN/Bak 
TMD apoptosis induction was not affected by the presence of these anti-apoptotic 
members (Figure 4.16A). Interestigly, Bcl-xL but not Bcl-2 FL protein specifically 
abolishes the pro-apoptotic effect induced by VN/Mcl-1 TMD, (Figure 4.16B). These 
findings highlight the exquisitely specific network of TMD interactions found in the 
apoptotic events. 
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Figure 4.16. Effect of the anti-apoptotic proteins overexpression in the apoptotic activation promoted by 
the BCL-2 TMDs in HCT 116 Wt. The maximum percentage of apoptotic induction (100%) represents the 
caspase-3 activity referred to the BiFC VN Bax TMD (A), VN Bak TMD (A) and VN Mcl-1 TMD (B). Bars 
represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001).  
 
Apoptosis induction based on sequestration of anti-apoptotic proteins by ABT-263 
showed that combination of VN Bax TMD and ABT-263 resulted in additive apoptotic 
activation. In contrast, Mcl-1 and Bak TMD transfection combined with ABT-263 
treatment produced a clear synergic behavior on apoptosis induction. Different behavior 
of Bax, Mcl-1 and Bak TMDs probably reflect different networks of protein-protein 
interactions established by their transmembrane anchors within the mitochondrial 
membrane. Furthermore, Bid TMD does not generate apoptosis by itself and does not 
modify the apoptotic activation promoted by ABT-263 (Figure 4.17). 
Altogether these results underscore the necessity to conduct further studies regarding 
the interaction network that regulates MOMP to properly understand and predict cellular 
outcome upon anti or pro-apoptotic stimuli. 
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Figure 4.17. Combined treatment of the BH3 mimetic ABT-263 and the BCL-2 TMDs in HCT 116 Wt. 
Caspase-3 activity ((A.U) Arbitrary units) of BiFC VN BCL-2 TMDs alone and in combination with BH3 
mimetic ABT-263. Bars represent the mean of three independent experiments ± s.d. (*p < 0.1; **p < 0.05; ***p 
< 0.001). 
4.3. Concluding remarks. 
Members of the BCL-2 family constitute the main players in the control of mitochondrial 
outcome, developing a crucial role in the decision of the cellular fate (57, 191). In fact 
several diseases, including cancer, result from an inadequate equilibrium of BCL-2 
expression (365). Therefore, to gain in-depth knowledge about their interactions is the 
first step in the development of new pharmacological strategies (323). There is 
considerable evidence for implication of cytosolic domains from BCL-2 proteins in 
MOMP control (123, 258). However, it has been unclear whether BCL-2 TMDs play also 
a role in the permeabilization process, either by participation in the different models of 
pore complexes or by regulation of interactions between anti- and pro-apoptotic members 
of the BCL-2 family (366). 
To answer some of these questions, this study has addressed the structural 
organization of BCL-2 TMDs. Making use of bacterial and eukaryotic systems it was 
demonstrated that most BCL-2 TMDs are non-isolated in membranes. On the contrary, 
they are able to interact themselves and with other members of the BCL-2 family in a 
highly specifical manner, generating a network of putative interactions that take place in 
the mitochondrial membrane and presumably participate in MOMP. We have defined for 
the first time a large network of BCL-2 TMD interactions. Recent works also suggest the 
capability of particular BCL-2 TMDs to oligomerize in the membrane, corroborating 
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some of the self-interactions obtained for Bax (367) and Bcl-xL (220) TMDs, as well as 
the existence of Bax/Bcl-2 hetero-oligomers in mitochondria (368). Some of the 
interactions observed in this work, as the Bax-Bak TMD hetero-oligomerization, could be 
crucial in the process of the pore complex formation. In addition, it is also relevant the 
different pattern of interactions observed for the anti-apoptotic Mcl-1 TMD when 
compared to other TMDs derived from anti-apoptotic proteins (i.e. Bcl-2 and Bcl-xL). 
Despite all three proteins exert a pro-survival function in apoptosis, several studies have 
demonstrated significant differences in their apoptotic behavior in different cellular 
systems (55, 56, 369). The present interacting network established for these BCL-2 
proteins in the MOM could provide clues about the role of the TMDs in the apoptotic 
regulation mechanisms. 
Furthermore, the work included in this chapter demonstrates the insertion of Bid TMD 
into different biological membranes (ToxRed and BiFC data), although the interaction 
map obtained shows that Bid TMD does not establish any direct interactions to any BCL-
2 derived TMD. Of note, some authors have postulated a role for cardiolipin for the 
location of Bid at the lipidic contact sites (CS) present in mitochondria (116, 370), and 
probably Bid TMD actively participates in this anchoring function. 
Besides elucidate the BCL-2 TMD interaction network, the putative role of several 
TMDs in apoptosis has been also investigated. Mcl-1, Bax and Bak TMD were able to 
promote apoptosis by different mechanism (68, 138). Introduction of point mutations in 
the TMD of Bax FL produces a decrease in the apoptosis induction capability of this 
protein, indicating the relevance of this domain in the regulation of apoptosis. It has also 
been demonstrated the capability of some BCL-2 TMDs to induce apoptosis in a genetic 
background, where the apoptosis effectors Bax and Bak were absent, probably by the 
activation of alternative MOM pores. However, the behavior of BCL-2 TMDs in a wild 
type context, where the capability of full length anti-apoptotic BCL-2 proteins to interfere 
with the TMD apoptosis induction has been demonstrated, supports the existence of 
intricated regulatory crossroads in the mitochondrial membrane.  
Altogether the results suggested a new role in apoptosis for BCL-2 TMDs beyond 
serving as passive anchors. Our results are in good agreement with recent reports where, 
for instance, it has been demonstrated that Bax ΔTM induces membrane destabilization 
but the FL makes it with greater potency (371), or where it has been defined that the C-
terminal of Bax could be involved in forming channels (235, 236, 240). It has also been 
described that Bax C-terminal mutants impaired the anti-apoptotic effect of Bcl-xL over 
Bax insertion (231, 232), or that the C-terminal deleted mutants of Bcl-w lose their anti-
apoptotic function (63).  
These results outline a mitochondrial membrane landscape where different BCL-2 
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members interact with each other through their TMDs and the equilibrium of BCL-2 
TMD interactions contributes to the final full length BCL-2 interaction network, thereby 
defining the cellular fate, death or survival.  In this scenario, in the same way that BH3 
mimetics are being employed for cancer treatment (323), modulation of specific BCL-2–
TMD-interactions emerges as a new molecular target in cancer treatment. 
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5.1 Introduction. 
Apoptosis is regulated by the BCL-2 family of proteins. Members of this family can be 
divided in three groups, depending on their function and on the presence of different 
BCL-2 homology domains, known as BH1-BH4. A type of pro-apoptotic BCL-2 family 
proteins contains only the BH3 region and hence is referred to as BH3-only proteins. 
Interaction of BH3-only proteins with other BCL-2 family members is critical for 
understanding the core machinery that controls commitment to apoptosis by 
mitochondrial outer membrane permeabilization. BH3-only proteins promote apoptosis by 
both directly activating Bax and Bak and by suppressing the anti-apoptotic proteins in the 
cytosol. To prevent constitutive cell death, BH3-only proteins are regulated by a variety 
of mechanisms including transcription and post-translational modifications that govern 
specific protein–protein interactions.  
Some BH3-only proteins (like Bid, Bim and Puma) are termed activators, as they 
directly induce Bax/Bak-dependent mitochondrial outer membrane (MOM) 
permeabilization (372). Other BH3-only proteins (like Bad, Noxa, Bik and Bmf) are 
termed as sensitizers, as they promote apoptosis by binding to anti-apoptotic proteins to 
induce release of either activator BH3-only proteins (113) or activated Bax or Bak (373). 
Several BCL-2 family members also contain a carboxyl-terminal (C-terminal) 
hydrophobic domain to insert and anchor the BCL-2 proteins into different intracellular 
membranes (356),  such as the nucleus, endoplasmic reticulum (ER), and the MOM, 
where they can promote release of apoptotic factors (374). Since interactions with the 
membrane play an active role in the regulation of apoptosis by changing the affinities of 
the interactions between partner proteins (375), it would be highly valuable to investigate 
if BH3-only proteins may exist as integral membrane proteins via C-terminal tail-anchor 
sequences. In particular, some reports have examined the anchoring capacity of BH3-only 
proteins to the MOM, although the existence of a transmembrane (TM) region is still 
unclear (207). 
In this chapter we will study the ability of the TMDs from BH3-only proteins to insert 
in different biological membranes. 
5.2 Results and discussion. 
5.2.1. Putative BH3-only TMDs insertion in biological membranes in vitro. 
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To define the hydrophobic C-terminal region of human BH3-only proteins Bim, Puma, 
Noxa, Bik and Bmf, their amino acid sequences were parsed by the ΔG Prediction Server 
(http://dgpred.cbr.su.se/). Given the amino acid sequences, this algorithm provides a 
prediction of the corresponding apparent free energy difference, ΔGapp, for insertion of 
this sequence into the ER membrane by means of the Sec61 translocon (376). Table 5.I. 
shows the predicted ΔGapp values for the BH3-only proteins analyzed. The negative 
ΔGapp value for Bik C-terminal region predicts a TM disposition, whereas the positive 
values computed for Bim, Noxa, Bmf and Puma predicted that these sequences do not 
integrate into membranes. 
 
 
 
Subsequences with lowest ΔG marked in red. ΔG values are expressed in kcal/mol, both for the experimental 
(third column) and the predicted data (376, 377) (forth column). Negative and positive ΔG values are shown in 
green and red, respectively and denote spontaneous insertion or non-insertion, respectively. The probability of 
insertion (Pi) has been calculated from the experimental data as showed in Figure 5.1 and probabilities above 
and below 50% are shown in green and red, respectively for consistency.ΔGexp (experimental); ΔGapp (predicted).!!
Membrane insertion capability of these C-terminal regions was investigated using an 
experimental system based on the Escherichia coli inner membrane protein leader 
peptidase (Lep), which accurately reports the integration of TM helices into biological 
membranes. Since BCL-2 family proteins are predominantly exposed to the cytosol and 
anchored to intracellular membranes by a C-terminal sequence, in our experimental setup 
we tested the candidate sequences according to its predicted topology (122). The Lep 
construct used consists of two TM segments (H1 and H2) connected by a cytoplasmic 
loop (P1) and a large C-terminal domain (P2), and inserts into ER-derived microsomal 
membranes with both termini located in the lumen harboring engineered acceptor sites 
each (G1 and G2) for N-linked glycosylation (Figure 5.1A). The BH3-only C-terminal 
sequence analyzed (BH3-Ct) replaced the Lep H2 domain. The glycosylation site (G2) 
located in the beginning of the P2 domain will be modified only if this C-terminus 
domain is translocated across the membrane, while G1 site, embedded in an extended N-
Table 5.I.Analyzed proteins using ΔG Prediction Server v1.0 (http://dgpred.cbr.su.se/). 
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terminus sequence is always glycosylated. Single glycosylation (i.e., non-integration of 
the tested sequence) results in an increase of molecular mass of ~2.5 kDa relative to the 
observed molecular mass of Lep expressed in the absence of microsomes; the molecular 
mass shifted ~5 kDa upon double glycosylation (i.e., membrane insertion of the tested 
sequence). Proteinase K (PK) added to microsomal vesicles will digest the cytoplasmic 
exposed, non-glycosylated form of the P2 domain (Fig. 5.1A, right), or will produce a 
protected, glycosylated BH3 Ct/P2 fragment when the P2 domain is located in the lumen 
of the microsomal vesicles (Fig. 5.1A, left). 
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Figure 5.1. BH3 C-terminal insertion into microsomal membranes. (A) Schematic of the engineered leader 
peptidase (Lep) model protein. (B), (C) and (D) In vitro translation in the presence (+) or absence (−) of rough 
microsomes (RM) and PK. Non-glycosylated protein bands are indicated by an empty dot; single and double 
glycosylated proteins are indicated by one or two black dots, respectively. The protected glycosylated H2/P2 or 
BH3-Ct/P2 fragments are indicated by a black triangle. 
 
The translation in the presence of membranes of constructs harboring the Bik C-
terminal region (constructed as previously described (339, 378)) clearly resulted in mainly 
double glycosylated forms (Figure 5.1B, lane 5). PK treatment of this sample rendered a 
protected glycosylated Bik-Ct/P2 fragment (lane 6), indicating membrane insertion of this 
C-terminal region. Similar results were obtained when constructs harboring Bmf C-
terminal region were assayed (Figure 5.1C lanes 7-9). In this case, as opposite to its 
prediction (Table 5.I), the C-terminal region of Bmf inserted efficiently into the 
membrane (above 60% of the molecules were doubly glycosylated, quantifications were 
performed as described previously (377)). Regarding Bim and Puma C-terminal regions 
we found that one fourth of the molecules insert into the biological membranes (Figure 
5.1B, lanes 7-9 and Figure 5.1D lanes 4-6). Finally, Noxa C-terminal region 
transcription/translation assays in the presence of microsomal vesicles yielded singly-
glycosylated forms sensitive to PK digestion (Figure 5.1C, lanes 4-6), indicative of non-
TM disposition. 
The dispersion of charged residues, especially in the case of Bim C-terminal sequence 
would explain the predicted penalty to insert into the core of the bilayer (Table 5.I). 
Nevertheless, the hydrophobic contribution of the neighboring residues in this sequence 
may reduce the free energy of membrane integration, as observed previously for some 
model hydrophobic/cationic sequences (339), thus allowing the low level of insertion 
observed. 
5.2.2. BH3-only TMD insertion in bacterial systems. 
The microsomal in vitro system closely mimics the conditions of in vivo membrane 
protein assembly. Bik, Bmf and, at a certain level, Bim and Puma C-terminal regions are 
properly recognized by the translocon as TM segments out of its native context (Figure 
5.1). However, the presence of Lep fused domains can influence its membrane insertion 
capacity. Hence, we next sought to investigate whether these BH3-only C-terminal 
regions could direct integration into biological membranes in the absence of any 
membrane protein-derived domain. To this end, we used an assay for the insertion and 
topology in E. coli that exploits the function of maltose binding protein (MBP) in the 
maltose transport pathway. E. coli MM39 cells, which lack endogenous MBP, cannot 
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transport maltose into the cytoplasm for metabolism, and consequently cannot grow on 
media in which the only available carbon source is maltose (332). If the chimeric 
ToxR(BH3-Ct)MBP are correctly inserted in the inner membrane (Figure 5.2A), the 
periplasmic MBP domain will complement MM39 malE-deficient phenotype and support 
growth on maltose (379). To demonstrate the requirement for periplasmic localization of 
MBP in the complementation assay, constructs harboring Bax C-terminal (α9) TM 
segment (380) or lacking a TM segment (ΔTM) were used as a positive and negative 
controls, respectively. Those controls and constructs harboring BH3-only C-terminal 
regions were transformed into MM39 cells and cultured on M9-maltose (a media that uses 
maltose as an only carbon source). As shown in Figure 5.2B, cells expressing Bax, Bik 
and Bmf C-terminal regions grow on M9-maltose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. The maltose complementation assay for TM insertion and topology. (A) Schematic of the 
engineered cytoplasmic ToxR and periplasmic MBP domains fused to BH3 C-terminal regions at the N- and C-
termini, respectively. (B) malE-deficient E. coli MM39 cells transformed with various expression constructs 
were cultured on M9 agar. (C) Serial dilutions (10-fold) from exponentially growing cultures of the malE-
deficient strain (NT326) transformed with plasmids bearing the corresponding chimera were spotted on to M9 
agar (minimal media) containing 0.4% maltose. C +, ToxR(Bax α9)MBP. C −, ToxR(ΔTM)MBP.  
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Cells that lack a TM segment or contain Bim or Noxa C-terminal region fail to grow 
(expression of all contructs was verified by growing the cells in complete media with the 
appropriate antibiotic selection, Figure 5.3). These experiments demonstrate that both Bik 
and Bmf C-terminal-containing chimerae anchor their MBP domains to the E. coli inner 
membrane with its proper orientation, consistent with the insertion data obtained with the 
microsomal system. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. All the chimeric constructs are able to grow in LB Amp media.. malE-deficient E. coli MM39 
(DE3) cells (araD lacΔU1269, malEΔ444, strR; kindly supplied by W.F. DeGrado, University of Pennsylvania) 
transformed with various expression constructs (ampicillin resistance plasmids) were cultured on complete agar 
media (LB) in the presence of ampicillin as a selection marker. C +, ToxR(Bax α9)MBP. C −, ToxR(ΔTM)MBP. 
Bik, ToxR(Bik-Ct)MBP. Bim, ToxR(Bim-Ct)MBP. Noxa, ToxR(Noxa-Ct)MBP. Bmf, ToxR(Bmf-Ct)MBP. 
5.2.3. Subcellular localization and apoptotic activity of BH3-only TMDs in 
human cells. 
Emerging evidences indicate that the interaction of BH3-only proteins with membranes 
regulates binding of other Bcl-2 family members, thereby specifying function. Targeting 
and subcellular localization of the human BH3-only C-terminal regions were evaluated 
using GFP-BH3-only-Ct fusion proteins. Mitotracker dye and Grp78 protein were used to 
analyze the capability of the BH3-only-Ct to target GFP moiety to different cellular 
organelles in eukaryotic cells (Figure 5.4A and B).  
GFP/Bcl-2-Ct was used as control of mitochondrial targeting (Figure 5.4A). However, 
some authors (195) postulated that a fraction of Bcl-2 is also localized in the ER 
membrane, as we found in Figure 5.4B. Bik-Ct is not present in mitochondria and 
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localizes exclusively in the ER membrane, which nicely correlates with the ER 
distribution described for the full-length Bik protein (381). Similar results were obtained 
in the case of Bim-Ct, therefore indicating that this C-terminal region is not enough to 
target MOM, at least in absence of apoptotic stimuli. Surprisingly, Bmf-Ct displayed a 
clear cytosolic pattern and neither mitochondrial nor ER localization was observed. This 
BH3-only protein probably needs association (or activation to expose its C-terminal 
hydrophobic upon apoptotic stimuli) with other proteins to move from the citosol to 
MOM. Noxa-Ct fusions showed a reticular distribution that did not co-localize neither 
with ER nor MOM. Some works (207, 255) have localized Noxa protein in mitochondria, 
usually associated throught its BH3 domain with other BCL-2 family members. 
Consistently, the C-terminal hydrophobic region of Noxa is not enough to target the GFP 
fusions to the mitochondrial membranes. Finally, Puma-Ct fusions showed partial 
insertion in MOM and ER, confirming the ability of this hydrophobic region to span ER 
membranes (Figure 5.1). These studies highlighted the different functions of the C-
terminal hydrophobic regions of the BH3-only proteins, strongly suggesting that these 
domains could have an important role in defining each BH3-only protein as sensitizers or 
de-repressors. 
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Figure 5.4. GFP/BH3-Ct targeting and insertion to different cellular organelles. Confocal images of HeLa 
cells transfected with the different GFP/BH3-Ct constructs (green channel). Cells were incubated with 
Mitotracker (A) and Grp78 (B) as mitochondrial and ER markers, respectively (red channel). Co-localizations 
were shown in yellow.  
Function of BH3-only proteins as promoters of apoptosis has been largery analized 
(382).  However, the role of the C-terminal hydrophobic regions of these proteins in the 
process is still controversial. Previous studies have demonstrated that some BCL-2 TM 
regions in the absence of the rest of the repective proteins are able to destabilize the outer 
mitochondrial membrane! (217, 231) and/or generate pores to produce the release of 
apoptogenic proteins in order to induce apoptosis (68, 240). According to this, we 
analized the capability of BH3-only C-terminal regions to induce apoptosis. 
Overexpression of the GFP/BH3-Ct fusions in HeLa cells did not produce apoptosis 
(Figure 5.5A). These observations were confirmed by immunolocalization assays. The 
absence of Cyt-c release was observed in all BH3-only C-terminal regions analized in the 
present study by confocal microscopy (Figure 5.5B). 
These results indicate that despite the hydrophobic C-terminus of these proteins are 
not directly related with the pro-apoptotic activity of the BH3-only proteins, they could 
play a relevant role in protein targeting and membrane sorting. 
 
 
 
 
 
 
 
 
 
 
 
 
M
oc
k
AB
T-
26
3
Bc
l-2
Pu
ma No
xa Bi
k
Bim Bm
f
Ba
x 
0
10
20
30
C
as
pa
se
-3
/7
-li
ke
 a
ct
iv
ity
 (A
.U
)
GFP-TMD
GFP
Į-tubulin
35 kDa
50 kDa
A 
5                                                                                    CHAPTER II 
Insertion of the C-terminal domain of apoptotic BH3-only proteins into biological membranes. 
   123 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
GFP-tail Cytochrome-c Merge 
Bcl-2 
Bim 
Bik 
Bmf 
Noxa 
Puma 
20 µm !
5                                                                                    CHAPTER II 
Insertion of the C-terminal domain of apoptotic BH3-only proteins into biological membranes. 
   124 
Figure 5.5. GFP/BH3-Ct fusions do not promote apoptosis activation. (A) Caspase-3-like activity measured 
in the HeLa cells. Bars represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001. 
ABT-263 10 µM was used as apoptotic inductor. Western blot was developed against GFP antibody and α-
tubulin (load control).  (B) Release of Cytochrome c in HeLa cells. Confocal images from HeLa cells transfected 
with different GFP/BH3-Ct constructs (green channel). Cells were fixed and incubated with Cyt-c antibody 
(apoptotic marker, red channel). Co-localizations were shown in yellow.  
4.3. Concluding remarks. 
Structural and biophysical studies have been invaluable in deciphering the role of BH3-
only proteins (383), but gaps remain in our knowledge specially concerning the way BH3-
only proteins influences on Bax/Bak membrane association (207). BH3-only proteins are 
crucial in the regulatory mechanism of apoptosis, inhibiting the anti-apoptotic BCL-2 
members or activatying directly the pro-apoptotic effectors Bax and Bak. In this dual 
action mechanism the subcellular distribution of BH3-only proteins, especially their 
MOM localization can be of paramount relevance. The presence of C-terminal 
hydrophobic region in BH3-only proteins can play a role in targeting and apoptotic 
function of these proteins. Our results clearly show that Bik and Bmf C-termini and, to 
some extent, Puma and Bim insert in biological membranes in vitro. Similar results were 
obtained in the bacterial ToxR system, where Noxa C-terminal region again did not 
display any insertion capacity in the bacterial membranes. However, when C-terminal 
regions were tested in human cells some differences were observed.  Insertion capacity 
and subcellular localization of Bik C-terminus demonstrated proper targeting to the ER 
membrane (106) and (Figure 5.4). Puma and Bim partially localized in the ER, altought 
the presence of both fusions in MOM were also observed. This distribution correlates 
with their apoptotic function as direct activators of Bax and Bak in MOM (100). The ER 
localization of BH3-only C-terminus can be related to the ER-mitochondria associated 
membranes (MAMs) contact sites between ER and MOM, where different ER and 
mitochondrial proteins are switched (384, 385). 
Cytosolic Bmf C-terminus distribution indicates that this BH3-only protein did not 
contains MOM targeting information in its C-terminal hydrophobic region. In fact, this 
BH3-only sensitizer protein could interact with the anti-apoptotic proteins in the cytosol 
to be probably later carried to MOM, where the C-terminal hydrophobic region inserts.  
5                                                                                    CHAPTER II 
Insertion of the C-terminal domain of apoptotic BH3-only proteins into biological membranes. 
   125 
Noxa C-terminus did not show capability to insertion into any of the membranes 
tested. However, the microscopy data indicated that the distribution of this fused protein 
was reticular, although neither ER nor MOM localization was observed. Recently some 
authors have described that the C-terminal tail of Noxa regulates the stability of 
both Noxa and Mcl-1 (386). Reticular distribution observed for Noxa C-terminal region is 
similar to that observed for some proteasome components and could be related with this 
recently attributed function in protein turnover. Noxa C-terminal did not then behave as a 
classical TM domain because did not show neither targeting neither insertion capacity to 
subcellular membranes.  
Overall, current data describe a non-mitochondrial distribution for BH3-only C-
terminal regions in clear contrast with the mitochondrial location found for the equivalent 
region in other pro- and anti-apoptotic BCL-2 family proteins. BH3-only proteins have to 
associate with other anti- or pro-apoptotic BCL-2 partners to exert their apoptotic 
functions (387). Through these interactions, BH3-only proteins are probably targeted to 
MOM only when the apoptotic machinery is activated. 
The C-terminal regions of the BH3-only proteins analyzed have a moderate to low 
hydrophobicity score (except for Bik C-terminus) that, however, do not preclude them to 
insert into biological membranes. Interestingly, all the C-terminal regions analyzed lack 
the flanking positives charges, which have been extensively described as a signal for 
mitochondrial targeting (193). The ER is the preferred location for Bik, Bim and to some 
extent Puma, whilst their MOM translocation will probably require the enrollment of 
additional factors involved in mitochondrial targeting (194). For that reason, most of 
BH3-only C-terminal regions analyzed do not reach MOM by themselves and remain at 
the cytosol or inserted into the ER. Furthermore, a tight relation between the membrane of 
ER and mitochondrial has been recently described through the MAMs regions. These 
physical interaction sites between ER and mitochondria could have a role in the 
transmission of apoptotic signals through BH3-only proteins! (384, 385). Then, BH3-only 
proteins could be transferred through the MAMs from the ER membrane to the MOM or 
stablish interactions with some BCL-2 family members located in the MOM to switch to 
mitochondria. In conclusion, BH3-only proteins exert their pro-apoptotic functions by 
differents ways and, as a consequence, their C-terminal regions have diferent targeting 
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and insertion capabilities in subcellular membranes. Further studies devoted to the 
mechanisms that control BH3-only proteins-mediated apoptotic activation need to be 
done in order to expand our knowledge of this puzzling and well orchestated process. 
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6.1 Introduction. 
Traditionally, Bcl-2 TMDs were referred to as membrane inserting domains (388). 
However, it is becoming apparent that the TMDs are more than mere insertion domains 
and may play a key role in the function of the Bcl-2 proteins (389-391). Synthetic 
peptides derived from such domains may thus represent useful analysis tools when 
analyzed in the appropriate in vitro assays, as demonstrated for other membrane-related 
biological disorders (392). Moreover, the sensitivity of tumor cells to MOMP when 
challenged with BH3 domain-derived peptides was recently exploited to increase the 
cellular response to chemotherapy (326, 393). This novel ‘mitochondrial priming’ concept 
extended to targeted membrane perturbation may therefore provide new directions in the 
pharmacological manipulation of cell death. We hypothesize that the BCL-2 derived 
TMD plays a central role in the function of Bcl-2 proteins and that characterization of the 
TMD membrane-binding properties will provide the initial step to understanding the 
specific role of the mitochondrial membrane in the apoptosis pathway. The aim of this 
chapter therefore was to perform a systematic evaluation of Bcl-2 TMD-derived peptides 
(TMD-pepts) in complementary biophysical and cellular studies to provide new insight 
into the role of the TMD in this prevalent cellular pathway.  
6.2 Results and Discussion. 
6.2.1. Peptide Design and Conformational Flexibility of Bcl-2 TMD-derived 
Peptides. 
In order to perform a comparative study of the biophysical properties and putative in 
cellulo activity of the C-terminal region of Bcl-2 proteins, we designed and analyzed a 
series of peptides identified as TMDs (TMD-pepts). To determine the most appropriate 
sequence regions to synthesize, the entire sequence of anti-apoptotic (Bcl-2, Bcl-xL, Bcl-
w, Mcl-1) and pro-apoptotic (Bax and Bak) proteins were analyzed using several 
transmembrane predicting algorithms (see Methods). The C-terminal residues of all 
proteins were found to be the most hydrophobic and therefore highly probable TMD 
segments. According to these results individual peptides were designed and N- and C-
terminal lysine residues were added to facilitate synthesis, purification and 
characterization (Table 6.I). 
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Table 6.I. CD characterization of Bcl2-derived peptides 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 Percentages of α-helical secondary structure obtained from the CD data interpreted with the K2D program of 
Dichroweb (available on the World Wide Web).2 Prediction of ΔG (394).obtained from ΔG prediction server 1.0 
(http://dgpred.cbr.su.se) considering only the TMDs of the proteins without added flanking Lys (shown in 
italics) (336)(394). 
 
The native TMD sequence of each protein contain at least one positively-charged 
amino acids and the insertion of additional terminal lysine residues have previously been 
shown to not interfere with the interacting properties of the hydrophobic sequences of 
many TMD core sequences (395, 396). Although the sequence alignment of the peptides 
derived from the TMD revealed less than 25% sequence identity, all the original 
sequences displayed a similar hydrophobicity profile with segregation of positive net 
charge balance towards the N- and C-termini while the hydrophobic residues were located 
in the central region (Table 6.I), a gradation of hydrophobicity statistically found in TM 
segments of solved integral membranes protein structures (397). 
The secondary structure of each peptide in different media was evaluated by circular 
dichroism (CD) spectroscopy. A control peptide derived from the TMD sequence of the 
well characterised plasma membrane protein glycophorin A (GpA) was also included. All 
peptides analyzed showed conformational flexibility, adopting different secondary 
structures in buffers and membrane-like environments analyzed. In phosphate buffered 
saline (PBS), the CD spectra of the TMD-pepts showed characteristics of extended 
conformation except for those derived from the pro-apoptotic protein Bak (TMD-Bak), 
which showed a moderate percentage of secondary structure (Table 6.I and Figure 6.1). In 
order to initially examine the propensity of each peptide to adopt a defined secondary 
structure, CD spectra were also recorded in the presence of TFE (100% vol/vol), a solvent 
!
    Percentage of α-helix1 
TMD-pepts Peptide sequence MW ΔG  (kcal/mol)2 PO4-3 Buffer 50mM SDS 10mM 
GpA Ac-KKEITLIIFGVMAGVIGTILLISYGIKK-NH2 3317.3 -1.150 13 36 
Bcl-2 Ac-KKKTLLSLALVGACITLGAYLKKK-NH2 2601.8 -1.356 22 100 
Bcl-xL Ac-KKRWFLTGMTVAGVVLLGSLFSRKK-NH2 2864.9 -0.355 8 78 
Bcl-w Ac-KKKRTVLTGAVALGALVTVGAFFAKKK-NH2 2843.9 -0.418 8 49 
Mcl1 Ac-KKRNVLLAFAGVAGVGAGLAYLIRKK-NH2 2754.8 -0.275 7 79 
Bax Ac-KKTWQTVTIFVAGVLTASLTIWKK-NH2 2760.6 0.510 12 40 
Bak Ac-KKKILNVLVVLGVVLLGQFVVRRFFKKK-NH2 3311.3 -0.735 46 100 
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known to induce helicity in single-stranded potentially α-helical polypeptides (398); in the 
presence of methanol (MeOH), which can increase β-structure population (399); and at 
the criticalmicellar concentrations (10 mM) of SDS (400), which may stabilize both α-
helical or β-sheet conformations depending on the intrinsic secondary structure propensity 
of the polypeptide (401). In 100% TFE, the TMD-pepts adopted mainly α-helical 
conformation, while TMD-Bcl-w and TMD-Mcl-1 adopted mixed random and helical 
conformations (Figure 6.1). In the presence of both MeOH and 10 mM SDS, TMD-Bcl-2, 
TMD-Bcl-xL and TMD-Bak exhibited α-helical structure; TMD-Bcl-w and TMD-Mcl-1 
adopted mixed random and helical conformations, while TMD-Bax preferentially adopted 
a β-sheet conformation (Table 6.I and Figure 6.1). 
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Figure 6.1. Circular Dichroism (CD) spectra of TMD derived peptides. CD spectra were measured between 
190 and 240 nm at a temperature of 25° C using a Jasco J-810 spectropolarimeter. Each measurement was 
recorded using 2,2,2 – Trifluoroethanol (TFE 100%), Methanol (MeOH 100%), and Sodium dodecyl sulfate 
(SDS) 10 mM and Phosphate Buffer. 
 
Overall, the solution CD data demonstrate that TMD-pepts, with similar hydrophobic 
and charge distribution characteristics, exhibit different propensities to adopt a defined 
secondary structure in membrane-mimetic environments suggesting conformational 
flexibility (402). While TMD-Bax was the only peptide that exhibited β-sheet 
conformation, overall, the α-helical conformation was predominant in membrane-like 
environments for all TMD-pepts.  
6.2.2. Membrane Binding Properties of TMD-pepts.   
Bcl-2 family proteins are not commonly classified as integral membrane proteins but have 
been recognized to act exclusively on the cytoplasmic face of mitochondria and/or ER 
membranes (403), where they most probably insert via their C-terminal TMD. Bcl-2 
proteins are synthesized by free ribosomes as full-length proteins (including the C-
terminus) in the aqueous cytosol before reaching any lipid bilayer, where C-terminal 
TMDs are energetically more stable. This process entails selective TMD shielding from 
the aqueous cytosol, targeting to the membrane surface and integration into the lipid 
bilayer, most likely with the assistance of as yet undiscovered chaperones. In order to 
evaluate the membrane affinity of the TMD of Bcl-2 proteins we analysed the binding of 
each TMDpept to synthetic model lipid membranes. We used the mitochondrial model 
membrane system (POPC/POPE/POPS/POPI/ 5/3/1/1 - Mito-like) that mimics the lipid 
composition of the outer mitochondrial membrane.  POPC/POPE/POPS/POPI/TOCL 
4.8/2.8/1/1/0.4 (Mito-like+CL) was used to determine the effect of cardiolipin, a 
mitochondrion-specific lipid (174, 404, 405), that is predominantly located in the inner 
mitochondrial membrane but may also translocate to the outer mitochondrial membrane in 
some circumstances (406). POPC was used as a model of the plasma membrane (PM-like). 
The binding of TMD-pepts to each model membrane and the effect of peptide binding on 
the membrane structure was analyzed by dual polarization interferometry (DPI) (407, 
408) (see Methods) in collaboration with Prof. Aguilar’s laboratory.  The structural 
parameters of each supported bilayer formed via in-situ liposome deposition and 
characterized by DPI are listed in Table 6.II. 
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Table 6.II. Properties of the lipid bilayers formed on the planar silicon oxynitride chip surface at 20°C. (Values 
are averages of 12-14 repeats). Value error is one standard deviation.  
 
 
The accumulative binding of each TMD-pepts was characterized by the transmagnetic 
(TM) and transelectric (TE) phase changes, which were subsequently resolved into the 
mass of membrane-bound peptide and birefringence for each lipid bilayer. The overall 
amount of bilayer-bound peptide at the end of the 20µM injection is plotted in Figure 6.2. 
Relative to the PM-like bilayer, only Bcl-w and Bak showed a statistically significant 
increase in mass bound to the Mito-like bilayer. However, there was a meaningful 
increase in the total amount of peptide bound in the presence of cardiolipin for all 
peptides except Mcl-1-derived TMD-pept. Globally, the binding experiments indicate that 
all peptides interact more efficiently with the cardiolipin-containing Mito-like bilayers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. TMD-pepts preferential binding to mitochondrial membrane-derived bilayers. The total mass 
of TMD-pepts bound to the PM-like (POPC), Mito-like (POPC /POPE/POPS/POPI = 60:30:10:10) and Mito-
like+CL (POPC/POPE/POPS/POPI/TOCL = 58:28:10:10:4) obtained at the end of 20µM injection. Values 
indicate mean values +/- S.E.M. (*: p < 0.02, **: p < 0.005 and ***: p < 0.001). 
 
Birefringence is a measure of membrane ordering that permits a systematic analysis of 
changes in bilayer order (a measure of structure), and allows the impact of peptide 
binding on the membrane structure (346, 408, 409) to be investigated.  The changes in the 
order of the PM-like and both Mito-like bilayers induced by the TMD-pepts 
! 
Lipid Thickness (nm) Birefringence 
Mass 
(ng/mm2) 
PM-like 
POPC 4.76 ± 0.03 0.0199 ± 0.0005 4.76 ± 0.03 
MITO-like 
POPC/POPE/POPS/POPI (5:3:1:1) 4.48 ± 0.06 0.0176 ± 0.0005 4.47 ± 0.07 
MITO-like+CL POPC/POPE/POPS/POPI/POCL 
(4.8.:2.8:1:1:0.4) 4.89 ± 0.18 0.0198 ± 0.0001 4.88 ± 0.33 
Bcl-2 Bcl-xL Bcl-w Mcl-1 Bak Bax GpA
0
2
4
6
8 PM-like
Mito-like
Mito-like+CL
nd nd
*
*
*
*****
***
M
em
br
an
e-
Bo
un
d 
TM
D
pe
pt
 M
as
s 
(n
g/
m
m
2 )
6                                                                                   CHAPTER III 
Peptides derived from the transmembrane domain of Bcl-2 proteins as potential mitochondrial priming tools. 
   134 
(birefringence vs mass plots) are shown in Figure 6.3, which reflect the overall profile of 
bilayer disordering during peptide binding. For each bilayer, injection of each peptide at 
increasing concentrations resulted in increased mass bound to the bilayer. There was little 
to no dissociation of any of TMD-pepts indicating that all peptides bound irreversibly 
under the conditions used. Furthermore, These plots demonstrate that all peptides caused 
minimal disruption to the PM-like membrane but reduced the ordering of both Mito-like 
membranes. 
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The dependence of both mass and birefringence on peptide concentration as shown in 
Figure 6.4 allows further analysis of the effect of each peptide on the structure of the three 
model membranes. On the PM-like bilayer, the membrane ordering increased slightly 
(increase in birefringence) or decreased (drop in birefringence), reflecting small changes 
in bilayer structure and demonstrating the ability of the PM-like bilayer to recover from 
peptide binding. However, in comparison, the Mito-like bilayer exhibited a significant 
degree of re-ordering to accommodate the bound peptide, which increased further in the 
presence of cardiolipin. For the TMD-pepts derived from anti-apoptotic proteins (TMD-
Bcl-2, TMD-Bcl-xL, TMD-Bcl-w and TMD-Mcl-1), the birefringence of both 
mitochondrial membrane-derived bilayers approached a plateau at higher levels of bound 
peptide (Figure 6.3 and 6.4). In contrast, the birefringence of the Mito-like bilayer 
Figure 6.3. Changes in bilayer order induced by TMD-pepts. Dual Polarisation Interferometry. The 
effect of peptides on membrane disordering is analyzed by the changes of birefringence (Dnf) as a function 
of membrane bound-peptide mass, in POPC (PM-like, left panels), in POPC/POPE/POPS/POPI (5:3:1:1) 
(MITO-like, central panels) and in POPC/POPE/POPS/POPI/POCL (4.8:2.8:1:1:0.4) (MITO-like/CL, right 
panels). A decrease in birefringence corresponds to a decrease in bilayer order, while an increase in 
birefringence reflects an increase bilayer ordering. 
TMD-Bak
0.011
0.013
0.015
0.017
0.019
0.021
2μM
5μM
10μM
20μM
TMD-Bak TMD-Bak
Mass (ng/mm2)
4 6 8 10 12
TMD-Bax
0.011
0.013
0.015
0.017
0.019
0.021 TMD-Bax
TMD-GpA
Mass (ng/mm2)
4 6 8 10 12
0.011
0.013
0.015
0.017
0.019
0.021 TMD-GpA
Mass (ng/mm2)
4 6 8 10 12
PM-like Mito-like Mito-like + CL
Δ
n f
Δ
n f
Δ
n f
6                                                                                   CHAPTER III 
Peptides derived from the transmembrane domain of Bcl-2 proteins as potential mitochondrial priming tools. 
   136 
continued to drop for the TMD-pept derived from pro-apoptotic protein Bak (Figure 6.3 
and 6.4), suggesting a higher membrane perturbing effect on this mitochondrial 
membrane-derived bilayer.  As expected, the GpA-derived TMD-peptide, a protein that is 
not associated with mitochondrial membranes, caused a much smaller drop in bilayer 
order. In summary, the results indicate that a lower concentration of the TMD peptides is 
required to induce a significant change in membrane order in both mitochondrial 
membrane-derived bilayers, and suggests a potential role of cardiolipin for the differential 
localization of the Bcl-2 proteins in membranes, especially for TMD-Bcl-xL and TMD-
Bak (Figure 6.4).  
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Figure 6.4. Changes in bilayer order induced by TMD-pepts. Measurements of bilayer mass and 
birefringence at different TMD-pept concentration. Dependence of mass (Dependence of mass (ng/mm2) 
and birefringence (Δnf) on concentration of each TMD-derived peptide PM-like (black line), Mito-like 
(green line) and Mito-like+CL like bilayers (red line). A decrease in birefringence corresponds to a decrease 
in bilayer order, while an increase in birefringence reflects an increase bilayer ordering. 
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Next, we analyzed the influence of the membrane environment in the secondary structure 
of TMD-pepts by means of CD spectroscopy. CD spectra were obtained in the presence of 
synthetic liposomes at different lipid:peptide molar ratios (L:P). In the presence of PM-
like liposomes, TMD-pepts were found to populate random or β-sheet-like conformations 
characterized by a minimum centered at 217 nm (Figure 6.5). 
The CD spectra in the presence of Mito-like liposomes exhibited a minimum at 222-224 
nm suggesting the coexistence of dynamic mixed structures characterized by the presence 
of helical conformation. In addition, the 208 nm minimum characteristic of helical 
conformations was less defined. The less defined double minima associated with α-helical 
spectra is commonly observed for peptides that bind strongly to liposomes (410, 411). 
TMD-Bax precipitated out from solution in the presence of Mito-like liposomes 
precluding structural analysis by CD. 
In contrast to the behavior in PM-like liposomes, all TMD-pepts caused Mito-like 
liposome solutions to become turbid over time and dynamic light scattering (DLS) was 
therefore utilized to understand this phenomenon. The size and distribution of particles 
present upon addition of each peptide are shown in Figure 6.6. At low lipid:peptide (L:P) 
ratios (red lines) we found a single species approximately 60 - 100 nm in size 
corresponding to the expected size for liposomes produced by extrusion through a 100 nm 
pore size filter.  However, at higher L:P ratios, all peptides except TMD-Bax (which had 
low solubility under the conditions) and TMD-GpA, caused the formation of larger 
species in the range of 800–1000 nm and up to 5000 nm in diameter.  Thus, the addition 
of TMD-Bcl-2, TMD-Bcl-xL, TMD-Bcl-w, TMD-Mcl-1 and TMD-Bak all caused 
changes in the properties of the model Mito-like membrane leading to liposome fusion. 
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Figure 6.5. CD spectra of TMD-derived peptides in POPC (left panels) and POPC:POPE:POPS:POPI (5:3:1:1, 
right panels) at two different lipid:peptide ratios, 1:51 (black) and 1:201 (blue). 
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Figure 6.6. Analysis of the effect of TMD-derived peptides on liposome diameter in POPC and 
POPC:POPE:POPS:POPI (5:3:1:1), at four different lipid:peptide ratios, 1:31, 1:51, 1:101 and 1:201. 
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6.2.3. TMD-pepts promote calcein release from liposomes and Cytochrome c 
Release from Isolated Mitochondria.  
To determine whether membrane binding of TMD-pepts induced bilayer disruption, 
membrane leakage was analyzed by dye release assays. We measured the rate of 
liposome-encapsulated calcein release from model PM-like and Mito-like membranes. 
The TMD-pepts were evaluated at the biologically active concentration of 10 µM (see 
below) and all Bcl-2-derived peptides, except Bcl-w, consistently induced higher calcein 
release from Mito-like than from PM-like liposomes (Table 6.III), suggesting a specific 
role in the perturbation of mitochondrial membranes, especially for TMD-Bcl-xL, TMD-
Mcl-1, and TMD-Bax and TMD-Bak. Moreover, the control TMD-GpA peptide induced 
more calcein leakage from PM-like than from Mito-like membranes and can therefore be 
described as a mitochondrial inactive peptide. These results, together with the results 
obtained from DPI, suggest that TMD-pepts derived from Bcl-2 proteins are poorly active 
at plasma membranes inducing minor damage that can easily self-repair.  
 
Table 6.III . TMD-pepts-induced calcein release from liposomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a The % of calcein release was calculated taken into account as total release that obtained when liposomes 
were treated with the 10% Triton X-100.  The TMD-pepts were evaluated at 10 µM. 
TMD-pept 
% of released calcein
a  
 
PM-like Mito-like t-student 
Bcl-2 28  ± 4 40  ± 7 * 
Bcl-xL 4  ± 7  75  ± 16 *** 
Bcl-w 20  ± 6  28 ± 5 n.s. 
Mcl-1 15  ± 6  53  ± 6 *** 
Bax 6  ± 8  52  ± 7 *** 
Bak 41  ± 12  88  ± 3 *** 
GpA 47  ± 12 11  ± 6 ** 
!
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Interestingly, the damage that these peptides induce in mitochondrial membranes may 
find application in the apoptotic activation of tumor cells by mitochondrial priming. We 
then evaluated the potential biological activity of TMD-pepts in isolated intact 
mitochondria purified from mouse embryonic fibroblasts (MEFs) cells. In control (N.T., 
non-treated) mitochondria, cytochrome c (Cyt-c) was found in the pellet that contained 
the mitochondrial fraction characterized by the presence of the mitochondrial voltage-
dependent anion selective channel protein 1 (VDAC 1) (412) (Figure 6.7a and b). A 
similar result was found with the mitochondrial inactive peptide TMD-GpA. In contrast, 
TMD-Bcl-xL, TMD-Bax and TMD-Bak induced the highest level of mitochondrial Cyt-c 
release, while TMD-Mcl-1 was consistently the less active peptide (Figure 6.7a and b). In 
order to further characterize the effect of TMD-pepts on the integrity of the isolated 
mitochondria, we developed a mitochondrial-swelling assay. TMD-pepts did not induce 
swelling when compared to Ca2+-only induced experiments (Figure 6.7c). Thus, although 
TMD-pepts induced Cyt-c release, the molecular mechanism by which this occurs does 
not disrupt mitochondrial integrity. These results correlate with previous studies, 
suggesting that the molecular mechanism of full length Bcl-2 proteins-induced Cyt-c 
release specifically perturbed the mitochondrial outer membrane, while the inner 
membrane and the ultra-structure of mitochondria remained unaffected (413). The 
biophysical activity of TMD-pepts in synthetic membranes, together with the Cyt-c 
release capacity from isolated mitochondria support the notion that TMD peptides not 
only act as membrane anchoring domains but can also be considered as biologically active 
agents in their own right.  
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Figure 6.7. TMD-pepts promote cytochrome c release from intact isolated mitochondria.  (a)  VDAC and 
Cyt-c immunoblotting from pure mitochondria fractions (Pellet).  Data are representative of three independent 
assays. (b) Western Blot quantification of Cyt-c release using ImageJ software. Experiments were performed 
independently three times (N=3) (***p < 0.001, compared with NT). (c) Mitochondrial swelling of TMD-pepts 
compared with CaCl2 as positive control measured as absorbance change at 540nm.  
6.2.4. Biological Activity of TMD-pepts on Human Cervix Adenocarcinoma 
Cells. 
To further characterize the marked effect of TMD-pepts in isolated mitochondria, their 
biological activity in human cervix adenocarcinoma (HeLa) cells was evaluated. Firstly, 
HeLa cells were incubated in the presence of TMD-pepts at 10 µM for 24h. In these 
experimental conditions, cells were resistant to TMD-pepts and showed normal behavior. 
In fact, the levels of free lactate dehydrogenase (LDH) in the media revealed that cells did 
not lose permanent or transient membrane integrity due to TMD-pepts treatment (data not 
shown). In addition, the TMD-pepts did not induce plasma membrane disruption-induced 
cell death. As previously described (343, 414) Lipofectamine 2000 was used to facilitate 
the access of the peptides to the cell cytosol through the plasma membrane. We found that 
10 µM TMD-Bcl-2, TMD-Bcl-xL, TMD-Bax and TMD-Bak promoted a significant 
increase in HeLa cell death percentages under these experimental conditions (Figure 6.8a). 
As expected, compromised cell viability correlated with loss of mitochondrial 
functionality (Figure 6.8b, Figure 6.9a), and a moderate release of Cyt-c from 
mitochondria, in particular with TMD-Bcl-xL and TMD-Bak (Figure 6.8c). These two 
highly active peptides also caused a significant drop in intracellular ATP levels in the 
early stages of treatment when the effect of the apoptotic inducer (CDDP) was still not 
apparent (Figure 6.8d). The drop in ATP was most probably caused by the TMD-pepts 
induced mitochondrial destabilization. Furthermore, we found no evidence of caspase-like 
activity in either case (Figure 6.8e, lanes 1-5). In this context the TMD-pepts drive cells to 
necrotic rather than apoptotic cell death despite having a moderate amount of Cyt-c 
released in the cytoplasm (415).  
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Figure 6.8. Bcl-2-derived peptides effect on viability, mitochondrial membrane potential, Cyt-c release 
and caspase 3/7 activity in HeLa cell cultures at TMD-pepts 10 µM. (a) Cell viability measured by trypan 
blue exclusion assay of cultures transfected with peptides at 10 µM for 24 h. (b) Mitochondrial membrane 
potential was measured by flow cytometry with TMRM.  (c) Mitochondrial permeabilization was analyzed by 
flow cytometry with Cyt-c FITC. (d) Measurement of intracellular ATP by luminescence, peptide treatment 
decreased intracellular ATP levels compared with the not treated cells. Representative data are shown, bars 
represent the mean of three independent experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001, compared with 
NT). (e) Caspase 3-like activity measured in the HeLa cells. Bars represent the mean of three independent 
experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001 compared with CDDP). Western blot developed against 
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caspase 3 antibody  using α-tubulin like load control. The fraction at 17 and 19 KDa represents the active form 
of the enzyme. (f) Effect of Bcl-2 and Bcl-xL Full length on cell death was assayed by flow cytometry with 
FITC Annexin V and Propidium Ioride (PI). (g) Correlation Graph for HeLa cell line according to the results 
showed in Figure 6.7, Figure 6.8 and Table 6.III. 
 
Accordingly, when cell fate was monitored by the combined staining with the dye 
Propidium iodide (PI, which is excluded from cells with intact plasma membranes) and 
FITC-labeled Annexin V (AnnV, which binds to phosphatidylserine moieties exposed on 
the surface of dying apoptotic cells) we found that the most active peptides TMD-Bcl-2, 
TMD,Bcl-xL, TMD-Bax and TMD-Bak generate predominantly necrotic cell death 
(Figure 6.9b, brown bars). Focusing on the most active peptides TMD-Bcl-xL and TMD-
Bak, it should be highlighted that their behavior correlates well with their biophysical 
properties in the MOM. Nevertheless, their pro-death effect could not always be related to 
that of the full-length protein; especially for TMD-Bcl-xL, which is an anti-apoptotic 
member. Previous studies support the ability of Bcl-2-derived TMDs, and other natural or 
synthetic cytotoxic peptides (416-420) to permeabilize mitochondria, through possible 
pore formation (421-423). 
To better understand the functional correlation between TMD-pepts and full length 
(FL) Bcl-2 proteins we have analyzed the effect of TMD-Bcl-xL and TMD-Bak in the 
presence of the anti-apoptotic proteins Bcl-2 and Bcl-xL. Flow cytometry analysis 
showed a slight decrease in cell death in the presence of the anti-apoptotic FL proteins, 
while the necrotic pathway was not significantly affected (Figure 6.8f). This indicates that 
anti-apoptotic proteins are able to partially block the residual apoptotic pathway promoted 
by Cyt-c release due to the presence of TMD-peptides. Based on this result we can 
speculate on the existence of a putative (direct or indirect) interaction among TMD-pepts 
and the FL Bcl-2 proteins. 
As shown in Figure 6.8g, there is a good correlation between the biophysical effects of 
TMD-pepts on synthetic membranes and the outcome of their treatment in cell cultures. 
The more they perturb model membranes the larger are the cellular consequences. 
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Figure 6.9. Mitochondrial dysfunction of HeLa cells co-treated with CDDP and Bcl-2 TM domain 
peptides (10 µM and 3 µM) measured by MTT. (a) Cells were treated with TM peptides at 10 µM for 24 h. 
(b) Apoptotic cell death promoted by the TMD-pepts at 10 µM was analyzed by flow cytometry with FITC 
Annexin V and PI. (c) Cells were treated with CDDP (40µM) for 12 h after transfection with TM peptides at 10 
µM. (d) Cells treated with TM peptides at 3 µM for 24 h represented by white bars. Cells treated with CDDP 
(40µM) for 12 h after transfection with TM peptides at 3 µM represented by black bars. All bars represent the 
mean of three independent experiments ± s.d. (*p < 0.1; **p < 0.05, ***p < 0.001).  
6.2.5. Mitochondrial priming effect of TMD-pepts.  
It has been proposed that mitochondrial priming, understood as the readiness of 
mitochondria to actively engage the apoptotic program, inversely correlates with 
resistance to chemotherapy (324, 326). Mitochondrial priming can be forced by 
decreasing the cellular content of anti-apoptotic Bcl-2 proteins or by using BH3-mimetics 
such as ABT-737 (326). We were therefore interested in the evaluation of TMD-pepts as 
novel mitochondrial priming tools. Thus, we evaluated the sensitivity of HeLa cells to co-
treatment with the chemotherapeutic agent cisplatin (cis-diammineplatinum (II) dichloride, 
CDDP) and TMD-pepts. Control cells treated with CDDP in the absence of TMD-pepts 
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showed close to 50% apoptotic cell death (Figure 6.10a) characterized by mitochondrial 
dysfunction (Figure 6.9c), loss of mitochondrial membrane potential (Figure 6.10b), Cyt-c 
release (Figure 6.10c) and caspase-3/7-like activity (Figure 6.10d). Interestingly, we 
observed that a significant decrease in cell viability correlated with an increase in 
apoptotic markers when CDDP treated cells where co-treated with TMD-Bcl-2, TMD-
Bcl-xL, TMD-Bax and TMD-Bak peptides (Figure 6-10).  
 
Figure 6.10. Co-treatment of TMD-pepts (10µM) with CDDP significantly enhances the effect of the 
chemotherapeutic drug in HeLa cells. Cells were treated with CDDP (40 µM) for 12 h after peptides 
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transfection protocol. (a) Viability measured by trypan blue assay. (b) Mitochondrial membrane potential was 
measured by flow cytometry with TMRM. (c) Mitochondrial permeabilization was analyzed by flow cytometry 
with anti Cyt-c FITC. (d) Caspase 3-like activity measured in the HeLa cells. Bars represent the mean of three 
independent experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001 compared with CDDP). (e) Apoptotic cell 
death was analyzed by flow cytometry with FITC Annexin V and PI. HeLa.  
 
Moreover, the less mitochondrial active peptide, TMD-Mcl-1, and the mitochondrial 
inactive peptide, TMD-GpA, did not increase the chemotherapeutic effect of CDDP 
(Figure 6.10). It should be noted that the effect of the co-treatment on the caspase-3/7-like 
activity is the result of a cooperative effect between the peptides and the drug, provided 
that cell treatment with TMD-pepts in the absence of CDDP did not activate caspases 
(Figure 6.9e lanes 2-4). The caspase-3 activity induced by the TMD-pepts in combination 
with CDDP was abolished in the presence of the general caspase inhibitor zVAD (Figure 
6.11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11. HeLa cells treated with TMD-Bcl-xL and TMD-Bak peptides and CDDP in presence of 
Caspase inhibitor zVaD. Cells were transfected with the peptides at 10µM. zVaD (10uM) was added before 
CDDP (40uM) treatment, 4 h later peptide transfection (total time 24h). (a) Apoptosis activation was measured 
by Caspase 3-like activity measured in HeLa cells. All bars represent the mean of three independent experiments 
± s.d. (ns, no significant; *p < 0.1).   
 
Flow cytometry analyses showed that CDDP-induced apoptotic cell death (AnnV+/PI- 
and AnnV+/PI+, light and dark gray bar segments) significantly increased in the presence 
of the mitochondrial active peptides TMD-Bcl-2, TMD-Bcl-xL, TMD-Bax and TMD-Bak, 
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but was not affected by the presence of the mitochondrial inactive peptide TMD-GpA 
(Figure 6.10e). These results also correlated with a change in the behavior of peptides, 
observed by flow cytometry, from mainly necrotic when used alone (Figure 6.9b), to 
mainly apoptotic when used in combination with CDDP (Figure 6.10e). Altogether, these 
results indicate the existence of a switch from necrosis to apoptosis when TMD-pepts are 
used in combination with CDDP.   
To better define the cooperative behavior observed in the experiments described above 
we studied the cell death properties at sub-lethal concentrations of TMD-pepts when used 
in combination with CDDP. 
We then evaluated the active TMD-pepts at 3 µM in HeLa cells. At this concentration, 
all peptides by themselves, with the exception of TMD-Bak, showed less than 10% 
reduction in cell viability (Figure 6.12a, white bars), and only a partial loss of 
mitochondrial potential, as indicated by an increase in the number of cells with low 
transmembrane potential (Figure 6.12b). Moreover, neither Cyt-c release nor caspase-3/7-
like activity was observed (Figure 6.12 panels c and d, respectively). To explore whether 
the priming exerted by the mitochondrial active TMD-pepts at sub-lethal concentrations 
could increase the sensitivity of HeLa cells to chemotherapeutic agents, we used co-
treatment with CDDP (black bars). The mitochondrial priming resulted in a large increase 
in CDDP-induced cytotoxicity (Figure 6.12a, Figure 6.9d) accompanied by an increase in 
the percentage of cells with low mitochondrial transmembrane potential (Figure 6.12b), in 
the Cyt-c released to the cytosol (Figure 6.12c) and in the caspase-3/7-like activity 
(Figure 6.12d). Accordingly, CDDP induced apoptotic death significantly increased in the 
presence of the TMD-pepts (see AnnV+/PI- and AnnV+/PI+ population in Figure 6.12e). 
These results confirm the behavior observed at lethal concentrations of TMD-pepts and 
strongly support their mitochondrial priming properties. 
Interestingly, some TMD-pepts from anti-apoptotic proteins, such as Bcl-xL, show 
pro-death function in the tumor cell lines analyzed. It has been previously demonstrated 
that Bcl-xL is cleaved by caspase 3 and calpains, converting Bcl-xL from an anti-
apoptotic to a pro-apoptotic factor (424).  
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Figure 6.12. Mitochondrial priming by TMD peptides. A Sub-lethal TMDpepts doses induce a 
mitochondrial priming effect in co-treatments with CDDP in HeLa cells. Comparison of the effect of 
treatment with TMDpepts alone at 3 µM (white bars) or with co-treatment with CDDP at 40 µM for 12 h (black 
bars). (a) Cell viability measured by trypan blue exclusion assay of cultures treated with peptides for 24 h. (b) 
Mitochondrial membrane potential was measured by flow cytometry with TMRM. (c) Mitochondrial 
permeabilization was analyzed by flow cytometry with anti Cyt-c FITC. (d) Caspase 3-like activity measured in 
the HeLa cells. Bars represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001 NT 
(white bars) and CDDP (black bars)). (e) Apoptotic cell death was analyzed by flow cytometry with FITC 
Annexin V and PI. 
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Here we show that the Bcl-xL TMD could be the protein domain responsible for this 
switch. This behavior could be explained taking into account the common evolutionary 
origin of Bcl-2 proteins. The programmed cell death is executed with very few members 
in invertebrates but new members appear with the genomic expansion of vertebrates. In 
simpler systems, the same protein could be responsible for the final decision of cell death 
or survival depending on post-translational modifications (425, 426). All these proteins 
share one to four conserved Bcl-2 homology domains (BH) and most possess a C-terminal 
hydrophobic amino acid. The divergent evolution of pro- and anti-apoptotic members 
could be explained considering only the cytosolic regions of Bcl-2 proteins (425). 
Therefore we speculate that the pore formation capability of TMD-pepts could be 
modulated by the folding of their soluble regions. Overall, from these experiments we 
conclude that TMD-pepts clearly enhance the cell apoptosis-inducing effects of the 
chemotherapeutic agent CDDP in HeLa cells independently of their pro- or anti-apoptotic 
origin. 
6.2.6. Mitochondrial priming effect can be extended to other cancer cells. 
In order to generalize our findings and to better understand their physiological relevance, 
we analysed the behavior of the most active TMD-pepts in the human colorectal 
carcinoma HCT116 and HCT116 Bax/Bak double knock out (DKO) cell lines (427, 428).  
We observed that HCT116 cells had a similar behavior to HeLa cells although they 
were slightly more resistant to TMD-pepts treatment. Hence, we characterized the effect 
of these TMD-pepts at 20 µM (lethal) and 10 µM (sub-lethal) concentrations (Figure 
6.13).  
We examinated that for both cell lines, treatment at lethal concentrations provoked 
loss of cell viability, which correlates with a decrease in ATP levels (Figure 6.13 a to d) 
and an increase in mitochondrial destabilization (Figure 6.14 panels a and b). However, 
there was no effect in caspase 3 activity in any case (Figure 6.13 e and f) as previously 
described for HeLa cells. Interestingly, in the presence of CDDP, HCT116 wt cells also 
showed the previously observed switch from necrosis to apoptosis (Figure 6.14c). 
However, there were no changes in the necrotic populations when the co-treatments were 
applied to the HCT116 DKO cell line (Figure 6.14d).  
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Figure 6.13. HCT116 wt and DKO were treated with TMD-Bcl-xL and TMD-Bak peptides for 24h. Cells 
were transfected with TMD-pepts (10 and 20 µM). (a, b) Viability was measured by trypan blue assay after 24h 
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of peptide transfection. (c, d)  Measurement of intracellular ATP/cell by luminescence, bars represent the mean 
of three independent experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001, compared with NT). (e, f) 
Apoptosis activation was measured by Caspase 3-like activity. Bars represent the mean of three experiments ± 
s.d. (*p < 0.1; **p < 0.05; ***p < 0.001 compared with NT (white bars) and CDDP (black bars)). 
 
 
 
Figure 6.14. HCT116 wt and DKO were treated with TMD-Bcl-xL and TMD-Bak peptides for 24h. Cells 
were treated with TMD-pepts (20 µM) 4 hours after CDDP treatment. (a, b) Mitochondrial dysfunction was 
measured by MTT assay  after 24h of peptide transfection.(c, d) Apoptotic cell death was analyzed by flow 
cytometry with FITC Annexin V and PI. 
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dysfunction (Figure 6.15 panels a and b), cell viability and ATP levels (Figure 6.13 a-d) 
for both wild type and DKO cell lines. However, in the presence of CDDP, we observed a 
notable increase in caspase 3 activity for HCT116 wild type cells (Figure 6.15 panels c 
and e) but not for DKO cells (Figure 6.15 panels d and f). The absence of an apoptotic 
switch in the HCT116 DKO cell line highlights the relevance of the Bcl-2 apoptotic 
machinery in the TMD-pepts-mediated mitochondrial priming. 
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Figure 6.15 Mitochondrial priming effect of TMD-pepts in HCT 116 cell lines wt and Bax/Bak KO.  Cells 
were treated with TMD-pepts at 10µM and CDDP is added at 20 µM. (a, b) Mitochondrial dysfunction was 
measured by MTT assays 24h after peptide transfection.  (c, d) Caspase 3-like activity measured in HCT 116 
cell lines. Bars represent the mean of three experiments ± s.d. (*p < 0.1; **p < 0.05; ***p < 0.001 compared 
with NT (white bars) and CDDP (black bars)). (e, f)  Apoptotic cell death was analyzed by flow cytometry with 
FITC Annexin V and PI. 
6.3. Concluding remarks. 
The existing paradigm for Bcl-2 protein-mediated control of mitochondria and cell fate in 
apoptotic signaling involves protein-protein interactions among Bcl-2 members mediated 
by BH3 domains (123). However, there is increasing evidence the role of the membrane 
(120, 429) and the interaction of Bcl-2 proteins within the membrane through their TMDs 
(116, 196, 387, 388, 429, 430) must also be included. The present study has led to the 
establishment of an activity-based classification of the Bcl-2 TMD-derived peptides. 
Overall, both biophysical and cellular data point toward a clear correlation between 
mitochondrial membrane insertion/perturbation capability and cellular activity (Figure 
6.8g and Figure 6.16), sustaining an active role of these peptides in MOMP.   
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Figure 6.16. Preferential TMD-pepts binding to mitochondrial membrane induces mitochondrial 
membrane disruption. Schematic representation depicting the relatively low binding of TMD-pepts to the 
plasma membrane compared to its higher binding to the mitochondrial membrane. This preferential binding 
disrupts the mitochondrial membrane structure leading to Cyt-c release to the cytosol.  
 
The control of apoptosis exerted by Bcl-2 proteins has led to the use of BH3-derived 
peptides and BH3 mimetics as potential drugs to improve cancer treatments (307, 324, 
326, 431). Targeting the BH3 domain of Bcl2 proteins to induce apoptosis in cancer cells 
is not always effective and mostly depends on pro-survival Bcl2 members (393, 432, 433). 
Therefore, combination treatments have emerged as novel pharmacological strategies to 
avoid toxicities and increase efficacy of anti-tumor treatments (342, 394, 434). In this 
scenario, we demonstrate that the combination of CDDP with sub-lethal dosages of TMD-
pepts, especially TMD-Bcl-xL and TMD-Bak, increases its pro-apoptotic activity, 
exerting a mitochondrial priming effect. We speculate that TMD-pepts need direct or 
indirect interactions with the Bcl-2 network to produce the apoptotic priming effect.  
In light of the TMD-pepts effect in mitochondrial priming, we envisage that Bcl-2-
derived TMD-pepts have the potential to make significant contributions to our 
understanding of apoptosis-induced clinical disorders and to establish a basis for the 
design of new cancer therapeutics. 
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7.1. Introduction. 
Current anti-tumour treatments based in inducing apoptosis target cancer cells and rapidly 
dividing normal cells as well as other especially sensitive differentiated cells. Therefore, 
these treatments do not differentiate between malignant and normal cells. Chemotherapy 
causes toxicity, leading to side effects like those reported for apoptosis-inducing and 
DNA-damaging agent cisplatin (cis-diammineplatinum(II) dichloride, CDDP), which 
induces ototoxicity (435) and alopecia (436). These undesirable effects may be 
ameliorated by the discovery of new more specific cell death-inducing drugs (437), or by 
selectively and locally inhibiting apoptosis in defined sensitive cells. 
The proposal of developing BH3-mimetics as chemotherapeutic drugs originates from 
understanding the role of the Bcl-2 protein family in regulating the intrinsic apoptotic 
pathway by controlling mitochondria outer membrane permeability (MOMP). The small 
molecule compounds developed as inhibitors of anti-apoptotic Bcl-2 proteins, generically 
named BH3-mimetics such as ABT-737 (Abbott Laboratories) or obatoclax (GX15-070, 
Gemin X Biotechnologies), release pro-apoptotic binding partners and suffice to induce 
apoptosis. ABT-737 binds selectivity to anti-apoptotic Bcl-2, but has a low affinity to 
Mcl-1 and A1 (307, 438). GX15-070 has been proposed to influence the activity of the 
Bak/Mcl-1 and Bim/Mcl-1 complexes (320) to induce mitochondrial- mediated apoptosis, 
which would imply Bax/Bak-mediated MOMP and apoptosome-mediated activation of 
caspases. However, in some cell lines that are relevant for disease, GX15-070-treatment 
has also been described to render phenotypic cell characteristics, which could be 
associated with GX15-070 activities, including autophagy, independently of 
mitochondrial-mediated apoptosis. The cytotoxic activity of GX15-070 and ABT-737 in 
Bax/Bak double knockout cells has also been reported (305, 322), while the role of the 
apoptosome (Figure 7.1) is unclear as it is still to be explored in detail. This is particularly 
relevant for studying the activity of BH3-mimetics in cells with low Apaf-1 contents that 
correlate with resistance to chemotherapeutic treatments (439, 440) and for preclinically 
evaluating a new class of apoptosis inhibitors targeting the apoptosome (441, 442), which 
are currently being evaluated as agents to locally prevent chemotherapy-induced 
secondary effects. It would then be of interest to comparatively analyze the activity of 
BH3-mimetics and CDDP (as a representative of established cytotoxic drugs) in cells in 
which Apaf-1 has been genetically deleted and to also analyze whether apoptosome 
inhibitors can inhibit BH3-mimetics-induced cell death. 
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7.2. Results and discussion. 
7.2.1. Apaf-1 inhibitor QM31 reduces the activation of apoptosis promoted 
by different apoptotic inductors. 
The immortalisation process may affect the genetic background of mouse embryonic 
fibroblasts (MEFs) cell lines and might be responsible for the differences observed in the 
behavior of the different MEFs knock out (KO) Apaf1 cellular models. For this reason, it 
was initially analysed the apoptotic response to ABT-737 of the embryonic fibroblast 
wild-type (WT) MEFs and Apaf1 KO mouse (MEFs KO Apaf1) cell lines, (351) which 
were previously established by spontaneous immortalisation (SIM) or by infection with 
SV40 antigen T (SV40IM) (443). ABT-737 treatment induced activation of caspase-3, 
release of Cyt-c and death in SV40IM-MEFs WT. However in SV40IM-MEFs KO Apaf-
1 and SIM-MEFs, these parameters remain unaffected (Figure 7.2A,B and C)! (444). 
These results suggest that ABT-737 trigger signalling is not fully perceived by the Apaf-1 
SIM-MEFs cells. Thus, the immortalisation process may affect the genetic background 
Figure 7.1. The structure of apoptosome complex. Cytochrome c (showed in red) is released 
from mitochondria when apoptotis is induced and it binds to the cytosolic protein Apaf-1 (blue) 
to facilitate the formation of apoptosome in the presence of dATP (purple), the third component 
of the complex. Once formed, the apoptosome can then recruit and activate the inactive pro-
caspase-9. Once activated, this initiator caspase can then activate effector caspases and trigger a 
cascade of events leading to apoptosis.!(http://www.rcsb.org/pdb/101/motm.do?momID=177) 
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and might be responsible for the differences between both MEFs cellular models. For this 
reason, we selected SV40IM-MEFs to evaluate the response of different cells lines 
towards several apoptotic insults.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. ABT-737 treatment induces cell death in SV40IM WT MEFs but not SV40IM KO MEFs and 
SIM MEFs. (A) Percentage of cell survival measured by the trypan blue exclusion assay in SV40IM and SIM 
MEFs, WT and Apaf1 depleted, in the presence or absence of ABT-737 (20 µM) for 24 h. (B) Caspase-3 like 
activity was measured under the same conditions described above. (C) Cells with Cyt-c released measured by 
the flow cytometry analysis after incubation with ABT-737 (20 µM) for 24 h. In all cases, bars represent the 
mean of three experiments ± s.d. 
 
MEFs from wild-type mouse (MEFs wt Apaf-1 and MEFs wt Bax/Bak) (351) were 
treated with ABT-737, GX15-070 or cisplatin (cis-diammineplatinum(II) dichloride, 
CDDP), either alone or in combination with apoptosome inhibitor compound QM31 (441, 
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442), or with broad spectrum caspase inhibitor Z-Val-Ala-Asp(OMe)-fluoromethylketone 
(zVADfmk). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3. Apaf-1 inhibitor QM31 prevents cell death in non tumor cells treated with both ABT-737 
and CDDP, but not in cells treated with GX15-070. (A and D) Caspase 3-like activity was measured in 
MEFs wt Apaf-1 and MEFs wt Bax/Bak treated with ABT-737 (25 µM), GX15-070 (1 µM) and CDDP (30 
µM) in the presence or absence of QM31 (10 µM) and zVADfmk (5 µM). (B and E) Mitochondrial 
dysfunction was measured by an MTT assay under the same conditions described above. Bars represent the 
mean of three experiments ± s.d. (**p,0.05). (C and F) Apoptotic cell death was determined by flow 
cytometry with FITC Annexin V and DRAQ7. Data are representative results of three independent 
experiments. 
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Cultured cells were evaluated at 24 h post-treatment. ABT-737 and CDDP treatments 
induced activation of caspase-3, which was inhibited by zVADfmk and by QM31. 
However, when cells were treated with GX15-070, only residual caspase-3 activity was 
observed (Figure 7.3A and D). Cell viability was determined by MTT (Figure 7.3B and E) 
to find that ABT-737- and CDDP-induced death (20% and 60%, respectively) was 
inhibited by QM31, but not by zVADfmk, while the cell death induced by GX15-070 
(around 50%) was not inhibited by either zVADfmk or QM31. Annexin V/DRAQ7 flow 
cytometry assays corroborate viability and apoptotic cell death results (Figure 7.3C and F).  
7.2.2. QM31 needs the presence of Apaf-1 and the Bax/Bak pro-apoptotic 
effectors to block apoptosis. Obatoclax and CDDP induce cell death by 
dependent and non-dependent apoptotic mechanism. 
The same experiments were conducted in Apaf-1 knockout (KO) mouse embryonic 
fibroblasts (MEFs KO Apaf-1) (351), in MEFs KO Bax/Bak (84) and in cervix 
adenocarcinoma cells (HeLa). In MEFs KO Apaf-1 (Figure 7.4A) and MEFs KO Bax/Bak 
(Figure 7.4D), none of the treatments induced caspase-3 activity, while cell viability was 
unaffected by the ABT-737 treatment, but decreased with both GX15-070 and CDDP 
treatments (Figure 7.4B and E). GX15-070- and CDDP- induced cell death in these cells 
was not inhibited upon apoptosome or caspase inhibition. Consequently, treatments with 
QM31 and zVADfmk did not significantly modify the percentage of Annexin V stained 
cells (Figure 7.4C and F).  
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Figure 7.4. GX15-070 and CDDP induce caspase 3 independent cell death in Apaf-1 and Bax/Bak 
deficient cells. (A and D) Caspase 3- like activity was measured in MEFs KO Apaf-1 and MEFs KO Bax/Bak 
treated with ABT-737 (25 µM), GX15-070 (1 µM) and CDDP (30 µM) in the presence or absence of QM31 
(10 µM) and zVADfmk (5 µM). (B and E) Mitochondrial dysfunction was measured by an MTT assay under 
the same conditions described above. Bars represent the mean of three experiments ± s.d. (C and F) Apoptotic 
cell death was analyzed by flow cytometry with FITC Annexin V and DRAQ7. Data are representative results 
of three independent experiments. 
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These results suggest that in the absence of key death-related cellular components, 
such as the Bcl-2 proteins Bax and Bak and the apoptosome constituent protein Apaf-1, 
ABT-737-triggering signaling is not fully perceived by the cell, while CDDP-depending 
signaling found caspase- independent cell death pathways. CDDP-induced cell death was 
partially recovered by necrostatin-1 (Nec), an inhibitor of RIPK1 in MEFs KO Apaf-1 
and MEFs KO Bax/Bak (Figure 7.5A), suggesting that necroptosis (a form of 
programmed necrosis that depends on activity of RIPK1) could participate in CDDP-
induced death in these cells. In fact, nuclear staining upon CDDP treatment showed non 
apoptotic cell death in MEFs KO Apaf-1 and MEFs KO Bax/Bak cells (Figure 7.5B), 
while treatment induced canonical apoptotic bodies in MEFs wt Apaf-1, indicating that 
DNA damaging agents may activate alternative cell death pathways when the intrinsic 
pathway of apoptosis is blocked. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5. Non apoptotic cell death upon CDDP treatment in Apaf-1- and Bax/Bak-deficient cells. 
(A) Cell survival was measured by trypan blue exclusion upon treatment with CDDP (30 µM) in the 
presence or absence of necrostatin (Nec; 100 µM). Bars represent the mean of three experiments ± s.d. 
(**p,0.05). (B) MEFs wt Apaf-1, MEFs KO Apaf-1 and MEFs KO Bax/Bak were stained with DAPI upon 
CDDP (30 µM) treatment. Nuclei are considered to have the normal phenotype when glowing bright and 
homogenously. Apoptotic nuclei can be identified by the fragmented morphology of nuclear bodies. White 
arrows indicate dying cells. 
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In human cervix adenocarcinoma (HeLa) cells, rather than inducing caspase-3 activity, 
GX15-070 induced a type of cell death that was not inhibited by zVADfmk or QM31 
(Figure 7.6A, B and C), which correlates with the phenotypes observed in all the MEFs 
cell lines. CDDP induced caspase-3 activation, which was inhibited in the presence of 
QM31 or zVADfmk (Figure 7.6A), and also generated cell death (Figure 7.6B and C). 
CDDP-induced death was partially prevented by QM31, but not by zVADfmk (Figure 
7.6B and C). Nonetheless, the zVADfmk inhibition of ABT-737-induced cas- pase-3 
activity was unable to protect cells from dying (Figure 7.6B and C). Interestingly, and 
unlike the results found in the MEFs wt, apoptosome inhibition by QM31 did not inhibit 
ABT-737-induced caspase-3 and cell death (Figure 7.6A and C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6. Apaf-1 inhibition does not protect tumor HeLa cells from death induced by ABT-737 and 
GX15-070. (A) Caspase 3-like activity was measured in the HeLa cells treated with ABT-737 (25 µM), 
GX15-070 (1 µM) and CDDP (30 µM) in the presence or absence of QM31 (10 µM) and zVADfmk (5 µM). 
(B) Mitochondrial dysfunction was measured by an MTT assay under the same conditions described above. 
Bars represent the mean of three experiments ± s.d. (*p,0.1; **p,0.05). (C) Apoptotic cell death was analyzed 
by flow cytometry with FITC Annexin V and DRAQ7. Data are representative results of three independent 
experiments. 
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7.2.3. Obatoclax (GX15-070) acts as autophagy activator. 
To proceed with an initial analysis of the cell death pathway induced by GX15-070 in the 
MEFs wt Apaf-1, MEFs wt Bax/ Bak, MEFs KO Apaf-1, MEFs KO Bax/Bak, and HeLa 
cells, we analyzed the expression of anti-apoptotic proteins Bcl-2, Bcl-xL and Mcl-1 and 
found no significant changes (data not shown). We also explored the induction of 
autophagy. Autophagy is a catabolic process involving the formation of autophagosomes 
and autolysosomes. Light chain 3 (LC3, a mammalian ortholog of yeast Atg8 (445)) is 
essential for autophagosome formation and can be used as a reporter protein. When the 
process of autophagy proceeds, LC3-I (the cytosolic form) is processed to the 
autophagosomal membrane-bound LC3-II form (445). The LC3-II form increased 
considerably with GX15-070 treatment (Figure 7.7A–E), suggesting that evaluated GX15-
070-induced cell death was mediated by autophagy activation in all the cell lines. 
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The activity of III phosphoinositide 3-kinase (PI3K III) is important in Beclin-1 (the 
human ortholog of yeast Atg-6)-induced autophagy (446), and 3-methyladenine (3MA, an 
inhibitor of PI3K III) is commonly used to determine the dependence of Beclin-1 in 
autophagy. 3MA did not modify GX15-070-induced LC3 processing (Fig. 7.8). Therefore, 
GX15-070-induced autophagy in both MEFs wt and MEFs KO Apaf-1 is independent of 
Beclin-1, as also reported for MEFs KO Bax/Bak and HeLa cells (322). As an internal 
control, we induced autophagy by rapamycin and found that rapamycin-induced 
autophagy was inhibited by 3MA in all four cell lines analyzed (Fig. 7.8A-D). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7. GX15-070 promotes the activation of the autophagic pathway via LC3 in all the cell lines. 
(A–E) LC3 detection in MEFs wt Apaf-1, MEFs wt Bax/Bak, MEFSs KO Apaf-1, MEFs KO Bax/Bak and 
HeLa cells treated 24h with ABT-737 (25 µM), GX15-070 (1 µM), CDDP (30 µM ) and QM31 (10 µM). 
!
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It has been reported that GX15-070 is able to induce apoptosis and autophagy in 
several cell lines (447). Thus we performed a time-course analysis to examine whether 
GX15-070-treatment induces both autophagy and apoptosis. We used LC3 conversion as 
a marker of autophagy (Fig. 7.7) and caspase-3 activity as a marker of apoptosis. After 24 
h we did not observe GX15-070-induced caspase-3 activation in the cell lines analyzed in 
the present study (Fig. 7.9). At 48 h however, we noted that GX15-070- induced caspase-
3 activity in both MEFs wt and in HeLa cells. 
GX15-070-induced apoptosis at 48 h was inhibited by apoptosome inhibitor QM31. In 
contrast, GX15-070 did not induce apoptosis in MEFs KO Bax/Bak and in MEFs KO 
Apaf-1 at 48 h. These results suggest that GX15-070 can induce multiple cell death 
pathways, such as caspase-dependent apoptosis and autophagy. Nevertheless, GX15-070-
induced apoptosis is not only dependent in Bax/Bak, as previously demonstrated (322, 
447), but also in Apaf-1. 
 
 
 
 
 
 
 
 
 
Figure 7.8. GX15-070 activates Beclin-1 non-dependent autophagy in all the cell lines. (A–D) LC3 
immunoblotting in the MEFs wt Apaf-1, MEFs KO Apaf-1, MEFs KO Bax/Bak and HeLa cell lines treated 
with rapamycin (30 μM) and GX15-070 (1 μM) for 24 h in the presence or absence of 3MA (10 μM). 
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7.3. Concluding remarks. 
In conclusion, the present study reveals that BH3-mimetic ABT-737 not only requires 
Bax/Bak to exert its apoptosis-inducing effect, but also Apaf-1, indicating the exclusive 
targeting of ABT-737 to Bcl-2 anti-apoptotic proteins. ABT-737 upon binding to Bcl-2 
and Bcl-xL removes the anti-apoptotic activity of these proteins in pro-apoptotic Bax/Bak 
and induces MOMP. However, MOMP-dependent signaling needs the components of the 
apoptotic pathway downstream of mitochondria, such as the formation of the apoptosome, 
to induce cell death. Hence, ABT-737 treatments to cancer cells would have less side 
effects to differentiated cells containing low levels of Apaf-1, such as neurons and 
cardiomyocytes (448, 449), than other treatments with lesser dependence of Apaf-1. In 
contrast, BH3-mimetic GX15-070 and DNA damage-inducing CDDP induce cell death in 
the absence of both Bax/Bak and Apaf-1. While GX15-070 induces mainly autophagy-
based cell death at 24 h, a cell fraction dies by apoptosis at longer times post-treatment 
(48h). On the other hand, CDDP induces necroptosis when apoptosis signaling pathway is 
not available. Our results extend findings by describing not only the sensitivity of 
different cells to the cell-inducing agents explored, but also the behavior of current 
apoptosis inhibitors, which could be useful in topical applications aimed to diminish 
unwanted cell death. Non tumor cells, as demonstrated herein with MEFs wt, could be 
protected from the cytotoxic effects of ABT-737 and CDDP by the chemical inhibition of 
the apoptosome through QM31, which lowered caspase-3 activity and improved cell 
survival, while the use of caspase inhibitors prevented caspase activation, but did not 
improve survival. This scenario correlates with proposals in mammals that solely caspase 
inhibition, downstream of MOMP delays, and in defined circumstances, modifies the 
outcome rather than preventing cell death (450). However, the autophagy-based cell death 
induced by GX15-070 was not prevented by QM31 or caspase inhibitors. These results 
will be of interest when defining future combination therapies where the systemic 
administration of cytotoxic agents, which aims to kill malignant cells, could be locally 
counteracted by apoptosis inhibitors. For instance, dermatopic and intra-cochlear 
administration of apoptosome inhibitors would probably find applications as anti-alopecia 
and anti-ototoxic agents, respectively, for anti-cancer treatments based on ABT-7373 and 
CDDP.
Figure 7.9. GX15-070 induces caspase 3-like activity after 48 h in HeLa and MEFs wt. Caspase 3-like 
activity was measured at 24 h and 48 h upon treatment with GX15-070 (1 µM) in the presence or absence 
of QM31 (10 µM) in HeLa, MEFs wt Apaf-1, MEFs KO Apaf-1, MEFs wt Bax/Bak and MEFs KO 
Bax/Bak. 
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• The results of this Thesis show that BCL-2 TMDs are not isolated in the 
mitochondrial membrane and establish for the first time the putative interaction 
map of BCL-2 TMDs. In addition, the potential contribution of these TMDs to 
apoptotic regulation has been demonstrated. BCL-2 TMDs, together with soluble 
domains, participate in the equilibria that govern MOMP. 
 
• In the subfamily of BH3-only proteins, we have demonstrated that the predicted 
TMDs of Bik, Puma and Bim are able to insert in cellular membranes efficiently. 
These results open the field to study potential interactions with other Bcl-2 
TMDs. In contrast, Noxa and Bmf TMD show low insertion capability in cellular 
membranes. 
 
• The studies with Bcl-2 TMD derived peptides have demonstrated that some 
TMD-pepts can integrate specifically into mitochondrial membranes. Moreover, 
Bcl-2, Bcl-xL, Bax and Bak TMD-pepts induce Cyt-c release. Consequently, 
insertion of these peptides induces cell death or synergizes at sublethal 
concentrations with chemotherapeutic treatments. 
 
• BH3-mimetic ABT-737 not only requires Bax/Bak to exert its apoptosis-
inducing effect, but also Apaf-1, while GX15-070 and CDDP induce different 
modalities of cell death in the absence of Bax/Bak or Apaf-1. Apoptosome 
inhibitor QM31 protects from the cytosolic effects of ABT-737 and partially 
against CDDP but not against the autophagy-based cell death induced by GX15-
070. 
 
 
 
 
 
 
 
 
 
 
 
 
8                                                                                CONCLUSIONS 
 
    174 
 
 
     
 
 
 
BIBLIOGRAPHY
     
9                                                                              BIBLIOGRAPHY 
    177 
 
1. Clarke PG & Clarke S (1995) Historic apoptosis. Nature 378(6554):230. 
2. Lockshin RA & Williams CM (1965) Programmed Cell Death--I. Cytology of 
Degeneration in the Intersegmental Muscles of the Pernyi Silkmoth. Journal of insect 
physiology 11:123-133. 
3. Kerr JF, Wyllie AH, & Currie AR (1972) Apoptosis: a basic biological phenomenon with 
wide-ranging implications in tissue kinetics. British journal of cancer 26(4):239-257. 
4. Galluzzi L, et al. (2012) Molecular definitions of cell death subroutines: 
recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 
19(1):107-120. 
5. Galluzzi L, et al. (2014) Essential versus accessory aspects of cell death: 
recommendations of the NCCD 2015. Cell death and differentiation. 
6. Horvitz HR (1999) Genetic control of programmed cell death in the nematode 
Caenorhabditis elegans. Cancer research 59(7 Suppl):1701s-1706s. 
7. Hengartner MO & Horvitz HR (1994) Programmed cell death in Caenorhabditis elegans. 
Current opinion in genetics & development 4(4):581-586. 
8. Zou H, Li Y, Liu X, & Wang X (1999) An APAF-1.cytochrome c multimeric complex is 
a functional apoptosome that activates procaspase-9. The Journal of biological chemistry 
274(17):11549-11556. 
9. Kroemer G, et al. (2005) Classification of cell death: recommendations of the 
Nomenclature Committee on Cell Death. Cell death and differentiation 12 Suppl 2:1463-
1467. 
10. Kroemer G, et al. (2009) Classification of cell death: recommendations of the 
Nomenclature Committee on Cell Death 2009. Cell death and differentiation 16(1):3-11. 
11. Miura M (2011) Active participation of cell death in development and organismal 
homeostasis. Development, growth & differentiation 53(2):125-136. 
12. Norbury CJ & Hickson ID (2001) Cellular responses to DNA damage. Annual review of 
pharmacology and toxicology 41:367-401. 
13. Adams JM & Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic 
potential. Current opinion in immunology 19(5):488-496. 
14. Strasser A, Cory S, & Adams JM (2011) Deciphering the rules of programmed cell death 
to improve therapy of cancer and other diseases. The EMBO journal 30(18):3667-3683. 
15. Elmore S (2007) Apoptosis: a review of programmed cell death. Toxicologic pathology 
35(4):495-516. 
16. Tsujimoto Y, et al. (1984) Molecular cloning of the chromosomal breakpoint of B-cell 
lymphomas and leukemias with the t(11;14) chromosome translocation. Science 
224(4656):1403-1406. 
17. Vaux DL, Cory S, & Adams JM (1988) Bcl-2 gene promotes haemopoietic cell survival 
and cooperates with c-myc to immortalize pre-B cells. Nature 335(6189):440-442. 
18. Golstein P & Kroemer G (2007) Cell death by necrosis: towards a molecular definition. 
Trends in biochemical sciences 32(1):37-43. 
19. Degterev A, et al. (2005) Chemical inhibitor of nonapoptotic cell death with therapeutic 
potential for ischemic brain injury. Nature chemical biology 1(2):112-119. 
20. Proskuryakov SY, Konoplyannikov AG, & Gabai VL (2003) Necrosis: a specific form of 
programmed cell death? Experimental cell research 283(1):1-16. 
21. Whelan RS, et al. (2012) Bax regulates primary necrosis through mitochondrial dynamics. 
Proceedings of the National Academy of Sciences of the United States of America 
109(17):6566-6571. 
22. Mizushima N & Kuma A (2008) Autophagosomes in GFP-LC3 Transgenic Mice. 
Methods in molecular biology 445:119-124. 
9                                                                              BIBLIOGRAPHY 
    178 
23. Meijer AJ & Codogno P (2009) Autophagy: regulation and role in disease. Critical 
reviews in clinical laboratory sciences 46(4):210-240. 
24. Baehrecke EH (2005) Autophagy: dual roles in life and death? Nature reviews. Molecular 
cell biology 6(6):505-510. 
25. White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. 
Nature reviews. Cancer 12(6):401-410. 
26. Kundu M & Thompson CB (2008) Autophagy: basic principles and relevance to disease. 
Annual review of pathology 3:427-455. 
27. Levine B, Sinha S, & Kroemer G (2008) Bcl-2 family members: dual regulators of 
apoptosis and autophagy. Autophagy 4(5):600-606. 
28. Maiuri MC, et al. (2007) BH3-only proteins and BH3 mimetics induce autophagy by 
competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy 
3(4):374-376. 
29. Gonzalez-Polo RA, et al. (2005) The apoptosis/autophagy paradox: autophagic 
vacuolization before apoptotic death. Journal of cell science 118(Pt 14):3091-3102. 
30. Vercammen D, et al. (1998) Dual signaling of the Fas receptor: initiation of both 
apoptotic and necrotic cell death pathways. The Journal of experimental medicine 
188(5):919-930. 
31. Han W, Xie J, Li L, Liu Z, & Hu X (2009) Necrostatin-1 reverts shikonin-induced 
necroptosis to apoptosis. Apoptosis : an international journal on programmed cell death 
14(5):674-686. 
32. Liu P, et al. (2012) Dysregulation of TNFalpha-induced necroptotic signaling in chronic 
lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia 26(6):1293-1300. 
33. Lieberthal W, Triaca V, & Levine J (1996) Mechanisms of death induced by cisplatin in 
proximal tubular epithelial cells: apoptosis vs. necrosis. The American journal of 
physiology 270(4 Pt 2):F700-708. 
34. Leontieva OV, Gudkov AV, & Blagosklonny MV (2010) Weak p53 permits senescence 
during cell cycle arrest. Cell cycle 9(21):4323-4327. 
35. Salvesen GS & Renatus M (2002) Apoptosome: the seven-spoked death machine. 
Developmental cell 2(3):256-257. 
36. Igney FH & Krammer PH (2002) Death and anti-death: tumour resistance to apoptosis. 
Nature reviews. Cancer 2(4):277-288. 
37. Green DR (2005) Apoptotic pathways: ten minutes to dead. Cell 121(5):671-674. 
38. Ashkenazi A & Dixit VM (1998) Death receptors: signaling and modulation. Science 
281(5381):1305-1308. 
39. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis factor 
superfamily. Nature reviews. Cancer 2(6):420-430. 
40. Wajant H, Pfizenmaier K, & Scheurich P (2002) TNF-related apoptosis inducing ligand 
(TRAIL) and its receptors in tumor surveillance and cancer therapy. Apoptosis : an 
international journal on programmed cell death 7(5):449-459. 
41. Kischkel FC, et al. (1995) Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins 
form a death-inducing signaling complex (DISC) with the receptor. The EMBO journal 
14(22):5579-5588. 
42. Fulda S, Meyer E, & Debatin KM (2002) Inhibition of TRAIL-induced apoptosis by Bcl-
2 overexpression. Oncogene 21(15):2283-2294. 
43. Orzaez M, Gortat A, Mondragon L, & Perez-Paya E (2009) Peptides and peptide mimics 
as modulators of apoptotic pathways. ChemMedChem 4(2):146-160. 
44. Green DR & Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 
305(5684):626-629. 
9                                                                              BIBLIOGRAPHY 
    179 
45. Zamzami N, et al. (1995) Reduction in mitochondrial potential constitutes an early 
irreversible step of programmed lymphocyte death in vivo. The Journal of experimental 
medicine 181(5):1661-1672. 
46. Petit PX, et al. (1995) Alterations in mitochondrial structure and function are early events 
of dexamethasone-induced thymocyte apoptosis. The Journal of cell biology 130(1):157-
167. 
47. Saelens X, et al. (2004) Toxic proteins released from mitochondria in cell death. 
Oncogene 23(16):2861-2874. 
48. Garrido C, et al. (2006) Mechanisms of cytochrome c release from mitochondria. Cell 
death and differentiation 13(9):1423-1433. 
49. Liu X, Kim CN, Yang J, Jemmerson R, & Wang X (1996) Induction of apoptotic program 
in cell-free extracts: requirement for dATP and cytochrome c. Cell 86(1):147-157. 
50. Li P, et al. (1997) Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 
complex initiates an apoptotic protease cascade. Cell 91(4):479-489. 
51. van Loo G, et al. (2002) The serine protease Omi/HtrA2 is released from mitochondria 
during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced 
caspase activity. Cell death and differentiation 9(1):20-26. 
52. Schimmer AD, et al. (2004) Small-molecule antagonists of apoptosis suppressor XIAP 
exhibit broad antitumor activity. Cancer cell 5(1):25-35. 
53. Susin SA, et al. (1999) Molecular characterization of mitochondrial apoptosis-inducing 
factor. Nature 397(6718):441-446. 
54. Li LY, Luo X, & Wang X (2001) Endonuclease G is an apoptotic DNase when released 
from mitochondria. Nature 412(6842):95-99. 
55. Cory S & Adams JM (2002) The Bcl2 family: regulators of the cellular life-or-death 
switch. Nature reviews. Cancer 2(9):647-656. 
56. Youle RJ & Strasser A (2008) The BCL-2 protein family: opposing activities that mediate 
cell death. Nat Rev Mol Cell Biol 9(1):47-59. 
57. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, & Green DR (2010) The BCL-2 family 
reunion. Molecular cell 37(3):299-310. 
58. Huang DC & Strasser A (2000) BH3-Only proteins-essential initiators of apoptotic cell 
death. Cell 103(6):839-842. 
59. Chen L, et al. (2005) Differential targeting of prosurvival Bcl-2 proteins by their BH3-
only ligands allows complementary apoptotic function. Molecular cell 17(3):393-403. 
60. Hinds MG, et al. (2007) Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins 
that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. 
Cell death and differentiation 14(1):128-136. 
61. Borner C, et al. (1994) The protein bcl-2 alpha does not require membrane attachment, 
but two conserved domains to suppress apoptosis. The Journal of cell biology 
126(4):1059-1068. 
62. Schlesinger PH, et al. (1997) Comparison of the ion channel characteristics of 
proapoptotic BAX and antiapoptotic BCL-2. Proceedings of the National Academy of 
Sciences of the United States of America 94(21):11357-11362. 
63. Hinds MG, et al. (2003) The structure of Bcl-w reveals a role for the C-terminal residues 
in modulating biological activity. Embo J 22(7):1497-1507. 
64. Suzuki M, Youle RJ, & Tjandra N (2000) Structure of Bax: coregulation of dimer 
formation and intracellular localization. Cell 103(4):645-654. 
65. Muchmore SW, et al. (1996) X-ray and NMR structure of human Bcl-xL, an inhibitor of 
programmed cell death. Nature 381(6580):335-341. 
66. Hossini AM, Geilen CC, Fecker LF, Daniel PT, & Eberle J (2006) A novel Bcl-x splice 
product, Bcl-xAK, triggers apoptosis in human melanoma cells without BH3 domain. 
Oncogene 25(15):2160-2169. 
9                                                                              BIBLIOGRAPHY 
    180 
67. Plotz M, Gillissen B, Hossini AM, Daniel PT, & Eberle J (2012) Disruption of the 
VDAC2-Bak interaction by Bcl-x(S) mediates efficient induction of apoptosis in 
melanoma cells. Cell death and differentiation 19(12):1928-1938. 
68. Basanez G, et al. (2001) Pro-apoptotic cleavage products of Bcl-xL form cytochrome c-
conducting pores in pure lipid membranes. The Journal of biological chemistry 
276(33):31083-31091. 
69. Day CL, et al. (2005) Solution structure of prosurvival Mcl-1 and characterization of its 
binding by proapoptotic BH3-only ligands. The Journal of biological chemistry 
280(6):4738-4744. 
70. Liu Q, et al. (2010) Apoptotic regulation by MCL-1 through heterodimerization. The 
Journal of biological chemistry 285(25):19615-19624. 
71. Smits C, Czabotar PE, Hinds MG, & Day CL (2008) Structural plasticity underpins 
promiscuous binding of the prosurvival protein A1. Structure 16(5):818-829. 
72. Petros AM, et al. (2001) Solution structure of the antiapoptotic protein bcl-2. Proceedings 
of the National Academy of Sciences of the United States of America 98(6):3012-3017. 
73. Petros AM, Olejniczak ET, & Fesik SW (2004) Structural biology of the Bcl-2 family of 
proteins. Biochimica et biophysica acta 1644(2-3):83-94. 
74. Aouacheria A, Brunet F, & Gouy M (2005) Phylogenomics of life-or-death switches in 
multicellular animals: Bcl-2, BH3-Only, and BNip families of apoptotic regulators. 
Molecular biology and evolution 22(12):2395-2416. 
75. Zhu W, et al. (1996) Bcl-2 mutants with restricted subcellular location reveal spatially 
distinct pathways for apoptosis in different cell types. The EMBO journal 15(16):4130-
4141. 
76. Bouillet P, Cory S, Zhang LC, Strasser A, & Adams JM (2001) Degenerative disorders 
caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. 
Developmental cell 1(5):645-653. 
77. Motoyama N, et al. (1995) Massive cell death of immature hematopoietic cells and 
neurons in Bcl-x-deficient mice. Science 267(5203):1506-1510. 
78. Print CG, et al. (1998) Apoptosis regulator bcl-w is essential for spermatogenesis but 
appears otherwise redundant. Proceedings of the National Academy of Sciences of the 
United States of America 95(21):12424-12431. 
79. Rinkenberger JL, Horning S, Klocke B, Roth K, & Korsmeyer SJ (2000) Mcl-1 
deficiency results in peri-implantation embryonic lethality. Genes & development 
14(1):23-27. 
80. Opferman JT, et al. (2005) Obligate role of anti-apoptotic MCL-1 in the survival of 
hematopoietic stem cells. Science 307(5712):1101-1104. 
81. Griffiths GJ, et al. (1999) Cell damage-induced conformational changes of the pro-
apoptotic protein Bak in vivo precede the onset of apoptosis. The Journal of cell biology 
144(5):903-914. 
82. Kvansakul M, et al. (2008) Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like 
domain-swapped dimer that binds a highly selective subset of BH3-containing death 
ligands. Cell death and differentiation 15(10):1564-1571. 
83. Wang H, et al. (2009) Novel dimerization mode of the human Bcl-2 family protein Bak, a 
mitochondrial apoptosis regulator. Journal of structural biology 166(1):32-37. 
84. Wei MC, et al. (2001) Proapoptotic BAX and BAK: a requisite gateway to mitochondrial 
dysfunction and death. Science 292(5517):727-730. 
85. Lindsten T, et al. (2000) The combined functions of proapoptotic Bcl-2 family members 
bak and bax are essential for normal development of multiple tissues. Molecular cell 
6(6):1389-1399. 
9                                                                              BIBLIOGRAPHY 
    181 
86. Knudson CM, Tung KS, Tourtellotte WG, Brown GA, & Korsmeyer SJ (1995) Bax-
deficient mice with lymphoid hyperplasia and male germ cell death. Science 
270(5233):96-99. 
87. Day CL, et al. (2008) Structure of the BH3 domains from the p53-inducible BH3-only 
proteins Noxa and Puma in complex with Mcl-1. Journal of molecular biology 
380(5):958-971. 
88. Chou JJ, Li H, Salvesen GS, Yuan J, & Wagner G (1999) Solution structure of BID, an 
intracellular amplifier of apoptotic signaling. Cell 96(5):615-624. 
89. Gross A, et al. (1999) Caspase cleaved BID targets mitochondria and is required for 
cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-
R1/Fas death. The Journal of biological chemistry 274(2):1156-1163. 
90. Willis SN, et al. (2007) Apoptosis initiated when BH3 ligands engage multiple Bcl-2 
homologs, not Bax or Bak. Science 315(5813):856-859. 
91. Ludwinski MW, et al. (2009) Critical roles of Bim in T cell activation and T cell-
mediated autoimmune inflammation in mice. The Journal of clinical investigation 
119(6):1706-1713. 
92. Coultas L, et al. (2007) Hrk/DP5 contributes to the apoptosis of select neuronal 
populations but is dispensable for haematopoietic cell apoptosis. Journal of cell science 
120(Pt 12):2044-2052. 
93. Jeffers JR, et al. (2003) Puma is an essential mediator of p53-dependent and -independent 
apoptotic pathways. Cancer cell 4(4):321-328. 
94. Ranger AM, et al. (2003) Bad-deficient mice develop diffuse large B cell lymphoma. 
Proceedings of the National Academy of Sciences of the United States of America 
100(16):9324-9329. 
95. Labi V, et al. (2008) Loss of the BH3-only protein Bmf impairs B cell homeostasis and 
accelerates gamma irradiation-induced thymic lymphoma development. The Journal of 
experimental medicine 205(3):641-655. 
96. Coultas L, et al. (2005) Concomitant loss of proapoptotic BH3-only Bcl-2 antagonists Bik 
and Bim arrests spermatogenesis. The EMBO journal 24(22):3963-3973. 
97. Villunger A, Scott C, Bouillet P, & Strasser A (2003) Essential role for the BH3-only 
protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte 
survival. Blood 101(6):2393-2400. 
98. Kuwana T, et al. (2002) Bid, Bax, and lipids cooperate to form supramolecular openings 
in the outer mitochondrial membrane. Cell 111(3):331-342. 
99. Wei MC, et al. (2000) tBID, a membrane-targeted death ligand, oligomerizes BAK to 
release cytochrome c. Genes & development 14(16):2060-2071. 
100. Ren D, et al. (2010) BID, BIM, and PUMA are essential for activation of the BAX- and 
BAK-dependent cell death program. Science 330(6009):1390-1393. 
101. Inohara N, Ding L, Chen S, & Nunez G (1997) harakiri, a novel regulator of cell death, 
encodes a protein that activates apoptosis and interacts selectively with survival-
promoting proteins Bcl-2 and Bcl-X(L). The EMBO journal 16(7):1686-1694. 
102. Nakano K & Vousden KH (2001) PUMA, a novel proapoptotic gene, is induced by p53. 
Molecular cell 7(3):683-694. 
103. Oda E, et al. (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate 
mediator of p53-induced apoptosis. Science 288(5468):1053-1058. 
104. Puthalakath H, et al. (2001) Bmf: a proapoptotic BH3-only protein regulated by 
interaction with the myosin V actin motor complex, activated by anoikis. Science 
293(5536):1829-1832. 
105. Yang E, et al. (1995) Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax 
and promotes cell death. Cell 80(2):285-291. 
9                                                                              BIBLIOGRAPHY 
    182 
106. Chinnadurai G, Vijayalingam S, & Rashmi R (2008) BIK, the founding member of the 
BH3-only family proteins: mechanisms of cell death and role in cancer and pathogenic 
processes. Oncogene 27 Suppl 1:S20-29. 
107. Kataoka T, et al. (2001) Bcl-rambo, a novel Bcl-2 homologue that induces apoptosis via 
its unique C-terminal extension. The Journal of biological chemistry 276(22):19548-
19554. 
108. Oltvai ZN, Milliman CL, & Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a 
conserved homolog, Bax, that accelerates programmed cell death. Cell 74(4):609-619. 
109. Willis SN, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not 
Bcl-2, until displaced by BH3-only proteins. Genes & development 19(11):1294-1305. 
110. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, & Korsmeyer SJ (2003) VDAC2 inhibits 
BAK activation and mitochondrial apoptosis. Science 301(5632):513-517. 
111. Vogel S, et al. (2012) Cytosolic Bax: does it require binding proteins to keep its pro-
apoptotic activity in check? The Journal of biological chemistry 287(12):9112-9127. 
112. Chi X, Kale J, Leber B, & Andrews DW (2014) Regulating cell death at, on, and in 
membranes. Biochimica et biophysica acta 1843(9):2100-2113. 
113. Letai A, et al. (2002) Distinct BH3 domains either sensitize or activate mitochondrial 
apoptosis, serving as prototype cancer therapeutics. Cancer cell 2(3):183-192. 
114. Bleicken S, et al. (2010) Molecular details of Bax activation, oligomerization, and 
membrane insertion. The Journal of biological chemistry 285(9):6636-6647. 
115. Tan C, et al. (2006) Auto-activation of the apoptosis protein Bax increases mitochondrial 
membrane permeability and is inhibited by Bcl-2. The Journal of biological chemistry 
281(21):14764-14775. 
116. Lovell JF, et al. (2008) Membrane binding by tBid initiates an ordered series of events 
culminating in membrane permeabilization by Bax. Cell 135(6):1074-1084. 
117. Basanez G & Hardwick JM (2008) Unravelling the bcl-2 apoptosis code with a simple 
model system. PLoS biology 6(6):e154. 
118. Leber B, Lin J, & Andrews DW (2010) Still embedded together binding to membranes 
regulates Bcl-2 protein interactions. Oncogene 29(38):5221-5230. 
119. Annis MG, et al. (2005) Bax forms multispanning monomers that oligomerize to 
permeabilize membranes during apoptosis. The EMBO journal 24(12):2096-2103. 
120. Garcia-Saez AJ, Ries J, Orzaez M, Perez-Paya E, & Schwille P (2009) Membrane 
promotes tBID interaction with BCL(XL). Nat Struct Mol Biol 16(11):1178-1185. 
121. Terrones O, et al. (2004) Lipidic pore formation by the concerted action of proapoptotic 
BAX and tBID. The Journal of biological chemistry 279(29):30081-30091. 
122. Shamas-Din A, Kale J, Leber B, & Andrews DW (2013) Mechanisms of action of Bcl-2 
family proteins. Cold Spring Harbor perspectives in biology 5(4):a008714. 
123. Llambi F, et al. (2011) A unified model of mammalian BCL-2 protein family interactions 
at the mitochondria. Molecular cell 44(4):517-531. 
124. Gavathiotis E, Reyna DE, Davis ML, Bird GH, & Walensky LD (2010) BH3-triggered 
structural reorganization drives the activation of proapoptotic BAX. Molecular cell 
40(3):481-492. 
125. Chipuk JE, et al. (2012) Sphingolipid metabolism cooperates with BAK and BAX to 
promote the mitochondrial pathway of apoptosis. Cell 148(5):988-1000. 
126. Basanez G, Soane L, & Hardwick JM (2012) A new view of the lethal apoptotic pore. 
PLoS biology 10(9):e1001399. 
127. Kim H, et al. (2009) Stepwise activation of BAX and BAK by tBID, BIM, and PUMA 
initiates mitochondrial apoptosis. Mol Cell 36(3):487-499. 
128. Ferrer PE, Frederick P, Gulbis JM, Dewson G, & Kluck RM (2012) Translocation of a 
Bak C-terminus mutant from cytosol to mitochondria to mediate cytochrome C release: 
implications for Bak and Bax apoptotic function. PLoS One 7(3):e31510. 
9                                                                              BIBLIOGRAPHY 
    183 
129. Oh KJ, et al. (2010) Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 
family member, upon membrane insertion and direct evidence for the existence of BH3-
BH3 contact interface in BAK homo-oligomers. The Journal of biological chemistry 
285(37):28924-28937. 
130. Dewson G, et al. (2009) Bak activation for apoptosis involves oligomerization of dimers 
via their alpha6 helices. Molecular cell 36(4):696-703. 
131. Karbowski M, Norris KL, Cleland MM, Jeong SY, & Youle RJ (2006) Role of Bax and 
Bak in mitochondrial morphogenesis. Nature 443(7112):658-662. 
132. Hsu YT, Wolter KG, & Youle RJ (1997) Cytosol-to-membrane redistribution of Bax and 
Bcl-X(L) during apoptosis. Proc Natl Acad Sci U S A 94(8):3668-3672. 
133. Edlich F, et al. (2011) Bcl-x(L) retrotranslocates Bax from the mitochondria into the 
cytosol. Cell 145(1):104-116. 
134. Czabotar PE, et al. (2013) Bax crystal structures reveal how BH3 domains activate Bax 
and nucleate its oligomerization to induce apoptosis. Cell 152(3):519-531. 
135. Kroemer G, Galluzzi L, & Brenner C (2007) Mitochondrial membrane permeabilization 
in cell death. Physiol Rev 87(1):99-163. 
136. Godlewski MM, Gajkowska B, Lamparska-Przybysz M, & Motyl T (2002) Colocalization 
of BAX with BID and VDAC-1 in nimesulide-induced apoptosis of human colon 
adenocarcinoma COLO 205 cells. Anti-cancer drugs 13(10):1017-1029. 
137. Basanez G, et al. (2002) Bax-type apoptotic proteins porate pure lipid bilayers through a 
mechanism sensitive to intrinsic monolayer curvature. The Journal of biological 
chemistry 277(51):49360-49365. 
138. Bleicken S, Landeta O, Landajuela A, Basanez G, & Garcia-Saez AJ (2013) Proapoptotic 
Bax and Bak proteins form stable protein-permeable pores of tunable size. The Journal of 
biological chemistry 288(46):33241-33252. 
139. Shoshan-Barmatz V, Keinan N, & Zaid H (2008) Uncovering the role of VDAC in the 
regulation of cell life and death. Journal of bioenergetics and biomembranes 40(3):183-
191. 
140. Shoshan-Barmatz V & Mizrachi D (2012) VDAC1: from structure to cancer therapy. 
Frontiers in oncology 2:164. 
141. Baines CP, et al. (2005) Loss of cyclophilin D reveals a critical role for mitochondrial 
permeability transition in cell death. Nature 434(7033):658-662. 
142. Shoshan-Barmatz V & Gincel D (2003) The voltage-dependent anion channel: 
characterization, modulation, and role in mitochondrial function in cell life and death. 
Cell biochemistry and biophysics 39(3):279-292. 
143. Tsujimoto Y & Shimizu S (2007) Role of the mitochondrial membrane permeability 
transition in cell death. Apoptosis : an international journal on programmed cell death 
12(5):835-840. 
144. Kokoszka JE, et al. (2004) The ADP/ATP translocator is not essential for the 
mitochondrial permeability transition pore. Nature 427(6973):461-465. 
145. Belizario JE, Alves J, Occhiucci JM, Garay-Malpartida M, & Sesso A (2007) A 
mechanistic view of mitochondrial death decision pores. Brazilian journal of medical and 
biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade 
Brasileira de Biofisica ... [et al.] 40(8):1011-1024. 
146. Baines CP, Kaiser RA, Sheiko T, Craigen WJ, & Molkentin JD (2007) Voltage-dependent 
anion channels are dispensable for mitochondrial-dependent cell death. Nature cell 
biology 9(5):550-555. 
147. Banerjee J & Ghosh S (2004) Bax increases the pore size of rat brain mitochondrial 
voltage-dependent anion channel in the presence of tBid. Biochemical and biophysical 
research communications 323(1):310-314. 
9                                                                              BIBLIOGRAPHY 
    184 
148. Shimizu S, Narita M, & Tsujimoto Y (1999) Bcl-2 family proteins regulate the release of 
apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399(6735):483-
487. 
149. Tajeddine N, et al. (2008) Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-
induced cell death. Oncogene 27(30):4221-4232. 
150. Rostovtseva TK, et al. (2004) Bid, but not Bax, regulates VDAC channels. The Journal of 
biological chemistry 279(14):13575-13583. 
151. Tsujimoto Y & Shimizu S (2000) VDAC regulation by the Bcl-2 family of proteins. Cell 
death and differentiation 7(12):1174-1181. 
152. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, & Tsujimoto Y (2001) Essential role of 
voltage-dependent anion channel in various forms of apoptosis in mammalian cells. The 
Journal of cell biology 152(2):237-250. 
153. Debatin KM, Poncet D, & Kroemer G (2002) Chemotherapy: targeting the mitochondrial 
cell death pathway. Oncogene 21(57):8786-8803. 
154. Malia TJ & Wagner G (2007) NMR structural investigation of the mitochondrial outer 
membrane protein VDAC and its interaction with antiapoptotic Bcl-xL. Biochemistry 
46(2):514-525. 
155. Zalk R, Israelson A, Garty ES, Azoulay-Zohar H, & Shoshan-Barmatz V (2005) 
Oligomeric states of the voltage-dependent anion channel and cytochrome c release from 
mitochondria. The Biochemical journal 386(Pt 1):73-83. 
156. Keinan N, Tyomkin D, & Shoshan-Barmatz V (2010) Oligomerization of the 
mitochondrial protein voltage-dependent anion channel is coupled to the induction of 
apoptosis. Molecular and cellular biology 30(24):5698-5709. 
157. Lemasters JJ & Holmuhamedov E (2006) Voltage-dependent anion channel (VDAC) as 
mitochondrial governator--thinking outside the box. Biochimica et biophysica acta 
1762(2):181-190. 
158. Feldmann G, et al. (2000) Opening of the mitochondrial permeability transition pore 
causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis 
in mice. Hepatology 31(3):674-683. 
159. Wigdal SS, Kirkland RA, Franklin JL, & Haak-Frendscho M (2002) Cytochrome c 
release precedes mitochondrial membrane potential loss in cerebellar granule neuron 
apoptosis: lack of mitochondrial swelling. Journal of neurochemistry 82(5):1029-1038. 
160. Dejean LM, Martinez-Caballero S, & Kinnally KW (2006) Is MAC the knife that cuts 
cytochrome c from mitochondria during apoptosis? Cell death and differentiation 
13(8):1387-1395. 
161. Martinez-Caballero S, Dejean LM, & Kinnally KW (2004) Some amphiphilic cations 
block the mitochondrial apoptosis-induced channel, MAC. FEBS letters 568(1-3):35-38. 
162. Martinez-Caballero S, et al. (2009) Assembly of the mitochondrial apoptosis-induced 
channel, MAC. The Journal of biological chemistry 284(18):12235-12245. 
163. Stiban J, Fistere D, & Colombini M (2006) Dihydroceramide hinders ceramide channel 
formation: Implications on apoptosis. Apoptosis : an international journal on 
programmed cell death 11(5):773-780. 
164. Yuan H, Williams SD, Adachi S, Oltersdorf T, & Gottlieb RA (2003) Cytochrome c 
dissociation and release from mitochondria by truncated Bid and ceramide. 
Mitochondrion 2(4):237-244. 
165. Birbes H, et al. (2005) A mitochondrial pool of sphingomyelin is involved in TNFalpha-
induced Bax translocation to mitochondria. The Biochemical journal 386(Pt 3):445-451. 
166. Oh HL, Seok JY, Kwon CH, Kang SK, & Kim YK (2006) Role of MAPK in ceramide-
induced cell death in primary cultured astrocytes from mouse embryonic brain. 
Neurotoxicology 27(1):31-38. 
9                                                                              BIBLIOGRAPHY 
    185 
167. Beverly LJ, et al. (2013) BAK activation is necessary and sufficient to drive ceramide 
synthase-dependent ceramide accumulation following inhibition of BCL2-like proteins. 
The Biochemical journal 452(1):111-119. 
168. Galluzzi L & Kroemer G (2007) Mitochondrial apoptosis without VDAC. Nature cell 
biology 9(5):487-489. 
169. Betaneli V, Petrov EP, & Schwille P (2012) The role of lipids in VDAC oligomerization. 
Biophysical journal 102(3):523-531. 
170. Claypool SM & Koehler CM (2012) The complexity of cardiolipin in health and disease. 
Trends in biochemical sciences 37(1):32-41. 
171. Van Brocklyn JR & Williams JB (2012) The control of the balance between ceramide and 
sphingosine-1-phosphate by sphingosine kinase: oxidative stress and the seesaw of cell 
survival and death. Comparative biochemistry and physiology. Part B, Biochemistry & 
molecular biology 163(1):26-36. 
172. Colbeau A, Nachbaur J, & Vignais PM (1971) Enzymic characterization and lipid 
composition of rat liver subcellular membranes. Biochimica et biophysica acta 
249(2):462-492. 
173. Schlame M, Rua D, & Greenberg ML (2000) The biosynthesis and functional role of 
cardiolipin. Progress in lipid research 39(3):257-288. 
174. Ardail D, et al. (1990) Mitochondrial contact sites. Lipid composition and dynamics. J 
Biol Chem 265(31):18797-18802. 
175. Lutter M, Perkins GA, & Wang X (2001) The pro-apoptotic Bcl-2 family member tBid 
localizes to mitochondrial contact sites. BMC cell biology 2:22. 
176. Gonzalvez F, et al. (2008) Cardiolipin provides an essential activating platform for 
caspase-8 on mitochondria. The Journal of cell biology 183(4):681-696. 
177. Esposti MD, Erler JT, Hickman JA, & Dive C (2001) Bid, a widely expressed 
proapoptotic protein of the Bcl-2 family, displays lipid transfer activity. Molecular and 
cellular biology 21(21):7268-7276. 
178. Hekman M, et al. (2006) Reversible membrane interaction of BAD requires two C-
terminal lipid binding domains in conjunction with 14-3-3 protein binding. The Journal of 
biological chemistry 281(25):17321-17336. 
179. Montero J, et al. (2010) Cholesterol and peroxidized cardiolipin in mitochondrial 
membrane properties, permeabilization and cell death. Biochimica et biophysica acta 
1797(6-7):1217-1224. 
180. Lucken-Ardjomande S, Montessuit S, & Martinou JC (2008) Bax activation and stress-
induced apoptosis delayed by the accumulation of cholesterol in mitochondrial 
membranes. Cell death and differentiation 15(3):484-493. 
181. Lee SK, Kim YC, Song SB, & Kim YS (2010) Stabilization and translocation of p53 to 
mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced 
apoptosis. Biochemical and biophysical research communications 391(4):1592-1597. 
182. Montero J, et al. (2008) Mitochondrial cholesterol contributes to chemotherapy resistance 
in hepatocellular carcinoma. Cancer research 68(13):5246-5256. 
183. Obeid LM, Linardic CM, Karolak LA, & Hannun YA (1993) Programmed cell death 
induced by ceramide. Science 259(5102):1769-1771. 
184. Cremesti A, et al. (2001) Ceramide enables fas to cap and kill. The Journal of biological 
chemistry 276(26):23954-23961. 
185. Zhang T & Saghatelian A (2013) Emerging roles of lipids in BCL-2 family-regulated 
apoptosis. Biochimica et biophysica acta 1831(10):1542-1554. 
186. Beddoe T & Lithgow T (2002) Delivery of nascent polypeptides to the mitochondrial 
surface. Biochimica et biophysica acta 1592(1):35-39. 
9                                                                              BIBLIOGRAPHY 
    186 
187. Horie C, Suzuki H, Sakaguchi M, & Mihara K (2002) Characterization of signal that 
directs C-tail-anchored proteins to mammalian mitochondrial outer membrane. Molecular 
biology of the cell 13(5):1615-1625. 
188. Wattenberg B & Lithgow T (2001) Targeting of C-terminal (tail)-anchored proteins: 
understanding how cytoplasmic activities are anchored to intracellular membranes. Traffic 
2(1):66-71. 
189. Antonsson B (2001) Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their 
victim the mitochondrion. Cell and tissue research 306(3):347-361. 
190. Hardwick JM, Chen YB, & Jonas EA (2012) Multipolar functions of BCL-2 proteins link 
energetics to apoptosis. Trends in cell biology 22(6):318-328. 
191. Borner C (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death 
decisions. Molecular immunology 39(11):615-647. 
192. Puthalakath H & Strasser A (2002) Keeping killers on a tight leash: transcriptional and 
post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell death 
and differentiation 9(5):505-512. 
193. Motz C, Martin H, Krimmer T, & Rassow J (2002) Bcl-2 and porin follow different 
pathways of TOM-dependent insertion into the mitochondrial outer membrane. Journal of 
molecular biology 323(4):729-738. 
194. Lindsay J, Esposti MD, & Gilmore AP (2011) Bcl-2 proteins and mitochondria--
specificity in membrane targeting for death. Biochimica et biophysica acta 1813(4):532-
539. 
195. Lithgow T, van Driel R, Bertram JF, & Strasser A (1994) The protein product of the 
oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and 
the outer mitochondrial membrane. Cell growth & differentiation : the molecular biology 
journal of the American Association for Cancer Research 5(4):411-417. 
196. Nguyen M, Millar DG, Yong VW, Korsmeyer SJ, & Shore GC (1993) Targeting of Bcl-2 
to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J Biol 
Chem 268(34):25265-25268. 
197. Kaufmann T, et al. (2003) Characterization of the signal that directs Bcl-x(L), but not 
Bcl-2, to the mitochondrial outer membrane. The Journal of cell biology 160(1):53-64. 
198. O'Reilly LA, et al. (2001) Tissue expression and subcellular localization of the pro-
survival molecule Bcl-w. Cell death and differentiation 8(5):486-494. 
199. Wilson-Annan J, et al. (2003) Proapoptotic BH3-only proteins trigger membrane 
integration of prosurvival Bcl-w and neutralize its activity. The Journal of cell biology 
162(5):877-887. 
200. Shirane M & Nakayama KI (2003) Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to 
mitochondria and inhibits apoptosis. Nature cell biology 5(1):28-37. 
201. Yang T, Kozopas KM, & Craig RW (1995) The intracellular distribution and pattern of 
expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. The Journal of 
cell biology 128(6):1173-1184. 
202. Scorrano L, et al. (2003) BAX and BAK regulation of endoplasmic reticulum Ca2+: a 
control point for apoptosis. Science 300(5616):135-139. 
203. Breckenridge DG, Germain M, Mathai JP, Nguyen M, & Shore GC (2003) Regulation of 
apoptosis by endoplasmic reticulum pathways. Oncogene 22(53):8608-8618. 
204. Echeverry N, et al. (2013) Intracellular localization of the BCL-2 family member BOK 
and functional implications. Cell death and differentiation 20(6):785-799. 
205. Bouillet P & Strasser A (2002) BH3-only proteins - evolutionarily conserved proapoptotic 
Bcl-2 family members essential for initiating programmed cell death. J Cell Sci 115(Pt 
8):1567-1574. 
9                                                                              BIBLIOGRAPHY 
    187 
206. Schinzel A, Kaufmann T, & Borner C (2004) Bcl-2 family members: integrators of 
survival and death signals in physiology and pathology [corrected]. Biochimica et 
biophysica acta 1644(2-3):95-105. 
207. Wilfling F, et al. (2012) BH3-only proteins are tail-anchored in the outer mitochondrial 
membrane and can initiate the activation of Bax. Cell death and differentiation 
19(8):1328-1336. 
208. Datta SR, et al. (2002) Survival factor-mediated BAD phosphorylation raises the 
mitochondrial threshold for apoptosis. Developmental cell 3(5):631-643. 
209. Puthalakath H, Huang DC, O'Reilly LA, King SM, & Strasser A (1999) The proapoptotic 
activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor 
complex. Molecular cell 3(3):287-296. 
210. Gonzalvez F, et al. (2010) Mechanistic issues of the interaction of the hairpin-forming 
domain of tBid with mitochondrial cardiolipin. PloS one 5(2):e9342. 
211. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, & Korsmeyer SJ (1993) Bcl-2 
functions in an antioxidant pathway to prevent apoptosis. Cell 75(2):241-251. 
212. Nguyen M, et al. (1994) Role of membrane anchor domain of Bcl-2 in suppression of 
apoptosis caused by E1B-defective adenovirus. The Journal of biological chemistry 
269(24):16521-16524. 
213. Peng J, et al. (2009) Oligomerization of membrane-bound Bcl-2 is involved in its pore 
formation induced by tBid. Apoptosis : an international journal on programmed cell 
death 14(10):1145-1153. 
214. Schendel SL, et al. (1997) Channel formation by antiapoptotic protein Bcl-2. Proceedings 
of the National Academy of Sciences of the United States of America 94(10):5113-5118. 
215. Thuduppathy GR, Craig JW, Kholodenko V, Schon A, & Hill RB (2006) Evidence that 
membrane insertion of the cytosolic domain of Bcl-xL is governed by an electrostatic 
mechanism. Journal of molecular biology 359(4):1045-1058. 
216. Aisenbrey C, et al. (2007) Helix orientations in membrane-associated Bcl-X(L) 
determined by 15N-solid-state NMR spectroscopy. European biophysics journal : EBJ 
37(1):71-80. 
217. Zheng JY, et al. (2008) The C-terminal transmembrane domain of Bcl-xL mediates 
changes in mitochondrial morphology. Biophysical journal 94(1):286-297. 
218. Hossini AM, Eberle J, Fecker LF, Orfanos CE, & Geilen CC (2003) Conditional 
expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro 
and delays growth of melanoma xenografts. FEBS letters 553(3):250-256. 
219. Plotz M, et al. (2012) Mutual regulation of Bcl-2 proteins independent of the BH3 domain 
as shown by the BH3-lacking protein Bcl-x(AK). PloS one 7(4):e34549. 
220. Ospina A, Lagunas-Martinez A, Pardo J, & Carrodeguas JA (2011) Protein 
oligomerization mediated by the transmembrane carboxyl terminal domain of Bcl-XL. 
FEBS letters 585(19):2935-2942. 
221. Todt F, Cakir Z, Reichenbach F, Youle RJ, & Edlich F (2013) The C-terminal helix of 
Bcl-x(L) mediates Bax retrotranslocation from the mitochondria. Cell Death Differ 
20(2):333-342. 
222. Herold MJ, et al. (2006) The stability and anti-apoptotic function of A1 are controlled by 
its C terminus. The Journal of biological chemistry 281(19):13663-13671. 
223. Brien G, et al. (2009) C-terminal residues regulate localization and function of the 
antiapoptotic protein Bfl-1. The Journal of biological chemistry 284(44):30257-30263. 
224. Ko JK, et al. (2011) Amphipathic tail-anchoring peptide and Bcl-2 homology domain-3 
(BH3) peptides from Bcl-2 family proteins induce apoptosis through different 
mechanisms. The Journal of biological chemistry 286(11):9038-9048. 
9                                                                              BIBLIOGRAPHY 
    188 
225. Weng C, Li Y, Xu D, Shi Y, & Tang H (2005) Specific cleavage of Mcl-1 by caspase-3 in 
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in 
Jurkat leukemia T cells. The Journal of biological chemistry 280(11):10491-10500. 
226. Rautureau GJ, Day CL, & Hinds MG (2010) The structure of Boo/Diva reveals a 
divergent Bcl-2 protein. Proteins 78(9):2181-2186. 
227. Ke N, Godzik A, & Reed JC (2001) Bcl-B, a novel Bcl-2 family member that 
differentially binds and regulates Bax and Bak. The Journal of biological chemistry 
276(16):12481-12484. 
228. Kang Y, et al. (2007) NM23-H2 involves in negative regulation of Diva and Bcl2L10 in 
apoptosis signaling. Biochemical and biophysical research communications 359(1):76-82. 
229. Valentijn AJ, Upton JP, & Gilmore AP (2008) Analysis of endogenous Bax complexes 
during apoptosis using blue native PAGE: implications for Bax activation and 
oligomerization. The Biochemical journal 412(2):347-357. 
230. Fresquet V, Rieger M, Carolis C, Garcia-Barchino MJ, & Martinez-Climent JA (2014) 
Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic 
ABT-199 in lymphoma. Blood 123(26):4111-4119. 
231. Oliver L, et al. (2000) The substitution of the C-terminus of bax by that of bcl-xL does 
not affect its subcellular localization but abrogates its pro-apoptotic properties. FEBS 
letters 487(2):161-165. 
232. Arokium H, Camougrand N, Vallette FM, & Manon S (2004) Studies of the interaction of 
substituted mutants of BAX with yeast mitochondria reveal that the C-terminal 
hydrophobic alpha-helix is a second ART sequence and plays a role in the interaction 
with anti-apoptotic BCL-xL. The Journal of biological chemistry 279(50):52566-52573. 
233. Ausili A, de Godos A, Torrecillas A, Corbalan-Garcia S, & Gomez-Fernandez JC (2009) 
The interaction of the Bax C-terminal domain with membranes is influenced by the 
presence of negatively charged phospholipids. Biochimica et biophysica acta 
1788(9):1924-1932. 
234. Gahl RF, He Y, Yu S, & Tjandra N (2014) Conformational Rearrangements in the Pro-
apoptotic Protein, Bax, as It Inserts into Mitochondria: A CELLULAR DEATH SWITCH. 
The Journal of biological chemistry 289(47):32871-32882. 
235. Lin SH, et al. (2011) Bax forms two types of channels, one of which is voltage-gated. 
Biophysical journal 101(9):2163-2169. 
236. Torrecillas A, Martinez-Senac MM, Ausili A, Corbalan-Garcia S, & Gomez-Fernandez 
JC (2007) Interaction of the C-terminal domain of Bcl-2 family proteins with model 
membranes. Biochimica et biophysica acta 1768(11):2931-2939. 
237. del Mar Martinez-Senac M, Corbalan-Garcia S, & Gomez-Fernandez JC (2001) 
Conformation of the C-terminal domain of the pro-apoptotic protein Bax and mutants and 
its interaction with membranes. Biochemistry 40(33):9983-9992. 
238. Oldfield E & Chapman D (1972) Dynamics of lipids in membranes: Heterogeneity and 
the role of cholesterol. FEBS letters 23(3):285-297. 
239. Garg P, Nemec KN, Khaled AR, & Tatulian SA (2013) Transmembrane pore formation 
by the carboxyl terminus of Bax protein. Biochimica et biophysica acta 1828(2):732-742. 
240. Tatulian SA, Garg P, Nemec KN, Chen B, & Khaled AR (2012) Molecular basis for 
membrane pore formation by Bax protein carboxyl terminus. Biochemistry 51(46):9406-
9419. 
241. Boohaker RJ, et al. (2012) Rational development of a cytotoxic peptide to trigger cell 
death. Molecular pharmaceutics 9(7):2080-2093. 
242. Kiefer MC, et al. (1995) Modulation of apoptosis by the widely distributed Bcl-2 
homologue Bak. Nature 374(6524):736-739. 
9                                                                              BIBLIOGRAPHY 
    189 
243. Martinez-Senac Mdel M, Corbalan-Garcia S, & Gomez-Fernandez JC (2002) The 
structure of the C-terminal domain of the pro-apoptotic protein Bak and its interaction 
with model membranes. Biophysical journal 82(1 Pt 1):233-243. 
244. Hsu SY, Kaipia A, McGee E, Lomeli M, & Hsueh AJ (1997) Bok is a pro-apoptotic Bcl-2 
protein with restricted expression in reproductive tissues and heterodimerizes with 
selective anti-apoptotic Bcl-2 family members. Proceedings of the National Academy of 
Sciences of the United States of America 94(23):12401-12406. 
245. Hsu SY & Hsueh AJ (1998) A splicing variant of the Bcl-2 member Bok with a truncated 
BH3 domain induces apoptosis but does not dimerize with antiapoptotic Bcl-2 proteins in 
vitro. The Journal of biological chemistry 273(46):30139-30146. 
246. Kim TH, et al. (2004) Bid-cardiolipin interaction at mitochondrial contact site contributes 
to mitochondrial cristae reorganization and cytochrome C release. Molecular biology of 
the cell 15(7):3061-3072. 
247. Schendel SL, et al. (1999) Ion channel activity of the BH3 only Bcl-2 family member, 
BID. The Journal of biological chemistry 274(31):21932-21936. 
248. Kudla G, et al. (2000) The destabilization of lipid membranes induced by the C-terminal 
fragment of caspase 8-cleaved bid is inhibited by the N-terminal fragment. The Journal of 
biological chemistry 275(30):22713-22718. 
249. Oh KJ, et al. (2005) Conformational changes in BID, a pro-apoptotic BCL-2 family 
member, upon membrane binding. A site-directed spin labeling study. The Journal of 
biological chemistry 280(1):753-767. 
250. Polzien L, et al. (2011) Pore-forming activity of BAD is regulated by specific 
phosphorylation and structural transitions of the C-terminal part. Biochimica et biophysica 
acta 1810(2):162-169. 
251. Bernabeu A, Guillen J, Perez-Berna AJ, Moreno MR, & Villalain J (2007) Structure of 
the C-terminal domain of the pro-apoptotic protein Hrk and its interaction with model 
membranes. Biochimica et biophysica acta 1768(6):1659-1670. 
252. Barrera-Vilarmau S, Obregon P, & de Alba E (2011) Intrinsic order and disorder in the 
bcl-2 member harakiri: insights into its proapoptotic activity. PloS one 6(6):e21413. 
253. Kim JY, So KJ, Lee S, & Park JH (2012) Bcl-rambo induces apoptosis via interaction 
with the adenine nucleotide translocator. FEBS letters 586(19):3142-3149. 
254. Rashmi R, Pillai SG, Vijayalingam S, Ryerse J, & Chinnadurai G (2008) BH3-only 
protein BIK induces caspase-independent cell death with autophagic features in Bcl-2 null 
cells. Oncogene 27(10):1366-1375. 
255. Weber A, Auslander D, & Hacker G (2013) Mouse Noxa uses only the C-terminal BH3-
domain to inactivate Mcl-1. Apoptosis : an international journal on programmed cell 
death 18(9):1093-1105. 
256. Yee KS & Vousden KH (2008) Contribution of membrane localization to the apoptotic 
activity of PUMA. Apoptosis : an international journal on programmed cell death 
13(1):87-95. 
257. Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57-70. 
258. Rooswinkel RW, et al. (2014) Antiapoptotic potency of Bcl-2 proteins primarily relies on 
their stability, not binding selectivity. Blood 123(18):2806-2815. 
259. Liu Y, Hernandez AM, Shibata D, & Cortopassi GA (1994) BCL2 translocation 
frequency rises with age in humans. Proceedings of the National Academy of Sciences of 
the United States of America 91(19):8910-8914. 
260. Campos L, et al. (1993) Peripheral blood stem cells harvested after chemotherapy and 
GM-CSF for treatment intensification in patients with advanced lymphoproliferative 
diseases. Leukemia 7(9):1409-1415. 
261. Weller M, Malipiero U, Aguzzi A, Reed JC, & Fontana A (1995) Protooncogene bcl-2 
gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant 
9                                                                              BIBLIOGRAPHY 
    190 
glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. 
The Journal of clinical investigation 95(6):2633-2643. 
262. Joensuu H, Pylkkanen L, & Toikkanen S (1994) Bcl-2 protein expression and long-term 
survival in breast cancer. The American journal of pathology 145(5):1191-1198. 
263. McDonnell TJ, et al. (1992) Expression of the protooncogene bcl-2 in the prostate and its 
association with emergence of androgen-independent prostate cancer. Cancer research 
52(24):6940-6944. 
264. Sinicrope FA, Hart J, Michelassi F, & Lee JJ (1995) Prognostic value of bcl-2 
oncoprotein expression in stage II colon carcinoma. Clinical cancer research : an official 
journal of the American Association for Cancer Research 1(10):1103-1110. 
265. Henderson S, et al. (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homologue of 
Bcl-2, protects human B cells from programmed cell death. Proceedings of the National 
Academy of Sciences of the United States of America 90(18):8479-8483. 
266. Boise LH, et al. (1993) bcl-x, a bcl-2-related gene that functions as a dominant regulator 
of apoptotic cell death. Cell 74(4):597-608. 
267. Kirsh EJ, Baunoch DA, & Stadler WM (1998) Expression of bcl-2 and bcl-X in bladder 
cancer. The Journal of urology 159(4):1348-1353. 
268. Naik P, Karrim J, & Hanahan D (1996) The rise and fall of apoptosis during multistage 
tumorigenesis: down-modulation contributes to tumor progression from angiogenic 
progenitors. Genes & development 10(17):2105-2116. 
269. Castilla C, et al. (2006) Bcl-xL is overexpressed in hormone-resistant prostate cancer and 
promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 
147(10):4960-4967. 
270. Nagane M, Levitzki A, Gazit A, Cavenee WK, & Huang HJ (1998) Drug resistance of 
human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor 
receptor through modulation of Bcl-XL and caspase-3-like proteases. Proceedings of the 
National Academy of Sciences of the United States of America 95(10):5724-5729. 
271. Shigemasa K, et al. (2002) Increased MCL-1 expression is associated with poor prognosis 
in ovarian carcinomas. Japanese journal of cancer research : Gann 93(5):542-550. 
272. Kaufmann SH, et al. (1998) Elevated expression of the apoptotic regulator Mcl-1 at the 
time of leukemic relapse. Blood 91(3):991-1000. 
273. Rampino N, et al. (1997) Somatic frameshift mutations in the BAX gene in colon cancers 
of the microsatellite mutator phenotype. Science 275(5302):967-969. 
274. Pohland T, Wagner S, Mahyar-Roemer M, & Roemer K (2006) Bax and Bak are the 
critical complementary effectors of colorectal cancer cell apoptosis by chemopreventive 
resveratrol. Anti-cancer drugs 17(4):471-478. 
275. Du X, Xiang L, Mackall C, & Pastan I (2011) Killing of resistant cancer cells with low 
Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist 
antibody. Clinical cancer research : an official journal of the American Association for 
Cancer Research 17(18):5926-5934. 
276. Jackson S, Harwood C, Thomas M, Banks L, & Storey A (2000) Role of Bak in UV-
induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes & 
development 14(23):3065-3073. 
277. Rosen K, et al. (1998) Downregulation of the pro-apoptotic protein Bak is required for the 
ras-induced transformation of intestinal epithelial cells. Current biology : CB 8(24):1331-
1334. 
278. Ionov Y, Yamamoto H, Krajewski S, Reed JC, & Perucho M (2000) Mutational 
inactivation of the proapoptotic gene BAX confers selective advantage during tumor 
clonal evolution. Proceedings of the National Academy of Sciences of the United States of 
America 97(20):10872-10877. 
9                                                                              BIBLIOGRAPHY 
    191 
279. Manoochehri M, Karbasi A, Bandehpour M, & Kazemi B (2013) Down-Regulation of 
BAX Gene During Carcinogenesis and Acquisition of Resistance to 5-FU in Colorectal 
Cancer. Pathology oncology research : POR. 
280. Erler JT, et al. (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors 
occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and 
contributes to drug resistance. Molecular and cellular biology 24(7):2875-2889. 
281. Wang X, et al. (2014) BAX and CDKN1A polymorphisms correlated with clinical 
outcomes of gastric cancer patients treated with postoperative chemotherapy. Medical 
oncology 31(11):249. 
282. Shibue T, et al. (2003) Integral role of Noxa in p53-mediated apoptotic response. Genes 
& development 17(18):2233-2238. 
283. Li J, Lee B, & Lee AS (2006) Endoplasmic reticulum stress-induced apoptosis: multiple 
pathways and activation of p53-up-regulated modulator of apoptosis (PUMA) and NOXA 
by p53. The Journal of biological chemistry 281(11):7260-7270. 
284. Fricker M, O'Prey J, Tolkovsky AM, & Ryan KM (2010) Phosphorylation of Puma 
modulates its apoptotic function by regulating protein stability. Cell death & disease 
1:e59. 
285. Villunger A, et al. (2003) p53- and drug-induced apoptotic responses mediated by BH3-
only proteins puma and noxa. Science 302(5647):1036-1038. 
286. Sinicrope FA, et al. (2008) Prognostic impact of bim, puma, and noxa expression in 
human colon carcinomas. Clinical cancer research : an official journal of the American 
Association for Cancer Research 14(18):5810-5818. 
287. Bouillet P, et al. (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic 
responses, leukocyte homeostasis, and to preclude autoimmunity. Science 
286(5445):1735-1738. 
288. Upton JP, et al. (2008) Caspase-2 cleavage of BID is a critical apoptotic signal 
downstream of endoplasmic reticulum stress. Molecular and cellular biology 
28(12):3943-3951. 
289. Kamer I, et al. (2005) Proapoptotic BID is an ATM effector in the DNA-damage response. 
Cell 122(4):593-603. 
290. Desagher S, et al. (2001) Phosphorylation of bid by casein kinases I and II regulates its 
cleavage by caspase 8. Molecular cell 8(3):601-611. 
291. Zinkel SS, et al. (2003) Proapoptotic BID is required for myeloid homeostasis and tumor 
suppression. Genes & development 17(2):229-239. 
292. Kaufmann T, et al. (2007) The BH3-only protein bid is dispensable for DNA damage- 
and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129(2):423-433. 
293. Blume-Jensen P, Janknecht R, & Hunter T (1998) The kit receptor promotes cell survival 
via activation of PI 3-kinase and subsequent Akt-mediated phosphorylation of Bad on 
Ser136. Current biology : CB 8(13):779-782. 
294. She QB, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK 
and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer cell 8(4):287-297. 
295. Schmelzle T, et al. (2007) Functional role and oncogene-regulated expression of the BH3-
only factor Bmf in mammary epithelial anoikis and morphogenesis. Proceedings of the 
National Academy of Sciences of the United States of America 104(10):3787-3792. 
296. Olie RA & Zangemeister-Wittke U (2001) Targeting tumor cell resistance to apoptosis 
induction with antisense oligonucleotides: progress and therapeutic potential. Drug 
resistance updates : reviews and commentaries in antimicrobial and anticancer 
chemotherapy 4(1):9-15. 
297. Jansen B, et al. (1998) bcl-2 antisense therapy chemosensitizes human melanoma in SCID 
mice. Nature medicine 4(2):232-234. 
9                                                                              BIBLIOGRAPHY 
    192 
298. Bedikian AY, et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in 
patients with advanced melanoma: the Oblimersen Melanoma Study Group. Journal of 
clinical oncology : official journal of the American Society of Clinical Oncology 
24(29):4738-4745. 
299. Heere-Ress E, et al. (2002) Bcl-X(L) is a chemoresistance factor in human melanoma 
cells that can be inhibited by antisense therapy. International journal of cancer. Journal 
international du cancer 99(1):29-34. 
300. Zangemeister-Wittke U, et al. (2000) A novel bispecific antisense oligonucleotide 
inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 6(6):2547-2555. 
301. Sieghart W, et al. (2006) Mcl-1 overexpression in hepatocellular carcinoma: a potential 
target for antisense therapy. Journal of hepatology 44(1):151-157. 
302. Piche A, et al. (1998) Modulation of Bcl-2 protein levels by an intracellular anti-Bcl-2 
single-chain antibody increases drug-induced cytotoxicity in the breast cancer cell line 
MCF-7. Cancer research 58(10):2134-2140. 
303. Wang JL, et al. (2000) Cell permeable Bcl-2 binding peptides: a chemical approach to 
apoptosis induction in tumor cells. Cancer research 60(6):1498-1502. 
304. Sattler M, et al. (1997) Structure of Bcl-xL-Bak peptide complex: recognition between 
regulators of apoptosis. Science 275(5302):983-986. 
305. van Delft MF, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins 
and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 
10(5):389-399. 
306. Wesarg E, et al. (2007) Targeting BCL-2 family proteins to overcome drug resistance in 
non-small cell lung cancer. International journal of cancer. Journal international du 
cancer 121(11):2387-2394. 
307. Oltersdorf T, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of 
solid tumours. Nature 435(7042):677-681. 
308. Hann CL, et al. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, 
in small cell lung cancer. Cancer research 68(7):2321-2328. 
309. Park CM, et al. (2008) Discovery of an orally bioavailable small molecule inhibitor of 
prosurvival B-cell lymphoma 2 proteins. Journal of medicinal chemistry 51(21):6902-
6915. 
310. Wang G, et al. (2006) Structure-based design of potent small-molecule inhibitors of anti-
apoptotic Bcl-2 proteins. Journal of medicinal chemistry 49(21):6139-6142. 
311. Zaidi R & Hadi SM (1992) Complexes involving gossypol, DNA and Cu(II). 
Biochemistry international 28(6):1135-1143. 
312. Wei J, et al. (2010) Synthesis and biological evaluation of Apogossypolone derivatives as 
pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family 
proteins. Journal of medicinal chemistry 53(22):8000-8011. 
313. Wang Z, et al. (2008) TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth 
and invasion in pancreatic cancer. International journal of cancer. Journal international 
du cancer 123(4):958-966. 
314. Mohammad RM, et al. (2007) Preclinical studies of TW-37, a new nonpeptidic small-
molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug 
action on both Bcl-2 and Mcl-1. Clinical cancer research : an official journal of the 
American Association for Cancer Research 13(7):2226-2235. 
315. Hu ZY, Sun J, Zhu XF, Yang D, & Zeng YX (2009) ApoG2 induces cell cycle arrest of 
nasopharyngeal carcinoma cells by suppressing the c-Myc signaling pathway. Journal of 
translational medicine 7:74. 
9                                                                              BIBLIOGRAPHY 
    193 
316. Paoluzzi L, et al. (2008) Targeting Bcl-2 family members with the BH3 mimetic AT-101 
markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in 
vivo models of B-cell lymphoma. Blood 111(11):5350-5358. 
317. Wei J, et al. (2009) Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family 
proteins. Molecular cancer therapeutics 8(4):904-913. 
318. Wei J, et al. (2011) An optically pure apogossypolone derivative as potent pan-active 
inhibitor of anti-apoptotic bcl-2 family proteins. Frontiers in oncology 1:28. 
319. Trudel S, et al. (2007) The Bcl-2 family protein inhibitor, ABT-737, has substantial 
antimyeloma activity and shows synergistic effect with dexamethasone and melphalan. 
Clinical cancer research : an official journal of the American Association for Cancer 
Research 13(2 Pt 1):621-629. 
320. Nguyen M, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and 
overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A 
104(49):19512-19517. 
321. Konopleva M, et al. (2008) Mechanisms of antileukemic activity of the novel Bcl-2 
homology domain-3 mimetic GX15-070 (obatoclax). Cancer research 68(9):3413-3420. 
322. McCoy F, et al. (2010) Obatoclax induces Atg7-dependent autophagy independent of 
beclin-1 and BAX/BAK. Cell death & disease 1:e108. 
323. Thomas S, et al. (2013) Targeting the Bcl-2 family for cancer therapy. Expert opinion on 
therapeutic targets 17(1):61-75. 
324. Ni Chonghaile T, et al. (2011) Pretreatment mitochondrial priming correlates with clinical 
response to cytotoxic chemotherapy. Science 334(6059):1129-1133. 
325. Opferman JT & Korsmeyer SJ (2003) Apoptosis in the development and maintenance of 
the immune system. Nature immunology 4(5):410-415. 
326. Vo TT, et al. (2012) Relative mitochondrial priming of myeloblasts and normal HSCs 
determines chemotherapeutic success in AML. Cell 151(2):344-355. 
327. Ryan J & Letai A (2013) BH3 profiling in whole cells by fluorimeter or FACS. Methods 
61(2):156-164. 
328. Brunelle JK, Ryan J, Yecies D, Opferman JT, & Letai A (2009) MCL-1-dependent 
leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. 
The Journal of cell biology 187(3):429-442. 
329. Deng J, et al. (2007) BH3 profiling identifies three distinct classes of apoptotic blocks to 
predict response to ABT-737 and conventional chemotherapeutic agents. Cancer cell 
12(2):171-185. 
330. Yip KW & Reed JC (2008) Bcl-2 family proteins and cancer. Oncogene 27(50):6398-
6406. 
331. Chonghaile TN, et al. (2014) Maturation stage of T-cell acute lymphoblastic leukemia 
determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer 
discovery 4(9):1074-1087. 
332. Russ WP & Engelman DM (1999) TOXCAT: a measure of transmembrane helix 
association in a biological membrane. Proceedings of the National Academy of Sciences 
of the United States of America 96(3):863-868. 
333. Li R, et al. (2004) Dimerization of the transmembrane domain of Integrin alphaIIb 
subunit in cell membranes. The Journal of biological chemistry 279(25):26666-26673. 
334. Yin H, et al. (2007) Computational design of peptides that target transmembrane helices. 
Science 315(5820):1817-1822. 
335. Kerppola TK (2008) Bimolecular fluorescence complementation (BiFC) analysis as a 
probe of protein interactions in living cells. Annual review of biophysics 37:465-487. 
336. Kerppola TK (2009) Visualization of molecular interactions using bimolecular 
fluorescence complementation analysis: characteristics of protein fragment 
complementation. Chemical Society reviews 38(10):2876-2886. 
9                                                                              BIBLIOGRAPHY 
    194 
337. Kodama Y & Hu CD (2010) An improved bimolecular fluorescence complementation 
assay with a high signal-to-noise ratio. BioTechniques 49(5):793-805. 
338. Hessa T, et al. (2005) Recognition of transmembrane helices by the endoplasmic 
reticulum translocon. Nature 433(7024):377-381. 
339. Martinez-Gil L, Perez-Gil J, & Mingarro I (2008) The surfactant peptide KL4 sequence is 
inserted with a transmembrane orientation into the endoplasmic reticulum membrane. 
Biophysical journal 95(6):L36-38. 
340. Navarro JA, et al. (2006) RNA-binding properties and membrane insertion of Melon 
necrotic spot virus (MNSV) double gene block movement proteins. Virology 356(1-2):57-
67. 
341. Sauri A, Tamborero S, Martinez-Gil L, Johnson AE, & Mingarro I (2009) Viral 
membrane protein topology is dictated by multiple determinants in its sequence. Journal 
of molecular biology 387(1):113-128. 
342. Orzaez M, Guevara T, Sancho M, & Perez-Paya E (2012) Intrinsic caspase-8 activation 
mediates sensitization of erlotinib-resistant tumor cells to erlotinib/cell-cycle inhibitors 
combination treatment. Cell death & disease 3:e415. 
343. Palacios-Rodriguez Y, et al. (2011) Polypeptide modulators of caspase recruitment 
domain (CARD)-CARD-mediated protein-protein interactions. The Journal of biological 
chemistry 286(52):44457-44466. 
344. Hall K, Lee TH, Mechler AI, Swann MJ, & Aguilar MI (2014) Real-time measurement of 
membrane conformational states induced by antimicrobial peptides: balance between 
recovery and lysis. Scientific reports 4:5479. 
345. Hirst DJ, et al. (2011) Effect of acyl chain structure and bilayer phase state on binding 
and penetration of a supported lipid bilayer by HPA3. European biophysics journal : EBJ 
40(4):503-514. 
346. Lee TH, et al. (2010) Real-time quantitative analysis of lipid disordering by aurein 1.2 
during membrane adsorption, destabilisation and lysis. Biochimica et biophysica acta 
10(86):30. 
347. Sila M, Au S, & Weiner N (1986) Effects of Triton X-100 concentration and incubation 
temperature on carboxyfluorescein release from multilamellar liposomes. Biochimica et 
Biophysica Acta (BBA) - Biomembranes 859(2):165-170. 
348. Frezza C, Cipolat S, & Scorrano L (2007) Organelle isolation: functional mitochondria 
from mouse liver, muscle and cultured fibroblasts. Nat Protoc 2(2):287-295. 
349. Karch J, et al. (2013) Bax and Bak function as the outer membrane component of the 
mitochondrial permeability pore in regulating necrotic cell death in mice. eLife 2:e00772. 
350. Moure A, et al. (2011) Chemical modulation of peptoids: synthesis and conformational 
studies on partially constrained derivatives. Chemistry 17(28):7927-7939. 
351. Cecconi F, Alvarez-Bolado G, Meyer BI, Roth KA, & Gruss P (1998) Apaf1 (CED-4 
homolog) regulates programmed cell death in mammalian development. Cell 94(6):727-
737. 
352. Valentijn AJ, Upton JP, Bates N, & Gilmore AP (2008) Bax targeting to mitochondria 
occurs via both tail anchor-dependent and -independent mechanisms. Cell death and 
differentiation 15(8):1243-1254. 
353. Berger BW, et al. (2010) Consensus motif for integrin transmembrane helix association. 
Proc Natl Acad Sci U S A 107(2):703-708. 
354. Adair BD & Engelman DM (1994) Glycophorin A helical transmembrane domains 
dimerize in phospholipid bilayers: a resonance energy transfer study. Biochemistry 
33(18):5539-5544. 
355. Treutlein HR, Lemmon MA, Engelman DM, & Brunger AT (1992) The glycophorin A 
transmembrane domain dimer: sequence-specific propensity for a right-handed supercoil 
of helices. Biochemistry 31(51):12726-12732. 
9                                                                              BIBLIOGRAPHY 
    195 
356. Gomez-Fernandez JC (2014) Functions of the C-terminal domains of apoptosis-related 
proteins of the Bcl-2 family. Chemistry and physics of lipids 183:77-90. 
357. Russ WP & Engelman DM (2000) The GxxxG motif: a framework for transmembrane 
helix-helix association. Journal of molecular biology 296(3):911-919. 
358. Vilar M, et al. (2009) Activation of the p75 neurotrophin receptor through conformational 
rearrangement of disulphide-linked receptor dimers. Neuron 62(1):72-83. 
359. Nakagawa C, Inahata K, Nishimura S, & Sugimoto K (2011) Improvement of a Venus-
based bimolecular fluorescence complementation assay to visualize bFos-bJun interaction 
in living cells. Bioscience, biotechnology, and biochemistry 75(7):1399-1401. 
360. Merabet S, et al. (2011) Insights into Hox protein function from a large scale 
combinatorial analysis of protein domains. PLoS genetics 7(10):e1002302. 
361. Corsten MF, Hofstra L, Narula J, & Reutelingsperger CP (2006) Counting heads in the 
war against cancer: defining the role of annexin A5 imaging in cancer treatment and 
surveillance. Cancer research 66(3):1255-1260. 
362. Suh DH, Kim MK, Kim HS, Chung HH, & Song YS (2013) Mitochondrial permeability 
transition pore as a selective target for anti-cancer therapy. Frontiers in oncology 3:41. 
363. Shoshan-Barmatz V, Mizrachi D, & Keinan N (2013) Oligomerization of the 
mitochondrial protein VDAC1: from structure to function and cancer therapy. Progress in 
molecular biology and translational science 117:303-334. 
364. Tahir SK, et al. (2010) Identification of expression signatures predictive of sensitivity to 
the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and 
leukemia/lymphoma cell lines. Molecular cancer therapeutics 9(3):545-557. 
365. Coultas L & Strasser A (2003) The role of the Bcl-2 protein family in cancer. Seminars in 
cancer biology 13(2):115-123. 
366. Gomez-Fernandez JC (2014) Functions of the C-terminal domains of apoptosis-related 
proteins of the Bcl-2 family. Chemistry and physics of lipids 183C:77-90. 
367. Gahl RF, He Y, Yu S, & Tjandra N (2014) Conformational Rearrangements in the Pro-
Apoptotic Protein, Bax, as it inserts into mitochondria: A Cellular Death Switch. The 
Journal of biological chemistry. 
368. Mahajan NP, et al. (1998) Bcl-2 and Bax interactions in mitochondria probed with green 
fluorescent protein and fluorescence resonance energy transfer. Nature biotechnology 
16(6):547-552. 
369. Dzhagalov I, Dunkle A, & He YW (2008) The anti-apoptotic Bcl-2 family member Mcl-1 
promotes T lymphocyte survival at multiple stages. Journal of immunology 181(1):521-
528. 
370. Gonzalvez F, et al. (2005) tBid interaction with cardiolipin primarily orchestrates 
mitochondrial dysfunctions and subsequently activates Bax and Bak. Cell death and 
differentiation 12(6):614-626. 
371. Basanez G, et al. (1999) Bax, but not Bcl-xL, decreases the lifetime of planar 
phospholipid bilayer membranes at subnanomolar concentrations. Proc Natl Acad Sci U S 
A 96(10):5492-5497. 
372. Kim H, et al. (2006) Hierarchical regulation of mitochondrion-dependent apoptosis by 
BCL-2 subfamilies. Nature cell biology 8(12):1348-1358. 
373. Uren RT, et al. (2007) Mitochondrial permeabilization relies on BH3 ligands engaging 
multiple prosurvival Bcl-2 relatives, not Bak. The Journal of cell biology 177(2):277-287. 
374. Andreu-Fernandez V, et al. (2014) Peptides derived from the transmembrane domain of 
Bcl-2 proteins as potential mitochondrial priming tools. ACS chemical biology 9(8):1799-
1811. 
375. Aranovich A, et al. (2012) Differences in the mechanisms of proapoptotic BH3 proteins 
binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Molecular cell 45(6):754-
763. 
9                                                                              BIBLIOGRAPHY 
    196 
376. Hessa T, et al. (2007) Molecular code for transmembrane-helix recognition by the Sec61 
translocon. Nature 450(7172):1026-1030. 
377. Tamborero S, Vilar M, Martinez-Gil L, Johnson AE, & Mingarro I (2011) Membrane 
insertion and topology of the translocating chain-associating membrane protein (TRAM). 
Journal of molecular biology 406(4):571-582. 
378. Martinez-Gil L, Sauri A, Vilar M, Pallas V, & Mingarro I (2007) Membrane insertion and 
topology of the p7B movement protein of Melon Necrotic Spot Virus (MNSV). Virology 
367(2):348-357. 
379. Bano-Polo M, et al. (2012) Polar/Ionizable residues in transmembrane segments: effects 
on helix-helix packing. PloS one 7(9):e44263. 
380. Garcia-Saez AJ, Mingarro I, Perez-Paya E, & Salgado J (2004) Membrane-insertion 
fragments of Bcl-xL, Bax, and Bid. Biochemistry 43(34):10930-10943. 
381. Germain M, Mathai JP, McBride HM, & Shore GC (2005) Endoplasmic reticulum BIK 
initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. The 
EMBO journal 24(8):1546-1556. 
382. Shamas-Din A, Brahmbhatt H, Leber B, & Andrews DW (2011) BH3-only proteins: 
Orchestrators of apoptosis. Biochimica et biophysica acta 1813(4):508-520. 
383. Kvansakul M & Hinds MG (2014) The structural biology of BH3-only proteins. Methods 
in enzymology 544:49-74. 
384. Garofalo T, et al. (2015) Role of mitochondrial raft-like microdomains in the regulation 
of cell apoptosis. Apoptosis : an international journal on programmed cell death. 
385. Grimm S (2012) The ER-mitochondria interface: the social network of cell death. 
Biochimica et biophysica acta 1823(2):327-334. 
386. Pang X, et al. (2014) The carboxyl-terminal tail of Noxa protein regulates the stability of 
Noxa and Mcl-1. The Journal of biological chemistry 289(25):17802-17811. 
387. Shamas-Din A, Brahmbhatt H, Leber B, & Andrews DW (2011) BH3-only proteins: 
Orchestrators of apoptosis. Biochimica et biophysica acta 4:508-520. 
388. Garcia-Saez AJ (2012) The secrets of the Bcl-2 family. Cell death and differentiation 
19(11):1733-1740. 
389. Edlich F, et al. (2011) Bcl-xL Retrotranslocates Bax from the Mitochondria into the 
Cytosol. Cell 145(1):104-116. 
390. Todt F, Cakir Z, Reichenbach F, Youle RJ, & Edlich F (2013) The C-terminal helix of 
Bcl-xL mediates Bax retrotranslocation from the mitochondria. Cell death and 
differentiation 20(2):333-342. 
391. Wilfling F, et al. (2012) BH3-only proteins are tail-anchored in the outer mitochondrial 
membrane and can initiate the activation of Bax. Cell Death Differ 19(8):1328-1336. 
392. Slivka PF, Wong J, Caputo GA, & Yin H (2008) Peptide probes for protein 
transmembrane domains. ACS chemical biology 3(7):402-411. 
393. Chonghaile TN & Letai A (2008) Mimicking the BH3 domain to kill cancer cells. 
Oncogene 27 Suppl 1:S149-157. 
394. Michels J, et al. (2013) Synergistic interaction between cisplatin and PARP inhibitors in 
non-small cell lung cancer. Cell cycle 12(6):877-883. 
395. Rath A, Tulumello DV, & Deber CM (2009) Peptide models of membrane protein folding. 
Biochemistry 48(14):3036-3045. 
396. Orzaez M, Salgado J, Gimenez-Giner A, Perez-Paya E, & Mingarro I (2004) Influence of 
proline residues in transmembrane helix packing. Journal of molecular biology 
335(2):631-640. 
397. Baeza-Delgado C, Marti-Renom MA, & Mingarro I (2013) Structure-based statistical 
analysis of transmembrane helices. European biophysics journal : EBJ 42(2-3):199-207. 
9                                                                              BIBLIOGRAPHY 
    197 
398. Vilar M, Esteve V, Pallas V, Marcos JF, & Perez-Paya E (2001) Structural properties of 
carnation mottle virus p7 movement protein and its RNA-binding domain. The Journal of 
biological chemistry 276(21):18122-18129. 
399. Pastor MT, Lopez de la Paz M, Lacroix E, Serrano L, & Perez-Paya E (2002) 
Combinatorial approaches: a new tool to search for highly structured beta-hairpin peptides. 
Proceedings of the National Academy of Sciences of the United States of America 
99(2):614-619. 
400. Orzaez M, Perez-Paya E, & Mingarro I (2000) Influence of the C-terminus of the 
glycophorin A transmembrane fragment on the dimerization process. Protein science : a 
publication of the Protein Society 9(6):1246-1253. 
401. Blondelle SE, Forood B, Houghten RA, & Perez-Paya E (1997) Secondary structure 
induction in aqueous vs membrane-like environments. Biopolymers 42(4):489-498. 
402. Vilar M, Sauri A, Marcos JF, Mingarro I, & Perez-Paya E (2005) Transient structural 
ordering of the RNA-binding domain of carnation mottle virus p7 movement protein 
modulates nucleic acid binding. Chembiochem 6(8):1391-1396. 
403. Schinzel A, Kaufmann T, & Borner C (2004) Bcl-2 family members: integrators of 
survival and death signals in physiology and pathology [corrected]. Biochimica et 
biophysica acta 1:2-3. 
404. Osman C, Voelker DR, & Langer T (2011) Making heads or tails of phospholipids in 
mitochondria. The Journal of cell biology 192(1):7-16. 
405. de Kroon AI, Dolis D, Mayer A, Lill R, & de Kruijff B (1997) Phospholipid composition 
of highly purified mitochondrial outer membranes of rat liver and Neurospora crassa. Is 
cardiolipin present in the mitochondrial outer membrane? Biochimica et biophysica acta 
3(1):108-116. 
406. Schug Z & Gottlieb E (2009) Cardiolipin acts as a mitochondrial signalling platform to 
launch apoptosis. Biochimica et biophysica acta 1788(10):2022-2031. 
407. Lee TH, et al. (2009) Molecular imaging and orientational changes of antimicrobial 
peptides in membranes. Adv Exp Med Biol 611:313-315. 
408. Lee TH, et al. (2010) The membrane insertion of helical antimicrobial peptides from the 
N-terminus of Helicobacter pylori ribosomal protein L1. Biochimica et biophysica acta 
3:544-557. 
409. Fernandez DI, Lee TH, Sani MA, Aguilar MI, & Separovic F (2013) Proline Facilitates 
Membrane Insertion of the Antimicrobial Peptide Maculatin 1.1 via Surface Indentation 
and Subsequent Lipid Disordering. Biophysical journal 104(7):1495-1507. 
410. Ouellet M, Otis F, Voyer N, & Auger M (2006) Biophysical studies of the interactions 
between 14-mer and 21-mer model amphipathic peptides and membranes: insights on 
their modes of action. Biochimica et biophysica acta 1758(9):1235-1244. 
411. Biron E, Voyer N, Meillon JC, Cormier ME, & Auger M (2000) Conformational and 
orientation studies of artificial ion channels incorporated into lipid bilayers. Biopolymers 
55(5):364-372. 
412. Borgne-Sanchez A, et al. (2007) Targeted Vpr-derived peptides reach mitochondria to 
induce apoptosis of alphaVbeta3-expressing endothelial cells. Cell death and 
differentiation 14(3):422-435. 
413. Von Ahsen O, Waterhouse NJ, Kuwana T, Newmeyer DD, & Green DR (2000) The 
'harmless' release of cytochrome c. Cell death and differentiation 7(12):1192-1199. 
414. Hayashida W, Horiuchi M, & Dzau VJ (1996) Intracellular third loop domain of 
angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. 
The Journal of biological chemistry 271(36):21985-21992. 
415. Eguchi Y, Shimizu S, & Tsujimoto Y (1997) Intracellular ATP levels determine cell death 
fate by apoptosis or necrosis. Cancer research 57(10):1835-1840. 
9                                                                              BIBLIOGRAPHY 
    198 
416. Ellerby HM, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nature 
medicine 5(9):1032-1038. 
417. Law B, Quinti L, Choi Y, Weissleder R, & Tung CH (2006) A mitochondrial targeted 
fusion peptide exhibits remarkable cytotoxicity. Molecular cancer therapeutics 
5(8):1944-1949. 
418. Mai JC, Mi Z, Kim SH, Ng B, & Robbins PD (2001) A proapoptotic peptide for the 
treatment of solid tumors. Cancer research 61(21):7709-7712. 
419. Marks AJ, et al. (2005) Selective apoptotic killing of malignant hemopoietic cells by 
antibody-targeted delivery of an amphipathic peptide. Cancer research 65(6):2373-2377. 
420. Rege K, Patel SJ, Megeed Z, & Yarmush ML (2007) Amphipathic peptide-based fusion 
peptides and immunoconjugates for the targeted ablation of prostate cancer cells. Cancer 
research 67(13):6368-6375. 
421. Torrecillas A, Martinez-Senac MM, Ausili A, Corbalan-Garcia S, & Gomez-Fernandez 
JC (2007) Interaction of the C-terminal domain of Bcl-2 family proteins with model 
membranes. Biochimica et biophysica acta 1768(11):2931-2939. 
422. Valero JG, et al. (2011) Bax-derived membrane-active peptides act as potent and direct 
inducers of apoptosis in cancer cells. Journal of cell science 124(Pt 4):556-564. 
423. Garg P, Nemec KN, Khaled AR, & Tatulian SA (2013) Transmembrane pore formation 
by the carboxyl terminus of Bax protein. Biochimica et biophysica acta 1828(2):732-742. 
424. Basanez G, Soane L, & Hardwick JM (2012) A new view of the lethal apoptotic pore. 
PLoS biology 10(9):25. 
425. Lanave C, Santamaria M, & Saccone C (2004) Comparative genomics: the evolutionary 
history of the Bcl-2 family. Gene 333:71-79. 
426. Aouacheria A, Rech de Laval V, Combet C, & Hardwick JM (2013) Evolution of Bcl-2 
homology motifs: homology versus homoplasy. Trends in cell biology 23(3):103-111. 
427. Zhang L, Yu J, Park BH, Kinzler KW, & Vogelstein B (2000) Role of BAX in the 
apoptotic response to anticancer agents. Science 290(5493):989-992. 
428. Wang C & Youle RJ (2012) Predominant requirement of Bax for apoptosis in HCT116 
cells is determined by Mcl-1's inhibitory effect on Bak. Oncogene 31(26):3177-3189. 
429. Kale J, Liu Q, Leber B, & Andrews DW (2012) Shedding light on apoptosis at subcellular 
membranes. Cell 151(6):1179-1184. 
430. Garg P, Nemec KN, Khaled AR, & Tatulian SA (2013) Transmembrane pore formation 
by the carboxyl terminus of Bax protein. Biochimica et Biophysica Acta (BBA) - 
Biomembranes 1828(2):732-742. 
431. Ni Chonghaile T & Letai A (2008) Mimicking the BH3 domain to kill cancer cells. 
Oncogene 27(1):52. 
432. Kang MH & Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic 
pathways in cancer therapy. Clinical cancer research : an official journal of the American 
Association for Cancer Research 15(4):1126-1132. 
433. Roy MJ, Vom A, Czabotar PE, & Lessene G (2013) Cell death and the mitochondria: 
therapeutic targeting of the BCL-2 family-driven pathway. British journal of 
pharmacology. 
434. Lee MJ, et al. (2012) Sequential application of anticancer drugs enhances cell death by 
rewiring apoptotic signaling networks. Cell 149(4):780-794. 
435. Slattery EL & Warchol ME (2010) Cisplatin ototoxicity blocks sensory regeneration in 
the avian inner ear. The Journal of neuroscience : the official journal of the Society for 
Neuroscience 30(9):3473-3481. 
436. Trueb RM (2009) Chemotherapy-induced alopecia. Seminars in cutaneous medicine and 
surgery 28(1):11-14. 
437. Hellwig CT & Rehm M (2012) TRAIL signaling and synergy mechanisms used in 
TRAIL-based combination therapies. Molecular cancer therapeutics 11(1):3-13. 
9                                                                              BIBLIOGRAPHY 
    199 
438. Zhai D, Jin C, Satterthwait AC, & Reed JC (2006) Comparison of chemical inhibitors of 
antiapoptotic Bcl-2-family proteins. Cell death and differentiation 13(8):1419-1421. 
439. Soengas MS, et al. (2001) Inactivation of the apoptosis effector Apaf-1 in malignant 
melanoma. Nature 409(6817):207-211. 
440. Soengas MS, Gerald WL, Cordon-Cardo C, Lazebnik Y, & Lowe SW (2006) Apaf-1 
expression in malignant melanoma. Cell death and differentiation 13(2):352-353. 
441. Mondragon L, et al. (2009) A chemical inhibitor of Apaf-1 exerts mitochondrioprotective 
functions and interferes with the intra-S-phase DNA damage checkpoint. Apoptosis : an 
international journal on programmed cell death 14(2):182-190. 
442. Mondragon L, et al. (2008) Modulation of cellular apoptosis with apoptotic protease-
activating factor 1 (Apaf-1) inhibitors. Journal of medicinal chemistry 51(3):521-529. 
443. Ferraro E, et al. (2011) Apaf1 plays a pro-survival role by regulating centrosome 
morphology and function. Journal of cell science 124(Pt 20):3450-3463. 
444. Sancho M, et al. (2014) Altered mitochondria morphology and cell metabolism in Apaf1-
deficient cells. PloS one 9(1):e84666. 
445. Kuma A, Matsui M, & Mizushima N (2007) LC3, an autophagosome marker, can be 
incorporated into protein aggregates independent of autophagy: caution in the 
interpretation of LC3 localization. Autophagy 3(4):323-328. 
446. Maiuri MC, Criollo A, & Kroemer G (2010) Crosstalk between apoptosis and autophagy 
within the Beclin 1 interactome. The EMBO journal 29(3):515-516. 
447. Heidari N, Hicks MA, & Harada H (2010) GX15-070 (obatoclax) overcomes 
glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis 
and autophagy. Cell death & disease 1:e76. 
448. Johnson CE, et al. (2007) Differential Apaf-1 levels allow cytochrome c to induce 
apoptosis in brain tumors but not in normal neural tissues. Proceedings of the National 
Academy of Sciences of the United States of America 104(52):20820-20825. 
449. Potts MB, Vaughn AE, McDonough H, Patterson C, & Deshmukh M (2005) Reduced 
Apaf-1 levels in cardiomyocytes engage strict regulation of apoptosis by endogenous 
XIAP. The Journal of cell biology 171(6):925-930. 
450. Kroemer G & Martin SJ (2005) Caspase-independent cell death. Nature medicine 
11(7):725-730. 
451. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 
144(5):646-674. 
452. Grover R & Wilson GD (1996) Bcl-2 expression in malignant melanoma and its 
prognostic significance. European journal of surgical oncology : the journal of the 
European Society of Surgical Oncology and the British Association of Surgical Oncology 
22(4):347-349. 
453. Mestre-Escorihuela C, et al. (2007) Homozygous deletions localize novel tumor 
suppressor genes in B-cell lymphomas. Blood 109(1):271-280. 
454. Rudin CM, et al. (2012) Phase II study of single-agent navitoclax (ABT-263) and 
biomarker correlates in patients with relapsed small cell lung cancer. Clinical cancer 
research : an official journal of the American Association for Cancer Research 
18(11):3163-3169. 
455. Tse C, et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. 
Cancer research 68(9):3421-3428. 
456. Kodama Y & Hu CD (2012) Bimolecular fluorescence complementation (BiFC): a 5-year 
update and future perspectives. BioTechniques 53(5):285-298. 
457. Perez-Gil J, Nag K, Taneva S, & Keough KM (1992) Pulmonary surfactant protein SP-C 
causes packing rearrangements of dipalmitoylphosphatidylcholine in spread monolayers. 
Biophysical journal 63(1):197-204. 
 
9                                                                              BIBLIOGRAPHY 
    200 
 
 
 
 
 
 
     
 
 
SUMMARY 
IN 
SPANISH 
 
 
 
     
 
 
 
 
 
 
 
10                                                                   SUMMARY IN SPANISH 
    203 
10.1. INTRODUCCIÓN 
La apoptosis ha sido definida clásicamente como un programa de muerte celular 
programada esencial para el mantenimiento de la homeostasis de los tejidos, los 
mecanismos inmunitarios así como la reorganización tisular durante el desarrollo del 
organismo. Este mecanismo de suicidio celular  es  ejecutado a través de la activación de 
una cascada de proteasas llamadas caspasas (3). Puede ser desencadenado a través de la 
activación de receptores de muerte celular situados en la membrana plasmática (vía 
extrínseca) o a través de un proceso de señalización celular originado desde la 
mitocondria (vía intrínseca) (38, 55). Principalmente la ruta intrínseca, aunque también la 
extrínseca, está regulada por una familia de proteínas llamadas BCL-2,  cuya localización 
es mayoritariamente mitocondrial (55).  
La modulación del proceso apoptótico por parte de las proteínas de la familia BCL-2 
tiene lugar mediante una compleja red de interacciones entre sus miembros que 
desemboca en último término en la permeabilización de la membrana mitocondrial 
externa (MOM) o en evitar dicha permeabilización. Esta permeabilización de la MOM 
resulta crítica, ya que es considerada como el punto de no retorno para la activación de la 
apoptosis (48) . Una vez permeabilizada la MOM se produce la liberación desde la matriz 
mitocondrial al citosol de factores pro-apoptóticos tales como SMAC, Diablo y citocromo 
c. Ya en el citosol, y en presencia de ATP, el citocromo c interactúa con Apaf-1 y con 
procaspasa-9 para formar el apoptosoma (49, 50) (ver Figura 7.1). En este complejo 
macromolecular la proteasa procaspasa-9 es procesada y activada para a su vez activar 
procaspasa-3, desencadenado una cascada de proteasas que genera la destrucción final de 
la célula. 
La familia de proteínas BCL-2 se caracteriza porque todos sus miembros comparten 
homología de secuencia en al menos una (el dominio BH3) de las cuatro regiones o 
dominios de homología de BCL-2 llamados BH1, BH2, BH3, y BH4. Además, muchos de 
los miembros de la familia poseen una región hidrófobica C-terminal cuya función es 
anclarse a las membranas intracelulares. Atendiendo a criterios funcionales y estructurales 
existen tres subgrupos dentro de esta familia de proteínas que son: proteínas anti-
apoptóticas (Bcl-2, Bcl-xL, Mcl-1, A1, Bcl-w), pro-apoptóticas (Bax, Bak y Bok ) y 
proteínas con un único dominio BH3, llamadas BH3-only (Bim, Rambo, Bik, Bad, Bmf, 
HRK (Harakiri) Puma y Noxa) (382)(Figura 10.1.1). 
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Figura 10.1.1. Organización estructural y funcional de las proteínas de la familia BCL-2. Se divide en tres 
subfamilias de proteínas con funciones anti y pro-apoptóticas. Los miembros anti-apoptóticos incluyen A1, Bcl-
2, Bcl-xL, Bcl-w, MCL-1 y Diva y comparten los 4 dominios de homología de Bcl-2 (BH1-4). Los miembros 
pro-apoptóticos se subdividen en proteínas "multidominio" y proteínas BH3-only. Las proteínas multidominio 
también presentan dominios de homología 1 a 4, mientras que las BH3-only contienen sólo un dominio BH, el 
BH3, que es el responsable de la unión a las proteínas anti-apoptóticas. La mayoría de las proteínas BCL-2 
también presentan un dominio transmembrana hidrofóbico (TMD). En el grupo BH3-only, el TMD esta 
confirmado en Bid, Bik, Rambo y Hrk (marcadas en rojo). 
 
A menudo el subgrupo de las proteínas BH3-only es dividido en dos dependiendo de 
su capacidad para interactuar bien con las proteínas anti-apoptóticas, o bien con las 
proteínas efectoras Bax y Bak. Uno de estos subgrupos está formado por los denominados 
activadores directos Bid, Bim y Puma, capaces de inhibir a las BCL-2 anti-apoptóticas, 
pero también de unirse a las proteínas efectoras para activarlas y favorecer su 
oligomerización entre sí, desencadenando la permeabilización de la membrana 
mitocondrial externa (MOMP). El segundo grupo está integrado por las proteínas 
sensibilizadoras/de-represoras (Bad, Bmf, Hrk y Noxa). Estas proteínas carecerían de la 
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capacidad para activar directamente Bak o Bax. Sin embargo, son capaces de unirse e 
inhibir a las proteínas anti-apoptóticas favoreciendo con ello la activación de las efectoras 
Bax y Bak, para promover el MOMP. 
En células sanas no sometidas a ningún tipo de estrés, la proteína pro-apoptótica Bax 
reside inactiva en el citosol, con su dominio C-terminal secuestrado dentro del llamado 
surco hidrofóbica (64). Tras la activación de la cascada de señalización apoptótica, Bax 
pasa a su forma activa tras uno o varios cambios conformacionales derivados de su 
interacción con otros miembros de la familia BCL-2; estos cambios conformacionales 
liberan el dominio C-terminal el cual dirige y ancla a Bax en la MOM. Una vez en la 
membrana, las proteínas efectoras Bax y Bak homo- y hetero-oligomerizan formando 
poros proteolíticos y/o proteolipídicos que promueven la permeabilización y la liberación 
de diversos factores apoptogénicos. 
En cualquiera de los tipos celulares existentes en el organismo el delicado equilibrio 
que se establece entre supervivencia o muerte es el que determina el destino celular. Por 
tanto, ligeros desajustes que alteran este balance hacia un destino u otro son responsables 
de un gran número de enfermedades. De hecho, las alteraciones que experimentan 
algunos de los mecanismos de muerte celular han sido reconocidos como una de las seis 
características que definen los procesos tumorales (451). Por tanto, la desregulación de las 
proteínas de la familia BCL-2, que actúan como moduladores cruciales del proceso de 
apoptosis, han sido relacionadas con el desarrollo de varios tipos de tumores (258). Estas 
proteínas podrían ser responsables directas de la enfermedad (conductores), aunque 
también podrían estar implicadas en la resistencia adquirida a los tratamientos anti-
tumorales. Este es el motivo por el que tradicionalmente muchos de los fármacos 
desarrollados contra el cáncer, independientemente de su mecanismo de acción principal, 
tengan como dianas las proteínas de la familia BCL-2, ya sean para tratar de activar a las  
proteínas efectoras Bax y Bak (153) como para bloquear la acción de las anti-apoptóticas 
que constituyen una forma de quimioresistencia intrínseca. 
El papel de las proteínas BCL-2 ha sido demostrado en diversos tumores 
hematológicos (260, 303). También se ha establecido la correlación entre la elevada 
expresión de la proteína anti-apoptotica Bcl-2 y el mal pronóstico en melanoma (452), 
cáncer de mama (262) y próstata (263). Por otro lado, la disminución de la expresión de la 
BH3-only Bim también se relaciona con varios tipos de cáncer, incluyendo el linfoma de 
células B y el cáncer de colon (286, 453). Debido a la amplia implicación de la familia 
BCL-2 en los procesos tumorales existen numerosas líneas de investigación en curso cuyo 
objetivo es restaurar la sensibilidad de las células cancerosas a las señales pro-apoptóticas.  
Uno de los primeros fármacos desarrollados para inhibir la acción de las proteínas 
antiapoptóticas de la familia Bcl-2 se denomina Oblimersen. Se trata de un 
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oligonucleótido antisentido modificado complementario al gen de la proteína Bcl-2 (298). 
Sin embargo, la eficacia de este fármaco es todavía objeto de estudio y presenta algunos 
problemas de toxicidad. Diversos estudios estructurales de las proteínas de la familia 
BCL-2 mostraron que las interacciones citosólicas  de estas proteínas se basan en la unión 
del dominio BH3 de miembros pro-apoptóticos con la región del surco hidrofóbico 
presente en las proteína anti-apoptóticas (59). Por este motivo uno de los puntos centrales 
en el diseño de fármacos antitumorales se focalizó en imitar el dominio BH3 de las 
proteínas BH3-only, surgiendo varias moléculas denominadas “miméticos de BH3” (305). 
Estos "miméticos de BH3" se unen a uno o varios de los miembros anti-apoptóticos de la 
familia BCL-2 para bloquear su acción pro-supervivencia, generando la liberación de Bax 
y Bak para crear poros en el MOM y activar el proceso apoptótico. Uno de los “miméticos 
de BH3” más eficientes hasta la fecha es un compuesto desarrollado por Abbott, llamado 
ABT-737, y su variante de ingesta oral ABT-263 (307). Ambos son inhibidores de las 
proteínas anti-apoptóticas Bcl-xL, Bcl-w y Bcl-2. En ensayos clínicos, ABT-263 ha 
mostrado prometedores resultados en algunos tipos de neoplasias linfoides (307, 454, 
455). Una variante de estos compuestos llamada ABT-199, que actúa específicamente 
sobre la proteína Bcl-2, también muestra resultados prometedores en ensayos de leucemia 
linfocítica crónica, en la actualidad en fase I de desarrollo. 
Aunque la aparición de estos “miméticos de BH3” representa un gran avance en el 
desarrollo de estrategias antitumorales, existen diversos tipos de cáncer dependientes de 
los niveles de proteínas BCL-2 que no responden al tratamiento con éstos compuestos. 
Recientemente ha sido introducido el concepto de ‘cebado’ mitocondrial para referirse la 
inducción de la permeabilización de las mitocondrias de células tumorales, lo conduciría a 
su muerte. Dependiendo de los niveles de expresión de proteínas anti-apoptóticas y de su 
presencia en la mitocondrias, las células tumorales serán más o menos susceptibles a los 
tratamientos antitumorales que tienen como diana a éstas BCL-2 anti-apoptóticas.   
Durante los últimos años se han propuesto diferentes modelos para la formación de 
poros en la membrana mitocondrial externa! (140): PTP (poro transitorio para la 
permeabilización), MAC (canal mitocondrial inducido por apoptosis), oligomerización de 
VDAC1, de Bax y Bak, y de ceramidas. La evolución de estos modelos ha provocado dos 
cambios fundamentales, por un lado la relevancia que adquiere la red de interacciones que 
se establecen entre las proteínas de la familia BCL-2 que regulan la formación de la 
mayor parte de estos poros mitocondriales; y por otro lado la inclusión de la propia 
membrana mitocondrial como un participante activo en el mantenimiento del equilibrio de 
esta red de interacciones que regulan todo el proceso apoptótico. 
Actualmente existe un mapa bastante completo de la red de interacciones en la que se 
comprende bien la contribución de las regiones citosólicas de las proteínas de la familia 
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BCL-2. Sin embargo, a pesar de que una gran parte de estas interacciones proteína-
proteína tienen lugar en el contexto de la membrana mitocondrial, la contribución de los 
regiones hidrofóbicas de estas proteínas BCL-2 (BCL-2 TMDs) a esta red está lejos de 
estar resuelta. Además, existen evidencias que sugieren un papel relevante de estas 
regiones transmembrana (TMD) en el control de la apoptosis. Estas y otras cuestiones que 
implican a los BCL-2 TMDs son las que hemos abordado durante el transcurso de la 
presente Tesis Doctoral. 
10.2. OBJETIVOS 
La apoptosis se define clásicamente como un tipo de muerte celular programada. La 
activación de este proceso está mayoritariamente regulada por las proteínas de la familia 
BCL-2. Los miembros de esta familia se localizan en citoplasma, ER y MOM en las 
células sanas. Sin embargo, durante la apoptosis, la mayor parte de las interacciones entre 
estas proteínas ocurren en las membranas de orgánulos intracelulares. El objetivo central 
de esta Tesis Doctoral es ampliar nuestros conocimientos del mecanismo de acción de las 
proteínas de la familia BCL-2 en presencia de membranas. Este objetivo general ha sido 
abordado mediante los siguientes objetivos específicos: 
• El primer objetivo de este trabajo ha sido determinar la participación de los 
BCL-2 TMDs en la red de interacciones que establecen los diferentes miembros 
de la familia BCL-2. Así mismo, Se ha estudiado la importancia de las 
interacciones de los BCL-2 TMDs en el contexto de las proteínas BCL-2 
completas así como la relevancia funcional de estos TMDs en las rutas 
apoptóticas.           
• La capacidad de inserción en la membrana mitocondrial de las proteínas BH3-
only es actualmente muy controvertida. Por ello, el segundo objetivo de esta tesis 
ha sido investigar la capacidad de las regiones hidrofóbicas del extremo C-
terminal de proteínas BH3-only para insertarse en diferentes membranas 
biológicas. 
• El papel de los dominios citosólicos de las proteínas BCL-2 como 
sensibilizadores de la permeabilización mitocondrial (MOMP) en quimioterapia 
ha sido ampliamente estudiado. Sin embargo, poco se sabe acerca del papel de 
los BCL-2 TMDs en este proceso. Así, el tercer objetivo de esta tesis ha sido 
investigar la contribución de péptidos sintéticos derivados de BCL-2 TMDs en el 
proceso de permeabilización de la membrana mitocondrial externa (MOMP). 
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• Este trabajo también aborda el estudio de las diferentes rutas de muerte celular 
que son activadas en respuesta a diferentes fármacos pro-apoptóticos, 
dependiendo de la maquinaria apoptótica disponible en la célula. 
10.3. MATERIAL Y MÉTODOS 
10.3.1. Metodología utilizada para el estudio de las interacciones entre 
dominios transmembrana de las proteínas de la familia BCL-2. 
Durante la realización de esta Tesis Doctoral se han abordado diferentes estrategias para 
el estudio y análisis de las regiones TM de las proteínas de la familia BCL-2. En lo 
referente a la determinación de posibles interacciones entre los diferentes TMDs se han 
realizado los análisis utilizando dos tecnologías que permiten estudiar interacciones 
proteína-proteína en célula vivas. En primer lugar se ha utilizado el sistema de 
complementación ToxRed en bacterias para la realización de un rastreo de interacciones 
entre los diferentes TMDs. En segundo lugar, se ha empleado la metodología de BiFC 
basada en complementación bimolecular de fluorescencia con el objetivo de analizar las 
interacciones en células eucariotas y determinar su localización subcelular. 
10.3.1.1. Diseño, clonaje, expresión y análisis de los BCL-2 TMD en el sistema 
ToxRed. 
El ensayo de complementación de maltosa (Figura10.3.1) fue realizado de acuerdo a un 
protocolo previamente descrito (332, 333). El objetivo de los experimentos realizados en 
este sistema fue determinar la correcta orientación, la capacidad de inserción así como la 
habilidad de los dominios TM de las proteínas BCL-2 de establecer asociaciones hélice-
hélice para formar homo y/o hetero-oligómeros en la membrana interna de las bacterias de 
la cepa MM39 de E. coli. Los plásmidos ToxR originales fueron proporcionados por el 
laboratorio del Profesor William De Grado (UCSF). En estas construcciones la clonación 
de las diferentes secuencias correspondientes a los TMD estudiados se llevó a cabo entre 
la secuencia que codifica para el dominio de activación del factor de transcripción de 
Vibrio cholerae ToxR y la secuencia que codifica para el dominio periplásmico del 
translocador de maltosa (MBP). Para determinar si las proteínas de fusión ToxR-TM-
MBP estaban correctamente insertadas y orientadas en la membrana bacteriana, se realizó 
el crecimiento de MM39, transformadas con las diferentes construcciones, en un medio 
que contenía maltosa como única fuente de carbono. La cepa MM39 presenta 
deleccionado el gen malE  que codifica para la MBP, de tal forma que solo aquellas 
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bacterias que expresen las construcciones ToxR-TM-MBP y que las tengan correctamente 
insertadas y orientadas en su membrana interna (de tal manera que el dominio MBP quede 
en el espacio periplásmico), podrán captar maltosa del medio y por ello serán capaces de 
crecer en este medio restrictivo. La capacidad de homo- y hetero-oligomerización de las 
diferentes proteínas de fusión se determinó mediante la expresión del gen RFP que 
codifica la proteína de fluorescencia roja (RFP), el cual se encuentra bajo el control del 
promotor ctx que es a su vez reconocido por el factor de transcripción ToxR. No obstante, 
el reconocimiento de la secuencia del promotor sólo tiene lugar cuando ToxR se 
encuentra en forma de dímero, y esta dimerización solo es posible si los segmentos TM 
ensayados interaccionan y acercan los monómeros de ToxR. Como control de este sistema, 
se realizaron las mismas construcciones con el mutante de ToxR R96K (ToxR*), que 
permite la dimerización del factor de transcripción pero no su unión al promotor ctx , por 
lo que RFP no se expresa (334) (Figura 10.3.1). 
 
 
 
 
 
 
 
Figura 10.3.1. Vista esquemática del sistema ToxR para el análisis de interacciones TM. Las construcciones 
están formadas por el activador transcripcional dependiente de dimerización ToxR, un dominio TM BCL-2 y el 
translocador de maltosa MBP. La interacción de los TMDs produce la activación mediada por ToxR de un gen 
reportero, en este caso RFP. El nivel de fluorescencia indica la afinidad de la asociación entre los TMDs. Este 
ensayo de fluorescencia ha sido normalizado con una construcción mutante ToxR* incapaz de activar la 
expresión del gen reportero. 
 
Para generar las diferentes construcciones quiméricas de ToxR, se diseñaron 
cebadores con las secuencias completas de los TMDs flanqueadas por los sitios de 
restricción HindIII/XhoI presentes en el plásmido ToxR (Tabla 10.I.). Una vez hibridados 
los cebadores, fueron tratados con polinucleótido quinasa para añadir los grupos fosfato y 
posteriormente se ligaron con la ligasa del bacteriófago T4 (Promega). Para facilitar la 
inserción de los TMD en los plásmidos ToxR se utilizó fosfatasa alcalina (Roche) para 
eliminar el fosfato 5’ en el vector de ToxR sin inserto. 
Para confirmar la especificidad de las interacciones, se diseñaron mutantes puntuales 
de cada BCL-2 TMD estudiado utilizando el kit Stratagene Quikchange II disponible 
comercialmente (Agilent, CA, EE.UU.). 
 
 
MBP MBP
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Tabla 10.I. Secuencia de los BCL-2 TMD clonados. Los aminoácidos subrayados fueron añadidos en la 
clonación para el sistema BiFC por su relevancia en el direccinamiento de los TMD a mitocondria. ΔG 
representa una medida de hidrofobicidad en las secuencias analizadas, valores negativos son indicativos de 
inserción en membranas biológicas. 
 
 
 
 
 
 
 
 
 
 
 
 
Las construcciones ToxR-TM-MBP (200 ng) fueron transformadas en células 
competentes MM39 mediante choque térmico a 42°C durante 90 seg. Tras crecer las 
células en agitación 1 h en LB, fueron sembradas en medio mínimo con agar y ampicilina 
100 mg/ml. Tras 48 h, las células MM39, que expresaron las proteínas quiméricas ToxR-
TM-MBP  fueron cultivadas medio LB  con ampicilina durante 6 h. Los cultivos fueron 
sedimentados y se incubaron con agitación a 37°C durante 48 h en medio mínimo hasta 
obtener una OD600 0,8. Las mediciones de fluorescencia de RFP se realizaron utilizando el 
espectrofotómetro Wallac 1420 con una longitud de onda de excitación de 570nm y 
longitud de onda de emisión de 620nm en placas de 24 pocillos (Thermo Scientific). 
Para evaluar los niveles de expresión de todas las construcciones ToxR-TM-MBP , las 
células MM39 se sedimentaron por centrifugación durante 5 min a 3000×g, se eliminó el 
sobrenadante y los sedimentos celulares se resuspendieron en 10× del reactivo de lisis 
FastBreak (Promega). A continuación, la mezcla se incubó a temperatura ambiente en 
agitación suave durante 30 min y posteriormente las muestras se centrifugaron durante 10 
min para separar la fracciones esferoplásmica y periplásmicas. Se cuantificaron todas las 
muestras con el kit de cuantificación de BCA (Thermo Scientific). 50 µg de proteína total 
de cada muestra fueron  cargados  en geles SDS-PAGE de acrilamida al 12%, se 
transfirieron a membranas de nitrocelulosa, se bloquearon con leche en TBS-Tween 20 
5%, y se incubaron durante la noche con el anticuerpo primario correspondiente (MBP de 
New England Biolabs (#E8038S ); HA C29F4 (#3724S) y c-myc 9B11 (#2276S) de cell-
!
!
!
!
!
!
!
!
!
BCL-2 
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Cloned sequence Length ΔG 
Bcl-2 FSWLSLKTLLSLALVGACITLGAYLGHK 23 -1.356 
Bcl-xL SRKGQERFNRWFLTGMTVAGVVLLGSLFSRK 23 -0.355 
Bcl-w REGNWASVRTVLTGAVALGALVTVGAFFASK 22 -0.418 
Mcl1 IRNVLLAFAGVAGVGAGLAYLIR 23 -0.275 
Bcl-B FWRKQLVQAFLSCLLTTAFIYLWTRLL 21 0.689 
Bax   TWQTVTIFVAGVLTASLTIWKKMG 20 0.510 
Bak ILNVLVVLGVVLLGQFVVRRFFKS 22 -0.735 
Rambo GKSILLFGGAAAVAILAVAIGVALRKK 21 -1.403 
Bik VLLALLLLLALLLPLLSGGLHLLLK 24 -3.253 
Bid KEKTMLVLALLLAKKVA 17 2.462 
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signalling). Las membranas se incubaron con el anticuerpo secundario apropiado 
conjugado con peroxidasa para la detección de la cantidad de proteína por 
quimioluminiscencia (Amersham Pharmacia Biotech). 
 A modo de ejemplo se muestran los resultados que se obtuvieron siguiendo esta 
metodología para los TMD de Bcl-2, Bcl-xL y Bax (Figura 10.3.2). En todos los ensayos 
realizados se utilizó como control positivo de homo-oligomerización el fragmento TM de 
glicoforina (GpA), cuya dimerización ha sido ampliamente demostrada en la bibliografía 
(332). En la misma línea, el mutante de GpA G83I fue empleado como control negativo. 
Además, la señal de fluorescencia obtenida fue normalizada respecto a la señal obtenida 
por respectivas las construcciones ToxR*. 
Los resultados obtenidos muestran que los TMDs de Bcl-2, Bcl-xL y Bax homo-
oligomerizan (Figura 10.3.2A). Mas aún, estas interacciones entre hélices TM presentan 
una elevada especificidad, dado que encontramos mutantes puntuales de las superfícies de 
interacción TMD-TMD capaces de romper estas homo-oligomerizaciones (10.3.2B). 
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Figura 10.3.2. Los TMDs de las proteínas de la familia BCL-2 son capaces de homo-oligomerizar. (A) La 
formación de oligómeros entre BCL-2 TMDs produce un aumento de la fluorescencia debido a la expresión RFP 
mediada por el factor de transcripción ToxR. Los resultados representan la señal de fluorescencia normalizada 
(ToxR / ToxR *). (B) Disminución de la señal de fluorescencia en el sistema ToxR inducida por mutaciones 
puntuales de BCL-2 TMDs. La caída de la señal de fluorescencia indica que los TMD no homo-oligomerizan. 
Las barras rojas representan las interacciones positivas y barras blancas representan las interacciones negativas. 
GpA actúa como control positivo y el mutante puntual GpA G83I negativo. Todos los resultados representan la 
media de tres experimentos independientes. Se utilizó el test de comparación múltiple de Dunnett (CI 95%) para 
la comparación con el control positivo glicoforina A TMD. 
 
Para analizar las interacciones entre diferentes BCL-2 TMDs se modificó la 
metodología descrita para el sistema ToxR en el caso de las homo-oligomerizaciones 
desarrollándose un ensayo de competencia (Figura 10.3.3B). Se transformó la cepa 
MM39 con dos construcciones: por un lado ToxR-TMD1-MBP, capaz de oligomerizar y 
de activar la expresión de RFP; por otro ToxR*-TMD2-MBP, capaz de oligomerizar pero 
no de reconocer la secuencia del promotor ctx. De esta forma, si consideramos que los 
TMD1 y TMD2 hetero-oligomerizan, la interacción de estas construcciones no producirá 
la expresión de RFP, ya que es necesario que ambos ToxR sean completamente 
funcionales para unirse al DNA del promotor. Por ello, se producirá un descenso en la 
señal de fluorescencia roja correspondiente a RFP. Si por el contrario no existe 
interacción, la construcción ToxR-TMD1-MBP interaccionará únicamente consigo misma 
y se mantendrá la señal de fluorescencia al mismo nivel que en el caso de las homo-
oligomerizaciones. 
Siguiendo el ejemplo para los TMDs de Bcl-2, Bcl-xL y Bax podemos observar que 
tanto Bcl-2 como Bcl-xL son capaces de hetero-oligomerizar con el TMD de Bax (Figura 
10.3.3B, C y D). Sin embargo los TMD de Bcl-2 y Bcl-xL no interaccionan entre sí como 
se observa en la figura 10.3.3B y C. En estos ensayos el TMD de GpA es usado como 
control negativo de interacción ya que no presenta ninguna relación con los TMD 
analizados. 
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Figura 10.3.3 hetero-oligomerizaciones entre TMDs de las proteínas de la familia BCL-2. (A) Vista 
esquemática del sistema ToxR adaptado para evaluar la formación de hetero-oligómeros. La cotransformación 
de una construcción ToxR de un BCL-2 TMD y ToxR * de otro TMD , genera tres posibles oligómeros 
diferentes: combinaciones fluorescentes (ToxR / ToxR) y no fluorescentes (ToxR / ToxR * y ToxR * / ToxR 
*).(B,C y D). El control de la construcción ToxR del TMD analizado en cada caso (primera columna) representa 
la máxima señal de fluorescencia (100% homo-oligomerización). Las barras rojas representan hetero-
oligomerizaciones positivas. La disminución de la fluorescencia indica la formación de hetero-oligómeros con 
las construcciones ToxR* evaluadas. Las barras blancas representan hetero-oligomerizaciones negativas. GpA es 
una proteína no relacionada y se utilizó como control negativo de hetero-oligomerización. los experimentos se 
realizaron para las construcciones  ToxR-TMD-MBP de Bcl-2 (B), Bcl-xL (C) y Bax (D) cotransfectadas con 
ToxR*-TMD-MBP de las diferentes proteínas BCL-2. 
10.3.1.2. Diseño, clonaje, expresión y análisis de segmentos TM en el sistema BiFC. 
Toda la metodología basada en el sistema de complementación bimolecular de 
fluorescencia (BiFC) ha sido realizada como se describió previamente en la bibliografía 
(335, 456). El objetivo de estos ensayos ha sido el análisis de la capacidad de interacción 
entre los TMD de las proteínas BCL-2 en células eucariotas, así como la localización 
subcelular de estas interacciones. Estos experimentos están basados en la idea de que la 
proteína Venus (un mutante de la proteína YFP que emite fluorescencia verde en lugar de 
amarilla) puede ser dividida en dos fragmentos: VN, que comprende la región desde el 
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aminoácido 1 al 155, y que además presenta la mutación I152L que disminuye 
considerablemente el ruido de fondo inespecífico, y VC (155-238, A206K). Cuando estos 
fragmentos se encuentran lo suficientemente próximos en el interior de la célula son 
capaces de reconstituir la proteína completa, que emite fluorescencia verde (Figura 
10.3.4). Esta propiedad permite que al fusionar a cada fragmento diferentes proteínas, 
podamos determinar si interaccionan dependiendo de si se produce o no la emisión de 
fluorescencia derivada de la reconstitución de la proteína fluorescente. Por ello, hemos 
fusionado tanto a VN como a VC cada uno de los TMDs de las  proteínas BCL-2. Dado 
que la topología de los TMD en todas las BCL-2 es C-terminal, han sido clonados tras las 
regiones VN y VC de Venus, separándose de ellas por medio de una serie de aminoácidos 
que actúan a modo de espaciadores. Como control positivo de oligomerización se utilizó 
la interacción conocida de las proteínas nucleares b-Jun y b-fos, así como una forma 
truncada de b-fos que no se asocia a b-jun para establecer un control negativo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 10.3.4.!Representación esquemática del sistema de complementación bimolecular de fluorescencia 
(BiFC) en células de mamífero para el análisis de interacciones TM de proteínas de la familia BCL-2. El 
sistema esta basado en la reconstitución de la fluorescencia a partir de los fragmentos VN y VC en los que se ha 
sido dividida la proteína Venus. Esta reconstitución depende del establecimiento de la interacción entre los 
TMDs. 
 
Para la clonación de las diferentes construcciones de BiFC se diseñaron cebadores con 
las secuencias completas de los TMDs flanqueadas por el sitio de restricción NotI, 
presente en la región C-terminal de los plásmidos de BiFC. Una vez hibridados los 
cebadores (95ºC 10 min, 60ºC 8 h), fueron tratados con polinucleótido quinasa para 
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añadir los grupos fosfato y posteriormente se ligaron con T4 DNA ligasa (Promega). Para 
facilitar la inserción de los TMD en los plásmidos BiFC se utilizó fosfatasa alcalina 
(Roche) para eliminar el 5’ fosfato. 
Para confirmar la especificidad de las interacciones en este sistema, se utilizaron 
aquellos mutantes puntuales de cada BCL-2 TMD que rompieron la interacción en el 
sistema ToxR. Se utilizó de nuevo el kit Stratagene Quikchange II (Agilent, CA, EE.UU.). 
Finalmente, todas las construcciones fueron verificadas por secuenciación del DNA. 
La líneas celulares utilizadas para todos los ensayos fueron HeLa y HCT 116 que 
fueron mantenidas en las condiciones recomendadas por la American Type Culture 
Collection. Los ensayos se realizaron en placas de seis pocillos al 60% de confluencia 
celular y se cotransfectaron usando Lipofectamine 2000 (Invitrogen) o Turbofect (Thermo 
scientific) con cantidades desde 0,25 a 1 µg de cada plásmido VN/VC. Las células 
transfectadas se incubaron a 37°C durante 24 h y a continuación fue medida la emisión de 
fluorescencia de Venus a 535 nm,  excitando a la longitud de onda de 500 nm utilizando 
el espectrofotómetro Wallac 1420. 
Para evaluar los niveles de expresión de todas las construcciones VN/VC BiFC-TMD 
se obtuvieron extractos celulares mediante lisis celular en un tampón que contiene: Tris-
HCl 25 mM pH 7,4, EDTA 1 mM, EGTA 1 mM, 1% SDS, así como inhibidores de 
proteasas. La concentración de proteína se determinó utilizando el kit de cuantificación de 
BCA (Thermo Scientific). 60 µg  de cada lisado celular se resolvieron mediante 
electroforesis SDS-PAGE y se transfirieron a membranas de nitrocelulosa. Tras la 
transferencia, las membranas se bloquearon utilizando 5% de leche en polvo en TBS-
Tween 20 y se incubaron durante la noche con el anticuerpo primario correspondiente. 
Tras tres lavados con TBS-Tween 20, las membranas se incubaron con el anticuerpo 
secundario apropiado conjugado con la enzima peroxidasa para la detección de proteína 
por quimioluminiscencia (Amersham Pharmacia Biotech). Los anticuerpos contra el 
epítopo de VC HA C29F4 (# 3724S), de VN c-myc 9B11 (# 2276S) , Bax (#2772)  y 
caspasa-3 (# 9662S) proceden de Cell Signalling y α-tubulina (# T8203) de Sigma-
Aldrich. 
Para determinar la localización subcelular de todas esta red de interacciones mediadas 
por los BCL-2 TMDs, se llevaron a cabo ensayos de localización subcelular e 
inmunolocalización por microscopía confocal de las construcciones de BiFC. Las células 
fueron sembradas y transfectadas sobre cubreobjetos de vidrio y tras la expresión de las 
construcciones durante 24 h, se lavaron repetidas veces en PBS para eliminar los restos 
celulares y de medio de cultivo. El proceso de fijación se realizó con paraformaldehído al 
4% durante 20 min. Después de tres lavados con PBS, las células se permeabilizaron con 
0,1% de Triton X-100 y posteriormente se llevó a cabo el bloqueo en 2% de gelatina en 
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PBS. Para el ensayo de liberación de citocromo c, las células se incubaron con el 
anticuerpo contra Cyt-c (1: 200; SC13561; Santa Cruz) durante 12h a 4ºC seguido de una 
incubación con el anticuerpo secundario anti-IgG de ratón-Alexa 555 (1: 400)(Invitrogen) 
durante 2 h. Los cristales fueron montados en portaobjetos de vidrio con Mowiol/DAPI 
(Sigma). Las imágenes se obtuvieron utilizando un microscopio confocal LSM 510 con 
un objetivo de 63x. Cada experimento fue repetido al menos tres veces. Se analizaron al 
menos 30 imágenes de cada muestra. Para la determinación de salida de citocromo c se 
contaron doscientas células y se clasificaron de acuerdo a la localización de Cyt-c en las 
mitocondrias (morfología tubular) o citosol (patrón difuso). Las imágenes de 
fluorescencia se analizaron y cuantificaron por colocalización con el software ImageJ. La 
colocalización de las construcciones BiFC-TMD y la sonda Mitotracker (500 nM, 20 min, 
37°C, Invitrogen) o el anticuerpo Grp78 (1:1000, Abcam, revelado con Alexa555 1:400) 
se definió como la superposición parcial o total de las señales verde y roja.  
Como aplicación de toda esta metodología pondremos dos ejemplos: la interacción y 
localización subcelular de los BCL-2 TMDs de Bcl-2, Bcl-xL y Bax (Figura 10.3.5); y un 
trabajo realizado en el transcurso de esta tesis doctoral con el TMD de la proteína SP-C 
del surfactante pulmonar que no ha sido incluido en la misma debido a que la temática 
abordada se aleja del tema principal de esta tesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 10.3.5.! Homodimerización de los segmentos transmembrana de Bcl-2, Bcl-xL y Bax en células 
HCT 116 usando el sistema BiFC. (A) Medida de fluorescencia de BiFC para los TMDs de Bcl-2, Bcl-xL y 
Bax. Las construcciones VC y VN  se transfectaron HCT 116 y la fluorescencia (A.U. unidades relativas) se 
midió a las 24 h. Las Barras representan La intensidad media de fluorescencia de tres experimentos 
independientes. El test de comparación múltiple de Dunnett (CI 95%) se utilizó para comparar la señal media 
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con el control negativo de fluorescencia Jun /ΔFos (control positivo Jun/Fos). (B) Imágenes de microcopia 
confocal en células HCT 116 transfectadas con construcciones VC y VN para Bcl-2, Bcl-xL y Bax TMD. La 
formación de homo-oligómeros se observa en el canal verde. El canal rojo (Mitotracker) corresponde al 
marcador mitocondrial. La  colocalización se muestra en amarillo. 
 
El surfactante pulmonar se compone en un 90-95% de lípidos (80% fosfolípidos y 5%-
10% lípidos neutros, en particular el colesterol), y un 8%-10% de proteínas. Estas 
proteínas son específicas de esta película biológica, e incluyen a la proteína surfactante 
A1 (SPA1), SPA2, SPB, SPC y SPD. Las SPA y SPD son hidrofílicas y las SPB y SPC 
(proteína del sulfactante pulmonar C) directamente afectan las propiedades biofísicas de 
los lípidos que constituyen el surfactante. La alteración tanto a  nivel génico como 
proteico de alguna de éstas proteínas es la responsable de diferentes patologías 
respiratorias. 
SPC humana es un péptido de 35 aminoácidos altamente hidrofóbico que se sintetiza 
como una proteína precursora mucho mayor de 21 kD. La SPC adopta una 
conformacional en hélice α con capacidad de inserción en las membranas alveolares (457). 
Alteraciones en la proteína SPC se asocian al síndrome de distress respiratorio en infantes 
prematuros y a la proteinosis alveolar pulmonar. Por este motivo resulta de gran 
importancia el estudio de la dinámica de membranas en la cual la dimerización de la SPC 
juega un papel esencial, así como su capacidad de asociación a otras proteínas y a los 
lípidos de la membrana alveolar.  
La figura 10.3.5. describe la capacidad de homo-oligomerización de la región TM de 
la proteína SPC en células humanas. Esta interacción es además específica ya que no se 
asocia con otros fragmentos TM como el de Bcl-2 (Figura 10.3.5A). SPC se localiza 
normalmente en el retículo endoplasmático y como se observa en los resultados de 
microscopia confocal es en este orgánulo donde tiene lugar la dimerización (Figura 
10.3.5B).  
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Figura 10.3.6. Homodimerización de segmentos TM de SPC en células HeLa usando el sistema BiFC. (A) 
Medida de fluorescencia de BiFC para los TMDs de SPC y Bcl-2. Las construcciones VC y VN  se transfectaron 
HeLa y la fluorescencia (A.U. unidades relativas)  se midió a las 24 h. Las Barras representan La intensidad 
media de fluorescencia de tres experimentos independientes. El test de comparación múltiple de Dunnett (CI 
95%) se utilizó para comparar la señal media con el control negativo de fluorescencia Jun /ΔFos (control 
positivo Jun/Fos) . (B) Imágenes de microcopia confocal en células HeLa transfectadas con construcciones VC y 
VN para SPC y Bcl-2. La formación de homo-oligómeros se observa en el canal verde. El canal rojo 
corresponde al marcador de retículo endoplasmático  Grp78. La  colocalización se muestra en amarillo.  
10.3.2. Metodología utilizada para el estudio de la función apoptótica de los 
dominios TM de las proteínas de la familia BCL-2. 
La función principal de las proteínas de la familia BCL-2 es el control de la ruta 
apoptótica. Por tanto, uno de los objetivos de esta Tesis fue determinar la relevancia de 
los BCL-2 TMD en apoptosis. Para ello, se emplearon diferentes estrategias y protocolos 
de medición de la activación apoptótica entre los que destacaremos aquí el ensayo de 
actividad enzimática para la proteasa ejecutora caspasa-3 y los experimentos de salida de 
citocromo c en mitocondrias aisladas. 
10.3.2.1 Determinación de la actividad de caspasa-3 frente a diferentes tratamientos. 
Esta metodología se basa en la extracción del contenido citosólico de células sometidas a 
diferentes tratamientos, para incubarlos posteriormente en presencia de un sustrato 
fluorogénico específico de caspasa-3, la cual sólo se encuentra activa en el citosol cuando 
ha sido procesada por la maquinaria apoptótica. Los extractos celulares se prepararon a 
partir de 2×105 células sembradas en placas de 6 pocillos. Después de 24 h, se llevaron a 
VN/VC Bcl-2
VN/VC Jun-Fos
Grp78 BiFC Merge
VN/VC SPC
B
Grp78 BiFC Merge
10                                                                   SUMMARY IN SPANISH 
    219 
cabo los tratamientos farmacológicos pertinentes según el diseño del ensayo. Tras el 
tratamiento, las células fueron recogidas con tripsina, lavadas con tampón salino (PBS) y 
sedimentadas por centrifugación a 400 g 5 min. Los sedimentos se resuspendieron en 
tampón de extracción (PIPES 50 mM, KCl 50 mM, EDTA 5 mM, MgCl2 2 mM, DTT 2 
mM) suplementado con un cóctel de inhibidores de proteasas (Sigma) y se mantuvieron 
en hielo durante 5 min. A continuación se congelaron y descongelaron tres veces en 
nitrógeno liquido para facilitar la lisis celular. Los lisados celulares se centrifugaron a 
14.000 rpm durante 5 min y se recogieron los sobrenadantes, que corresponden al extracto 
citosólico. La concentración de proteína total fue cuantificada utilizando el kit de proteína 
BCA (basado en el ácido bicinconínico, Thermo Scientific). 60 µg  proteína total se 
mezclaron con 200 µL de tampón de ensayo de caspasa (PBS 10% de glicerol, EDTA 0,1 
mM, DTT 2 mM) que contenía 100 µM del sustrato específico de caspase-3 (Ac-DEVD-
AFC (Enzo Life Sciences)). Finalmente la actividad caspasa-3 fue medida mediante 
liberación del grupo fluorescente AFC del sustrato a 37°C de forma continua utilizando 
un Wallac 1420 Workstation (λexc 400 nm; λem 508 nm). La actividad de esta proteasa 
se expresó como el incremento de unidades de fluorescencia relativa por minuto (AU). 
A modo de ejemplo se muestran los resultados obtenidos en las líneas celulares MEFs 
Wt Apaf-1 y Wt Bax/Bak del capítulo IV frente a diferentes tratamientos antitumorales 
(Figura 10.3.7.) 
 
 
 
 
 
 
 
 
 
 
 
Figura 10.3.7. Actividad caspasa-3 en MEFs Wt de Bax/Bak y Apaf-1. QM31 evita la apoptosis en células 
no tumorales tratadas tanto con ABT737 como con CDDP, pero no en las tratadas con GX15-070. La actividad 
caspasa-3 se midió en MEFs sometidas a los siguientes tratamientos: ABT737 (25 µM), GX15-070 (1 µM) y 
CDDP (30 µM) en presencia o ausencia de QM31 (10 µM) y zVADfmk (5 µM). Las barras representan la media 
de al menos tres experimentos independientes ± sd (** p, 0,05). 
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10.3.2.2 Liberación de citocromo c en mitocondrias aisladas tratadas con diferentes 
péptidos derivados de los TMD de proteínas BCL-2.  
Para realizar estos ensayos las mitocondrias fueron aisladas a partir de células MEFs 
mediante diferentes  etapas de centrifugación como ha sido previamente descrito (348). 
Brevemente, 6x106 células por placa de 150 mm fueron sembradas dos días antes de 
realizar el experimento. A continuación, fueron recogidas con tripsina y tras tres lavados 
con PBS se centrifugaron a 600 g 10 min a 4ºC. Descartado el sobrenadante, los 
sedimentos fueron resuspendidos en 3 ml de tampón IBC (125 mM KCl, 5 mM KH2PO4, 
2 mM MgCl2, 25 µM EGTA, 5 mM de succinato, rotenona 5 µM, y 10 mM HEPES-KOH 
(pH 7.2)). La lisis celular se llevó a cabo mediante rotura mecánica, utilizando el douncer 
adecuado y entre 20-30 golpes. Los lisados se centrifugaron a 600 g 10 min a 4ºC para 
eliminar las fracciones nucleares. El sobrenadante fue centrifugado a 7000 g 10 min a 4º. 
Se descartó el sobrenadante y se resuspendió el sedimento en IBC para volver a 
centrifugar a 7000 g 10 min a 4º. Volvimos a quedarnos con el sedimento que fue 
finalmente resuspendido en 20 µL de IBC. Una vez aisladas, las mitocondrias fueron 
incubadas con los diferentes TMD-pepts (50 µM) sintetizados químicamente en el tampón 
IBC durante 30 min a 30°C. A continuación se centrifugaron a 14.000 g durante 10 min. 
Las fracciones mitocondriales del sobrenadante y del sedimento fueron cuantificadas y 
analizadas por Western blot utilizando anticuerpos contra citocromo c (#4272, Cell 
Signalling), α-tubulina (#T8203,Sigma-Aldrich) y VDAC 1/2/3 (sc-98708, Santa Cruz), 
siendo estos dos últimos marcadores de citosol y mitocondria, respectivamente. Su 
utilidad reside en servir como referencia para mostrar la pureza de las diferentes 
fracciones obtenidas.  
La presencia de citocromo c en la fracción citosólica es indicativa de un proceso de 
desestabilización/permeabilización mitocondrial, por lo que aquellos TMD-pepts que 
promuevan este fenómeno tendrán funciones pro-apoptóticas. Como puede observarse a 
modo de ejemplo en la figura 10.3.8., algunos de los BCL-2 TMD-pepts son capaces de 
generar una desestabilización en la MOM que produce la salida de citocromo c, 
especialmente en el caso de Bcl-xL y Bak. En otros casos como Mcl-1 y Bcl-w, estos 
TMD-pepts no producen una permeabilización mitocondrial significativa, lo que además 
nos indica que los BCL-2 TMD-pepts no son fragmentos hidrofóbicos genéricos, sino que 
existe una especificidad en su secuencia para ejercer una función determinada. Como 
control negativo de la permeabilización mitocondrial se utilizó el péptido de GpA, cuyo 
TMD no tiene afinidad por las membranas mitocondriales ni funciones apoptóticas 
conocidas.  
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Figura 10.3.8. Liberación de citocromo c en mitocondrias aisladas. (A) Las mitocondrias aisladas fueron 
tratadas con 50 µM del TMD-pept que se indica en la parte superior durante 30 min a 30ºC. El Western blot de 
las diferentes fracciones mitocondrias purificadas fue revelado contra los anticuerpos de VDAC 1/2/3, utilizado 
como marcador mitocondrial, y citocromo c para determinar la permeabilización mitocondrial ejercida por los 
diferentes TMD-pepts. GpA TMD-pept fue utilizado como control negativo al tratarse de una proteína no 
relacionada con apoptosis y sin funciones mitocondriales descritas. Los datos son representativos de tres ensayos 
independientes. 
10.4. CONCLUSIONES 
• Los resultados de esta Tesis muestran que los dominios TM de las proteínas 
BCL-2 no se encuentran aislados en la membrana mitocondrial sino que son 
capaces de asociarse entre ellos. Los estudios de hetero-oligomerizaciones nos 
han permitido establecer por primera vez el mapa de interacciones de los TMD 
de las proteínas BCL-2. Además, se ha demostrado la contribución potencial de 
estos TMD a la regulación del proceso apoptótico. Por todo ello, concluimos que 
los BCL-2 TMDs, junto con los dominios solubles, participan en el delicado 
equilibrio que regula la permeabilización de la membrana mitocondrial (MOMP). 
 
• En la subfamilia de las proteínas BH3-only hemos demostrado que las regiones 
hidrofóbicas C-terminales de Bik, Bim y Puma son capaces de insertarse en las 
membranas celulares de manera eficiente. Estos resultados abren un campo de 
estudio sobre las posibles interacciones con otros Bcl-2 TMDs. Por el contrario, 
las regiones C-terminales de Noxa y Bmf muestran una capacidad de inserción 
baja en las membranas celulares. 
 
• Los estudios con péptidos derivados de los BCL-2 TMD han demostrado que 
algunos TMD-pepts pueden integrarse de manera específica en las membranas 
mitocondriales. Por otra parte, los TMD-pepts de Bcl-2, Bcl-xL, Bax y Bak 
inducen la liberación de citocromo c. En consecuencia, la introducción de estos 
péptidos induce muerte celular o bien establecen sinergismos con tratamientos 
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quimioterapéuticos cuando son empleados a concentraciones subletales, lo que 
les capacita para su potencial uso terapéutico. 
 
• El BH3 mimético ABT737 no sólo requiere Bax/Bak para inducir apoptosis, sino 
también Apaf-1, mientras que GX15-070 y CDDP inducen diferentes 
modalidades de muerte celular en ausencia de las proteínas pro-apoptóticas Bax 
y Bak o Apaf-1. Por otro lado, el inhibidor del apoptosoma QM31 protege a la 
célula de los efectos derivados del tratamiento con ABT737 y parcialmente de 
los de CDDP, pero no logra bloquear la inducción de muerte celular por 
autofagia inducida por GX15-070. 
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